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In order to better introduce this book, it is important to define regenerative medicine. 
This field is built through a combination of multiple elements including living cells, 
matrix to support the living cells (i.e. a scaffold), and cell communicators (or signaling 
systems) to stimulate the cells, and their surrounding environment to grow and 
develop into new tissue or organ. Indeed, regenerative medicine is an emerging 
multidisciplinary field involving biology, medicine, and engineering that is likely to 
revolutionize the ways we improve the health and quality of life for millions of people 
worldwide by restoring, maintaining, or enhancing tissue and organ function. 
Even if the origins of regenerative medicine can be found in Greek mythology, as 
attested by the story of Prometheus, the Greek god whose immortal liver was feasted 
on day after day by Zeus' eagle; many challenges persist in order to successfully 
regenerate lost cells, tissues or organs and rebuild all connections and functions.  In 
this book, we will cover a few aspects of regenerative medicine highlighting major 
advances and remaining challenges in cellular therapy (including cell communicators) 
and tissue/organ engineering.  
Cell replacement therapy 
The types of cells that are used are dependent on the type of tissue that needs to be 
repaired. Several cells have been suggested as suitable for cellular therapies: i.e. 
embryonic stem cells (ES), induced pluripotent stem cells (iPS); somatic stem cells 
from fetal or adult tissues. The potential use of fetal tissue or differentiated embryonic 
stem cells from allogenic sources suffer limitations due to tissue availability, ethical 
issues or safety concerns. On the contrary, adult somatic stem cells can be used in 
autologus graft procedure, avoiding patient’s immunosuppression.  In this book, 
several chapters will discuss stem cell applications in regenerative medicine focusing 
on several organs or tissues like brain, heart, liver or retina.   
Cell communicators  
The circulatory system is involved in the transport of a wide variety of biological 
molecules and cells and can be considered as the body's basic communication system. 
Cell communicators act as a signaling system, which stimulates the cells into action.  
X Preface 
 
In some cases those communicators could lead cells to integrate damage tissues and 
rebuild lost connections, however, some signals could also induce cellular stress 
responses conducting to cell death.  Few of those aspects will be directly addressed in 
this book. 
Tissue engineering or …where biology meets engineering.  
All cells within tissues are separated and interlinked by a matrix or structure. The 
consistency of the matrix may vary from liquid, as in blood; to semi-solid, as in 
cartilage; to solid, as in bone.  Tissue engineers either implant cells into a matrix or 
create the proper conditions for the living cells to build their own three dimensional 
matrix. Such a matrix provides the structure that supports the cells and creates the 
physiological environment for them to interact within the host tissue. The success or 
failure of an implant material in the body depends on a complex interaction between a 
synthetic ‘foreign body’ and the ‘host tissue’, which involves not only biological, but 
also mechanical, physical and chemical mediated factors.  The latest advances in tissue 
engineering will be discussed in this book underlying many challenges that remain 
pending in this field. 
Finally, I would like to conclude this preface by expressing my deepest gratitude to all 
the authors who contributed to the realization of this book.  
 
Sabine Wislet-Gendebien, PhD 
GIGA Neurosciences 
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1. Introduction 
Neurodegenerative disease is a generic term used for a wide range of acute and chronic 
conditions whose etiology is unknown such as Parkinson's disease, Huntington's disease, 
amyotrophic lateral sclerosis (ALS), Alzheimer's disease, but also now for other neurological 
diseases whose etiology is better known but which are also concerned by a chronic lost of 
neurons and glial cells such as multiple sclerosis (MS), stroke, and spinal cord injury. 
Although the adult brain contains small numbers of stem cells in restricted areas, the central 
nervous system exhibits limited capacity of regenerating lost tissue. Therefore, cell 
replacement therapies of lesioned brain have provided the basis for the development of 
potentially powerful new therapeutic strategies for a broad spectrum of human neurological 
diseases. However, the paucity of suitable cell types for cell replacement therapy in patients 
suffering from neurological disorders has hampered the development of this promising 
therapeutic approach.  
Stem cells are classically defined as cells that have the ability to renew themselves 
continuously and possess pluripotent or multipotent ability to differentiate into many cell 
types. Besides the germ stem cells devoted to give rise to ovocytes or spermatozoïdes, those 
cells can be classified in three subgroups: embryonic stem cells (ES), induced pluripotent 
stem cells (iPS) and somatic stem cells (Figure 1). ES cells are derived from the inner mass of 
blastocyst and are considered as pluripotent stem cells as these cells can give rise to various 
mature cells from the three germ layers. iPS cells are also pluripotent stem cells, however, 
those cells derived from adult somatic cells such as skin fibroblasts are genetically modified 
by introduction of four embryogenesis-related genes (Takahashi et al., 2007; Park et al., 
2008). Finally, tissue-specific stem cells known as somatic or adult stem cells are more 
restricted stem cells (multipotent stem cells) and are isolated from various fetal or adult 
tissues (i.e. hematopoietic stem cells, bone marrow mesenchymal stem cells, adipose tissue-
derived stem cells, amniotic fluid stem cells, neural stem cells, etc.; Reviewed by Kim and de 
Vellis, 2009).  
 




Fig. 1. Stem cell type and origin. Besides germ stem cells, three group of stem cells can be 
defined according to their differentiating abilities: A. pluripotent embryonic stem cells (ES), 
B. induced pluripotent stem cells (iPS) and C. multipotent fetal or adult somatic stem cells 
(Figure adapted from Sigma-Aldrich). 
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In recent years, neurons and glial cells have been successfully generated from stem cells 
such as embryonic stem cells (Patani et al., 2010), iPS (Swistowski et al., 2010), mesenchymal 
stem cells (MSC) (Wislet-Gendebien et al., 2005), and adult neural stem cells (reviewed by 
Ming et Song, 2011), and extensive efforts by investigators to develop stem cell-based brain 
transplantation therapies have been carried out. Over the last decade, convincing evidence 
has emerged of the capability of various stem cell populations to induce regeneration in 
animal models of Parkinson’s disease (PD), Huntington’s disease, Alzheimer’s disease (AD), 
multiple sclerosis or cerebral ischemia (Reviewed by Gögel et al., 2011). Some of the studies 
have already been carried out to clinical trials. In example, in the case of Parkinson’s disease, 
transplantation of fetal ventral mesencephalon tissue directly into the brains of PD patients has 
been done in a few centers with varying results (Kordower et al., 2008; Li et al., 2008 ; Mendez et al., 
2008) and it appeared that using fetal ventral mesencephalon tissue raised numerous 
problems from ethical issues to heterogeneity and relative scarcity of tissue (reviewed by 
Wakeman et al., 2011) suggesting that other stem cells (like adult somatic stem cells) may be 
more suitable for such a therapy. Likewise, ES cells have also been grafted in patients with 
injured spinal cord, as USA Federal Regulators have cleared the way for the first human 
trials of human ES-cell research, authorizing researchers to test whether those cells are safe 
or not (Schwarz et al., 2010). It is still to early to know the effect of ES cells on patient 
recovery; however, several concerns have been previously raised on animal models as ES 
cells induced teratocarcimas and some exploratory clinical trials are confirming the animal 
studies (reviewed by Solter, 2006).  
In this chapter, we will review our results concerning identification and characterization of 
neural crest stem cells (NCSC) in adult bone marrow as a potential source for cellular 
therapy in neurological disorders. We will also discuss what are the main questions that 
remain pending concerning the use of those cells in cellular therapy protocols for 
neurological disorders.  
2. Somatic stem cells isolated from adult bone marrow 
The post-natal bone marrow has traditionally been seen as an organ composed of two main 
systems rooted in distinct lineages—the hematopoietic tissue and the associated supporting 
stroma. The evidence pointing to a putative stem cell upstream of the diverse lineages and 
cell phenotypes comprising the bone marrow stromal system has made marrow the only 
known organ in which two separate and distinct stem cells and dependent tissue systems 
not only coexist but functionally cooperate, defining hematopoietic stem cells (HSC) and 
mesenchymal stem cells (MSC) (reviewed by Bianco et al., 2001).  
MSC were first isolated from the bone marrow (BM-MSC) stem cell niche. More recently, 
extensive research has revealed that cells with morphological and functional 
characteristics similar to BM-MSC can be identified in a large number of organs or tissues 
including adipose tissue and peripheral blood. Despite having different origins, these 
MSC populations maintain cell biological properties typically associated with stem cells. 
These include continuous cell cycle progression for self-renewal and the potential to 
differentiate into highly specialized cell types of the mesodermal phenotype including 
chondroblast, osteoblast, and adipocyte lineages. Interestingly, BM-MSC have also been 
reported to be inducible via the ectodermal or endodermal germline, demonstrating the 
expression of neuron-like factors insulin production or hepatic lineage-associated genes 
respectively. In addition to these general stem cell properties, the International Society for 
Cellular Therapy proposed a more specific panel of markers for the characterization of 
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MSC. Due to the failure to identify a certain unique MSC cell-surface molecule, a set of 
minimal criteria for MSC was recommended, which includes the capability of adherence 
to plastic surfaces and the expression of the cell surface markers CD44, CD73, CD90, and 
CD105 with a concomitant absence of CD14, CD19, CD34, CD45, and HLA-DR expression 
(Reviewed by Hilfiker et al., 2011). 
Originally analyzed because of their critical role in the formation of the hematopoietic 
microenvironment (HME), bone marrow stromal cells became interesting because of their 
surprising ability to differentiate into mature neural cell types. More recently, a third stem 
cell group has been identified as originating from the neural crest, which could explain the 
capacity of stromal stem cells to differentiate into functional neurons. 
2.1 Neural phenotypic plasticity of adult bone marrow stromal cells 
Several years ago, we demonstrated that a fraction of bone marrow stromal cells were able 
to differentiate into functional neurons. Those specific cells were characterized as nestin-
positive mesenchymal stem cells (Wislet-Gendebien, 2003-2005). Electrophysiological 
analyses using the whole-cell patch-clamp technique revealed that adult rat bone marrow 
stromal cells (Wislet-Gendebien et al., 2005a and 2005b) were able to differentiate into 
excitable neuron-like cells when they were co-cultivated with mouse cerebellar granule 
neurons. First, we demonstrated that those cells express several neuronal markers (NeuN 
and Beta-III-tubulin ; Figure 2), an axonal marker (neurofilament protein recognized by the 
 
 
Fig. 2. Neuronal marker expressed by bone marrow stromal cells. Bone marrow stromal cells 
were co-cultivated for 5 days with GFP-positive cerebellar granule neurons (green). 
Immunofluorescence labeling showed that beta-III tubulin recognize by Tuj1 antibodies 
(red) was expressed by about 20% of bone marrow stromal cells (GFP-negative or non-green 
cells) (Wislet-Gendebien et al., 2005).  
 
Neural Crest Stem Cells from Adult Bone Marrow: A New Source for Cell Replacement Therapy? 
 
7 
monoclonal antibody, SMI31) and a dendritic marker (MAP2ab). Electrophysiological 
recordings of these nestin-positive bone marrow-derived neuron-like cells (BMDN) were 
performed and three maturation stages were observed (Table 1). At 4–6 days of co-culture, 
BMDN showed some neurotransmitter responsiveness (GABA, glycine, serotonin and 
glutamate) and voltage-gated K+ currents inhibited by TEA (tetraethylammonium). 
However, those cells did not express functional sodium voltage-gated channels and have a 
low membrane potential (Vrest) (-37.6°  3mV, n = 61). During the second week of co-
culture, BMDN started to display Na+ currents reversely inhibitsed by TTX (tetrodotoxin) 
and became able to fire single spike of action potential. In those older co-cultures, the Vrest 
reaches a more negative value, which was closer to the value usually measured in neurons 
(7–9 days, -50.3  2mV, n = 76 and 10–15 days, -56.7  2.3mV, n = 97). 
As only nestin-positive bone marrow stromal cells were able to differentiate into functional 
neurons, we performed several proteomic and transcriptomic comparisons that pointed out 
several characteristics like ErbB3 and Sox10 over-expression in nestin-positive MSC, 
suggesting that these cells could actually be neural-crest derived cells (reviewed by Wislet-
Gendebien et al., 2008). Few months later, Nogoshi et al. (2008) confirmed the presence of 
neural crest derived cells in adult bone marrow. 
 
 
Table 1. Maturation steps of bone marrow derived neuron-like cells 
2.2 Characterization of neural crest stem cells from adult bone marrow 
2.2.1 Neural crest stem cell origin 
In early vertebrate development, the neural crest is specified in the embryonic ectoderm at 
the boundary of the neural plate and the ectoderm. Once specified, the neural crest cells 
undergo a process of epithelium to mesenchyme transition (EMT) that will confer them the 
ability to migrate. The EMT involves different molecular and cellular machineries and 
implies deep changes in cell morphology and in the type of cell surface adhesion and 
recognition molecules. When the EMT is complete, they delaminate from the neural 
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folds/neural tube and migrate along characteristic pathways to differentiate into a wide 










Fig. 3. Neurulation and neural crest migration. As neurulation proceeds, the neural plate 
rolls up and the neural plate border becomes the neural folds. Near the time of neural tube 
closure (depending on the species), the neural crest cells go through an epithelial to 
mesenchymal transition (EMT) and delaminate from the neural folds or dorsal neural tube 
and migrate along defined pathways.  
In 2000, Jiang et al. developed a two-component genetic system based on Cre/lox 
recombination to label indelibly the entire mouse neural crest population at the time of its 
formation, and to detect it at any time thereafter. Briefly, the fate of neural crest cells was 
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mapped in vivo by mating ROSA26 Cre reporter (R26R) mice, which express β-
galactosidase upon Cre-mediated recombination, with mice expressing Cre recombinase 
under the control of the Wnt1 promoter. In Wnt1-Cre/R26R double transgenic mice, 
virtually all neural crest stem cells express β-galactosidase. Using this transgenic model, 
Sieber-Blum and Grim (2004) demonstrated the presence of pluripotent neural crest stem 
cells in adult follicle hairs, Wong et al. (2006) demonstrated the presence of neural crest 
cells in the mouse adult skin and Nagoshi et al. (2008) confirmed the presence of NCSC in 
adult bone marrow (Table 2). 
 
 
Table 2. Presence of neural crest derived cells in adult tissues. 
2.2.2 Self-renewal ability and multipotency of adult bone marrow NCSC 
To consider NCSC from adult bone marrow as a potential source for cellular therapy 
protocol, a better characterization of those cells was mandatory. In our study, we first 
address the self-renewal ability, as first characteristic of stemness. Indeed, we demonstrated 
that NCSC were able to grow as spheres, which is one of the main hallmarks of immature 
neural cells and proliferate from a single cell culture (clonal culture). We then addressed the 
multipotency and verify if those NCSC clones were able to differentiate into multiple 
mature cell types. Indeed, we observed that NCSC were able to differentiate into adipocytes, 
melanocytes, smooth muscles, osteocytes, neurons and astrocytes (Figure 4, Glejzer et al., 
2011). 
2.2.3 Maintenance and proliferation of adult bone marrow NCSC 
Before using NCSC from adult bone marrow, we have to face some limiting factors like the 
fact that NCSC are a minority population (less than 1%) in adult bone marrow. As Wnt1 and 
BMP2 factors were described to help for maintenance and proliferation of NCSC isolated 
from embryo (Sommer, 2006), we tested those two factors, on adult NCSC isolated from 
adult bone marrow. Interestingly, we demonstrated that Wnt1 and BMP2 were able to 
increase the number of NCSC present in bone marrow stromal cell culture, up to four times 
within 2 passages (Glejzer et al., 2011) reaching 20 % of NCSC.  
 




Fig. 4. Multipotency of adult bone marrow NCSC. NCSC clones were subjected to 
differentiating protocols and were shown to be able to differentiate into adipocytes (Oil Red 
O labeling), melanocytes (L-DOPA labeling), smooth muscles (SMA-labeling) and 
Osteocytes (alkaline phosphatase activity). Moreover, when co-cultured with cerebellar 
granule neurons, we were able to differentiate NCSC clones into neurons (betaIII-tubulin 
labeling by Tuj1 monoclonal antibody) or astrocytes (GFAP labeling). 
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3. In vivo characterization of neural crest stem cells and/or bone marrow 
stromal cells in neurological disorder mice models 
3.1 Spinal stroke  
Among others, the spinal cord is the collection of fibers that runs from or to the brain 
through the spine, carrying signals from or to the brain to or from the rest of the body. 
Those signals control a person’s muscles and enable the person to feel various sensations. 
The main consequence of injuries to the spinal cord is the interference with those signals. 
Those injuries are characterized as “complete” or “incomplete”: if the injured person loses 
all sensation and all ability to control the muscles below the point of the injury, the injury is 
said “complete”; in the case of an “incomplete” injury, the victim retains some ability to feel 
sensations or control movement below the injured area.  
Main goals in spinal cord repair include reconnecting brain and lower spinal cord, building 
new circuits, re-myelination of demyelinated axons, providing trophic support, and 
bridging the gap of the lesion (Reviewed by Enzmann et al., 2006). Overcoming myelin-
associated and/or glial-scar-associated growth inhibition are experimental approaches that 
have been most successfully studied in in vivo experiments. Further issues concern gray 
matter reconstitution and protecting neurons and glia from secondary death (Reviewed by 
Enzmann et al., 2006).  
In this purpose, neural crest stem cells isolated from the bulge of hair follicle have been 
grafted in rat model of spinal cord lesion (reviewed by Sieber-Blum 2010). Those cells 
survived, integrated and intermingled with host neurites in the lesioned spinal cord. NCSC 
were non-migratory and did not proliferate or form tumors. Significant subsets of grafted 
cells expressed the neuron-specific beta-III tubulin, the GABAergic marker glutamate 
decarboxylase 67 (GAD67), the oligodendrocyte markers RIP or myelin basic protein (MBP) 
(Sieber-Blum et al., 2006). More interestingly, functional improvement was shown by two 
independent approaches, spinal somatosensory evoked potentials (SpSEP) and the Semmes-
Weinstein touch test (Hu et al., 2010). The strength of NSCS was fully characterized as they 
can exert a combination of pertinent functions in the contused spinal cord, including cell 
replacement, neuroprotection, angiogenesis and modulation of scar formation. However, 
those results have never been confirmed with human NCSC, which should be the next 
promising step. 
Similar studies were previously performed with bone marrow stromal cells. Indeed, several 
researches reported the anti-proliferative, anti-inflammatory and anti-apoptotic features of 
bone marrow stromal cells (reviewed by Uccelli et al., 2011). Indeed, Zeng et al. (2011) 
demonstrated that BMSC seeded in a three dimensions gelatin sponge scaffold and 
transplanted in a transected rat spinal cord resulted in attenuation of inflammation, 
promotion of angiogenesis and reduction of cavity formation. Those BMSC were isolated 
from 10 weeks old rats and passaged 3 to 6 times. Likewise, Xu et al. (2010) demonstrated 
that a co-culture of Schwann cell with BMSC had greater effects on injured spinal cord 
recovery than untreated BMSC. Indeed, analyses of chemokine and cytokine expression 
revealed that BMSC/Schwann cell co-cultures produced far less MCP-1 and IL-6 than BMSC 
or Schwann cells cultured alone. Transplanted BMSC may thus improve recovery in spinal 
cord injured mice through immunosuppressive effects that can be enhanced by a Schwann 
cell co-culturing step. These results indicate that the temporary presence of BMSC in the 
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injured cord is sufficient to alter the cascade of pathological events that normally occurs 
after spinal cord injury and therefore, generating a microenvironment which favours an 
improved recovery. In this study, BMSC were isolated from adult mice and used after 4 
passages.  
3.2 Multiple sclerosis  
Multiple sclerosis (MS) is a common neurological disease and a major cause of disability, 
particularly affecting young adults. It is characterized by patches of damage occurring 
throughout the brain and spinal cord with loss of myelin sheaths accompanied by loss of 
cells that make myelin (oligodendrocytes) (reviewed by Scolding, 2011). In addition, we 
now know that there is damage to neurons and their axons too, and that this occurs both 
within these discrete patches and in tissue between them. The cause of MS remains 
unknown, but an autoimmune reaction against oligodendrocytes and myelin is generally 
assumed to play a major role and early acute MS lesions almost invariably show prominent 
inflammation. Efforts to develop cell therapy of nervous system lesion in MS have long been 
directed towards directly implanting cells capable of replacing lost oligodendrocytes and 
regenerating myelin sheaths.  
To our knowledge, no experiment has been performed to characterize the effect of neural 
crest stem cells on the improvement of Multiple Sclerosis disease; however, several data can 
be collected concerning the positive effect of Schwann cells (derived from NCSC) and of 
bone marrow stromal cells.  
As previously described in injured spinal cord, bone marrow stromal cells have been 
characterized on their anti-proliferative, anti-inflammatory and anti-apoptotic features. 
These properties have been exploited in the effective treatment of experimental autoimmune 
encephalomyelitis (EAE), an animal model of multiple sclerosis where the inhibition of the 
autoimmune response resulted in a significant neuroprotection (reviewed by Uccelli et al., 
2011). Based on recent experimental data, a number of clinical trials have been designed for 
the intravenous (IV) and/or intrathecal (ITH) administration of BMSCs in MS patients 
(Grigoriadis et al., 2011).  
3.3 Parkinson disease  
Parkinson's disease (PD) is a chronic, progressive neurodegenerative disorder 
characterized by a continuous and selective loss of dopaminergic neurons in the substantia 
nigra pars compacta with a subsequent reduction of dopamine release mainly in the 
striatum. This ongoing loss of nigral dopaminergic neurons leads to clinical diagnosis 
mainly due to occurrence of motor symptoms such as rigidity, tremor and bradykinesia, 
which result from a reduction of about 70% of striatal dopamine (reviewed by Meyer et 
al., 2010). 
Levy et al. (2008) analyzed the effect of differentiated human BMSC onto dopaminergic 
precursor on hemi-Parkinsonian rats, after transplantation into striatum. This graft resulted 
in improvement of rat behavioral deficits quantified by apomorphine-induced rotational 
behavior. The transplanted induced-neuronal cells proved to be of superior benefit 
compared with the transplantation of naive BMSC. Immunohistochemical analysis of 
grafted brains revealed that abundant induced cells survived the grafting procedure and 
some of these cells displayed dopaminergic traits.  
 
Neural Crest Stem Cells from Adult Bone Marrow: A New Source for Cell Replacement Therapy? 
 
13 
Similarly, Zhang et al. (2008) isolated and characterized MSCs from Parkinson's disease 
(PD) patients and compared them with MSCs derived from normal adult bone marrow. 
These authors show that PD-derived MSCs are similar to normal MSCs in phenotype, 
morphology, and differentiation capacity. Moreover, PD-derived MSCs are able of 
differentiating into neurons in a specific medium with up to 30% having the characteristics 
of dopamine cells. At last, PD-derived MSCs could inhibit T-lymphocyte proliferation 
induced by mitogens. These findings indicate that MSCs derived from PD patients' bone 
marrow could be a promising cell type for cellular therapy and somatic gene therapy 
applications.  
3.4 Huntington disease  
Huntington disease (HD) is an autosomal dominant genetic disorder caused by the 
expansion of polyglutamine encoded by CAG repeats in Exon 1 of the IT15 gene encoding 
for Huntingtin (Htt). The polyglutamine repeat length determines the age of onset and the 
overall level of function, but not the severity of the disease (Vassos et al., 2007). Although 
the exact mechanism underlying HD disease progression remains uncertain, the hallmark of 
this disease is a gross atrophy of the striatum and cortex and a decrease of GABAergic 
neurons (DiFiglia et al., 1997). 
One strategy for HD therapy is to enhance neurogenesis, which has been studied by the 
administration of Stem/progenitor cells, including BMSC. Several studies (reviewed by 
Snyder et al., 2010) showed that BMSC promote repair of the CNS by creating a more 
favorable environment for neuroprotection and regeneration through the secretion of 
various cytokines and chemokines. Moreover, Snyder et al. (2010) demonstrated that BMSC 
injected into the dentate gyrus of HD mice model increased neurogenesis and decreased 
atrophy of the striatum. 
3.5 Alzheimer disease  
Alzheimer's disease (AD) is the most common form of dementia, affecting more than 18 
million people worldwide. With increased life expectancy, this number is expected to rise in 
the future. AD is characterized by progressive memory deficits, cognitive impairment, and 
personality changes associated with the degeneration of multiple neuronal types and 
pathologically by the presence of neuritic or amyloid plaques and neurofibrillary tangles 
(Reviewed by Selko, 2001). Amyloid β-peptide (Aβ) appears to play a key pathogenic role in 
AD, and studies have connected Aβ plaques with the formation of intercellular tau tangles, 
another neurotoxic feature of AD (Reviewed by Mattson, 2004). Currently, no treatment is 
available to cure or prevent the neuronal cell death that results in inevitable decline in AD 
patients.  
The innate immune system is the vital first line of defense against a wide range of pathogens 
and tissue injuries, triggering inflammation through activation of microglia and 
macrophages. Many studies have shown that microglia are attracted to and surround senile 
plaques both in human AD samples and in rodent transgenic models that develop AD-
related disease (Simard et al., 2006). In this context, Lee and al. (2010) demonstrated that 
treated APP/PS1 mice (mouse model of AD) with BM-MSCs promoted microglial 
activation, rescued cognitive impairment, and reduced Aβ and tau pathology in the mouse 
brain. 
 




The NCSC is one of the most intriguing cells in the field of regenerative medicine, because 
it is easily harvested from various accessible peripheral tissues, which could make 
autologous transplantation possible. Autologous transplantation would avoid 
immunological complications as well as the ethical concerns associated with the use of 
embryonic stem cells. Of the various NCSC, research on skin-derived NCSC is the most 
advanced mainly due to their easy isolation process. One of the critical questions for the 
application of NCSC to regenerative medicine is whether cells that are differentiated from 
NCSCs are functional. Some evidence supports this (reviewed by Nagoshi et al., 2009), 
however, lots of questions remained pending. By example, a very important question is 
the differentiation abilities of NCSC isolated from various tissues: are they similar or 
different? 
On the other hand, even if bone marrow stromal cells did not show a strong ability to 
replace lost neurons in neurodegenerative disorders such as Parkinson or Huntington 
disease, their impact on inflammation modulation or stimulation of endogenous cells were 
quite remarkable. This impact is also illustrated by a high number of ongoing clinical trials 
with these cells (Reviewed by Sensebé et Bourin, 2011). However, the main challenges 
remain the standardization of cell culture and isolation, to meet the international rules. 
Indeed, more than ever, it has been demonstrated that bone marrow stromal cells are 
constituted of an heterogenous population containing multiple stem/progenitor cell types 
including mesenchymal stem cells and neural crest stem cells, among other. Most of the 
studies describing the effects of BMSC on inflammation modulation or stimulation of 
endogenous cells were performed on low passages (< 4), which mainly contain MSC and 
less than 10 % of NCSC. So we could stipulate that most of these effects were probably due 
to MSC. However, in a perspective of cell therapy, a strong characterization of the role of 
each cell type in neuronal recovery seemed mandatory to establish strong and safe 
protocols. 
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1. Introduction  
Tissue plasminogen activator (t-PA) is the gold standard drug for cerebral infarction in the 
acute phase (Adams et al., 2007), but it cannot be administered to all cerebral infarction 
patients. Some patients who survive the acute phase of cerebral infarction suffer from 
permanent hemiparesis in the chronic phase, which highlights the need for regenerative 
medicine to play a more important role in treating such individuals. There are two primary 
approaches to the use of regenerative medicine for patients with cerebral infarction: 
exogenous stem cell therapies, and enhancement of endogenous stem cells.  
Stem cell transplantation is one of the most widely employed strategies using exogenous 
stem cells. Many studies with experimental animals have shown that stem cell 
transplantation enhances functional recovery after cerebral infarction (Kameda et al., 2007; 
Takahashi et al., 2008). Based on the results of animal experiments, several clinical trials for 
patients with cerebral infarction are currently ongoing, using stem cell transplantation 
techniques, typically with mesenchymal stem cells (Detante et al.). However, these clinical 
trials have been started despite a lack of results showing that transplanted stem cells can 
reliably replace infarct areas. The principal purpose of cell transplantation in these cases is 
cell replacement, or replacement and restoration of infarct areas. Nevertheless, only a few 
percent of the transplanted cells typically survive during the chronic phase of cerebral 
infarction (Lindvall & Kokaia, 2006). Even more problematic is the fact that few of these 
transplanted stem cells differentiate into neurons with immunohistological and 
electrophysiological properties (Anderova et al., 2006). Based on these reports, some 
scientists maintain that functional improvements can be achieved without cell-replacement, 
that the effects of trophic factors secreted by the transplanted cells are sufficient (Cabrer et 
al., 2010; Shimada & Spees, 2011).  
Another approach that regenerative medicine can take is enhancement of endogenous stem 
cells, based on methods that are less invasive than the use of exogenous stem cells. Deep 
brain stimulation (DBS) for Parkinson’s disease patients is an example of a standard therapy 
now used in clinical situations. A previous report using animal subjects has shown that DBS 
can enhance the neurogenesis of endogenous stem cells (Toda et al., 2008). Based on this 
report, we evaluated the effectiveness of electrical stimulation on animals with cerebral 
infarction. Recently, we showed that electrical stimulation of the cerebral cortex during the 
acute phase of cerebral infarction exerted anti-apoptotic, angiogenic and anti-inflammatory 
effects through the PI3K-Akt signaling pathway (Baba et al., 2009). Moreover, we showed 
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that striatal electrical stimulation during the chronic phase of cerebral infarction was 
effective due to enhancement of endogenous stem cells in response to glial cell-line derived 
neurotrophic factor (GDNF) and vascular endothelial growth factor (VEGF) upregulation 
(Morimoto et al., 2010). Electrical stimulation had therapeutic benefit in cerebral infarction 
cases not only during the acute phase, but also during the chronic phase, which suggests 
that electrical stimulation has considerable therapeutic potential.  
This review summarizes the current consensus concerning regenerative medicine for 
cerebral infarction, focusing on stem cell transplantation and electrical stimulation 
techniques, and briefly describes strategies for applying these methods in a clinical setting. 
2. Approaches to regenerative medicine for cerebral infarction 
2.1 Stem cell transplantation using exogenous stem cells 
2.1.1 Donor cell sources 
Stem cell transplantation is one of the most established strategies based on the use of 
exogenous stem cells. Currently, many different types of stem cell can be cultured and 
transplanted, including induced pluripotent stem cells (iPS cells) (Takahashi & Yamanaka, 
2006), embryonic stem cells (ES cells) (Wang et al., 2011), neural stem cells (NSCs) (Kameda 
et al., 2007; Muraoka et al., 2006) , mesenchymal stem cells (MSCs) (Kurozumi et al., 2004; 
Wang et al., 2010) , and hematopoietic stem cells (Shyu et al., 2006), and some of these have 
already been used in clinical trials. Every type of stem cell has unique advantages and 
disadvantages. Deciding what type of stem cell to transplant requires careful consideration 
of availability, immune system response, ethical concerns, and the possibility of tumor 
genesis. 
Concerning the availability of stem cells for transplantation, iPS and ES cells are the most 
promising candidates, but the possibility of tumor formation must be addressed. Many 
researchers have searched for methods that prevent tumor formation. Regarding iPS cells, 
for example, Maekawa et al. showed that using maternal transcription factor Glis1 instead of 
oncogenic c-Myc enhanced the generation of iPS cells when expressed together with key 
transcription factors Oct3/4, Sox2, and Klf4 (Maekawa et al., 2011). 
The majority of animal experiments have demonstrated the neuroprotective effect of 
transplantation using allografts of adult NSCs or MSCs in the acute phase of ischemia 
(Kameda et al., 2007; Takahashi et al., 2008), but the effectiveness of stem cell transplantation 
during the subacute or chronic phase of ischemia was not seen (de Vasconcelos Dos Santos., 
2011). To avoid the problem of rejection by the immune system, and ethical issues, 
autologous stem cell transplantation using adult NSCs and MSCs is attractive, but 
considerable time is needed to expand these cells so that sufficient quantities are available. 
Muraoka et al. established an autologous NSC transplantation model using adult rats, in 
which NSCs were removed from the subventricular zone of adult Fischer 344 rats using 
stereotactic methods (Muraoka et al., 2008). The NSCs were expanded, which required 
approximately three weeks, and microinjected into normal hippocampus in the autologous 
brain. At the present time, MSCs are considered to be a more useful donor cell source in 
clinical settings than adult NSCs. In Japan, the first clinical trial of autologous MSC 
transplantation was performed for a patient in the chronic phase of cerebral infarction 
(Honmou et al., 2011). Detante et al. have started a clinical Phase II trial using autologous 
MSC transplantation for patients with cerebral infarction, with inclusion criteria that 
patients must have ischemic stroke confirmed by MRI within the previous 14 days. Based on 
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the previous results from animal experiments as well as the current clinical situation, 
autologous stem cell transplantation is considered to be of significant benefit to patients 
who were not administered rt-PA, provided it is performed in the acute phase three hours 
after onset. 
2.1.2 Delivery methods 
There are several stem cell delivery methods, such as intraparenchymal transplantation, 
intravenous administration and intraarterial administration. With any of these methods, the 
number of surviving transplanted donor cells is thought to affect the extent of recovery from 
cerebral infarction. Intraparenchymal transplantation can be performed so that stem cells 
are delivered in the ischemic penumbra, and it is thus the best method for placing the 
largest number of stem cells in the desired area of the brain, but this is the most invasive 
method. Intravenous administration, on the other hand, is the least invasive, but most stem 
cells end up in the liver and lung (Wang et al., 2010), leaving a much smaller number of 
stem cells surviving in the area of the ischemic penumbra compared with the 
intraparenchymal transplantation method. This is why the quantity of stem cells 
administrated intravenously in animal experiments is roughly an order of magnitude larger 
than that used in other delivery methods (Li et al., 2008; Lundberg et al., 2011). Lappalainen 
et al. detected an accumulation of graft cells which were intraarterially administrated in the 
ischemic brain, using SPECT/CT, but such cells were not observed when administrated 
intravenously (Lappalainen et al., 2008). At the present time, relatively few papers have 
explored intraarterial methods of administering stem cells for cerebral infarction in animal 
models. However, an endovascular technique, superselective intraarterial administration to 
the penumbra via a micro-catheter, can be performed in a clinical situation, and this method 
is expected to be less invasive than intraparenchymal transplantation. 
2.1.3 Graft survival 
Although the therapeutic effect of stem cell transplantation depends upon the rate of stem 
cell survival, research to date has reported that only approximately 5% survives after 
transplantation (Lindvall et al., 2004). Cytoprotection can enhance the percentage of graft 
survival. In particular, GDNF has been shown to be an effective neurotropic factor against 
ischemic injury. Its neuroprotective effect mainly derives from activation of the 
phosphatidylinositide-3-kinase/Akt (PI3K/Akt) and mitogen-activated protein kinase/ERK 
(MAPK/ERK) pathways (Nicole et al., 2001; Treanor et al., 1996). During transplantation, 
stem cells are subject to hypoxic-ischemic injury. Wang et al. showed that graft survival was 
enhanced by pretreatment with GDNF for three days before NSC transplantation (Wang et 
al., 2011). Because brain tissue architecture is disrupted in the ischemic brain, the use of 
biodegradable scaffolds may help transplanted stem cells regenerate and/or restore 
damaged brain structures and functions, by affecting cell differentiation, morphology, 
adhesion, or gene expression (Kleinman & Martin, 2005; Steindler, 2002). Jin et al. showed 
that transplantation of human neural precursor cells (NPCs) in Matrigel scaffolding at the 
time of transplantation partially improved therapeutic outcome compared to that of NPCs 
without Matrigel scaffolding, and that the use of NPC/Matrigel cultures dramatically 
improved the therapeutic effect (Jin et al., 2010). These reports indicate that, when using 
transplantation methods employing pre-treatment with GDNF, or Matrigel scaffolding, 
cytoprotective effects that enhance the survival rate of stem cells require time to develop in 
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vitro before transplantation and that such development might be related to the enhanced 
cytoprotective effects observed after transplantation. 
2.1.4 Functional recovery mechanisms: cell-replacement versus paracrine effects 
In experiments with animals, many researchers have confirmed that stem cell 
transplantation provides neuroprotective effects immediately after transplantation, based on 
behavioral analyses and histological analyses that show reductions in infarct volume 
(Kameda et al., 2007; Kurozumi et al., 2004; Takahashi et al., 2008). Histological analyses also 
showed that the neuroprotective effects were due to enhanced angiogenesis (Onda et al., 
2008), anti-apoptotic effects (Kameda et al., 2007; Kurozumi et al., 2004), and so on. A recent 
paper showed that mononuclear bone marrow cells played a role in a rapidly developed 
neuroprotective effect by increasing cerebral blood flow six hours after transplantation, 
followed by evidence of angiogenesis (Fujita et al., 2010). Yilmaz et al. described remarkable 
induction of genes for nerve guidance survival (e.g., cytokine receptor-like factor 1, glypican 
1, Dickkopf homolog2, osteopontin), as well as increased expression of neurogenerative, 
nerve guidance, and angiogenic factors (bFGF, bone morphogenetic protein, angiopoietins, 
neural growth factor), after transplantation with bone marrow stromal cells (Yilmaz et al., 
2010). Angiogenesis and anti-apoptotic effects are preferable for neuroprotection, and if the 
goal were limited to functional recovery, these neuroprotective mechanisms might be 
sufficient. However, in a strict sense, stem cell transplantation is expected to provide for cell 
replacement, since stem cells have two outstanding capacities, namely, self-renewal and 
pluripotency, which means that they can produce neurons, astrocytes and oligodendrocytes 
(Gage, 2000; Okano, 2002; Temple, 2001). 
Cell-replacement therapy requires that transplanted stem cells survive in the damaged 
brain, differentiate into mature cells, then replace neurons of several phenotypes, and 
reconstruct new networks with host cells. Several approaches have been studied to enhance 
neuronal differentiation, and one approach is to transplant site-specific cells. If the site-
specific characteristics of NSCs can be maintained during in vitro expansion, such cells may 
differentiate into site-specific neurons after transplantation. Another approach is to modify 
the cellular characteristics of the stem cells differentiation by transfecting a trophic factor 
gene (Kameda et al., 2007; Kurozumi et al., 2004). We have showed that, compared with 
unmodified stem cells, neuronal differentiation is enhanced by transplanting into the 
ischemic brain adult neural stem/progenitor cells that were modified to secrete GDNF. This 
enhancement of the differentiation is usually difficult to detect in the ischemic core, and is 
typically found only in the small ischemic boundary zone. Also, we are still not able to effect 
a complete replacement of the damaged infarct area using transplanted stem cells. 
Liu et al. have shown that DCX-expressing immature neurons in the subventricular zone 
(SVZ) do not exhibit a Na+ current, and their resting membrane potential is approximately  
-25mV in the absence of ischemic insult, however, after ischemic insult, such neurons do 
exhibit a Na+ current, and the membrane potential is hyperpolarized to about -54mV, a 
voltage similar to that of mature neurons. They also showed that gene analysis indicates that 
immature DCX cells express immature markers for Sox 2 and nestin in the absence of 
ischemic insult, but tyrosine hydroxylase (TH) is expressed as a mature marker after 
ischemic insult (Liu et al., 2009). After ischemic insult, immature stem cells become able to 
express the same phenotypes as mature neurons. 
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Research published during the last three years, however, indicates that cell replacement via 
stem cells transplantation is not essential to functional recovery (Ramos-Cabrer et al., 2010; 
Shimada & Spees, 2011). Previously, there was a research trend that aimed specifically at 
developing cell replacement therapies, as many researchers sought better methods to 
improve graft survival rates and enhance neuronal differentiation. Nevertheless, the present 
survival rate for transplanted cells during the chronic phase of cerebral infarction remains in 
the single digits (Lindvall et al., 2004), and few transplanted stem cells differentiate into 
neurons with immunohistological and electrophysiological properties (Anderova et al., 
2006). This has been interpreted by some researchers as indicating that functional 
improvements can be achieved without cell replacement, and that the effects of trophic 
factors secreted by the transplanted cells are sufficient. Ramos-Cabrer et al. recently have 
shown that post-stroke functional recovery after stem cell transplantation is due to paracrine 
mechanisms, not cell replacement. They found no evidence of surviving grafted stem cells 
six months after stem cell transplantation, and, compared with control animals, functional 
recovery was confirmed even during the chronic phase of cerebral infarction (Ramos-Cabrer 
et al., 2010). This report supports a new interpretation concerning the importance of 
paracrine mechanisms to functional recovery from cerebral infarction. Based on this new 
interpretation, clinical trials using stem cells to treat cerebral infarction are presently 
ongoing (Detante et al.). 
2.1.5 Future directions 
An increasing number of research papers on stem cell transplantation are focused on the 
neuroprotective effects provided by paracrine mechanisms (Shimada & Spees, 2011; Sun et 
al., 2010). Although cell replacement therapy is likely to remain an important target of stem 
cell transplantation, the focus on paracrine mechanisms will spur the development of 
clinical trials, for which long-term efficacy and safety are crucial evaluative factors. Thus, 
standardization of techniques will be more important compared with the procedures used 
in animal experiments. Furthermore, it has been reported that the quality of transplanted 
stem cells profoundly affects the functional outcome. Assmus et al. reported the results of 
the REPAIR-AMI (Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute 
Myocardial Infarction) trial, and showed that contamination by red blood cells affected the 
functionality of isolated bone marrow-derived progenitor cells, and ultimately inhibited 
recovery from acute myocardial infarction (Assmus et al., 2010). An increasing number of 
clinical trials applying stem cell therapies for cerebral infarction will be started in the near 
future, and cell preparation will play a vital role for proper interpretation of the results.  
2.2 Enhancement of endogenous stem cells 
2.2.1 Long-term potentiation (LTP) 
Another useful approach for regenerative medicine in cerebral infarction cases is to enhance 
endogenous stem cells. LTP is thought to be a cellular and molecular mechanism of 
hippocampal learning and memory (Bliss & Collingridge, 1993). LTP is observed as a long-
lasting enhancement in the efficacy of synaptic transmissions, which requires NMDA 
receptor activation and increased Ca2+ influx. LTP can be induced by brief high-frequency 
stimulation. Chen et al. showed that high-frequency stimulation or tetanic stimulation 
induced the release of Wnt3a from hippocampal neurons (Chen et al., 2006). Wnt3a has been 
shown to be a major regulator of neurogenesis in vivo and in vitro, and blocking Wnt3a 
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expression has been reported to cause a significant decline in neuronal generation 
(Davidson et al., 2007). Moreover, recent papers suggest that LTP per se enhances 
neurogenesis (Bruel-Jungerman et al., 2006; Chun et al., 2006, 2009). These findings, linking 
LTP stimulation to the activation of a large latent neural precursor pool in the dentate gyrus, 
could explain the ability of specific environmental stimuli to increase the rate of 
neurogenesis in the hippocampus over prolonged periods.  
2.2.2 Exercise 
It is now widely accepted that exercise (van Praag et al., 1999), enriched environments 
(Kempermann et al., 1997), and learning tasks (Gould et al., 1999), can enhance the 
neurogenesis of endogenous stem cells, and affect regulatory mechanisms that may be 
linked to LTP. Exercise has been shown to enhance neurogenesis in both intact and disease 
animal models. Tajiri et al. showed that exercise had neuroprotective effects on a 
Parkinson’s disease model in rats, with enhanced neurogenesis and migration toward the 
lesioned striatum observed. Furthermore, brain-derived neurotrophic factor (BDNF) and 
glial cell line-derived neurotrophic factor (GDNF) showed increases in the striatum as a 
consequence of exercise (Tajiri et al., 2010). Li et al. showed that whisker stimulation, as a 
peripheral stimulation after focal barrel cortex ischemia, enhanced migration from the 
subventricular zone, and increased the neurogenesis of endogenous stem cells, due to 
increased vascular endothelial growth factor (VEGF) and stromal-derived factor-1 
expression (SDF-1) in the penumbra. They also showed that local cerebral blood flow 
recovered to a greater degree due to whisker stimulation (Li et al., 2008). This indicates that 
increased peripheral stimulation and afferent signals to the ischemic cortex can activate 
endogenous neural stem cells, cause them to migrate to the injured region, and differentiate 
into mature neurons. Thus, the beneficial aspects of rehabilitation are recognized as being 
vital to long-term recovery from ischemic stroke. 
2.2.3 Electrical stimulation and repetitive transcranial magnetic stimulation 
Electrical stimulation and repetitive transcranial magnetic stimulation have been used in 
clinical situations for treatment of many central nervous system diseases, for example 
Parkinson’s disease (PD) (Fasano et al., 2010), epilepsy (Fisher et al., 2010), depression 
(Horvath et al.,2010) , and chronic pain (Rasche et al., 2006). Deep brain stimulation (DBS) 
has become a standard clinical therapy for PD patients and it can ameliorate motor function 
in such individuals, although the mechanism remains poorly understood. Toda et al. 
showed that DBS of the anterior nucleus of the thalamus (AN) enhanced the presence of 
endogenous stem cells in the hippocampal dentate gyrus and enhanced neurogenesis, which 
were associated with enhanced behavioral performance. Moreover, they showed that DBS of 
the AN reversed steroid-induced reductions in neurogenesis (Toda et al., 2008), implying 
that DBS can modulate synaptic plasticity and hippocampal neurogenesis. 
Based on these reports, we have tried to evaluate whether electrical stimulation has a 
neuroprotective effect that mitigates cerebral infarction damage by the enhancement of 
endogenous stem cells and neurogenesis. We began with epidural stimulation because we 
wanted to stimulate the brain using a method that is less invasive compared with the use of 
exogenous stem cells for stem cell transplantation. In one of our experiments, rats received 
continuous electrical stimulation above the cerebral cortex during the acute phase of 
cerebral infarction. This stimulation increased cerebral blood flow, enhanced behavioral 
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recovery and reduced infarct volume. The neuroprotective effect was derived from anti-
apoptotic, angiogenic and anti-inflammatory effects through the PI3K-Akt signaling 
pathway (Baba et al., 2009). As a next step, we hypothesized that electrical stimulation of the 
striatum could enhance the proliferation, migration, and neuronal differentiation of 
endogenous stem cells in the subventricular zone even during the chronic phase of the 
ischemic brain. Striatal electrical stimulation during the chronic phase of cerebral infarction 
was observed to enhance behavioral recovery and reduce infarct size. This neuroprotective 
effect was derived from stimulation of endogenous angiogenesis and neurogenesis with 
GDNF and VEGF upregulation (Morimoto et al., 2010). Machado et al. showed that chronic 
contralesional electrical stimulation of the lateral cerebellar nucleus improved motor 
recovery in rats following ischemic strokes, an effect derived from increased perilesional 
cortical excitability via chronic activation of the dentatothalamocortical pathway (Machado 
et al., 2009).  
Transcranial direct current stimulation (tDCS) has been used in animal experiments and for 
chronic stroke patients. tDCS is thought to strengthen synaptic connections (Cheeran et al., 
2008; Hummel et al., 2005; Nitsche et al., 2003, 2004), through a mechanism similar to that of 
LTP. Fritsch et al. showed that tDCS improved motor skill learning through enhanced 
synaptic plasticity that required brain-derived neurotrophic factor (BDNF) secretion and 
TrkB activation (Fritsch et al., 2010). 
Vagus nerve stimulation (VNS) has been used in an animal model of ischemia, and patients 
given this therapy have demonstrated enhanced behavioral recovery and reduced infarction 
size (Ay et al., 2009). The potential mechanisms for the observed beneficial effects of VNS 
are thought to be the suppression of increased neuronal excitability, and the reduction of 
cytokine overproduction and inflammation. Collectively, electrical stimulation has been 
shown to have therapeutic benefit in cases of cerebral infarction not only in the acute phase 
but also in the chronic phase, which suggests that electrical stimulation has considerable 
therapeutic potential. 
In addition to electrical stimulation, repetitive transcranial magnetic stimulation (rTMS) has 
been used in animal models of ischemia (Kaga et al., 2003), and in infarct patients with 
aphasia (Weiduschat et al., 2011), and has shown enhanced functional recovery. Compared 
with electrical stimulation, rTMS is more widely used because patients can avoid the 
surgery required for electrode implantation. It is presumed that the mechanism of its 
neuroprotective effect derives from increased glucose metabolism, inhibition of apoptosis in 
the ischemic hemisphere (Gao et al., 2010), and increased expression of c-fos, which is 
followed by upregulation of BDNF (Zhang et al., 2007). 
2.2.4 Rehabilitation combined with electrical stimulation  
Currently, after cerebral infarction, electrical stimulation (especially epidural electrical 
stimulation) is mainly performed together with rehabilitation, to enhance the functional 
recovery that normally occurs during rehabilitation. Northstar Neuroscience has performed 
clinical trials using epidural electrical stimulation for infarct patients with upper extremity 
hemiparesis (Northstar Neuroscience, formerly of Seattle, WA, U.S.A.). Unfortunately, the 
results of a Phase III randomized trial were unsuccessful, but the Phase II study showed that 
this therapeutic intervention is both safe and effective. Recently, preliminary study results 
from the same group showed that patients with non-fluent aphasia benefitted from speech-
language therapy in combination with epidural electrical stimulation of the premotor cortex, 
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identified by fMRI. Patients with moderate as well as severe aphasia showed functional 
improvements after epidural electrical stimulation (Cherney et al., 2010). 
2.2.5 Parameters and stimulation patterns 
As mentioned above, electrical stimulation and transcranial magnetic stimulation can be of 
significant functional benefit to individuals who have suffered a cerebral infarction. 
However, stimulation parameters can vary widely even for the same stimulation method. 
For example, in some of our research on epidural stimulation, we used continuous 
stimulation with 2Hz pulses of 1ms width at an intensity of 100μA. On the other hand, 
Moon et al. used intermittent stimulation with 50Hz pulses of 194ms width whose intensity 
was flexibly adjusted to evoke movement of a forelimb. They also compared the duration of 
stimulation, and observed that compared to continuous stimulation, intermittent 
stimulation enhanced functional recovery more effectively (Moon et al., 2009). 
The neuroprotective and neurorestorative effects of electromagnetic stimulation depend on 
the stimulation parameters and pattern. Moon et al. mentioned that the pattern and 
intensity of stimulation should be modified on an individual basis depending on the extent 
of the infarct. The efficacy of the results is affected by a large number of parameters, such as 
the frequency, intensity, pulse width, and duration of the stimulation (i.e., whether it is 
continuous or intermittent), and the stimulation target area and electrode resistance. Since 
the best combination of stimulation parameters and pattern are unknown at the outset, 
researchers tend to stimulate the ischemic brain using different stimulation parameters and 
patterns, searching for the combination that best enhances the neuroprotective and 
neurorestorative effects. 
Regarding the frequency of stimulation, the difference in effect between high-frequency 
stimulation and low-frequency stimulation is usually explained as a consequence of 
different cellular and molecular mechanisms, LTP versus long-term depression (LTD), 
because synaptic plasticity is one of the mechanisms responsible for enhanced functional 
recovery due to electrical stimulation. Based on numerous previous reports, brief high-
frequency stimulation (100Hz or higher) can induce long-term potentiation (LTP). On the 
other hand, brief low-frequency stimulation (1 or 2Hz) can induce long-term depression 
(LTD), which impairs long-lasting enhancement of synaptic transmission. Thus, the 
mechanism of enhanced recovery observed in response to high-frequency stimulation is 
discussed in terms of LTP, whereas low-frequency stimulation fails to induce functional 
recovery. 
The duration of stimulation also affects the outcome. Brief high-frequency stimulation 
induces LTP, but this does not mean that continuous high-frequency stimulation will do the 
same. In a preliminary study, we could not confirm reductions in infarction volume after 
continuous high-frequency stimulation, compared with application of low-frequency 
stimulation (Baba et al., 2009). This implies that inappropriate parameters and stimulation 
patterns may simply cause tissue damage, and provide no therapeutic effect. 
The condition of the brain also affects the results. Most LTP experiments conducted in the 
field of electrophysiological research are performed using intact rats and mice. As described 
above, NMDA receptor activation and increased Ca2+ influx are required for the induction 
of LTP. Increased Ca2+ influx is also observed in ischemia and because the ischemic brain 
has already been exposed to increased Ca2+ influx, the response to high-frequency 
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stimulation that can induce LTP in intact animals would be different in animals with 
cerebral infarction.  
Although LTP is a possible mechanism whereby electrical stimulation enhances functional 
recovery, it is likely that other mechanisms are also involved. Electrical stimulation can 
induce increased regional cerebral blood flow, suppress inflammatory responses, induce 
anti-apoptotic responses, and enhance angiogenesis, which, individually and in 
combination, modulate the microenvironment of the infarct brain to enable functional 
recovery. This implies that electrical stimulation should be performed using appropriate 
parameters and stimulation patterns that are tailored for the condition of the brain. 
2.2.6 Future directions 
Due to a recent finding, that aged mice contain a larger pool of latent stem cells than can be 
activated (Walker et al., 2008), determining the best parameter settings and pattern of 
electromagnetic stimulation that will yield the best possible functional outcomes in patients 
with cerebral infarction is of paramount importance. To find ideal parameter values and 
patterns, the mechanism of electrical and magnetic stimulation must be elucidated in more 
detail. Given the failure of the Northstar Neuroscience Phase III trial in which epidural 
electric stimulation was used, rTMS will likely play a more important role for cerebral 
infarction patients in the future, because it is a less invasive technique. And, although 
improving cerebral infarction treatment procedures is of vital importance, primary stroke 
prevention is also essential. Simvastatin enhances hippocampal LTP in mice and causes a 
significant increase in Akt phosphorylation (Mans et al., 2010), and since LTP per se can 
enhance neurogenesis, as mentioned earlier, this medication should be effective for 
preventing primary stroke as well as hyperlipidemia. In short, the protection and 
enhancement of endogenous stem cells may be a key factor in the maintenance and 
prolongation of health.  
2.3 Progress in ischemia analysis methods 
Thus far, we have outlined basic therapeutic strategies for treating cerebral ischemia, based 
on the use of exogenous stem cells and the enhancement of endogenous stem cells. 
Improvement in therapeutic strategies and further elucidation of the ischemia mechanism in 
greater detail are both important. 
To elucidate the mechanism of ischemia, and the actions of regenerative medicine, we need 
to analyze the neuronal activity in the ischemic brain by examining the response of single 
cells, as well as the response of large populations of neurons. For this purpose, the 
combination of MRI examinations (especially fMRI) and electrophysiological analysis are 
useful, because fMRI signals are thought to be proportional to the local average of neuronal 
activity. 
The use of fMRI provides a major breakthrough not only in animal experiments but also in 
treatment of patients. As mentioned above, fMRI enables the enhancement of patient 
rehabilitation after stroke, via epidural electrical stimulation and detection of premotor 
cortex function. Using fMRI techniques, functional recovery after ischemia can be 
monitored, as originally functional areas are reactivated, with preservation of neurovascular 
coupling (Weber et al., 2008). fMRI also can reveal ipsilateral cortical fMRI responses after 
peripheral nerve damage, so that increased interneuron activity can be observed. Thus, 
fMRI enables analysis of modifications in fiber connections, such as callosal 
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interhemispheric projections (Pelled et al., 2009). The use of voltage-sensitive dyes also 
provides a similar correlation with extracellular direct current potential recording, which 
enables the analysis of molecular mechanisms of ischemia from an electrophysiological 
point of view (Farkas et al., 2008). Voltage-sensitive dye techniques allow sensory-evoked 
depolarization after cerebral infarction to be analyzed in considerable detail (Siglera et al., 
2009). 
The comparison of results derived from MRI examinations with those obtained from 
electrophysiological analysis would also be useful. The ischemic penumbra is a major target 
when attempting to treat cerebral infarction. From an electrophysiological point of view, 
depolarization is induced in the ischemic core and brief depolarization is induced in peri-
infarct areas. Unlike electrophysiological analysis, diffusion-weighted imaging (DWI) in 
MRI does not include peri-infarct areas, defined as areas where a brief depolarization is seen 
during an electrophysiological examination. Thus, electrophysiological analysis can detect 
wider areas of damage than those detectable using histological or MRI techniques (Breschi 
et al., 2010). Behavioral analysis and fMRI analysis are typically usually used when 
analyzing and evaluating functional recovery, but electrophysiological analysis is seldom 
performed. The pursuit of cross-sectional analysis in greater depth should help to clarify the 
mechanism of cerebral infarction. 
3. Conclusion 
We have reviewed the therapeutic effect of stem cell transplantation and techniques for the 
enhancement of endogenous stem cells. As described above, previous studies have shown 
that functional recovery after cerebral infarction can be enhanced by stem cell 
transplantation, and that electromagnetic stimulation can provide neuroprotective and/or 
neurorestorative effects in animal models of ischemia. These results will stimulate 
additional clinical studies, but the development of more effective and reliable therapies will 
require further analysis. 
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Stroke causes irreversible and permanent damage in the brain immediately adjacent to the 
region of reduced blood perfusion. The only Food and Drug Administration (FDA)-
approved drug treatment for acute ischemic stroke is the thrombolytic, tissue-plasminogen 
activator (t-PA), which acts by dissolving the blood clot in the vessel, and restoring proper 
blood flow, but is only effective if administered within 3 hours of onset. However, only a 
few stroke patients are seen within 3 hours of the initial onset of an ischemic stroke and thus 
have the opportunity at full restoration of blood flow with rapid management by t-PA 
therapy. Meanwhile, the irreversible loss of myocytes after myocardial infarction (MI) also 
caused by impaired blood flow, followed by fibrosis of the myocardial scar, infarct 
expansion, concentric hypertrophy, and left ventricular dilation ultimately leads to 
progressive heart failure. Current clinical interventions to minimize the devastating effects 
of myocardial infarction are frequently not sufficient to prevent left ventricular remodeling 
and subsequent development of heart failure, emphasizing the need for more effective 
therapies. 
These two disorders are related by common features as they are both prevalent in the 
elderly worldwide. The obstruction of blood vessels reduces the availability of blood to the 
tissues, causes the specific tissue-related symptoms, and eventually damages or destroys the 
tissues. Despite interventional and medical advances, the number of people suffering from 
these disorders is on the rise. Most importantly, there are currently no effective treatments 
for these ischemic disorders after permanent tissue injury. 
Human umbilical cord blood (HUCB) has been used to treat children with various 
hematological malignant and nonmalignant diseases (Sirchia and Rebulla, 1999). More than 
six thousand HUCB transplantations have been performed worldwide (Laughlin et al., 2001; 
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Tse and Laughlin, 2005; Wagner et al., 1992), since HUCB was first used to successfully treat 
a 5-year-old child suffering from Fanconi anemia in 1988 (Gluckman et al., 1989). Recently, a 
number of reports reveal the many advantages of HUCB cells for cellular therapies, 
especially compared to bone marrow (BM) stem cells. HUCB cells are immature and elicit a 
lower incidence of graft rejection, graft versus host disease (GvHD), and post-transplant 
infections even though they primarily come from an allogeneic origin (Knutsen and Wall, 
1999; Tse and Laughlin, 2005). The immaturity of cord blood stem cells has been implicated 
in the optimal effects of these cells for hematopoietic and somatic organ therapy. Over the 
past years, many researchers have investigated the therapeutic potential of progenitor cells 
found within HUCB for stroke and MI. We have demonstrated that systemic administration 
of HUCB cells provides significant benefits in the stroke and MI animal models. 
Interestingly, rather than the conventional cell replacement mechanism, we advance 
alternative pathways of graft-mediated brain repair involving trophic effects resulting from 
release of various growth factors that afford cell survival, angiogenesis, and anti-
inflammation. Here is a critical literature review of the therapeutic benefits of HUCB stem 
cell transplantation for stroke and MI in pre-clinical experiments. 
2. The nature of human umbilical cord blood cells 
Hematopoietic progenitors in HUCB are the most primitive and are able to repopulate blood 
lineages for a long time (Broxmeyer et al., 1992; Nayar et al., 2002; Todaro et al., 2000). The 
number of myeloid progenitors in HUCB is similar to the number found in BM (Broxmeyer 
et al., 1992), however, HUCB cells have a greater colony-forming ability (Nakahata and 
Ogawa, 1982). Thus, they can be expanded in long-term cultures in vitro using different 
growth factors and have longer telomeres than other adult stem cells (Vaziri et al., 1994). 
Furthermore, it has been shown that HUCB grafts, compared to adult BM stem cells, are 
more efficient at restoring the host’s hematopoietic progenitor cell reservoir (Frassoni et al., 
2003). 
The mononuclear fraction of HUCB, is primarily composed of lymphocytes and monocytes 
(Pranke et al., 2001). It has a comparable B-cell population and a lower absolute number of 
cluster of differentiation 3 positive (CD3+) T-cells but a higher CD4+/CD8+ ratio compared 
to adult peripheral blood (Harris et al., 1992; Pranke et al., 2001). When comparing the 
characteristics of B-cell differentiation in vitro from CD34+ cord blood cells with those of 
peripheral blood, B-cell precursors that are differentiated from cord blood, appear to be 
more immature (Hirose et al., 2001). The relative immunological immaturity of HUCB, 
compared to adult cell sources, is further classified by a higher proportion of immature T-
cells and decreased numbers of mature memory T-cells (Harris et al., 1992). Moreover, cord 
blood lymphocytes express cytokine receptor profiles such as interleukin (IL)-2, IL-6, IL-7, 
tumor necrosis factor (TNF)-α, and interferon (IFN)-γ at lower levels compared to adult 
blood cells (Zola et al., 1995) and produce greater amounts of the anti-inflammatory 
cytokines such as IL-10 (Gluckman and Rocha, 2005, Rainsford and Reen, 2002). IL-10 down-
regulates expression of CD86 on dendritic cells (DCs), which may prevent initiation of the T-
cell mediated inflammatory reaction (Buelens et al., 1995). Increased levels of IL-10 may 
stimulate regulatory T-cells, which in turn inhibit antigen-specific immune responses 
(Asseman and Powrie, 1998). HUCB also contains more natural killer (NK) cells but lower 
numbers of CD56+ cytotoxic T-cells (D'Arena et al., 1998). NK cells can inhibit T-cell 
proliferation and reduce TNF- α production (El Marsafy et al., 2001). The DCs, which are the 
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sentinel cells of the body and initiate immune responses within the lymph nodes, in cord 
blood reflect lymphoid DCs that are most likely to be responsible for colonizing neonatal 
tissue, while they are more myeloid in adults (Willing et al., 2007). The lymphoid DCs 
induce T-helper cell 2 (anti-inflammatory) responses, which along with the naïve T-cells, 
may promote down-regulation of immune responses (Arpinati et al., 2000; Willing et al., 
2007). The immaturity of the immunological properties of HUCB cells probably causes a 
prolonged immunodeficient status after HUCB transplantation (Garderet et al., 1998; 
Thomson et al., 2000). This may explain the low incidence of GvHD and viral transmission. 
Such a cellular constitution could also allow for less strict donor-recipient matching 
requirements, hence leading to a shorter waiting period for treatment (Newcomb et al., 
2007). Rocha et al. found that GvHD incidence was significantly lower in children receiving 
HUCB transplants compared to BM recipients when the source was from an human 
leukocyte antigen (HLA)-identical sibling (Rocha et al., 2000).  
The level of maturity of a cell is identified by the cell’s combination of surface antigens. For 
example, the CD34+ population, a marker designated for its role in early hematopoiesis, in 
HUCB can be defined as more primitive than those found in BM because a higher 
proportion of them are negative for CD38, a marker for pre-lymphoid cells (Cardoso et al., 
1993; Conrad and Emerson, 1998). Not only does the mononuclear fraction contain roughly 
1% CD34+ cells but these cells appeared to be more immature than those found in BM 
(Newcomb et al., 2007). Another human antigen, CD133, has also been identified as a 
hematopoietic stem cell marker that may provide an alternative to CD34 for the selection 
and expansion of hematopoietic cells for transplantation (Kobari et al., 2001; Yin et al., 1997). 
It has been shown that about 80% of CD34+ cells express CD133 and more than 97% of CD 
133+ cells are CD133+CD34+ in fresh cord blood (Hao et al., 2003). Although CD133+ cells 
comprised 0.67% of the total mononuclear HUCB cells (Ma et al., 2002), expansion of CD 
133+ and CD133+CD34+ cells was significantly higher than those from the CD34+ cells (Hao 
et al., 2003). These findings suggest that CD133+ cells may be more primitive hematopoietic 
progenitor/stem cells than CD34+ cells. Furthermore, CD133+ cells have been identified in 
fetal brain and in this area they are considered to be neural stem cells (NSCs) (Tamaki et al., 
2002; Uchida et al., 2000). Meanwhile, we identified in vitro two different subpopulations of 
mononuclear HUCB cells- adherent and floating (N. Chen et al., 2005). Whereas the 
adherent cell population mainly contained lymphocytes expressing hematopoietic antigens, 
there are a significant number of stem cell and neural cell antigens expressed on cells in the 
floating population. These results suggest that a nonhematopoietic subpopulation of cells 
exists within the mononuclear fraction of HUCB cells and they seem to have the potential to 
become neural-like cells. Thus, HUCB seems to include a primitive stem cell population that 
may give rise to both hematopoietic and neural cells (Garbuzova-Davis et al., 2006). A recent 
study suggests that the CD133+ population of cells within cord blood can be induced to 
differentiate along specific lineages, but cell-cell contact is required (Park et al., 2009). 
However, as described below, other studies suggest that culture in the presence of specific 
factors is normally sufficient.    
A nonhematopoietic stem cell, the mesenchymal stem cell (MSC), has also been found in 
UCB (Goodwin et al., 2001; Yang et al., 2004). It has been confirmed that MSCs and MSC-like 
progenitors can be isolated from amniotic fluid, placenta, and HUCB. Moreover, MSCs 
derived from HUCB show impressive plasticity and differentiate into cells of all three germ-
line derivatives (Jeong et al., 2004; Lee et al., 2004; Yang et al., 2004). However, determining 
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a definitive phenotype as well as the surface antigens of MSCs from HUCB has proven to be 
controversial, unlike that from BM. HUCB MSCs failed to produce macrophage, 
granulocyte-erythroid-macrophage-megakaryocyte, or granulocyte-macrophage 
hematopoietic colonies in methylcellulose, whereas supernatants from cultured HUCB 
MSCs promoted survival of NT2N neural cells and peripheral blood mononuclear cells 
when cultured under conditions designed to induce cell stress and limit protein synthesis 
(El-Badri et al., 2006). Furthermore, after incubation in neural differentiation medium, 
HUCB MSCs expressed the neural cell surface antigen A2B5, the neurofilament polypeptide 
NF 200, the oligodendrocyte precursor marker 04, intermediate filament proteins 
characteristic of neural differentiation (nestin and vimentin), as well as the astrocyte marker 
glial fibrillary acidic protein (GFAP) and the neural progenitor marker class III -tubulin (El-
Badri et al., 2006). We also demonstrated the immunomodulatory effects of HUCB MSCs 
after co-culture with murine splenocytes (El-Badri et al., 2006). These results indicate that 
HUCB MSCs possess multiple utilities that may contribute to their therapeutic potency in 
the treatment of neurological diseases. 
3. HUCB in preclinical stroke research  
The therapeutic window of current stroke treatment is narrow and restrictive. Many 
patients seen outside of this window suffer from irreversible deficits. This reality should be 
taken into consideration when developing other therapeutic options, especially cell-based 
therapies. HUCB is one of the most promising sources of multipotent stem cells that have 
shown affirmative effects in in vivo studies for the treatment of stroke. We reviewed the 
literature focusing on delivery techniques such as the route of administration, time, and 
dose of HUCB cells given and underlying mechanisms responsible for beneficial effects 
from the transplantation of HUCB cells. 
3.1 Delivery routes, time, and dose of HUCB stem cells 
Chen et al. showed that the intravenous administration of mononuclear HUCB cells at 24 
hours or 7 days after middle cerebral artery occlusion (MCAO) in a rat model of stroke 
significantly improved neurological function (Chen et al., 2001). Upon histological 
examination of the brains, mononuclear HUCB cells were observed mainly in the cortex and 
striatum of the injured hemisphere in the ischemic boundary zone. Few cells were found in 
the contralateral hemisphere. It was determined that some of these mononuclear HUCB cells 
were immunoreactive for the endothelial cell marker blood clotting factor VIII (FVIII), 
GFAP, microtubule-associated protein 2 (MAP2), and neuronal nuclei (NeuN) by 
immunohistochemistry. Xiao et al. produced a line of cells isolated from HUCB that they 
called ‘nonhematopoietic umbilical cord blood stem cells’ by culturing of the mononuclear 
fraction and cell sorting for specific CD antigens (Xiao et al., 2005). A reduction in infarction 
volume was observed after intravenous transplantation of these cells into rats with ischemic 
brain injury. Histological analysis revealed that some of the transplanted cells were double 
labeled for human nuclei and NeuN, even though it was unlikely that they contributed to 
the recovery.  
Meanwhile, we compared the effect of intravenous versus intrastriatal injection of 
mononuclear HUCB cells to assess which route produced the greatest behavioral recovery in 
rats with a permanent MCAO (Willing et al., 2003a). Behavioral improvement was similar 
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for both cell delivery routes. Spontaneous activity was significantly less when cells were 
transplanted 24 hours after stroke compared with non-treated animals. However, 2 months 
after transplantation, significant improvements were found in the step test only after 
intravenous delivery of the mononuclear HUCB cells. Also, in the passive avoidance test, 
transplanted animals learned the task faster than non-transplanted rats. These results 
suggest that intravenous delivery of mononuclear HUCB cells may be more effective than 
direct striatal delivery in producing long-term functional benefits to the stroke animal. Next, 
we investigated the dose effect of mononuclear HUCB cells after MCAO (Vendrame et al., 
2004). Twenty-four hours after MCAO, rats were intravenously infused with from 104 up to 
3-5 x 107 mononuclear HUCB cells. At 4 weeks after infusion, there was a significant 
recovery in behavioral function, when 106 or more mononuclear HUCB cells were delivered. 
Infarct volume analysis showed an inverse relationship between cell dose and damage 
volume, which reached significance at the higher doses of mononuclear HUCB cells. 
Moreover, transplanted cells were observed by immunofluorescence for human nuclei 
antigen expression, to be localized only in the injured brain hemisphere and spleen. Taken 
together, this suggests that there may be a dose relationship between introduced 
transplanted cells, behavioral improvement, and neuronal sparing using mononuclear 
HUCB cell infusion in the MCAO rat stroke model.  
For translation from research to clinical application, it will be important to determine how 
soon after onset, HUCB cells should be transplanted for the best treatment of stroke. Our 
group determined the optimal time to administer these cells after a stroke. Using ischemic 
tissue extracts in an in vitro assay, we investigated the migration capability of mononuclear 
HUCB cells (Newman et al., 2005). This assay revealed increased migration of mononuclear 
HUCB cells towards both the hippocampal and striatal extracts that were harvested 24-72 
hours after stroke. Cytokine-induced neutrophil chemoattractant-1 (CINC-1) and monocyte 
chemotactic protein-1 (MCP-1) were increased in the extracts at 48 hours after MCAO. This 
suggests that these substances probably participate in the cell migration. Further analysis 
showed that growth-regulated oncogene/CINC-1 (the rat equivalent of human IL-8) and 
MCP-1 were expressed in a time-dependent pattern similar to that of the migration assays. 
The chemokines which are present in the supernatant may play a major role in the specific 
mechanisms responsible for the in vivo migration of mononuclear HUCB cells after stroke 
induction (Newman et al., 2005). Recently, we demonstrated that, in vivo, the HUCB 
treatment window is not particularly wide. When we intravenously injected the HUCB cells 
at times ranging from 3 hours to 30 days after MCAO, maximal improvements were 
observed with treatment at 48 hours (Newcomb et al., 2006). According to a recent study by 
Riegelsberger et al., neither the infarct volume nor cleaved caspase 3 activity was 
significantly affected by intravenous HUCB cell transplantation 24 hours after stroke onset 
(Riegelsberger et al., 2011). In addition, a recent study of MCAO in spontaneously 
hypertensive rats demonstrated a therapeutic window of upto 72 hours with intravenous 
injection of 1 x 106 HUCB mononuclear cells based on lesion size and behavioral impairment 
(Boltze et al., 2011a). The different rat species may explain the slightly longer therapeutic 
window compared with our studies. These results are promising in that by using 
mononuclear HUCB cell therapy, the current 3 hour time window of t-PA for the treatment 
of stroke may be extended to at least 24 hours after the stroke event. These findings suggest 
that relatively delayed systemic transplantation of HUCB cells failed to produce 
neuroprotective effects in a permanent stroke rat model. Taken together these results 
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suggest that the grafts actually exist over a very short time frame to either appropriately 
control the immune system or provide secretory products to cells within the brain to confer 
therapeutic effects.  
3.2 Probable mechanisms responsible for neural protection 
Although several reports revealed that HUCB cells expressed neural phenotypes both in 
vitro and in vivo (Garbuzova-Davis et al., 2003; Ha et al., 2001; Sanchez-Ramos et al., 2001; 
Zigova et al., 2002), few cord blood cells survive in the ischemic region compared to the 
number of infused cells (Chen et al., 2006; Vendrame et al., 2004, 2005; Willing et al., 2003a, 
2003b). In addition, two studies using mannitol to permeate the blood brain barrier showed 
that the passage of growth factors into the brain following MCAO and neonatal hypoxic 
ischemia was more important than cell migration from the circulation following intravenous 
injection (Borlongan et al., 2004; Yasuhara et al., 2010). These findings suggest that cell 
replacement is not the primary mechanism responsible for the functional improvements 
seen in these animal studies. Recent research in our team has found that HUCB may not 
only act as a cell replacement source, but also as a neurotrophic, neuroprotective and anti-
inflammatory agent. We found that there was an increase in the number of CD45+/CD11b+ 
and CD45+/B220+ B-cells in the brain of rats with permanent MCAO, while the number of 
CD45+/CD11b+ and CD45+/B220+ B-cells in the brain significantly decreased after 
mononuclear HUCB cell transplantation (Vendrame et al., 2005). The reduction of 
CD45+/CD11b+ cells is of particular interest, given that chronic microgliosis is believed to 
mediate neuronal damage, not only in ischemic injury but also in other neurodegenerative 
diseases (Streit et al., 1999; Tan et al., 1999). HUCB treatment also decreases the 
proinflammatory cytokines such as TNF-α and IL-1β, in the brain following stroke as well as 
reducing the presence of both activated microglia and astrocytes (Vendrame et al., 2005). 
Therefore, the potential anti-inflammatory effects of HUCB therapy may protect against 
neuronal death while evidence suggests that the CD34+ component of the transplant may 
facilitate revascularization (Taguchi et al., 2004). These cellular changes were accompanied 
by decreases in mRNA and protein expression of pro-inflammatory cytokines in the brain of 
stroke animals treated with mononuclear HUCB cells. In our next studies, we revealed that, 
following MCAO, rat spleen size was decreased concomitantly with their CD8+ T-cell counts 
(Vendrame et al., 2006). Interestingly, the MCAO-induced reduction in spleen size 
correlated with the extent of ischemic damage, however, HUCB cell treatment prevented the 
reduction in spleen weight and splenic CD8+ T-cell counts, as well as reducing the degree of 
brain injury. Additionally, splenocyte proliferation assays demonstrated that HUCB cell 
treatment opposed MCAO associated T-cell proliferation by increasing the production of IL-
10 while decreasing IFN-γ.  
As mentioned above, the HUCB cell preparation is a mixed population composed of 
immature T-cells, B-cells, monocytes/macrophages, and stem cells. Thus, it is important to 
determine whether the beneficial effects of HUCB injection can be attributed to a specific cell 
population. Recently, we found that the whole mononuclear fraction of cord blood, stem 
cell-, T-cell-, and B-cell-depleted preparations improved the function of the impaired left 
forelimb to a similar extent that exceeded the performance of MCAO-only animals (Womble 
et al., 2009). However, animals that received the monocyte/macrophage-depleted HUCB 
preparation performed more poorly than those receiving the other HUCB cells. 
Additionally, HUCB administration significantly reduced MCAO-induced hyperactivity, 
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while depletion of stem cells, monocytes (CD14+), and B cells prevented this recovery 
following stroke. These results suggest that stem cells, monocytes (CD14+), and B cells are 
critical to HUCB-induced recovery following stroke. A study performed in Germany 
confirmed that the mixed mononuclear cell population was most effective at 
neuroprotection against ischemia caused by MCAO in a spontaneously hypertensive rats 
(Boltze et al., 2011b). They showed that CD34+ cells contributed to this effect in vitro against 
oxygen-glucose deprivation (OGD), but did not appear to be important in vivo, since a 
CD34- cell population from HUCB was equally effective.  
The expression of cytokines and chemokines produced by HUCB cells under various culturing 
conditions was also investigated (Newman et al., 2006). The heterogeneous cells from 
mononuclear fractions of HUCB produced a variety of cytokines when grown in various 
culture conditions. In particular, IL-8, MCP-1, and IL-1β that have been implicated as the first 
line of defense in the inflammatory reaction, are more extensively produced than other 
chemokines in the human body, especially the brain. These results suggest that these factors 
may be partially responsible for the functional improvements that were observed in the animal 
stroke models investigating the therapeutic use of HUCB cells. On the other hand, we recently 
showed that chemokines are also elevated in the ischemic brain area in an in vivo study (Jiang 
et al., 2008). MCP-1 and macrophage inflammatory protein (MIP)-1α seem to play a role in the 
infiltration of monocytes into the central nervous system under pathological conditions 
(Babcock et al., 2003; Glabinski et al., 1998). We found that MCP-1 and MIP-1α expression were 
significantly increased in the ischemic brain, and significantly promoted HUCB cell migration 
compared to the contralateral side (Jiang et al., 2008). This cell migration was neutralized with 
polyclonal antibodies against MCP-1 and MIP-1α. Chemokine receptors were also expressed 
on the surface of transplanted HUCB cells. These findings suggest that the increased 
chemokines within the ischemic lesion can bind surface receptors on the HUCB cells, and 
induce homing of systemically delivered HUCB cells into the CNS in vivo. Recently, Ou et al. 
showed the potential of intravenous transplantation of HUCB CD34+ cells transfected with the 
glial cell line-derived neurotrophic factor (GDNF) gene to exert therapeutic benefits in 
spontaneous hypertensive rats exposed to a transient MCAO (Ou et al., 2010). The stroke 
animals transplanted with GDNF-modified CD34+ cells showed a significant increase in 
GDNF protein levels in the infarcted hemisphere, reduced brain infarction volume, and 
enhanced functional recovery compared to those that received CD34+ cells only. 
The immune system and inflammation are known to play a role in the development of 
stroke. Possible mechanisms of action for HUCB cells include the modification of this effect. 
Using an organotypic slice culture and OGD, a recent study showed that an intact immune 
system is not required for the beneficial effects of HUCB cells (Hall et al., 2009a). Cell 
survival was increased and the release of nitric oxide by resident microglia (an innate 
inflammatory response) was reduced back to normal levels following incubation with the 
cells. Further study showed that the secretion of IL-1 by microglia was impaired following 
hypoxia in the presence of HUCB cells and microglia viability was also decreased (Jiang et 
al., 2010). In vivo, HUCB cells were shown to impair the recruitment of pro-inflammatory 
microglia and hence the secretion of matrix metalloproteinase 9 and nitric oxide at the site of 
injury following MCAO (Leonardo et al., 2010). The microglia found at the site of injury 
tended to be of a ramified shape, which is believed to be a quiescent inactive form.  
Protein and microarray analysis of neuronal co-cultures with HUCB cells following OGD 
revealed the upregulation of a number of specific genes which coincided with improved 
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survival (Shahaduzzaman et al., 2010). Several of these genes e.g. peroxiredoxin were 
verified as being upregulated in vivo also, demonstrating that transplantation of HUCB cells 
promotes survival gene expression within the brain. OGD treatment of PC12 cells followed 
by co-culture with HUCB also demonstrated increased cell survival which was shown to be 
related to the appearance of antioxidants as well as neurotrophic and angiogenic factors 
(Arien-Zakay et al, 2009).  
The majority of studies on stroke and potential therapies focus on the neurons. However, 
ischemia also affects the white matter and therefore therapies should focus on both the 
neurons and the oligodendrocytes that myelinate the axons found in the white matter. Two 
recent studies by the Willing and Pennypacker group demonstrate that infusion of HUCB 
cells 48 hours after MCAO was also able to protect oligodendrocytes by reducing caspase 3 
activation (Hall et al., 2009b) and promoting the expression of genes associated with 
oligodendrocyte survival, proliferation and function (Rowe et al., 2010). A further study 
using HUCB-derived MSCs transduced to express hepatocyte growth factor revealed 
increased behavioral recovery and enhanced remyelination in an intracranial hemorrhage 
model compared to untransduced MSCs (Liu et al., 2010). In the latter study, the cells were 
transplanted one week after hemorrhage directly into the left ventricle. These studies 
demonstrate an additional means by which HUCBs could promote recovery from a stroke 
by aiding survival of oligodendrocyte survival and myelination of axons.  
While the majority of studies suggest mechanisms other than cell replacement, a recent 
study in canines demonstrated survival of intra-arterially injected HUCB-derived MSCs in a 
thromboembolic brain ischemia model at 4 weeks (Chung et al., 2009). The cells were 
injected one day after lesion and were shown to decrease the lesion volume and differentiate 
into neurons and astrocytes in the neighborhood of von Willebrand factor-positive 
endothelial cells suggesting an association with new blood vessels. 
4. HUCB in preclinical myocardial infarction research  
As shown in stroke investigations, the mechanisms by which HUCB stem cells protect 
cardiomyocytes and improve cardiac function seem to be complex and multifactorial. 
Transplanted HUCB cells can differentiate into cardiomyocyte-like cells (Cheng et al., 2003; 
Wu et al., 2006), induce neovascularization in the necrotic area (Botta et al., 2004; Ma et al., 
2005; Wu et al., 2007a), modulate the inflammatory reaction induced by ischemic cascades 
(Henning et al., 2006), and secrete growth factors including vascular endothelial growth 
factor (VEGF) (Hu et al., 2006; Tang et al., 2005). However, there are some in vitro studies 
that suggest that HUCB stem cells in culture do not differentiate into cardiomyocytes. Roura 
et al. used a number of different methods including culture of HUCB cells with 5-
azacytidine, early cardiomyogenesis growth factor cocktails, Wnt signaling activators or 
direct neonatal rat cardiomyocyte contact and did not observe any transdifferentiation 
(Roura et al., 2010). By comparison, Avitabile et al. recently reported that CD34+ HUCB cells 
adopted a cardiomyocyte-like phenotype following co-culture with mouse neonatal 
cardiomyocytes not due to transdifferentiation, but instead by cell fusion with the neonatal 
cardiomyocytes (Avitabile et al, 2011). These studies would seem to suggest that the in vivo 
influences which appear to cause transdifferentiation (Cheng et al., 2003; Wu et al., 2006), 
may not be adequately modeled in vitro. 
The optimal timing and dose of HUCB stem cell administration for treating MI are also 
critical issues as shown in the animal stroke studies. In most of the previous investigations, 
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HUCB stem cells that were administered within 24 hours after MI exerted benefits on 
cardiac function (Botta et al., 2004; H. K. Chen et al., 2005; Henning et al., 2004; Hirata et al., 
2005). By contrast, a wide range of HUCB cell numbers were examined in the MI animal 
models and functional benefits seem to be partly dose-dependent (Botta et al., 2004; H. K. 
Chen et al., 2005; Henning et al., 2004; Hirata et al., 2005; Kim et al., 2005; Ma et al., 2005). 
Meanwhile, as with stroke treatments, a variety of administration routes for HUCB cells, 
including intramyocardial injection, intracoronary injection and intravenous routes, were 
demonstrated as effective and safe. Henning et al. looked at a variety of doses and a variety 
of routes within 2 hours of ligation of the left coronary artery (Henning et al., 2007). They 
found that intramyocardial, intra-arterial and intravenous injection of cells, all produced 
similar significant reductions in infarct size when examined 1 month later, but with different 
optimum doses of cells (4 x 106, 4 x 106 and 16 x 106 respectively) and concluded that 
intramyocardial injection appeared to be best. Below we review further reports focusing on 
the delivery routes of HUCB stem cells to treat MI in animal models. 
4.1 Intramyocardial injection 
Direct transplantation of HUCB stem cells into the myocardium of the infarcted heart has 
been widely investigated in in vivo studies due to the advantage that it provides a direct 
route to the damaged area. Hirata et al. showed the therapeutic effects of HUCB CD34+ cells 
on MI in rats (Hirata et al., 2005). CD34+ cell transplantation significantly improved 
ventricular function as revealed by echocardiography and hemodynamic analysis. 
Immunohistochemistry studies for human CD34, CD45, and CD31 (Platelet endothelial cell 
adhesion molecule; PECAM-1) revealed that transplanted HUCB cells survived in the host 
rat myocardium. These findings suggest that transplanted HUCB cells survived, enhanced 
neovascularization and improved cardiac function after MI in the animal models. 
Interestingly, Higuchi et al. recently showed, using iron oxide and sodium iodide symporter 
reporter gene transfected CD34+ HUCB cells, that transplanted cells did not survive for 
more than 7 days when 4 x 106 cells were injected directly into normal rat hearts (Higuchi et 
al, 2009).  This suggests that the damaging effects of a myocardial infarction may promote 
the survival of transplanted cells. Botta et al. transplanted different subpopulations of HUCB 
cells into the peri-ischemic area at 24 hours after left anterior descending coronary artery 
(LAD) ligation in the non-obese diabetic–severe combined immune deficient (NOD-SCID) 
mouse model (Botta et al., 2004). They showed that CD34+KDR+ (kinase insert domain 
receptor) cells or CD34+ cells significantly improved the rate of rise of left ventricular 
pressure (dP/dt) and left ventricle (LV) end diastolic pressure in cardiac function after MI, 
whereas the same number of CD34+KDR- cells did not have any benefit. In histological 
studies, a limited number of human nuclear antigen positive cells were observed within the 
cardiomyocytes of mice receiving CD34+KDR+ HUCB cells. These results suggest that 
CD34+KDR+ cells are probably an active subpopulation within CD34+ cells. Their 
remarkable resistance to apoptosis and angiogenic ability may contribute to their beneficial 
effects on the damaged cardiac tissues.  
Meanwhile, Henning et al. injected 1 x 106 HUCB mononuclear cells into the infarcted 
myocardium 1 hour after rats underwent LAD ligation (Henning et al., 2004). Compared to 
the vehicle group, the ejection fraction of the HUCB cell-treated group was not decreased 
significantly at 1 month, but progressively increased at 3 and 4 months. At 4 months, in the 
HUCB cell-treated group, anteroseptal wall thickening and increased dp/dt (max) were 
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markedly greater than in the vehicle group. Infarct sizes in the HUCB cell treated group 
were smaller than the vehicle group at 3 and 4 months. These findings suggest that HUCB 
cell transplantation substantially reduces infarct size associated with improvement of left 
ventricular function in the rat MI model. Of interest, Kim et al. reported that HUCB cells 
improved cardiac function even when transplanted 4 weeks after ischemia (Kim et al., 2005). 
In this study, the distal LAD of Yorkshire pigs was occluded by endovascular coil 
embolization. Human unrestricted somatic stem cells (USSCs) isolated from HUCB 
following culturing of the mononuclear fraction under specific conditions (Kogler et al., 
2004) or culture media were directly injected into the infarcted area at 4 weeks after 
ischemia. At 4 weeks after transplantation, single-photon emission computed tomography 
technetium 99m sestamibi radioisotope scans revealed improved regional perfusion and 
wall motion of the infarct region in the cell-treated group compared to the non-treated 
control group. Ejection fraction decreased in the control group while it increased in the 
transplant group. The grafted cells were detected 4 weeks after transplantation by both 
immunohistochemistry and in situ hybridization, and they improved regional and global 
function after MI. Transplanting 1 x 105 or 1 x 106 USSCs intramyocardially, 20 minutes after 
ligation in a rat model, was recently shown to lead to a dose-dependent generation of 
human cardiomyocytes and vasculogenesis which could be detected 4 weeks later. This was 
determined by the colocalization of cardiac troponin-I and human nuclear antigen as well as 
class I HLA staining and smooth muscle actin and von Willebrand factor and human 
nuclear antigen respectively (Iwasaki et al, 2009). These findings suggest that USSCs from 
HUCB also can be a good candidate for cell-based therapies to treat MI and suggest that 
they may function to promote new blood vessel growth and cell replacement. Wu et al. also 
reported a significant improvement of cardiac function in rats with MI that were treated 
with HUCB-derived stem cells compared to the control untreated group (Wu et al., 2007b). 
Four weeks after transplantation, histological studies revealed that some of the grafted 
HUCB-derived stem cells survived in the host infarcted myocardium and accumulated 
around arterioles and scattered in capillary networks. Some of the cells expressed cardiac 
troponin-T, von Willebrand factor, and smooth muscle actin, suggesting that transplanted 
HUCB-derived stem cells in the infarcted myocardium can differentiate into cardiomyocytic, 
endothelial, and smooth muscle cells to repair damaged myocardium. The capillary and 
arteriole density were also significantly elevated in the HUCB cell-treated group, while the 
number of apoptotic cells decreased significantly. Taken together, cardiogenesis and 
angiogenesis probably exert a favorable influence on the recovery of cardiac function even 
after chronic administration of HUCB cells in the animals with acute MI. Hu et al. also 
demonstrated that angiogenesis induced by transplanted cells plays a major role in cardiac 
remodeling and improvement of cardiac function in animal MI models (Hu et al., 2006). 
HUCB mononuclear cells were transplanted into the marginal area of the infarcted 
myocardium immediately after LAD ligation. One month after MI, the grafted cells survived 
in the host heart and the collagen density in the LV was significantly lower in the 
transplanted group, which coincided with higher mRNA expression of VEGF. These results 
suggest that angiogenesis promoted by transplanted HUCB mononuclear cells in the 
infarcted area play a critical role in cardiac repair in the MI animal models. Recently, Hu et 
al. investigated the therapeutic efficacy and feasibility of intramyocardial transplantation of 
1 x 106 human umbilical cord blood-derived endothelial progenitor cells (hUCB-EPCs) in 
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rats with acute MI (Hu et al., 2009, 2010). These cells were obtained by culturing adherent 
cells from the mononuclear fraction under specific media conditions. The cell therapy group 
had increased microvessel formation and a decreased degree of myocardial fibrosis 
compared to the control non-treated group. The increased microvessel formation was shown 
to come from both upregulation of endogenous rat cells (as shown by increased rat 
proliferating cell nuclear antigen and rat PECAM expression) and colocalization of human 
nuclear antigen and CD31 and anti-VIII staining. Moreover, the degree of myocardial 
fibrosis was less than that of the control group. The improved global heart function and 
decreased cardiac fibrosis in rats with acute MI implies the potential benefit of hUCB-EPC 
transplantation. 
Meanwhile, Henning et al. revealed that the transplantation of HUCB cells attenuated the 
inflammatory and immune reaction induced by ischemic cascades (Henning et al., 2006), 
which likely contributed to the cardiac regeneration of the infarcted heart. Implantation of 
HUCB cells into infarcted myocardium of non-immunosuppressed rats within 2 or at 24 
hours after LAD occlusion, limited the expression of pro-inflammatory cytokines such as 
TNF-α, MCP-1, MIP-1α, and IFN-γ in the infarcted myocardium and it may be associated 
with significant decreases in infarct volume. Further analysis was carried out by 
transplanting 4 x 106 cells and performing cytokine analysis and inflammatory cell 
recruitment at 2, 6, 12, 24 and 72 hours after LAD ligation (Henning et al., 2008). They 
observed that the infiltration of inflammatory cells and secretion of inflammatory cytokines 
was significantly reduced by HUCB cells within 2 hours compared to non-treatment after 
LAD occlusion and this was maintained through to 72 hours. 
The number of cells required to be effective in clinical applications, is likely to mean that the 
cells would need to be expanded in vitro prior to delivery. Senegaglia et al. investigated 
whether in vitro expansion of CD133+ endothelial progenitor cells derived from HUCB 
affected their ability to improve the left ventricular ejection fraction following MI in a rat 
model (Senegaglia et al., 2010). 200,000 expanded or purified (non-expanded) cells were 
transplanted intramyocardially 7 days after infarction and the left ventricular ejection 
fraction was found to be equally improved. This suggested that in vitro expansion did not 
alter the transplanted cell’s function suggesting that it may be safe to expand these cells in 
vitro. Further studies would be necessary to see if any benefit is conferred by expansion 
(apart from the more readily available supply of cells) since the authors did report that the 
expanded cells expressed VEGF mRNA whereas non-expanded did not in vitro. However 
the expansion methods are currently not sufficiently reliable to be used routinely (see later).  
Of interest, Ma et al. compared the effects of cell transplantation between BM stem cells and 
HUCB stem cells for injured myocardium. HUCB CD133+ cells (5 x 105) were injected 
directly into the infarcted myocardium induced by cryoinjury of NOD/SCID mice (Ma et 
al., 2006a; 2006b).  An equivalent number of CD133+ BM cells were transplanted and a sham 
injection was performed in the respective control groups. Both BM CD133+ and HUCB 
CD133+ cells increased capillary density in the injured myocardium, whereas only BM 
CD133+ cells improved myocardial contractility assessed by echocardiography in vivo. 
Armiñán et al. also suggest that mesenchymal stem cells derived from bone marrow maybe 
more effective than CD34+ cells isolated from UCB following intramyocardial injection into 
a nude rat model of MI 7 days after infarction (Armiñán et al., 2010). Both cell types led to 
improved cardiac function, cardiac cell proliferation and neoangiogenesis, but the MSCs 
appeared to be more effective at reducing infarct size. However, it is important to note that 
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in their study Armiñán et al. used twice as many MSCs than CD34+ cells (1.2 x 106 vs. 6 x 105) 
making it difficult to really make a comparison. Gaebel et al. demonstrated that MSCs 
derived from 3 different sources – human BM, HUCB and human adipose tissue – were 
differentially able to heal male SCID mice after LAD ligation (Gaebel et al, 2011). 400,000 
cells were transplanted immediately after ligation and the hearts examined 6 weeks later. 
While each cell type had some benefit, the best results were seen with the BM-derived cells. 
However, they also showed that HUCB-derived MSCs had a lower proportion of CD105+ 
(endoglin, a type 1 membrane glycoprotein) cells compared to the other sources, which 
decreased further with additional passaging. A purified preparation of CD105+ HUCB cells 
was shown to possess a similar benefit as BM-derived MSCs. Endoglin is known to be 
involved in the development of the cardiovascular system and vascular remodeling, which 
may explain its apparent importance in transplanted cells (Gaebel et al, 2011). 
Using a right ventricle overload model, autologous sheep UCB mononuclear cells were shown 
to improve the diastolic properties of the right ventricle (Yerebakan et al., 2009). The authors 
suggested that this occurred due to increased angiogenesis. This is one of the few examples of 
autologous UCB cell transplantation for myocardial impairments so far reported.  
4.2 Systemic injection 
A number of studies explored the usefulness and effectiveness of the systemic route 
including intravenous and intra-arterial administration, which could have clinical potential 
because the procedure is minimally invasive and a minimal burden to the recipients 
suffering from critical diseases, even though it raises the doubt of adequate homing to the 
lesion. However, as shown in animal stroke or MI models, there has been emerging 
evidence suggesting that a significant proportion of the HUCB cells which are systemically 
administered, will migrate into the infarcted brain or heart lesion and the animals show 
improvement in their behavioral deficits.  
Ma et al. revealed the homing ability of HUCB mononuclear cells that were injected in the 
tail vein of NOD/SCID mice that had (MI+) or had not (MI–) received ligation of the LAD 
(Ma et al., 2005). Human DNA (hDNA) was detected in marrow, spleen, and liver of both 
MI+ and MI– mice from 24 hours to 3 weeks after cell injection. By contrast, hDNA was 
found in the hearts of 53% of MI+ mice but in none of the MI– mice. Infarct size was smaller 
and collagen deposition was reduced in the cell-treated group. Capillary density in the 
border zone of the MI was approximately 20% higher, and clusters of HUCB-derived cells 
were detected in the perivascular interstitium in cell-treated MI+ mice, though the vast 
majority of new vessels seemed to originate from the endogenous mouse cells. There was no 
evidence of cardiomyocyte differentiation of the intravenously grafted HUCB mononuclear 
cells. Interestingly, in infarcted myocardium, stromal cell-derived factor (SDF)-1 mRNA was 
expressed approximately 7-fold higher than in normal hearts. These results suggest that 
systemically administered HUCB cells can migrate into the faraway infarcted lesion where 
they play a role in neovascularization, and beneficially influence tissue-remodeling 
processes. Leor et al. administered HUCB-derived CD133+ progenitor cells intravenously at 
7 days after permanent coronary artery ligation in athymic nude rats (Leor et al., 2006). One 
month after transplantation, LV fractional shortening was much improved. Moreover, 
anterior wall thickness decreased significantly in control group but not in HUCB cell-treated 
group. The grafted HUCB cells were found to have migrated and survived in the infarcted 
myocardium on microscopic examination. Human originated-cells were detected near vessel 
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walls and LV cavity in the HUCB cell-treated rats. They were incorporated into endothelial 
cells in six out of the nine cell-treated animals. Scar tissue from cell-treated animals was 
significantly populated with autologous myofibroblasts as indicated by colocalization of 
HLA-DR and alpha-smooth muscle actin staining. These findings suggest that intravenous 
transplanted HUCB cells can migrate, survive, and be incorporated into the host 
myocardium and produce functional recovery in animal MI models.  
A couple of studies focused on the mechanisms of how the systemically transplanted HUCB 
cells are recruited into the site of tissue damage. Henning et al. revealed that the greatest 
HUCB cell migration into the infarcted myocardium persisted at 2 and 24 hours after LAD 
occlusion (Henning et al., 2006). Increased SDF-1 in the infarcted myocardium attracts 
circulating stem cells through the CXCR4 receptor, leading to activation of surface integrins 
and subsequent recruitment into the vasculature (Ma et al., 2005). These findings suggest 
that the recruitment of transplanted cells to the injured site was likely due to the 
concentrations of chemoattractants within the ischemic and infarcted tissues. 
Another study using an unspecified number of cells attempted to explore the optimal time 
for transplantation via the caudal vein (Xing et al., 2009). They injected HUCB cells 1, 5, 10 
or 30 days after LAD ligation and they measured cardiac function 4 weeks later. Animals 
transplanted 5 and 10 days after LAD ligation showed improved cardiac function, with the 
best results occurring in the 10 day transplant animals. The best survival, more pronounced 
angiogenesis and VEGF expression was observed within these animals, though no evidence 
of cardiac regeneration was seen. The authors proposed that the angiogenic effects were the 
main cause of the improvement. It is worth noting that the authors characterized the cells 
prior to transplantation and showed that only 35-42% of the cells were CD34+.  
Lineage-depleted HUCB cells that express high levels of the cytosolic enzyme aldehyde 
dehydrogenase (ALDH) were found to possess a high long term repopulation potential 
whereas cells with low levels of ALDH had negligible long term repopulation potential 
(Sondergaard et al., 2010). Intravenous administration of these cells one day after LAD 
ligation in NOD/SCID mice showed specific localization to the injured area within 48 hours 
and engraftment was higher 4 weeks later using the high ALDH expressing population 
compared to the low expressing population (Sondergaard et al., 2010). However none of the 
transplanted cells were observed to became cardiomyocytes, but a few became endothelial 
cells and the surviving cells were associated with increased vascular density. It is worth 
noting that only a small number of cells were transplanted (~400,000 cells), which may not 
be sufficient to see the best effects when administered systemically. These studies show that 
there are a number of cell types in HUCB which differ in their CD markers and enzyme 
levels which could affect their ability to be effective.  
4.3 Intracoronary delivery 
Intracoronary injection can be classified as via the systemic route as it is a subtype of intra-
arterial infusion. This method is somewhat more complicated than peripheral access, but 
can easily be accomplished within several minutes in a well-equipped coronary suite with 
well-trained physicians. Thus, this method is directly applicable to the real clinical situation. 
Moreover, intracoronary delivery has an advantage over the intravenous route since the 
stem cells can be delivered directly to the infarcted myocardium without passing through 
the systemic circulation. This aspect alleviates the possibility of systemic cell loss such as cell 
trapping within the lungs and spleen. However, there is also a disadvantage with intra-
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arterial infusion, since the transplanted cells can form clumps or aggregates if very large 
quantities of cells are infused, which can subsequently become an embolus (Qian et al., 
2006).  
While a number of studies have examined the feasibility and efficacy of intracoronary 
infusion of BM stem cells or peripheral blood-derived mononuclear cells for treating MI in 
animal and human models (Bartunek et al., 2005; Manginas et al., 2007; Qian et al., 2006), 
there are few published studies using HUCB cells. Moelker et al. failed to show 
improvement of LV function by intracoronary administration of HUCB cells after MI 
(Moelker et al., 2007). In this study, approximately 108 HUCB stem cells were injected via the 
intracoronary route 1 week after MI and reperfusion in a swine model. By this time point, 
end-diastolic volume and LV mass were larger, while ejection fraction was smaller. Regional 
wall thickening in the left circumflex coronary artery area became akinetic. There was no 
difference in global and regional LV function at 5 weeks between MI animals receiving 
HUCB stem cells or normal medium, while surprisingly the infarct size after HUCB stem 
cell treatment was significantly larger. Transplanted HUCB cells survived only in the infarct 
border zone at 5 weeks and did not express cardiomyocyte or endothelial markers. Of 
interest, histological examination revealed that HUCB stem cells transplanted through 
intracoronary infusion caused micro-infarctions by obstructing vessels. Although the 
feasibility and efficacy of intracoronary delivery of HUCB could not be determined because 
there has been few studies about this issue, these results raise safety concerns due to embolic 
infarction related with the high dose of transplanted HUCB cells required for the 
intracoronary route (Moelker et al., 2007; Qian et al., 2006). 
4.4 Tissue engineering and gene modification 
Recent investigations focusing on gene therapy or tissue engineering demonstrate that the 
combination of stem cell and gene modification may be a useful treatment modality for MI 
treatment (Mangi et al., 2003; Matsumoto et al., 2005). However, gene manipulation of stem 
cells outside the body and in the laboratory before transplantation raises safety problems as 
well as possible moral and ethical concerns when it is applied clinically. 
Cortes-Morichetti et al. examined the feasibility of a collagen matrix seeded with HUCB 
stem cells and their engraftment onto infarcted ventricles (Cortes-Morichetti et al., 2007). 
Echocardiography and histological examination implied that the cell-loaded matrix and the 
cell implants appeared to be an effective alternative to prevent post-MI ventricular dilation 
and cardiac remodeling compared to either HUCB cells or collagen matrix alone-treated 
groups. These results suggest that stem cell implantation accompanied with tissue 
engineering techniques, probably augment the efficacy of simple cellular therapy and could 
emerge as a new therapeutic modality to prevent adverse remodeling and progressive heart 
failure. 
Meanwhile, Chen et al. studied the efficacy of HUCB cells with genes inserted to overexpress 
angiogenic factors that were subsequently transplanted into infarcted ventricles (H. K. Chen 
et al., 2005). In this study, HUCB CD34+ cells were transfected with adeno-associated virus 
(AAV) vectors encoding either human angiopoietin (Ang1; AAV-Ang1) or VEGF (AAV-
VEGF) cDNA alone, or both combined (AAV-Ang1 plus VEGF). After LAD ligation in SCID 
mice, they administered the expanded CD34+ cells transduced with AAV-Ang1, AAV-VEGF 
or AAV-Ang1 plus VEGF intramyocardially at the left anterior wall. Western blot analysis 
revealed that Ang1 and VEGF expressions were increased in the CD34+ cells transduced 
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with AAV-Ang1 and AAV-VEGF, respectively. Infarct size significantly decreased and 
capillary density remarkably increased after treatment with CD34+/AAV-Ang1 plus VEGF 
compared to the treatment with CD34+ cells only. Combination therapy with CD34+/AAV-
Ang1, CD34+/AAV-VEGF, and CD34+/AAV-Ang1 plus VEGF, all expressed remarkably 
higher cardiac performance in echocardiography than the CD34+ cells alone 4 weeks after 
MI. These results suggest that combination therapy with HUCB CD34+ cells and 
overexpression of both Ang1 and VEGF genes decreases infarct size, improves cardiac 
dysfunction and elevates capillary density in acute MI in mice to a greater extent compared 
to HUCB hematopoietic stem cell only transplantation. 
Pretreatment of HUCB cells with oxytocin prior to transplant has been shown to promote 
their activity. Oxytocin stimulates cell proliferation and may promote cardiomyogenesis 
(Kim et al., 2010). Kim et al. transplanted 106 pretreated cells intramyocardially after LAD 
ligation and found that cardiac fibrosis and macrophage (CD68+) infiltration was reduced by 
oxytocin pretreatment. Engraftment, connexion 43 expression and cardiac contractility were 
increased, but angiogenesis did not appear to be altered in animals administered pretreated 
cells (Kim et al., 2010). This suggests that oxytocin pretreatment may increase the 
proliferation and differentiation of the transplanted cells, but does not appear to influence 
blood vessel growth.  
5. Conclusions 
Ischemic insults to neural tissue and the myocardium involve complicated inflammatory 
cascades that eventually lead to a pronounced cell death adjacent to the obstructed 
vasculature. The appropriate delivery of HUCB cells most likely prevents the apoptotic 
cascade, regenerates damaged cells and tissues, and modulates the inflammatory response 
to ischemic injury. Another advantage in using HUCB cells for the treatment of ischemic 
damage is the potential restoration of vascularity since cord blood contains endothelial 
progenitor cells and hematopoietic stem cells which may be of use in neovascularization 
therapy.  
However, there are still a number of obstacles that prevent the routine application of HUCB 
cell transplantation to treat human stroke or MI patients as follows. First, safety has not been 
effectively determined in terms of immunological rejection when allogeneic transplantation 
is considered. HUCB cells are likely to be used primarily for transplantation into allogeneic 
recipients, though as HUCB cell banking becomes more popular autologous transplants 
may become more common in the future. Although HUCB cells are less immunogenic, long 
term studies should be considered to evaluate the long term safety with or without 
immunosuppression. Jozwiak et al. and Yang et al. have reported on using HUCB cells for 
the safe treatment of a single case of global brain ischemia and in a number of neurological 
disorders (including stroke) respectively with short term follow-up (Jozwiak et al., 2010; 
Yang et al., 2010). Second, because HUCB collection can only be performed at single time-
points (i.e. during birth), and the number of stem cells extracted from one donor is very 
limited, expansion of the stem cells is mandatory. Unfortunately, current methods of 
expanding HUCB cells do not preserve the quality of the hematopoietic progenitor cells 
through to the end product (Jaroscak et al., 2003; Robinson et al., 2005). Current expansion 
methods cannot make up for the cells lost in the storage process, let alone augment them to 
a suitable dosing regimen (Hows et al., 1992; Liu et al., 2006; Traycoff et al., 1995; Yao et al., 
2006). However, in the last couple of years, there have been several studies looking at ways 
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to maximize yield, storage and recovery, and expansion which require validation (Gonzalez 
et al., 2010; Koestenbauer et al., 2009; Lin et al., 2010; Song et al., 2010; Vanneaux et al., 2010; 
Zeisburger et al., 2010). Third, the cause of limited graft survival in the recipient remains to 
be determined even though the paradigm of underlying mechanisms on the functional 
improvement after stem cell transplantation has been changed from cell replacement to a 
paracrine bystander effect. The longer the grafts survive, probably the better the 
neurological or cardiac function recovers. When these hurdles are overcome in the not too 
distant future, HUCB cell therapy may become a promising treatment modality for ischemic 
diseases including stroke and MI with multiple therapeutic potentials and a longer effective 
time frame in a single transplant that no other currently available pharmacological agent 
could mimic. 
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1. Introduction  
Despite significant progress in medical research, which has led to lower infant mortality 
rates and increased life expectancy, cardiovascular diseases (CVDs) continue to be the 
largest contributors of morbidity and mortality in both developed and developing countries. 
In fact, they are predicted to be the leading cause of death by 2020 and responsible for 13.4% 
of total world-wide deaths by 2030. These diseases have a multifactorial origin, notably non-
modifiable cardiovascular risk factors (CRFs) such as age, sex, race or family history, and 
modifiable CRFs, including smoking, hypertension, hypercholesterolemia, diabetes mellitus 
or hypertriglyceridemia (Picariello et al., 2011; Glynn  &  Rosner, 2005). 
Currently, there are no effective treatments available for many degenerative diseases caused 
by the death or malfunction of specific cells. In this regard, the main physiopathology of 
CVDs is related to ischaemic heart disease, and approximately two-thirds of patients 
surviving an acute myocardial infarction (AMI) are left with debilitating congestive heart 
failure. AMI causes apoptosis and necrosis of cardiomyocytes, a specialized and 
differentiated cell population responsible for ventricular contraction, the main event of 
cardiac function. The low self- renewal rate of these cells (~0.06% of the total population of 
cardiomyocytes under normal conditions) produces, in cases of acute stress, the ventricular 
remodelling of non-ischaemic myocardium with scar formation, increasing the likelihood of 
a new crisis, progressive ventricular dilatation and heart failure, ending in death (Torella et 
al., 2007). 
Organ transplantation is an appropriate therapeutic strategy for patients who have suffered 
end-stage heart failure and are unresponsive to conventional therapy but has drawbacks 
related to donor incompatibility, which can lead to rejection and eventually to Graft Versus 
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Host Disease (GVHD), among other conditions. However, there are a number of 
preoperative and postoperative risks, besides the major challenge of finding an optimal 
donor heart and the elevated healthcare costs involved (currently ranging from 27,839 € and 
51,575 € per patients), especially in view of the uncertain long-term outcomes of the 
procedure (Pérez -Romero et al., 2010). 
1.1 Worldwide costs: The DALY factor 
Besides the elevated mortality rates associated with CVDs, they contribute significantly to 
the burden of disability and disease in developing countries. In an update on the global 
burden of disease in 2004, the WHO provided a comprehensive assessment of the causes of 
loss of health in different regions of the world, demonstrating that the leading cost of the 
death in developed or high-income countries is heart disease, followed by stroke, lung 
cancer, pneumonia and asthma or bronchitis (WHO, 2004). The most widely-used measure 
of this burden is the life expectancy adjusted for disability (DALY), defined as the sum of 
life years lost due to premature death and years lost to disability. CVDs are considered to 
represent 86% of the total DALY-estimated disease burden among under 70-year-olds 
worldwide, indicating that global CVD-related deaths will rise from the 16.7 million 
estimated in 2002 to 23.3 million in 2030. 
1.2 Regenerative biomedicine: Breaking down old paradigms? 
Over the past decade, new therapeutic strategies have been proposed against diseases with 
an elevated prevalence world-wide for which standard treatments are not very effective, 
resulting in the emergence of a new medical science known as regenerative medicine. 
Scientific evidence has demonstrated that novel therapeutic solutions can be obtained for 
pathological situations with no current treatment and that existing therapies can be 
enhanced by the utilization of autologous or allogeneic stem cell transplantation. These 
derive from the discovery of adult stem cell populations in organs well known for their non-
existent regeneration capacity, such as the heart and brain, which correlate with their early 
development in the embryo stage. Thus, some cardiomyocytes with proliferative capacity 
have been found in the heart after a myocardial infarction, although inadequate to meet 
requirements after an extensive AMI. 
The discovery of multipotent cell populations in adult tissues has opened up new 
therapeutic possibilities for diseases that do not respond to conventional medical 
treatments. The ethical and legal issues involved in the use of embryonic stem cells (ESCs), 
the recently disclosed plasticity of adult-derived stem cells, their ability to be reprogrammed 
by defined factors into pluripotent stem cells and a greater understanding, thanks to a 
multidisciplinary approach, of the mechanisms underlying stem cell differentiation have led 
to the birth of the “Regenerative Medicine” concept. Unlike many existing products and 
therapies, this approach offers the potential for regenerative rather than merely palliative or 
symptomatic treatment. This novel specialty includes gene therapy, stem cell therapy, 
targeted drug therapy and cell reprogramming. 
This emerging field seeks the maintenance, improvement or restoration of cell function, 
tissues and organs by applying methods mainly related to cell therapy and tissue 
engineering (Greenwood et al., 2006). The ultimate goal is to repair, replace or regenerate 
cells, tissues or organs that have lost their normal function. The essential elements for the 
success of regenerative medicine include cells, soluble molecules and three-dimensional 
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scaffolds that serve as anchor and stimulation for new tissue formation. In relation to CVD, 
the regeneration of vascular and myocardial tissues is considered a primary endpoint to 
limit the consequences of acute and chronic ischaemic heart disorders. Current clinical 
approaches include transdifferentiation techniques and the utilization of organic scaffolds 
(e.g., vessels or even the whole heart) by means of decellularization methods. 
2. Stem cells and cardiovascular diseases 
Stem cells are unspecialized cells that can renew themselves through cell division or can be 
differentiated to become tissue- or organ-specific cells with special functions (Wobus &  
Boheler, 2005). Up to the 8-cell morulla stage, cells in the embryo are totipotent and can 
produce the whole organism. Their utilisation is limited by ethical issues and current 
legislation in developed countries, besides inadequate knowledge of their behaviour and 
action mechanisms and of their impact on the body homeostasis.  
Stem cells derived from the inner cell mass (ICM) of the blastocyst are no longer totipotent 
but they are pluripotent, having the ability to differentiate into all cell types of the body. 
These cells include human embryonic stem cells (hESCs) and induced pluripotent stem cells 
(iPSCs). hESCs are capable of proliferating extensively in an undifferentiated state and in co-
culture on fibroblast ‘feeder’ cells, and have the ability, once removed from feeders and/or 
grown in suspension as aggregates [called EBs (embryoid bodies)], to differentiate towards 
all three germ layers, and they can, in principle, give rise to all cell types of the body. hESCs 
contain factors that can induce reprogramming of the somatic cell nucleus (Allegrucci & 
Young, 2007; Cowan et al., 2005). Therefore, somatic cell fusion with ESCs regenerates 
pluripotent cells. However, pluripotent cells obtained by fusion contain both chromosomes 
from the ESCs and from the somatic cell, causing their post-implantation rejection 
(Takahashi & Yamanaka, 2006). 
iPSC technology  was developed to avoid these problems, generating a new type of 
pluripotent stem cell by directly reprogramming somatic cells rather than using embryos. It 
allows patient-specific stem cells to be obtained by using the same genome as that of the 
individual whose cells have been reprogrammed. Besides adult and foetal dermal 
fibroblasts, iPSCs have been created from multiple human tissues, including lung 
fibroblasts, keratinocytes (Aasen et al., 2008), fibroblast-like synoviocytes (Takahashi et al., 
2007), cord blood (Giorgetti et al., 2009; Haase et al.,2009) , peripheral blood (Loh et al., 2009, 
Ye et al., 2009) mesenchymal stromal cells (Oda et al., 2010), oral mucosa fibroblasts 
(Miyoshi et al., 2010) and T-cells (Loh et al., 2010; Seki et al., 2010). These cells can be 
differentiated and can serve as a cell or disease model or may even lead to future stem cell 
therapies (Dimos et al., 2008, Park et al., 2008). However, there are a number of drawbacks 
in the use of retroviral vectors to create iPSCs, and considerable efforts have been made to 
find alternatives. 
In addition, certain organs have multipotent stem cells with more limited differentiation 
ability (Wobus & Boheler, 2005), including foetal and adult stem cells obtained from bone 
marrow (BM) and postnatal organs and tissues. Stem cells of foetal origin express stem cell 
markers similar to hESCs, while their differentiation potential lies between that of hESCs and 
that of adult stem cells (Pappa & Anagnou, 2009). BM contains two types of multipotent stem 
cells: hematopoietic stem cells (HSCs), which give rise to all blood cell types (Orkin, 2000) and 
human mesenchymal stromal cells (hMSCs), which can be differentiated into multiple 
mesenchymal tissue cell types such as bone, cartilage, fat and muscle cells (Liu et al., 2009).  
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2.1 The quest for an optimal adult stem cell type: Cardiac Stem Cells (CSC) 
Although many different cell types have been considered for myocardial repair, the ideal 
candidate remains elusive. Adult cardiomyocytes are unable to survive, even when 
transplanted into normal myocardium, and the resident population of cardiac progenitors is 
insufficient after AMI. Therefore, researchers continue to search for the optimal cell type for 
myocardial repair, using various types of adult stem cells obtained from different sources, 
such as HSCs, endothelial progenitor cells (EPCs), cardiac stem cells (CSCs), muscle-derived 
stem cells (MdSTs), and MSCs. MSCs are frequently selected for their multiple advantages, 
such as their multiple anatomical localizations, easy isolation and cryopreservation, and 
paracrine potential. 
The characteristics of CSCs make them an excellent candidate for cardiac regeneration. CSCs 
isolated from myocardial biopsies (Smith et al., 2009) express stem cell factor receptor (c-Kit) 
(Bearzi et al., 2007) and stem cell antigen-1 (Sca-1) on their cell surface (Iwakura et al., 2011). 
A direct relationship has been demonstrated between higher patient age and a smaller 
population of these cells, which represents a drawback for their therapeutic application, 
given that the main incidence of CVDs is among the middle-aged. However, intensive work 
is ongoing to activate these cells to proliferate and differentiate in situ using different 
techniques, such as induction with 5-azacytidine (5-aza), a potent inhibitor of DNA 
methyltransferase (DNMT1), in combination with TGF-β1 and vitamin C (Smits et al., 2009). 
Recent proposals include the use of hyperpolarization to differentiate CSCs into the cardiac 
phenotype, changing charges in the membrane potential (specific for each cell type) to 
enhance intracellular calcium levels and calcineurin signalling in CSCs and, more 
importantly, to upregulate the expression of cardiac-specific genes and proteins, leading to 
the formation of spontaneously beating cardiomyocytes (Van Vliet et al., 2010). Nonetheless, 
the specific capabilities of functional cardiac cells from these progenitors need to be more 
thoroughly studied (Gonzales & Pedrazzini, 2009). 
2.2 Adult stem cell transplantation: Paracrine effects or change in phenotype?  
Recently, cell-based therapeutic strategies have been aimed at replenishing the loss of 
myocytes by apoptosis and necrosis and at inhibiting the adverse effects of cardiac 
remodelling (Singla, 2009). Some studies have demonstrated improvement in ventricular 
function as an achievement of cardiac regeneration (Singla, 2009, Kumar et al., 2005). 
However, if a real clinical translation is to be achieved, researchers must follow strict criteria 
for the selection of an appropriate source of stem cells, taking full account of patient safety, 
production methods, and ethical and legal norms. It is necessary to establish an in vitro 
differentiation strategy to transform these cells into functional cardiomyocytes that can 
integrate in a damaged heart and exert therapeutic action. 
The benefits of stem cell transplantation remain controversial and appear to depend on 
three mechanisms. First, the transplanted stem cells must be able to differentiate, even at a 
low rate, into heart or vascular cells. A second mechanism involves the immune and 
paracrine functions of stem cells and their interactions with an environment subject to 
cellular damage, with the transplanted cells having the capacity to induce the secretion of 
growth factors and cytokines that stimulate tissue repair after ischaemic injury, reducing the 
size of infarction. Finally, the pre-treatment of stem cells by transdifferentiation methods has 
been shown to produce a population of cells in pre-differentiated state, allowing their 
acquisition of the cardiac phenotype after transplantation. However, key issues have not yet 
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been elucidated, including identification of the most appropriate cell types or the factors 
released by stem cells and their role in cardiac repair and regeneration. The methods 
described below were conducted using hMCSs, which appear to be promising candidates 
for clinical translation, given their multipotency and ready availability, e.g., via liposuction. 
2.2.1 Direct transplantation and cell tracking  
Cell transplantation is emerging as a potential therapy to treat heart failure. Initial efforts 
have been focused on the cardiomyocytes and skeletal myoblasts. However, the 
mechanisms and the outcomes of transplanted cells during cardiac regenerative therapy 
remain unclear. In order to achieve the optimal concentration of stem cells for repairing the 
myocardial region of interest, cell delivery strategies need to consider different clinical 
settings and local milieus. Stem cells are believed to respond differently according to local 
signalling, and the success of transplantation depends to a large degree on damage 
signalling in the wounded area. In cardiovascular research stem cells have been delivered 
through coronary arteries or coronary veins or by means of peripheral-vein infusion. 
Alternatively, direct intramyocardial injections have been performed, utilizing a surgical, 
transendocardial, or transvenous approach. Delivery strategies also include the mobilization 
of stem cells from the bone marrow by means of cytokine therapy, with or without 
peripheral harvesting. In pre-clinical studies, when BM–derived hematopoietic cells were 
transplanted directly into the hearts of mice with AMI, no transdifferentiated BM–derived 
cardiomyocytes were found in the damaged myocardium. However, cell fusion has been 
found to occur at very low levels between BM–derived cells and host cardiomyocytes 
outside the infarction area (Nygren et al., 2004). A similar approach has been adopted using 
skeletal myoblast precursors. BM-stem cell (SC) transplantation has been the most widely 
used methodology in clinical studies, as shown in Table 1, although its association with 
arrhythmogenesis, among other adverse effects, has generated major controversy about its 
benefits. 
The main problem with these methods is the lack of knowledge on the behaviour and 
integration of the transplanted stem cells. Many studies have relied simply on the presence 
of histological differences between hearts receiving cell transplants compared with non-
transplanted patients (control group). However, the preferred approach is to utilize 
molecular analyses that are able to distinguish donor and host cells. For instance, treating 
donor cells with fluorescent cell-tracking dyes prior to transplantation has been used to 
monitor their survival in vivo. Because there is typically a high degree of donor cell death 
following transplantation, caution must be exercised to ensure that the observed signal 
arises from donor cells rather than from host cells, which have acquired dye released from 
dead or dying donor cells. Intrinsic genetic differences between donor and host cells as well 
as gene transfer have also been employed to monitor cell fate following transplantation (Lee 
& Segers, 2008). Hence, innovative non-invasive imaging techniques to effectively track the 
cells in vivo are vital for the adequate investigation of possible clinical applications, 
furnishing insights into the mechanisms underlying stem cell-based therapy and addressing 
some of the major concerns about translational cardiovascular stem cell therapy. Currently, 
there are three main approaches to stem cell tracking: (1) radioactive labelling for positron 
emission tomography (PET) and single photon emission computed tomography (SPECT) 
imaging, (2) iron particle labelling for magnetic resonance imaging (MRI), and (3) reporter 
gene labelling for bioluminescence, fluorescence, MRI, SPECT and PET imaging. 
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ADRCs: Adipose-Derived Stem and Regenerative Cells; EPC: Endothelial progenitor cells; BM-SCs: 
Bone Marrow stem cells; MSCs: Mesenchymal stromal cells; G-CSF: Granulocyte Colony Stimulating 
Factor; STEMI: ST-Elevation Myocardial Infarction; PCI: Percutaneous Coronary Intervention; CAD: 
Chronic Coronary Artery Disease; CABG: Coronary Artery Bypass Graft; IC: Intracoronary; IM: 
Intramyocardial; LVEF: Left Ventricular Ejection Fraction. 
Table 1. Closed/Not  recruiting  autologous cell therapy trials in patients with coronary 
heart disease or AMI 
2.2.2 Paracrine and immunology features  
Two important features of MSCs are their immune-privileged and immunosuppressive 
functions. These qualities are very attractive for cell-based therapy because they may 
facilitate the use of allogeneic rather than autologous cells, which offers many potential 
advantages. Thanks to their immunosuppressive capacity, they may also suppress the 
immune response to cell injections or to the damaged myocardium itself during myocardial 
infarction. Findings by Aggarwal and Pittengerin on the lack of T-cell response to allogeneic 
hMSC transplantation indicated that these cells can modify the immune response in a dose-
Therapeutic Approaches in Regenerative Medicine  
of Cardiovascular Diseases: From Bench to Bedside 
 
67 
dependent manner and can reduce the inflammatory response when present in appropriate 
amounts. Phase III clinical trials are under way on the optimal MSC regimen to prevent or 
treat GVHD during allogeneic HSC transplantation (Aggarwal & Pittenger 2005). 
Secreted growth factors and cytokines are known to be important signalling molecules for 
modulating acute and chronic immune responses (Table 2). With regard to their 
immunomodulatory properties, MSCs inhibit T-cell proliferation and influence the maturation 
and expression profile of antigen-presenting cells such as dendritic cells. Research on the 
paracrine effect of MSCs in rat AMI models, using intramyocardial injection of culture 
medium with MSC-secreted growth factors and cytokines (conditioned medium), 
demonstrated their role in stromal network creation, neovascularization enhancement, 
angiogenesis promotion, and cardiac function improvement. Paracrine effects of MSCs may 
include the activation of different mechanisms against cell damage. Therapeutic models have 
shown that MSCs are recruited to infarction areas by the hepatocyte growth factor (HGF), 
which is released during necrosis and apoptosis and acts as a “homing signal”. This migration 
of MSCs depends on interaction with c-Met, an HGF receptor (Parekkadan & Milwid, 2010).  
 
Growth factors and cytokines Functions References 
M-CSF, G-CSF, GM-CSF, SCF-1, 
LIF, SDF-1, Flt-3, IL 1, 6, 7, 8, 11, 
14 and 15. 
Signalling molecules 
and modulation of 
acute and chronic 
immune response. 
Sumanasinghe et al., 2009 
Kim et al., 2005. 
VEGF, bFGF, PLGF and MCP-1. Vasculogenesis and angiogenesis Kinnaird et al., 2004. 
M-CSF: Macrophage Colony-Stimulating Factor; G-CSF: Granulocyte Colony-Stimulating Factor; GM-
CSF: Granulocyte Macrophage Colony-Stimulating Factor; SCF-1: Stem Cell Factor; LIF: Leukemia 
Inhibitory Factor; SDF-1: Stromal Cell-Derived Factor-1; Flt-3: FMS-like tyrosine kinase 3; IL: 
Interleukin; VEGF: Vascular Endothelial Growth Factor; bFGF: basic Fibroblastic Growth Factor; PLGF: 
Placental Growth Factor; MCP-1: Monocyte Chemoattractant Protein-1 
Table 2. Paracrine activity of MSCs 
MSC-derived conditioned medium promotes the proliferation of CSCs and inhibits the 
apoptosis of CSCs induced by hypoxia and serum starvation. An upregulated expression of 
cardiomyocyte-related genes was also found in CSCs, including b-myosin heavy chain (b-
MHC) and atrial natriuretic peptide (ANP), demonstrating the protective effects of this 
medium on CSCs and the enhancement of their migration and differentiation (Nakanishi et 
al., 2008). Preliminary results of in vitro assays with human adipose-derived mesenchymal 
stromal cells (hADSCs) by our group indicate that cytokine- and growth factor-rich 
conditioned media obtained from human cardiomyocytes in culture influence the 
acquisition of cardiac phenotype by hADSCs (unpublished data). 
2.2.3 Cardiac regeneration: A transdifferentiation phenomenon  
Regenerative biomedicine efforts have focused on attempts to reverse heart muscle failure 
by increasing the amount of human functional heart muscle through the transplantation of 
various adult stem cell types, notably CSCs, skeletal myoblasts, endothelial stem cells, and 
MSCs. BM stem cells have been reported to offer a wide range of benefits in blood cell 
diseases, but the action mechanisms underlying the change in phenotype have not been 
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clarified. In vivo transplantation studies have shown that MSCs can replenish the whole BM 
system in irradiated rodents and generate not only mesodermal cells but also cells with the 
characteristics of neural progenitors and neurons (Song & Tuan, 2004). 
In this type of cross-lineage differentiation, also known as transdifferentiation, one cell type 
committed to and progressing along a specific developmental lineage is switched into 
another cell type from a different lineage by genetic reprogramming. This depends on the 
ability of adult stem cells to maintain their multidifferentiation potential even after exposure 
to specific inductive factors (Song & Tuan, 2004). 
The conversion from adult differentiated cells must involve both the suppression and 
regulation of different genes in the cells, implying that genes from both cell types are co-
expressed at some point. This phenomenon is currently under investigation by various research 
groups in an attempt to establish its true therapeutic value. Transdifferentiation studies have 
supported the notion that cell fate is controlled by master switch genes and that one or two 
factors can be sufficient to direct cells from one lineage to another (Burke & Tosh, 2005). 
 
 
Fig. 1. Guided cardiopoiesis. This diagram depicts the effects of cytokines in MSCs cultures.  
This process involves cardiopoiesis, defined as the final engagement of pluripotent or 
multipotent stem cells in the cardiac differentiation program. Cardiopoietic specification is 
based on emulation of the natural cardiac development in the embryo, which takes place in 
the mesoderm under the cardioinductive influence of the neighbouring endoderm (Figure 
1). Cardiopoietic guidance emulates natural cardiac differentiation and can be achieved by 
stimulating stem cells with TGF-β1, BMP-2/4, FGF-2/4, IL-6, IGF-1/2, VEGF-A, EGF and 
activin-A. The identification of these factors has enhanced our understanding of the 
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mechanisms involved in differentiation and the signals that play a role in heart development 
(Behfar et al., 2010). 
3. From the bench: Current status  
Greater knowledge of heart development in the embryo and of the effects of the 
microenvironment on cardiac maturation has prompted researchers to reproduce these 
processes in the laboratory by means of different transdifferentiation techniques (Figure 2). 
Some of them have attempted to recapitulate the activation of cell signalling cascades 
involved in heart development (e.g., TGF-β and Akt) through the expression of GATA4, 
Mef2c and FGF 8/10 growth factors. A wide range of cell types and methods have been 
used to achieve the cardiac phenotype. In this regard, there is major interest in the novel 
technique developed by Takahashi & Yamanaka (2006), to induce pluripotency by 
reprogramming fibroblasts with key factors Klf4, Sox2, Oct4 and c-Myc. It is expected that 
the ability to derive patient-specific hiPSCs by somatic cell reprogramming may be useful 




Fig. 2. Methods used to transdifferentiate MSCs to cardiomyocyte like-cells 
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3.1 Transdifferentiation methods using adult stem cells  
3.1.1 Use of allograft cardiac tissue: The co-culture and cell extracts methods  
The co-culturing of two different cell types, such as cardiomyocytes isolated from human 
biospies and hMSCs, which are grown together but separated by a membrane (with 0.4 – 0.3 
μm pore size to avoid direct cell-to-cell interaction), has revealed the importance of the 
microenvironment in stem cell differentiation. This method is used to determine whether 
soluble chemical factors released from one cell type (which can diffuse though the 
membrane) are sufficient to induce transdifferentiation of the other cell type. Using this 
mechanism, Wang et al. (2006) showed in vitro the differentiation of BM stem cells into 
cardiomyocyte-like cells with expression of cardiac-specific genes. Similar results have been 
obtained by various authors (Antonitsis et al., 2007; Rangappa et al., 2003).  
In the cell extract method, the intracellular components of one cell type are introduced into 
another cell type in order to switch from one cell pattern to another. Purified somatic nuclei 
or reversibly permeabilized somatic cells are incubated in a nuclear and cytoplasmic extract 
derived from a different cell type. The extract is believed to provide nuclear regulatory 
components that mediate alterations in the gene expression profile of the target genome. 
After exposure to the extract, the cells are resealed in a culture that contains calcium. By this 
means, hADSCs produced cardiomyocyte proteins after incubation with rat cardiomyocyte 
extracts. The success of these transdifferentiation strategies was demonstrated by 
observations of morphological changes, by findings on donor cell-specific genes, and by 
immunological evidence of alterations in protein expression (Gaustad et al., 2004). 
Our group reported that adult cardiomyocytes obtained from human donors retain their 
capacity to induce cardiomyocyte differentiation of MSCs. Human adipose stem cells 
(hASCs) isolated from lipoaspirates were transiently permeabilized, exposed to human 
atrial extracts and then allowed to recover in culture. After 21 days, the cells acquired a 
cardiomyocyte phenotype, as demonstrated by morphologic changes (appearance of 
binucleate striated cells and branching fibbers), immunofluorescence detection of cardiac-
specific markers (connexin-43, sarcomeric α-actinin, cardiac troponin I and T and desmin) 
and the presence of cardiomyocyte-related genes (cardiac myosin light chain 1, α-cardiac 
actin, cardiac troponin T and cardiac β-myosin). The relevance of these findings lies in the 
potential use of autologous extracts to induce stem cell reprogramming (Perán et al., 2010). 
In conclusion, both techniques have an interesting potential in a therapeutic framework, due 
to their capacity to avoid immunologic responses from patients and produce a good clinical 
outcome. 
3.1.2 Use of 5 –azacytidine and growth factors  
The acquisition of a cardiac phenotype has been induced by the use of demethylation agents 
such as 5-aza, a cytosine analogue that can reduce DNA methyltransferase activity in the 
cells (Quian   et al., 2011). However, in vivo studies with 5-aza showed that specific proteins 
were expressed in myocytes near the injection site in the myocardium, but these cells lacked 
the complete acquisition of cardiac phenotype and were not capable of symmetric 
contraction (Valiunas et al., 2004). Similar methods have been reported to produce cells with 
cardiomyocyte phenotype from human adipose-derived stem cells, and spontaneously 
beating cells were obtained after co-culture with neonatal rat cardiomyocytes (Choi et al., 
2010).  
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3.1.3 Genetic modifications: Use of viral vectors  
The genetic modification of MSCs is an interesting option for improving their therapeutic 
potential. The transfection of master genes or transcription factors that induce 
differentiation into the cardiac phenotype was recently developed as a transdifferentiation 
methodology. In cardiac research, efforts have been made to transfect BM-MSCs with viral 
constructions, using retroviral vectors that contain the master genes Csx/Nkx2.5 and 
GATA-4. Single-cell-derived MSCs overexpressing Csx/Nkx2.5 and GATA4 behaved as 
cardiac transient amplifying cells and retained their plasticity in vivo, but 5-aza treatment 
was required to achieve a complete cardiac phenotype. The frequency of cardiomyogenic 
differentiation was increased by co-culturing with foetal cardiomyocytes (Yamada et al., 
2007). 
For human clinical proposes, Ad- vectors are safer than RV- vectors because they do not 
integrate into the cellular DNA, and therapy with Ad-transduced MSCs is likely to be less 
immunogenic than the direct administration of Ad-vectors to affected tissues, due to the 
anti-inflammatory properties of MSCs. Moreover, transgenic expression in proliferating 
stem cells is only transient, due to the non-integrative properties of Ad-vectors. Nonetheless, 
short-term therapeutic gene expression may be sufficient or even desirable for the treatment 
of diseases such as myocardial infarction, in which the transient paracrine effects of MSCs 
enhance tissue healing and repair responses (Reiser et al., 2005). 
Two studies recently reported the direct reprogramming of murine fibroblasts into 
functional cardiomyocytes. Srivastrava´s group developed a method to recruit and 
transdifferentiate resident cardiac fibroblasts near the infarction area. This group enforced 
the expression of developmental cardiac transcription factors Gata4, Mef2c, and Tbx5 and 
produced cardiomyocytes that matched a normal cardiomyocyte gene expression profile 
(Ieda et al., 2010). The efficiency of this direct reprogramming was higher in comparison to 
reprogramming to iPSCs (20% vs. <0.1%) and it was more rapid, but the emergent 
cardiomyocytes could not be expanded in culture, which is a shortcoming. 
In another study, Ding´s group obtained cardiomyocytes by virally transducing mouse 
embryonic fibroblasts with genes encoding for the transcription factors Oct4, Sox2 and Klf4, 
followed by modified standard reprogramming medium, in which leukaemia inhibitor 
factor was removed and foetal bovine serum was added at 1-15% (Efe et al., 2011). This new 
development may help eliminate some of the obstacles to the use of traditional ESCs or 
iPSCS, including teratoma formation due to residual undifferentiated cells, and it may lower 
the cost and delivery time to patients thanks to higher yields and faster production. 
3.2 Transdifferentiation methods using iPSCs  
Induced pluripotent stem cells (iPSCs) are adult cells that have been genetically 
reprogrammed to an embryonic stem cell-like state by being forced to express genes and 
factors important for maintaining the defining properties of embryonic stem cells. The 
reprogramming of adult cells into ESCs enables the generation of patient-specific stem cells 
and therefore has enormous potential for the analysis and treatment of degenerative 
diseases. iPSCs are typically derived by transfection of certain stem cell-associated genes 
into non-pluripotent cells, such as adult fibroblasts. Transfection is typically achieved 
through viral vectors, such as retroviruses. Transfected genes include the master 
transcriptional regulators Oct-3/4 (Pouf51) and Sox2, although some other genes (e.g., Klf4, 
c-Myc) have been used to enhance the efficiency of induction.  
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Among various methods used to induce differentiation in pluripotent cell lines, the most 
widespread is to grow undifferentiated cells as aggregates in suspension, which causes them 
to form EBs in which cardiac cells spontaneously develop (Son et al., 2011). Cardiomyogenic 
mesodermal progenitors are normally formed in the embryo during gastrulation as cells of 
the epiblast pass through the primitive streak (Nury et al., 2009). 
Many protocols for directed differentiation to cardiomyocytes are based on these 
developmental principles. In general, two directed differentiation strategies have been 
applied. First, the co-culture of hESCs with cardio-inductive cell types, such as endodermal 
cell line END-2. Cardiac induction by END-2-conditioned medium can be (partly) mimicked 
by insulin depletion (Freund et al., 2008), inhibition of p38 MAPK (Graichen et al., 2008) and 
addition of prostaglandin E. 
A second method is to induce gastrulation by the use of specific growth factors. Several 
studies have shown that various combinations of BMP4, WNT3a and Activin A induce 
gastrulation-like events and meso-/endoderm development in hESCs (Sumi et al., 2008; 
Vijayagavan et al., 2009). A similar approach uses an efficient cardiac differentiation 
protocol based on transient stimulation with BMP4, bFGF and activin A followed by VEGF 
and WNT inhibition through DKK. Both approaches have allowed considerable progress to 
be made over the past few years with respect to the efficiency of cardiomyocyte 
differentiation, but its use in clinical therapies remains plagued with numerous problems, 
including inadequate purity. The same methods are currently used for the generation of 
iPSCs-derived cardiac cells. 
3.2.1 Future applications of iPSCs technology in heart disease 
The possibility of creating patient-specific embryonic stem cell-like cells may complement 
the rather slow development of heart disease models based on hESC. However, their value 
in elucidating disease mechanisms and as models for drug discovery remains to be 
demonstrated. The uniformity and reliability of the differentiation of several well-studied 
hESC lines may make these the most useful near-term research tool; therefore, research on 
the targeting and genetic modification of hESCs is still vital. In this regard, the use of iPSCs 
models has opened a new alternative to study illness, especially in countries were legal 
issues do not allow the use of hESC. 
The generation of heart disease models is a highly complicated process, due to the variety of 
aetiologies and subtypes of CVDs and their complexity. Initial approaches have avoided 
multi-gene diseases and focussed on heart diseases associated with mutations in single 
genes, which are most likely to have an effect at single cell level. This is the case of 
channelopathies, which are related to mutations in a small set of genes that encode cardiac 
ion channels and sarcomeric proteins. In this way, the phenotypes of these diseases are 
characterized by disturbed ion channel function (cardiac channelopathies) or impaired 
contractility (cardiomyopathies). Heritable cardiac channelopathies include long-QT 
syndrome (LQTS), Brugada syndrome, catecholaminergic polymorphic ventricular 
tachycardia, cardiac conduction disease and sinus node dysfunction (Priori & Napolitano, 
2006. 
Recent successes have been reported using human iPSCS as models for human heart 
disease. Two groups generated human iPSCS lines from heart disease patients that showed 
a disease phenotype in culture. Carvajal-Vergara et al. (2010) produced cardiomyocytes 
from two human iPSCs lines derived from two patients with a heterozygous T468M 
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substitution in PTPN11 (protein tyrosine phosphate, non-receptor type 11), which leads to 
Leopard syndrome, offering novel insights into signalling pathways related to this disease. 
Another study by Moretti et al. (2010) investigated an ion channel mutation in patients with 
LQT1. LQTS is a life-threatening congenital condition characterized by cardiac arrhythmias 
and sudden cardiac death. These patients have a KCNQ1 gene mutation that results in an 
elongated QT-interval. The KCNQ1 gene encodes IKs, the ion channel controlling the slow 
component of the delayed rectifier K+ current, which is partially responsible for the 
repolarising phase of the action potential. The authors were able to recapitulate this 
electrophysiological phenotype in culture by using a whole-cell patch-clamp 
electrophysiology method after creating human iPSCs lines from two patients in a single 
family with an R190Q missense mutation in KCNQ1. Using a similar method, Itzhaki et al. 
(2011) developed a patient/disease-specific human iPSCs line from a patient with type-2 
LQTS, which is due to the A614V missense mutation in the KCNH2 gene, coaxing these 
iPSCs to differentiate into the cardiac lineage. The LQTS human iPSC-derived cardiac-tissue 
was used as a model to evaluate the potency of existing and novel pharmacological agents 
that may either aggravate (potassium-channel blockers) or ameliorate (calcium-channel 
blockers, KATP-channel openers and late sodium-channel blockers) the disease phenotype. 
4. Pre-clinical studies: A step to the bedside 
Initial animal experiments found that the transplantation of BM-SCs after AMI and 
ischaemic cardiomyopathy is associated with a reduction in scar size and improvements in 
the ejection fraction of the left ventricle (LVEF) and tissue perfusion (Dawn & Bolli, 2005). 
Other pre-clinical studies demonstrated an improvement in myocardial function after repair 
of the infarcted area through implantation of EPCs derived from peripheral blood, BM or 
umbilical cord blood (UCB) (Leor & Marbel, 2006; Perin & López, 2006). 
MSCs have also been used in a model of chronic myocardial ischaemia in large animals. 
Twelve dogs that received intramyocardial injections of 100 million cells showed improved 
systolic function (by echocardiography) in comparison to controls, both at rest and under 
stress situations; in addition, the MSCs were able to transdifferentiate into endothelial cells 
and smooth muscle cells, enhancing vascularization (Perin et al., 2003).  Skeletal myoblasts 
were also studied in the setting of chronic myocardial ischaemia, specifically to treat 
myocardial scarring, and were found to improve the LVEF and the adverse effects of 
ventricular remodelling, due to their high capacity to engraft in scarred myocardial 
segments (Leor et al., 1996). 
5. To the bedside: Cardiac cell therapy 
The rapid development of stem cell technology has raised hopes for novel and even 
revolutionary treatments for cardiac and other disorders with tissue damage, awakening the 
keen interest of the pharmaceutical industry. These expectations are largely based on the 30-
year history of successful BM-HSC transplantations in patients with blood diseases and 
cancer (Thomas et al., 1959; Shizuru et al., 2005). However, few stem cell therapies have been 
widely accepted by the medical community, and all of these use tissue-specific stem cells. 
These include BM or UCB stem cell transplantation to treat blood diseases or restore the 
blood system after cancer treatments, skin stem cell therapies for burns and limbal stem cells 
for corneal replacement, among others. In each case, stem cells repair the same tissue as that 
from which they are derived. 
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Cardiac cell therapy has been attempted in more than 1000 patients worldwide, and the 
results of the first meta-analysis recently became available. The interest in the use of adult 
stem cells in cardiac regeneration began after the demonstration by Orlic et al. (2001a) that 
murine BM-derived cells regenerated heart muscle after direct injection at the site of the 
previously induced myocardial infarction. These promising results generated significant 
interest in its clinical application, with the launch of numerous randomized clinical trials on 
the efficacy of cell therapy in patients with coronary disease, including 37 trials in Europe 
alone. The interpretation of their results should consider the effectiveness of the cell 
transplantation method, the delivery time and the cell type used. In this section, the NIH-
supported ClinicalTrials website (ClinicalTrials.gov) was searched for closed and ongoing 
clinical trials in the field. Keywords included “heart”, “myocardial infarction”, “heart 
failure” and “cell therapy” (Table 3). 
5.1 Bone marrow-derived stem cells 
The TOPCARE-AMI study provided the first major clinical report on the transplantation of 
BM stem cells after myocardial infarction (Leistner et al., 2011). Patients were randomized to 
receive BM-derived mononuclear cells (29 patients) or EPCs (30 patients) by intracoronary 
infusion. Both groups showed improved LVEF at 4 months and reduced infarct size at 12 
months, but there was no randomized control group with which to compare results. More 
recently, in a sub-group of the same patients, the authors observed a significant increase in 
LVEF (by cardiac MRI) and a reduction in infarct size (by delayed enhancement MRI). 
Interestingly, the migratory capacity of the infused cells proved to be the most important 
predictor of myocardial remodelling (Britten et al., 2003). 
Some trials failed to show a significant increase in cardiac function, whereas others 
evidenced improvements comparable with those obtained by established treatment 
regimens (Reffelmann & Kloner, 2009). A range of results has been reported, from a low to a 
14% improvement in LVEF (Fernandez-Aviles et al., 2004; Perin & López, 2006; Stamm et al., 
2007; Tatsumi et al., 2007).  
Many clinical studies have evaluated the therapeutic potential of human BM-derived stem 
cells (e.g. MSCs or mononuclear cells) to improve cardiac function after myocardial 
infarction (Gonzales & Pedrazzini, 2009; Mathiasen et al., 2009; Wei et al., 2009). However, 
no evidence has been reported of cardiac regeneration through differentiation of implanted 
stem cells into cardiomyocytes and other cardiac cell lineages. Some studies, but not all, 
have reported beneficial effects on heart function and on symptoms (Janssens et al., 2006; 
Lunde et al., 2006; Schachinger et al., 2006; Meyert et al., 2006). However, it has been 
suggested that these benefits are short-term, and a five-year follow-up study found that 
treatment with BM cells did not achieve sustained improvements in heart function (Meyer et 
al., 2009). Nonetheless, according to the results of all of these studies, the therapeutic use of 
human BM stem cells appears to be safe. 
A meta-analysis of 18 randomized and non-randomized clinical trials, including 999 patients 
with AMI and chronic ischaemia, reported encouraging results after the transplantation of 
BM-MSCs. In comparison to controls, the transplantation improved the LVEF by 5.40% (P 
<0.001), reduced the post-AMI scar area by 5.49% (P = 0.003) and reduced the left 
ventricular end-systolic volume by 4.80 ml (P = 0.006). According to the results of this meta-
analysis, BM-MSC therapy appears to be safe and can be used in large-scale randomized 
trials to assess its impact on cell therapies (Abdel-Latif et al., 2007). 
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Basic Fibroblastic grow factor; CABG:  Coronary Artery Bypass Graft; eNOS: human endothelial nitric 
oxide synthase 
Table 3. Ongoing clinical trials using different autologous stem cells. 
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5.2 Mesenchymal stromal cells  
Animal studies are ongoing to determine whether MSCs can be used to treat arthritis, non-
healing bone fractures or spinal cord injuries, among other diseases. Although it is also 
possible that these or similar cells modulate the immune system in response to injury, their 
use as cardiomyocyte-like cells via transdifferentiation methods remains controversial. A 
major advance in this field was achieved by Behfar et al. (2010), whose results with MSCs 
using guided cardiopoiesis methods allowed this approach to be evaluated in preclinical 
studies. They obtained a complete cardiac phenotype by using an endoderm-like protein 
cocktail with hMSCs harvested from patients with coronary artery disease. The hMSCs were 
injected into the myocardium of nude infarcted mice and followed up for a year to assess 
functional and structural endpoints. The recombinant cardiogenic cocktail guidance secured 
the cardiopoietic phenotype across the patient cohort, achieving a superior functional and 
structural benefit in comparison to unguided counterparts, with no adverse side effects 
(Behfar et al., 2010). 
However, there is evidence of a low retention of the infused cells in the area of interest, 
which would reduce the effectiveness of this approach. Current strategies include the use of 
hMSCs modified with viral vectors carrying genes that increase the affinity of these cells to 
the sites of cell damage, e.g., through activation of HIF-α factor, which is expressed in states 
of hypoxia (Xue et al., 2010).  
5.3 Skeletal myoblasts  
The promising experimental results achieved by Leor et al. (1996) with skeletal myoblasts in 
a chronic myocardial ischaemia model, described above in section 4, generated significant 
interest in their possible clinical application. The first clinical trial was conducted at Paris-
Descartes University using autologous skeletal myoblasts isolated from muscle biopsies 
from patients with severe heart failure, expanded ex vivo and then transplanted. The clinical 
status and ejection fraction of the treated patients improved over time, with a strikingly low 
incidence of hospitalizations for heart failure (0.13/patient-years). Moreover, the risk of 
arrhythmia could be controlled by medical therapy and/or on-request automatic cardiac 
defibrillator implantation (Menasche et al., 2001).  
Therapy with skeletal myoblast transplantation was tested in the MAGIC trial (Myoblast 
Autologous Grafting in Ischaemic Cardiomyopathy). An injection of stem cells or culture 
medium was randomly administered to patients and, although initial fears of serious 
arrhythmias did not materialize, the results showed no significant benefit from the stem cell 
treatment. 
The ambiguous results of clinical trials reflect differences due to the diversity of cell types 
and administration routes used. The timing of the assessment of ventricular function post-
transplantation may also explain some discrepancies in the results. Several of the benefits 
achieved by this therapy appear to be transient (Meyer et al, 2009), consistent with the 
findings of similar studies conducted in animals (van Laake et al., 2008). 
5.4 iPSCs technology  
The need for deeper knowledge of iPSCs is acknowledged by the scientific community, but 
only one clinical trial is using this cell type, in an attempt to induce pluripotent stem cells 
from cell cultures of skin biopsies (Royan Institute, Iran, CI. NCT00953693). This trial is 
related to hepatic regeneration. The strategy is basically the same for all research purposes: 
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after isolation of fibroblasts from the patient`s skin biopsy, the cells are transfected after 3-4 
weeks with the four factors used by Yamanaka. Transfected cells are isolated by 
morphological selection in order to generate allogeneic hiPSCs (Seifinejad et al., 2010). In the 
field of heart disease, basic research includes aspects such as the generation of 
cardiomyocytes derived from human ES/iPS cells from post-AMI heart failure patients 
(Itzhaki et al, 2011). These results will be important for drug discovery screening in relation 
to QT prolongation and cardiac cell transplantation therapy. 
6. Funding research through industry: Development of patents in cell therapy 
Improved understanding of the development of the human heart has led to proposals for 
strategies that emulate the cardiogenic programme, which are currently being tested in pre-
clinical and clinical studies. There are an increasing number of patents in this area as well as 
on the establishment of cell lines. A patent operates as a quid pro quo: the patent owner 
obtains the exclusive right to make, use and sell an invention in exchange for its public 
disclosure. Some scientists believe that patents harm the research environment by increasing 
secrecy and costs. Others consider that the regenerative medicine sector requires access to 
funding and resources for the protracted procedures required, including not only the 
research and clinical trials but also the legal issues that must be addressed with respect to 
patent protection for regenerative medicine-related intellectual property. Interestingly, 
regenerative medicine may change the conventional reliance on patents and their finite 
exclusivity, which is a truly major issue for the pharmacy industry. Patent registers in the 
USA show a growing number of patents for the treatment of CVDs using stem cells, 
representing a validation of the therapeutic potential of this approach. In Europe, there is a 
slight trend towards the creation of patents related to methods for isolating cell populations 
with cardiopoietic potential and for preparing enrichment culture media, which are in pre-
clinical stages of application.  
A search of the sources “Patent Lens” of the organization “Initiative for Open Innovation 
(IOI)”, “Patentscope” of the World Intellectual Property Organization (WIPO), and the 
“Invenes”, “Esp@cenet”, “Free patents online” and “Latipat” databases of the Spanish 
Patents Office, shows that  patent applications to commercialise cell therapies for CVDs 
centre on three main topics: i) methods to deliver stem cells to the damaged myocardium, ii) 
methods to isolate and differentiate autologous cells harvested from patients, and, finally, 
iii) viral vectors for gene delivery. 
6.1 Achieving the cardiac cell phenotype: Producing stem cell- derived 
cardiomyocytes 
Given the difficulty of isolating and culturing heart cells, many studies have focused on 
developing methods to induce the differentiation of stem cells into the myocardial 
phenotype. For this purpose, MSCs are the most widely used cells in the patents and clinical 
trials reviewed, followed by HSCs, but knowledge of the existence of cardiac progenitor 
populations has made these the object of the most recent studies. One example is the 
development by Chien  et al.  (2011) (Patent application US 2011/0003327) of methods to 
identify and isolate atrial progenitors and, in some cases, atrial progenitors that are positive 
for Islet 1 (Isl1) and sarcolipin, which are growth factors responsible for the negative 
regulation of second heart field progenitor cell differentiation (Buckingham et al., 2005). 
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Another invention of this team relates to methods for isolating cardiovascular stem cells, 
placing cell populations in contact with agents reactive to Isl 1, Nkx2.5 and Flk-l and 
separating reactive from non-reactive cells (Chien & Chang 2008; Patent application WO 
2008/054819 A2). 
The use of MSCs from different sources is reflected in the patent of Büscher et al. (2010) (US 
patent application 20100304477), who characterized a novel population of human cardiac 
adipose tissue-derived adult stem cells from the epicardial area. These cells are isolated by 
their surface marker profile and their gene and protein expression of different cardiac 
muscle cell components, including the cardiac factors GATA-4 and Nkx2.5, the sarcomere 
components beta-myosin heavy chain and α-actinin, and the regulators of electrochemical 
connection and intracellular calcium distribution, connexin-43 (Cx43) and SERCA-2, 
respectively. 
6.2 How can stem cells be guided to the damaged myocardium? 
Numerous techniques have been developed for this purpose, including the use of growth 
factors and molecules that deliver and mobilize stem cells to the injured site. This paracrine 
effect has been described in MSCs and also includes the activation of different mechanisms 
against cell damage. In this respect, granulocyte colony-stimulating factor (G-CSF) has 
proven useful alone or in combination with the stem cell factor (SCF) in the mobilization of 
BM stem cells. The pre-AMI mobilization of primitive BMCs by the administration of G-CSF 
and SCF (US Patent 7220407) results in a significant degree of tissue regeneration at the 
ischaemic site (Orlic et al., 2001b). It is also contemplated that human G-CSF therapy may be 
used in a similar manner along with other agents commonly used for the treatment of AMI 
in conjunction with reperfusion. 
In the field of gene therapy, several methods have been developed for treating patients with 
CVDs, including heart disease and peripheral vascular disease. The preferred methods 
involve the in vivo delivery to the myocardium or peripheral ischaemic tissue of genes 
encoding angiogenic proteins or peptides by the introduction of a vector containing the gene 
into a blood vessel supplying the heart or into peripheral ischaemic tissue. The patent 
“Techniques and compositions for treating cardiovascular disease by in vivo gene delivery” 
(Hammond et al., 2003; US Patent Application 20030148968), describes a method that 
employs a replication-deficient adenovirus as vector. By injecting the viral vector stock with 
angiogenic protein- or peptide-encoding genes deeply into the lumen of one or both 
coronary arteries or grafts, it is possible to locally transfect an adequate number of cells, 
especially cardiac myocytes, into the affected myocardium. This methodology maximizes 
the therapeutic efficacy of gene transfer and minimizes undesirable angiogenesis at 
extracardiac sites and the possibility of an inflammatory response to viral proteins. 
7. Clinical translation 
The translation of research findings to the clinical setting can be a complex process. This 
discipline, based on interventional epidemiology, aims to increase the throughput of 
findings from the basic or early phase of clinical research in ageing and to use them to drive 
innovation in healthcare settings. The success of clinical translation depends on the capacity 
of scientists, clinicians, regulators and other experts to share their expertise with one other 
and on their ability to respond adequately to negative or positive clinical outcomes. 
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In the field of CVD, considerable efforts have been made to establish feedback between 
research groups and clinical practice. Universities and hospitals have developed clinical 
translation units in which stem cell-related issues are focused on the utility of plasma 
biomarkers of acute brain injury to improve the early diagnosis of acute stroke and on the 
prevalence and specific causes of ventricular repolarisation abnormalities in older patients 
undergoing psychoactive drug treatment, among others. 
7.1 Cell therapy  
As reported above, human cell-based medicine is proving increasingly attractive to the 
pharmaceutical and medical equipment industries, opening up the way for the self-funding 
needed for scientific development and the implementation of clinical trials. This is of 
particular importance at a time of intense pressure to reduce public health costs. 
Progress has been made in developing protocols for obtaining and isolating stem cells, in 
establishing legislation that specifies the parameters of good manufacturing practice for 
large-scale production, and in accumulating pre-clinical data that validating the effects of 
this therapy. As a result, several types of stem/progenitor cells have been proposed for use 
in regenerative medicine, leading to the consideration of stem cells as pharmaceuticals. 
Large pharmaceutical companies apply stem cell-based technologies and other proprietary 
methods in the area of regenerative medicine to bring patient-specific therapies from the 
laboratory to the bedside. This is the case of products being developed by Advanced Cell 
Technology, Bioheart Inc. and Cardio3 Bioscience companies (Figure 3). 
 
 
Fig. 3. Examples of products in development for cell therapy in diseases related to the 
cardiovascular system. 
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We highlight the initiatives taken by some U.S. drug companies, who have begun to market 
cell therapies after successful clinical trials. One example is Athersys Inc., whose MultiStem 
cell therapy has a broad potential to treat diseases such as AMI, stroke, and inflammatory 
bowel disease. MultiStem promotes tissue repair through the induction of therapeutic 
factors produced in response to signs of inflammation and tissue damage. Likewise, the 
Bioheart company is now marketing MyoCell as a result of the MARVEL trial, a 
randomized, double-blind, placebo-controlled, multicenter, phase II/III trial involving 330 
patients in North America and Europe. MyoCell uses muscle tissue samples from the 
patient, isolating and expanding stem cells and then transplanting them by endoventricular 
injection into the patient’s scar tissue (MyoStar ™). 
7.2 Scaffolding: The development and translation of the tissue-engineered vascular 
graft 
The post-mitotic and myogenic nature of myocardial tissue hampers the in vitro isolation 
and maintenance of cardiomyocytes. In vitro dedifferentiation is evidenced by the loss of 
sarcomeric distribution, observed in the distribution pattern of protein alpha actinin, 
troponin and connexin 43. These proteins are essential for muscle contraction. The same 
difficulty arises with the generation of cardiomyocytes in vitro, demonstrating that an 
effective approach for cardiac regeneration must include both specialized cells in a three-
dimensional support or scaffold that provides the physical properties necessary for 
contraction. However, because of the heterogeneous population residing in the 
myocardium, attempts have focused on the generation of vascular replacements for larger 
vessels such as arteries. The utilisation by Dr. Taylor’s group of a decellularisation method 
in mouse heart yielded encouraging findings in relation to the generation of bio-artificial 
hearts. They decellularised the hearts by coronary perfusion with detergents, preserving the 
underlying extracellular matrix and producing an acellular, perfusable vascular architecture 
with competent acellular valves and intact chamber geometry. They mimicked the 
composition of cardiac cells by reseeding these constructs with cardiac or endothelial cells. 
The group maintained eight constructs for up to 28 days by coronary perfusion in a 
bioreactor that simulated cardiac physiology, observing macroscopic contractions by day 4. 
By day 8, under physiological load and electrical stimulation, the constructs generate a 
pump function equivalent to around 2% of adult or 25% of 16-week foetal heart function in a 
modified working heart preparation (Ott et al., 2008). 
Research by Dr. Christopher Breuer and Dr. Toshiharu Shinoka on tissue engineered 
vascular grafts (TEVG) is in the process of clinical translation for congenital cardiovascular 
diseases. In the United States, around 1 in 100 infants is expected to have heart defects, i.e., 
around 36,000 infants per year. Ten percent of these cases—over 3,600 infants—result in 
death. TVEGs are biodegradable synthetic scaffolds made of the same material as absorbable 
sutures and seeded with the individual’s own cells. The scaffold degrades by hydrolysis, 
eventually leaving only the living vessel in the patient. Bone marrow aspiration is used to 
harvest the cells, inserting the needle through the cortex of the spinal bone and marrow. The 
marrow is drawn up and separated by density centrifugation, yielding BMCs that are 
directly seeded onto the scaffold by pipetting. The seeded scaffold is then incubated in the 
patient’s plasma for two hours to attach cells to the scaffold. The graft is then ready for 
implantation. The whole process takes only a few hours, allowing a viable TEVG to be 
obtained on the same day as the cell harvesting (Nuti, 2010).  
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There have been numerous clinical trials of cell therapies for CVDs, and several problems 
have been identified. Questions that remain to be addressed in translational research from 
animals to humans concern the cell type, preparation time, delivery, cell number and 
optimization. The measurement of results must also be resolved, including the efficacy 
assessment method and length of follow-up. Nevertheless, the potential therapeutic 
contribution of adult stem cells is enormous. hESCs have been widely studied in relation to 
heart disease, but their use in cell therapy has been limited, in part due to ethically-based 
restrictions on research with this cell type in some countries and the lack of adequate 
funding. 
With regard to iPSCs, the most important and immediate advances have been in relation to 
drug discovery, in the context of an urgent need for new approaches to meet the increasing 
incidence of myocardial infarction and heart failure in ageing populations. The number of 
novel drugs entering the market for heart disease is decreasing, whereas investment by the 
pharmaceutical industry in this area continues to increase, underlining the need for patents 
to safeguard the intellectual property of research groups and provide them with sufficient 
financial support to run clinical trials. 
Criteria established by international scientific organizations such as the European Society of 
Cardiology and the American Society of Cardiology must be followed by researchers who 
address these issues. The correct design of future clinical trials is of particular importance 
before clinical stem cell therapy can be widely applied. In this regard, the International 
Society of Stem Cell Research (ISSCR, 2011) is taking the exceptional step of developing 
guidelines for patients, researchers and physicians, establishing safety procedures and 
providing patients worldwide with information to meet their concerns and describe their 
legal rights. 
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1. Introduction  
Coronary heart disease is the leading cause of morbidity and mortality worldwide. To date, 
management of myocardial infarction (MI) has been limited to timely revascularization and 
drug therapy aimed to restore coronary blood flow and to reduce myocardial workload. 
When disease progresses to life-threatening end-stage heart failure, heart transplantation is 
the only effective therapeutic option available. However, its usage is very much restricted 
by the severe shortage of heart donors and the complications associated with enduring 
immune suppressive drug treatments (Miniati & Robbins, 2002). Therefore, innovative 
treatment strategies are clearly needed to improve patient outcomes. Recent advances in 
stem cell medicine have shed new light on potential MI therapies by exploiting the 
pluripotency of stem cells for cardiac repair and regeneration. Although immense progress 
has been made on the choice of cells and optimizing transplantation conditions, these 
remain critical issues when translating into the clinical setting of MI. In particular, poor 
survival of transplanted cells in the hostile microenvironment of the ischaemic myocardium 
and hence lack of significant engraftment in the heart has been a major impediment for 
achieving an effective stem cell therapy for MI (Pagani et al., 2003). Various cytoprotection 
strategies have been developed over the past decade to circumvent this limitation and the 
non-genetic approach of preconditioning has emerged as one of the most promising 
clinically adaptable strategies to promote stem cell survival and function under various 
ischaemic conditions. Although genetic enhancement of stem cells has been very successful 
in pre-clinical studies, the technical complexity and safety concerns (oncogenicity and 
mutagenesis) associated with this alternative approach have precluded its application in 
clinical translation (Bonaros et al., 2008; Penn & Mangi, 2008). This review will focus on 
current pre-clinical development of non-genetic preconditioning approaches to improve the 
therapeutic potential of stem and progenitor cells for repair of the heart after MI.  
2. History of ischaemic and pharmacological preconditioning 
The protective phenomenon of preconditioning was first described by Murry et al. in 1986 
whereby exposure to brief cycle(s) of sub-lethal ischaemia with intermittent reperfusion, 
which in itself does not induce injury, render the heart more resistant to subsequent lethal 
ischaemic insults; this phenomenon was termed ischaemic preconditioning (IPC) (Murry et 
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al., 1986). Subsequent studies by various laboratories have quickly established IPC as the most 
powerful and effective means of endogenous protection against ischaemic injury. Although 
this protective intervention can be easily reproduced in various pre-clinical studies, successful 
translation into clinical practice has been limited by the safety consideration of needing to 
manipulate the already injured heart. To circumvent this limitation, effort has been 
concentrated on clarifying the underlying molecular mechanisms governing the 
cardioprotective effect of IPC which have lead to the discovery of various pharmacological 
agents that can directly activate the protective signalling pathways to achieve myocardial 
protection without ischaemia, an intervention called pharmacological preconditioning. Despite 
extensive research, the mechanism(s) underlying the protective effect of preconditioning 
remain to be fully elucidated. It is believed to involve multiple intricate endogenous signalling 
pathways (Yellon & Downey, 2003; Huffmyer & Raphael, 2009) including agonists of G-
protein coupled receptors (adenosine, bradykinin, opioids, etc), growth factors (IGF, TGFβ, 
VEGF, etc), phosphodiesterase inhibitors, mitochondrial KATP channel openers, cytokines 
(TNFα, IL-1β, IL-6, etc), nitric oxide (NO), and others. Some of these have been promoted into 
the clinical arena, for example adenosine in AMISTAD I (Mahaffey et al., 1999) and II (Ross et 
al., 2005) trials. In general, non-genetic preconditioning strategies employed by current pre-
clinical studies to improve survival and function of stem and progenitor cells can be 
categorized into ischaemic/hypoxic and pharmacological preconditioning.   
3. Ex vivo ischaemic and hypoxic preconditioning of stem cells 
The ischaemic conditions used to simulate IPC in vitro are quite diverse. The majority of 
studies have experimented with hypoxia or anoxia alone, termed hypoxic preconditioning 
(HPC), while others include nutrient deprivation. In some studies, hydrogen peroxide 
(H2O2) was used to simulate the ischaemic condition of oxidative stress (Li et al., 2009; 
Sharma et al., 2008). Furthermore, different HPC protocols, from the classical multiple cycles 
of brief hypoxia with intermittent reoxygenation to a single long-term exposure to hypoxia, 
have been employed to demonstrate the cytoprotective effect of HPC on stem and 
progenitor cells in vitro. It is also interesting to note that subjecting stem and progenitor cells 
to heat shock, as a form of sublethal cell stress, also capable of promoting their survival and 
in vivo engraftment (Laflamme et al., 2005; Maurel et al., 2005; Suzuki et al., 2000). Despite 
these differences and the lack of an optimal protocol definition, the beneficial effects of HPC 
on stem and progenitor cell function were unequivocally demonstrated in all these studies 
and involved multiple signalling molecules (Table 1) (Figure 1).  
3.1 Survival 
The poor survival and retention of transplanted stem and progenitor cells has driven the 
investigation towards effective cytoprotective strategies which aim to enhance their survival 
in the ischaemic environment. The extent of retention of the delivered cells was documented 
to be rather low with recent studies suggesting that more than 90% are lost partly because of 
necrosis and apoptosis in the ischaemic myocardium following their delivery by 
intramyocardial, retrograde transvenous, intracoronary or systemic routes (Terrovitis et al., 
2010; Aicher et al., 2003; Goussetis et al., 2006). One means of overcoming this limitation 
would be to increase the survival of transplanted cells, thus avoiding the impractical and 
costly alternative of delivering large excesses of stem cells into the injured myocardium.  
 




Fig. 1. Mechanisms underlying the cytoprotective effect of hypoxic preconditioning in stem 
and progenitor cells. 
HPC by sublethal hypoxia has been shown to enhance the survival of stem and progenitor 
cells isolated from various species including humans in vitro (Table 1). Similarly, the 
cytoprotective effect of HPC was demonstrated in a number of in vivo studies using 
clinically relevant ischaemic models (Table 2). In these studies, ex vivo HPC rendered stem 
and progenitor cells more resilient to cell death when transplanted into the infarcted 
myocardium (He et al., 2009; Hu et al., 2008; Tang et al., 2009; Uemura et al., 2006), 
ischaemic limb (Akita et al., 2003; Kubo et al., 2008; Li et al., 2002; Rosova et al., 2008) or 
ischaemic brain (Theus et al., 2008), and this finding was significantly correlated with 
improved functional recovery of the ischaemic tissues. For instance, transplantation of 
hypoxic preconditioned mesenchymal stem cells (MSCs) into the ischaemic myocardium 
showed enhanced therapeutic benefits in terms of infarct size reduction, increased 
angiogenesis, improved ventricular function and less adverse cardiac remodelling (Hu et al., 
2008). These beneficial effects of hypoxic preconditioned stem cells are attributed to 
enhanced pleiotropic paracrine activities instead of transdiffentiation and cell fusion, which 
occurred at insignificantly low frequency. Convincing evidence in support of the paracrine 
paradigm were provided by in vitro studies with conditioned media, where media from 
hypoxia-conditioned MSCs was shown to be cytoprotective in cultured human aortic 
endothelial cells (Hung et al., 2007a) and primary rat cardiomyocytes (Gnecchi et al., 2006) 
subjected to hypoxic injury.  
Mechanistic evaluations of the cytoprotective effect of HPC in stem and progenitor cells 
have implicated the up-regulation of a diverse array of soluble survival proteins such as 
growth factor VEGF (Akita et al., 2003; Potier et al., 2007), anti-apoptotic proteins Bcl-2 and 
Bcl-xL (Francis & Wei, 2010; Hu et al., 2008; Theus et al., 2008; Wang et al., 2008a), 
antioxidants heme oxygenase-1, hexokinase-2, catalase and superoxide dismutase (Kubo et 
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 Stem cells PC stimulus End points Mechanisms References 
Hypoxia     
MSCs (mouse) <0.1% O2, 4 h 
↑ survival of co-
cultured adult CMs 




MSCs (mouse) 0.5% O2, 24 h ↑ survival 
HIF-1α; Ang-1; 
VEGF/Flk1; Bcl-2; 
Bcl-xL; p105; EPO; 
NFκB 
Hu et al., 
2008 
MSCs (mouse) 0.5% O2, 24 h ↑ survival HIF-1α; EPO; Bcl-2; Bcl-xL 
Theus et al., 
2008 
MSCs (mouse) 1% O2, 36 h 
Conditioned media ↑ 
cell migration Wnt4 
Leroux et 
al., 2010 
MSCs (mouse) 3% O2, 3-24 h 
↑ survival; 
↑ cell migration; 
↑ cell adhesion 
Akt; HIF-1α; 
CXCR4; CXCR7 
Liu et al., 
2010 
MSCs (rat) <0.1% O2 & serum-free, 3 h
↑ survival of co-
cultured neonatal CMs - 
He et al., 
2009 
MSCs (rat) 0.5% O2, 12 h 
Conditioned media ↑ 
adult CMs survival 




MSCs (rat) 0.5% O2, 24 h ↑ survival Akt; VEGF; HIF-1α Chacko et al., 2010 
MSCs (rat) 1% O2, 24 h ↑ survival Catalase, Mn-SOD, p38MAPK, Bcl-2 
Peterson et 
al., 2011 
MSCs (rat) 2% O2, 4-48 h 




Li et al., 
2002 
MSCs (rat) 8% O2, 10-30 min 
↑ survival 
 
Akt; ERK1/2; Bcl-2; 
Bax; VEGF 
Wang et al., 
2008a 
MSCs (rat) <0.1% O2, 10/30 min x 1-3 ↑ survival 
Akt; ERK1/2; Bcl-
xL; HIF-1α; miR-210 
Kim et al., 
2009 
MSCs (human) 1% O2, 22 h ↑ cell migration HIF-1α; CX3CR1; CXCR4 
Hung et al., 
2007b 
MSCs (human) 1% O2, 2 d 
↑ angiogenic factors 
secretion 
↓ osteogenic diff. 
VEGF Potier et al., 2007 
MSCs (human) 1% O2 & serum-free, 2 d 
Conditioned media ↑ 
endothelial cell survival 
& angiogenesis 
Akt; IL-6; eNOS Hung et al., 2007a 
MSCs (human) 2% O2, 3d 
Restore hypoxia-
induced ↓ of osteogenic 
diff. 
- Volkmer et al., 2010 
MSCs (human) 1-3% O2, 16 h ↑ cell migration Akt; HGF/cMet Rosova et al., 2008 
PB-MNCs 




Kubo et al., 
2008 
 








35mmHg, 7 d 
↑ endothelial diff.; 
↑ cell migration 
VEGF; KDR 
tyrosine kinase 




1% O2, 4-12 h + 
24 h Reoxy. 
↑ survival; 
↑ neuronal diff. HIF-1α; EPO; Bcl-2




0.1% O2, 12 h + 
0-5 d Reoxy. 
↑ survival; 
↑ neuronal diff. 
HIF-1α; HIF-2α; 




ASCs (human) 1% O2, 24 h + 24 h Reoxy. 
↑ survival of co-
cultured NSCs - 
Oh et al., 
2010 
CLK (mouse) 0.1% O2, 4-24 h ↑ cell migration HIF-1α; SDF-1/CXCR4 





1.5% O2, 24 h + 
2 d Reoxy. 
↑ endothelial diff.; 
↑ angiogenic-related 
genes 
- Ong et al., 2010 





Hydrogen peroxide    
MSCs (rat) 20 μM H2O2,   24 h 
↑ survival 
↑ cell migration 
SDF-1/CXCR4; 
ERK1/2 
Li et al., 
2009 
NPCs (mouse) 0.05-0.5 μM H2O2, 24 h ↑ survival - 
Sharma et 
al., 2008 
Heat shock    
Skeletal Mb 
(rat) 42
0C, 1 h ↑ survival HSP72 Suzuki et al., 2000 
Skeletal Mb 
(rat) 42
0C, 70 min ↑ survival HSP70 Maurel et al., 2005 
ESCM (human) 430C, 30 min ↑ survival HSP60, HSP70, HSP90 
Laflamme et 
al., 2005 
Table 1. Effect of ischaemic or hypoxic preconditioning on stem and progenitor cells in vitro. 
CLK (cardiosphere-derived Lin-c-kit+ progenitor cells), CMs (cardiomyocytes), diff. 
(differentiation), ESCM (embryonic stem cell-derived cardiomyocytes), ESNPCs (embryonic 
stem cell-derived neural progenitor cells), HO-1 (heme oxygenase-1), HSP (Heat shock 
protein), KDR (kinase insert domain receptor), Mb (myoblasts), NPCs (neural progenitor 
cells), NSCs (neural stem cells), PB-MNCs (peripheral blood mononuclear cells), Reoxy 
(reoxygenation), Wnt4 (wingless-related MMTV integration site 4).   
al., 2008; Peterson et al., 2011) , erythropoietin (EPO) (Hu et al., 2008; Theus et al., 2008) and  
NO (Uemura et al., 2006; Ii et al., 2005) as the contributing factors. Other potential cytokines 
and growth factors that have been suggested are basic fibroblast growth factor (bFGF) 
(Gnecchi et al., 2006), hepatocyte growth factor (HGF) (Gnecchi et al., 2006), IL-1β (Kubo et 
al. 2008), IL-6 (Hung et al., 2007a) and thymosin β4 (Gnecchi et al., 2006), though more 
supporting evidence for these factors in mediating the pro-survival effect of HPC in the 
context of stem cell preconditioning are warranted. In addition, HPC has also been shown to 
activate several transcription factors and signal transduction cascades that are known to be 
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 In vivo models Stem cells PC stimulus End points References 
MI (mouse) MSCs (mouse) 
Anoxia, 4 h + 2 h 
reoxygenation 
↓ infarct size & apoptosis;
↑ LV function 
Uemura et 
al., 2006 
MI (mouse) CLK (mouse) 0.1% O2, 6 hours
↓ infarct size; 
↑ angiogenesis; 
↓ LV remodelling; 
↑ LV function 
Tang et al., 
2009 
MI (rat) MSCs (mouse) 
0.5% O2, 24 h + 2 
h reoxygenation
↑ cell survival; 
↓ infarct size; 
↑ angiogenesis; 
↑ LV function 
Hu et al., 
2008 
MI (rat) MSCs (rat) Anoxia & serum-free, 3 h 
↓ infarct size & apoptosis;
↑ LV function 
He et al., 
2009 








(mouse) 1% O2, 36 h 
↑ cell survival; 
↑ skeletal muscle 
regeneration; 













(mouse) 2% O2, 24 h 
↑ cell survival; 
↑ limb perfusion; 
↑ neovascularization 
Kubo et al., 
2008 
Limb ischaemia 
(rat) MSCs (rat) 2% O2, 24 h 
↑ limb perfusion; 
↑ neovascularization 






pO2 of 35mmHg, 
7 d 
↑ limb perfusion; 
↑ neovascularization 





(mouse) 1% O2, 8 h 
↑ cell survival; 
↑ recovery of sensorimotor 
function 





MSCs (rat) Anoxia 
↓ apoptosis; 
↑ angiogenesis; 
↓ LV remodelling; 
↑ LV function 
Li et al., 
2008 




1% O2, 24 h + 24 h 
reoxygenation 
↑ survival of co-
transplanted NSCs 
Oh et al., 
2010 
Table 2. Therapeutic potential of hypoxic-preconditioned stem and progenitor cells.  
protective and functionally beneficial including the survival kinase Akt (Hung et al., 2007a; 
Kim et al., 2009), ERK1/2 (Wang et al., 2008a), p38MAPK and survivin (Peterson et al., 
2011), SDF-1/CXCR4 and CXCR7 chemokine signalling pathway (Liu et al., 2010), 
microRNA(miR)-210 (Kim et al., 2009), transcription factors HIF-1α (Kim et al., 2009; Francis 
& Wei, 2010) and NFκB (Hu et al., 2008). It is also important to note that these mechanistic 
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pathways and paracrine factors interact with each other and are not mutually exclusive. For 
example, stabilisation of HIF-1α by HPC, possibly through activation of the PI3K/Akt 
pathway (Francis & Wei, 2010; Liu et al., 2010), allows its translocation into the nucleus to 
up-regulate the transcription and translation of various anti-apoptotic proteins such as 
CXCR7 (Liu et al., 2010), Bcl-2 (Francis & Wei, 2010) and miR-210 (Kim et al., 2009) in stem 
and progenitor cells. Furthermore, up-regulation of miR-210 has been demonstrated to 
down-regulate the expression of CAP8AP2, a pro-apoptotic protein that activates death-
effector caspase-8 and promotes Fas-induced apoptosis (Kim et al., 2009).  
3.2 Differentiation and engraftment 
In addition to cell survival and retention, lack of significant functional cell engraftment of 
transplanted cells in the injured tissues has posed another significant challenge for cell-
based therapy. In most studies, transplanted stem and progenitor cells do not appear to be 
trans-differentiated and incorporated into host tissues. Instead, the functional improvement 
of the ischaemic conditions is likely attributed to the paracrine activities of transplanted 
cells. Therefore, interventions that can promote stem cell differentiation and functional 
engraftment in the target tissues post-transplantation should deserve much attention. HPC 
has been shown not only to enhance stem cell survival but also to promote their 
differentiation and engraftment. Hypoxia is a potent differentiation inducer of stem cells 
and studies have demonstrated an acceleration of MSC differentiation when cultured under 
hypoxic conditions (5-8% O2) compared with that in normoxic culture, possibly through 
stabilisation of the oxygen sensitive transcription factor HIF-1α (Lennon et al., 2001; Ren et 
al., 2006). In contrast, a number of studies have indicated that hypoxia strongly inhibits the 
differentiation capacity of human bone marrow-derived MSCs (Hung et al., 2007b; Potier et 
al., 2007; Salim et al., 2004; Volkmer et al., 2010) and adipose-derived mesenchymal stem 
cells (ASCs) (Malladi et al., 2006; Wang et al., 2005), without affecting the cell viability. 
Similar conflicting results on stem cell differentiation potential were demonstrated by 
studies on short-term exposure to hypoxia. Studies on mouse (Theus et al., 2008) and human 
(Francis & Wei, 2010) embryonic stem cells (ESCs) have indicated a favourable effect of HPC 
in promoting their neuronal differentiation. A recent study by Volkmer et al. has also 
reported that HPC can restore the osteogenic differentiation capacity of human MSCs which 
was otherwise compromised under hypoxic conditions (Volkmer et al., 2010). Conversely, 
Potier et al. showed that short-term exposure of human MSCs to hypoxia (<1% O2) has a 
negative impact on their osteogenic differentiation under normal in vitro culture condition 
(21% O2) (Potier et al., 2007). Although the reason for this discrepancy remains unclear, the 
differences in cell type and species, oxygen tension, duration of exposure to hypoxic 
conditions and culture conditions could be the answers to these contradictory results.  
In terms of functional engraftment, a recent in vitro study by Jaderstad and associates has 
reported an increased in gap-junctional intercellular communication between hypoxic 
preconditioned neural stem cells and host cells in vitro, a consequence of increased 
expression of connexin 43 (Jaderstad et al., 2010). In support of this finding was a previous 
study reporting that HPC of human MSCs enhanced their xenografting efficiency into chick 
embryos, a model employed to examine the in vivo engraftment and differentiation potential 
of stem cells (Hung et al., 2007b). In addition, Xie et al. has reported that conditioned 
medium from rat neonatal cardiomyocytes subjected to 2 hours of hypoxia followed by 
overnight reoxygenation can induce MSC differentiation into cardiomyocyte lineage as 
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indicated by an increase in cardiac myosin heavy chain and troponin T expression (Xie et al., 
2006). The latter study has also suggested that HPC may induce secretion of various soluble 
differentiation factors, whose identity remains to be determined and depend on the cell 
types. However, what remains unknown is whether these effects of HPC in promoting stem 
cell differentiation and in vivo engraftment can be translated when preconditioned stem cells 
are transplanted into adult tissues. To this end, early studies on peripheral blood 
mononuclear cells (Akita et al., 2003; Kubo et al., 2008) and MSCs (Leroux et al., 2010; Li et 
al., 2002) have indicated that HPC enhances not only their differentiation into endothelial 
progenitor cells (EPCs) in vitro but also promotes neovascularisation when transplanted into 
the ischaemic hindlimb. This effect was associated with improvement of blood perfusion 
and acceleration of tissue repair. Nevertheless, the lack of detailed histological analysis of 
angiogenesis in the host tissues, i.e. quantifying the blood vessels derived from implanted 
cells, has cast doubt on the enhanced functional integration of these transplanted cells as the 
contributing mechanism (Akita et al., 2003). Instead, the improvement in overall 
neovascularisation in these studies can be interpreted as a result of increased angiogenic 
cytokines released by preconditioned cells, such as VEGF (Akita et al., 2003; Leroux et al., 
2010; Li et al., 2002), thus promoting intrinsic angiogenesis in the host. Supporting this 
notion is a study that showed MSCs subjected to ex vivo HPC expressed a higher level of 
VEGF mRNA and induced greater local VEGF production in the ischaemic hindlimb after 
implantation, possibly through activation of the canonical Wnt (wingless-related MMTV 
integration site) pathway (Li et al., 2002; Leroux et al., 2010).  
3.3 Cell migration 
In cell-based therapy, effective treatment also relies on the ability of transplanted stem and 
progenitor cells to migrate to the site of injured tissues to exert reparative and regenerative 
effects. Short-term exposure to hypoxia has been shown to enhance the migratory capacity 
of stem and progenitor cells ex vivo by modulating the expression of various chemokines 
and cytokines receptors. Hung et al. reported an upregulation of CXC3R1 and CXCR4 
expression on both mRNA and protein levels when MSCs were cultured under hypoxic 
condition compared with normoxia, resulted in an increased cell migration in response to 
the fractalkine/CX3CL1 and SDF-1α/CXCL12, respectively (Hung et al., 2007b). A recent 
study also showed that HPC enhances MSC adhesion, an important step during cell 
trafficking in vivo, through upregulation of CXCR4 and CXCR7 (Liu et al., 2010). The 
induction of these chemokine receptors has been shown to be driven mainly by transcription 
factor HIF-1α (Liu et al., 2010; Hung et al., 2007b; Tang et al., 2009). Using low dose of H2O2 
as a preconditioning stimulus, Li et al. also showed that the enhanced chemotaxis of 
preconditioned MSCs was attributed to the up-regulation of CXCR4 in an ERK-dependent 
manner (Li et al., 2009). Translating these in vitro findings into an in vivo setting, Tang et al. 
has shown that short-term exposure of murine cardiac progenitor cells to hypoxia not only 
enhanced their migratory activity in vitro but also in vivo recruitment to the ischaemic 
myocardium when administered intravenously, through a CXCR4-dependent manner (Tang 
et al., 2009). In addition to the chemokine mechanisms, other studies have suggested that 
HPC enhanced migratory function of stem and progenitor cells through regulation of 
cytokine signalling (Akita et al., 2003; Rosova et al., 2008; Ii et al., 2005). For instance, 
hypoxia enhanced the migratory function of human EPCs in response to VEGF, possibly 
through up-regulation of KDR/VEGFR2 expression (Akita et al., 2003). In another study, 
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Rosova and colleagues showed that HPC increased the expression of the tyrosine kinase 
receptor, c-Met, in preconditioned MSCs rendered the cells more responsive to HGF 
(Rosova et al., 2008). Interestingly, HPC can also induce the secretion of chemo-attractants 
from preconditioned MSCs to promote endothelial cell migration through Wnt4-dependent 
signalling pathway (Leroux et al., 2010).  
3.4 Cell proliferation 
Stem and progenitor cells self-renew and this is one of the properties that make them an 
attractive autologous cell source for cell-based therapy and tissue engineering, where 
success is highly dependent on abundant cell supply. Ex vivo cell expansion is traditionally 
performed under ambient oxygen concentration of 20% O2, which is considered to be 
hyperoxia compared to their physiological niches (2-7% O2). Thus, it is imperative to 
simulate various aspects of the stem and progenitor cells’ endogenous microenvironment, 
including hypoxia, in order to maintain their native characteristics and to comprehend how 
they respond to a hypoxic environment in injured ischaemic tissues. Studies investigating 
the effect of hypoxia on stem cell proliferation potential have yielded contradictory results, 
possibly due to the differences in hypoxic conditions, cell type, serum concentration and 
culture duration (Das et al., 2010). Compared to the routine normoxic culture of 20% O2, 
long-term culture of human MSCs in 1% O2 has been shown to reduce their proliferative 
potential (Hung et al., 2007b). Conversely, bone marrow-derived MSCs (D'Ippolito et al., 
2006; Grayson et al., 2007; Lennon et al., 2001; Ren et al., 2006), but not ASCs (Wang et al., 
2005), cultured under hypoxic conditions with slightly higher oxygen tension (≥2% O2), 
showed increased cell proliferation. Importantly, short-term exposure to hypoxia did not 
negatively affect the proliferative potential of stem cells (Francis & Wei, 2010; Leroux et al., 
2010; Rosova et al., 2008), an observation that will alleviate the safety concerns of HPC when 
clinical applications are being considered. 
4. Ex vivo pharmacological preconditioning of stem cells 
While ischaemic or hypoxic preconditioning has been shown to regulate multiple stress-
responsive mechanisms that promote stem and progenitor cell survival under various 
ischaemic conditions, preconditioning with specific pharmacological agents seems to target 
a more linear signalling pathway.  This has been explored in various studies on stem and 
progenitor cells (Table 3). 
4.1 Diazoxide 
The mitochondrial ATP-sensitive potassium (mitoKATP) channel is an important mediator of 
cardioprotection (Yellon & Downey, 2003; O'Rourke, 2004) where opening of the channels 
has been shown to induce protection by preventing calcium overload, inhibiting 
mitochondrial permeability transition pore (mPTP) opening, preserving ATP production, 
uncoupling of mitochondrial oxidative phosphorylation, succinate dehydrogenase 
inhibition, reducing detrimental reactive oxygen species (ROS) production at reperfusion 
and PKC activation. Using the mitoKATP opener diazoxide, Baines and colleagues were the 
first to demonstrate that opening of mitoKATP channels prior to ischaemia could mimic the 
infarct-limiting effect of IPC in the setting of myocardial ischaemia-reperfusion injury 
(Baines et al., 1999). Recently, diazoxide has also featured in a number of studies by Ashraf’s 
group to precondition stem and progenitor cells. They have shown that ex vivo 
preconditioning with diazoxide can promote skeletal myoblasts (Haider et al., 2010; Niagara 
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PC stimulus Cells In vitro In vivo Mechanisms References 
Diazoxide (200 
μM), 30 min 
Skeletal Mb 
(rat) ↑ survival 
(MI) ↑ survival; ↑ 
angiomyogenesis;
↑ LV function 





μM), 30 min 
Skeletal Mb 
(rat) ↑ survival 
(MI) ↑ survival & 
proliferation; ↑ 
angiomyogenesis;




Haider et al., 
2010 
Diazoxide (200 




(MI) ↑ survival; 
↓ infarct size; ↑ 
angiomyogenesis;





Afzal et al., 
2010 
Diazoxide (200 
μM), 1-3 h MSCs (rat)
↑ survival 
 - 
NFκB; Fas;  
miR-146a 
Suzuki et al., 
2010 
Diazoxide (200 
μM), 30 min MSCs (rat)
↑ survival 
 
(MI) ↑ survival; ↓ 
infarct size; ↑ LV 
function 
Akt; bFGF;  
HGF 
Cui et al., 
2010 
SDF-1 (50 ng/mL), 
1 h MSCs (rat)
↑ survival; 
↑ proliferation 
(MI) ↑ survival; 
↓ infarct size; ↑ 
angiomyogenesis;
↑ LV function 
Akt; CXCR4; 
VEGF 
Pasha et al., 
2008 
SDF-1 (10-100 
ng/mL), 24 h MSCs (rat)
↑ survival 
 - CXCR4 
Chen et al., 
2009 







(MI) ↑ survival; ↓ 
infarct size; ↑ 
myogenic diff.; ↑ 
angiogenesis; 
↑ LV function 
Akt; Cx43 Lu et al., 2009

















μg/mL), 24 h 
MSCs 
(human) ↑ VEGF production - PI3K; MEK 
Wang et al., 
2008b 
TGFα (0.01-1 
μg/mL), 24 h 
MSCs 




Wang et al., 
2009b 
PDGF (0.4 nM), 
5 d MSCs (rat) ↑ adipogenic diff. - - 
Tamama et 
al., 2006 





↑ osteogenic- diff. - - 
Tamama et 
al., 2006 
BMP-2 + bFGF + 
IGF-1 (10, 50 & 2 
ng/mL), 1-7 d 
MSCs (rat) ↑ survival; ↑ myogenic diff.
(MI) ↑ survival; ↓ 




Hahn et al., 
2008 
IGF-1 + bFGF (50 &
50 ng/mL), 1 h 
MSCs 
(mouse) 






1; Bax; Bak; 
16INK4a; p66shc; 
p53 
Khan et al., 
2011 
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PC stimulus Cells In vitro In vivo Mechanisms References 
Sevoflurane (2%), 
30 min x 3 
EPCs 




mM), 10 min 
ESCM 
(human) ↑ survival - 
mitoKATP; 
ΔΨm; ROS 
Sepac et al., 
2010 
CsA (0.5-5 μM), 
30 min MSCs (rat) ↑ survival - 
Bcl-2; BAD; 
ΔΨm 
Wang et al., 
2008a 








Wang et al., 
2009c 




(MI) ↑ survival; ↓ 





Yao et al., 
2009 
Melatonin (5 μM), 
24 h MSCs (rat)




(Renal IR) ↑ 
survival; ↑ renal 





Mias et al., 
2008 
Trimetazidine 
(10 μM), 6 h MSCs (rat) ↑ survival 
(MI) ↓ infarct size; 




Wisel et al., 
2009 
Fucoidan (10 






- - Zemani et al.,2005 
LPA (10 μM), 1 h MSCs (rat) - (MI) ↑ survival; ↑ angiogenesis VEGF 
Liu et al., 
2009 
Lithium Chloride
(5-20 mM), 24 h 
Skeletal Mb 
(rat) 
↑ survival & 
proliferation; 






Du et al., 
2009 
rhHsp90α (0.1-10 
μM), 24 h MSCs (rat) ↑ survival - 
Akt; ERK1/2; 
NO; Bcl-2;  
Bcl-xL; Bax 
Gao et al., 
2010 
β-met (2 mM),  
1 h MSCs (rat) ↑ survival - HSP72 
Cizkova et 
al., 2006 
rhEPO (10 U/mL), 
24 h 
ESNPCs 
(mouse) ↑ survival - Bcl-2 
Theus et al., 
2008 
Carbamylated EPO 
(100 ng/mL), 30 
min 
ESCM 
(human) - (MI) ↑ survival Akt 
Robey et al., 
2008 
Simvastatin (25 
μM), 24 h 
EPCs 
(human) ↑ survival - - 
Henrich et 
al., 2007 
Ang (angiopoietin), β-met (β-mercaptoethanol), CFC (colony forming capacity), CREB (cAMP response 
element binding protein), Mb (myoblasts), rh (recombinant human), ΔΨm (mitochondrial membrane 
potential). 
 
Table 3. Pharmacological preconditioning of stem and progenitor cells. 
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et al., 2007) and MSCs (Afzal et al., 2010; Suzuki et al., 2010) survival both in vitro and in vivo 
post-transplantation. Furthermore, transplantation of these preconditioned cells into the 
infarcted myocardium was associated with smaller infarct size, improved LV function, 
myogenic differentiation and angiogenesis (Afzal et al., 2010; Haider et al., 2010; Niagara et 
al., 2007). The potential mechanisms responsible for the cytoprotective effect of diazoxide in 
skeletal myoblasts include enhanced release of paracrine growth factors such as bFGF and 
HGF, and activation of survival kinase PI3K/Akt (Niagara et al., 2007). A later study by the 
same group expanded the mechanistic finding to include IL-11, the ERK1/2-STAT3 
signalling pathway and up-regulation of miR-21 (Haider et al., 2010). In MSCs, Afzal et al. 
reported NFκB activation as another important underlying mechanism of diazoxide-
induced protection especially during the late phase preconditioning (Afzal et al., 2010). The 
activation of NFκB in diazoxide preconditioned MSCs was subsequently implicated to 
regulate the expression of miR-146a, which in turn acts as a negative regulator of the Fas 
gene, a death receptor of apoptosis (Suzuki et al., 2010). 
4.2 Stromal cell-derived factor-1 (CXCR12) 
SDF-1 or CXCL12 is a cytokine belonging to the CXC chemokine subfamily. Specific binding 
of SDF-1 to CXCR4 induces dimerization of the receptor and activates multiple signalling 
pathways to regulate trafficking and differentiation of stem and progenitor cells (Chen et al., 
2011; Kucia et al., 2004). In addition, activation of the SDF-1/CXCR4 axis has been shown to 
promote cell survival and proliferation (Broxmeyer et al., 2003; Kucia et al., 2004; Hu et al., 
2007). The therapeutic potential of SDF-1 was later illustrated in an experimental model of 
myocardial infarction (Takahashi, 2010). For example, SDF-1 administration conferred 
cardioprotection through the PI3K/Akt signalling pathway in the setting of acute ischaemia-
reperfusion injury (Hu et al., 2007) and chronic ischaemic heart failure (Saxena et al., 2008). 
In the setting of hindlimb ischaemia, intramuscular injection of SDF-1 increased angiogenic 
factor VEGF expression, and enhanced the retention and neovascularisation efficacy of 
transplanted EPCs (Yamaguchi et al., 2003). Other delivery methods for SDF-1 include direct 
gene delivery with adenoviral vector (Abbott et al., 2004) and plasmid DNA (Hiasa et al., 
2004) encoding for SDF-1, or transplantation of genetically modified cardiac fibroblasts 
(Askari et al., 2003), MSCs (Zhang et al., 2007) or skeletal myoblasts (Elmadbouh et al., 2007) 
that over-expressed SDF-1 into the ischaemic tissues. Therefore, it is not surprising that SDF-
1 has been exploited as a potential preconditioning agent to enhance stem and progenitor 
cells survival and function without the long-term concern of genetic manipulation. In this 
regard, pre-treatment with SDF-1 has been shown to enhance MSC survival both in vitro 
(Chen et al., 2009; Pasha et al., 2008) and following intramyocardial transplantation in the 
infarcted myocardium through activation of PI3K/Akt signalling pathway and is dependent 
on CXCR4 (Pasha et al., 2008). In this study, the authors also demonstrated that SDF-1 
preconditioning enhances paracrine activities of transplanted MSCs in the infarcted 
myocardium and contributes to a smaller infarct size, improved cardiac function and 
promoted revascularization. Interestingly, the cytoprotective effect of SDF-1 appears not to 
be limited to pre-treatment. Treatment of EPCs with SDF-1 at the end of lethal serum 
deprivation also significantly reduced apoptotic cell death (Yamaguchi et al., 2003). 
However, in vivo application of SDF-1 requires vigilant safety evaluation before translating 
into the clinical setting because of the potentially detrimental side effects of its cleavage 
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products. For instance, SDF-1(5-68), a toxic product of SDF-1 cleavage by exopeptidases and 
metalloproteinase-2, has been implicated in neuroinflammation and neuronal death (Zhang 
et al., 2003). In which case, SSDF-1(S4V), a modified SDF-1 that is resistant to endogenous 
proteases cleavage, may have a better clinical safety profile (Segers et al., 2007). 
 
4.3 Growth factors 
Various growth factors have been employed to precondition stem and progenitor cells in order 
to enhance their paracrine activity, cell survival and differentiation (Abarbanell et al., 2009). 
For example, Lu and colleagues showed that preconditioning with IGF-1 improved bone 
marrow Sca-1+ stem cell survival against simulated ischaemia in vitro and after in vivo 
transplantation. This pro-survival effect of IGF-1 was shown to be dependent on the activation 
of PI3K/Akt (Lu et al., 2009) and ERK1/2 (Lu et al., 2010) signalling pathways, and a down-
stream mediator connexin-43. A subsequent study indicated that pre-treatment with IGF-1 
also enhances Sca-1+ cell cardiomyogenesis potential and transplantation of these 
preconditioned cells into infarcted heart mitigated myocardial infarction and ventricular 
dysfunction (Lu et al., 2009). Moreover, MSCs exposed to IGF-1 had an enhanced migratory 
response to SDF-1, a response dependent on the PI3K/Akt signalling pathway (Li et al., 2007).  
It has been well documented that epidermal growth factor (EGF), the prototypical growth 
factor with intrinsic protein tyrosine kinase activity, plays an important role in the regulation 
of cell growth, proliferation and differentiation by binding to its receptor (Wells, 1999). In 
MSCs, EGF has been shown to promote cell proliferation and motility which are beneficial for 
ex vivo cell expansion prior to in vivo transplantation, but fail to rescue MSCs from low serum-
induced apoptosis despite an elevation of Akt. Similar effects were observed with platelet-
derived growth factor (PDGF) (Tamama et al., 2006). On the other hand, pre-treatment with 
TGFα, another member of the EGF superfamily and a potent activator of EGF receptor, has 
been shown to enhance the therapeutic potential of MSCs in an experimental model of acute 
myocardial ischaemia-reperfusion injury in terms of myocardial function recovery and 
inflammation (Herrmann et al., 2010b). These beneficial effects of TGFα have been attributed 
to the reduction in pro-inflammatory cytokine production and increased VEGF production. 
The latter effect was shown to be mediated by MEK and PI3K signalling pathways (Herrmann 
et al., 2010b). It is interesting to note that the effect of TGFα on VEGF production in MSCs has 
been demonstrated as bimodal, i.e. production of VEGF was suppressed by low concentrations 
of TGFα whereas high concentrations increased the secretion (Wang et al., 2008b). In addition 
to VEGF, TGFα treatment also increases the production of HGF from MSCs (Wang et al., 
2009b). HGF is an important signalling factor in stem cell-mediated repair where it promotes 
stem cell adhesion, migration and survival (Vandervelde et al., 2005). Although the potential 
of HGF as a preconditioning agent to promote stem and progenitor cell survival is yet to be 
confirmed, existing studies have showed that short-term exposure of MSCs to HGF can 
activate Akt and ERK1/2 pro-survival kinases, and induce expression of anti-apoptotic 
protein, Bcl-2 and Bcl-xL (Forte et al., 2006). Additionally, HGF treatment also increased MSC 
motility function through up-regulation of c-Met receptors and induced their differentiation 
along a myogenic lineage, effects that can enhance their therapeutic potential in cardiac repair 
(Forte et al., 2006; Neuss et al., 2004; Rosova et al., 2008). Regarding cell proliferation, HGF 
treatment was reported to have a negative impact on MSC proliferation by blocking cells in the 
G0-G1 phase through p38 MAPK pathway and concomitant up-regulation of cell cycle 
progression inhibitors, p21waf1 and p21kip (Neuss et al., 2004; Forte et al., 2006).  
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Although different growth factors may share some common downstream signalling 
pathways in modulating stem and progenitor cell functions, they also independently 
activate distinct signalling cascades (Abarbanell et al., 2009). This rationale that a 
combination of multiple growth factors may have additive and synergistic effects in 
promoting stem and progenitor cell survival and functional improvement, offers a strategic 
advantage over the approach involving the use of a single factor. In this respect, a recent 
study by Hahn et al has demonstrated the pro-survival effect of multiple growth factors in 
MSCs using a combination of IGF-1, bFGF and BMP-2 (Hahn et al., 2008). Treatment with 
this growth factor cocktail also enhanced MSC cardiac differentiation efficiency and 
incurred cytoprotection of co-cultured adult cardiomyocytes. This effect was dependent on 
gap-junction communication leading to phosphorylation of Akt and c-AMP response 
element binding protein (CREB) in cardiomyocytes. Moreover, the therapeutic efficacy of 
MSCs in infarcted myocardium was also significantly potentiated with this multiple growth 
factors preconditioning method (Hahn et al., 2008). Similarly, Khan et al preconditioned 
MSCs isolated from diabetic mice with a combination of IGF-1 and bFGF and showed 
enhanced cell survival, proliferation, motility and angiogenic potential compared to 
untreated cells or cells treated with single growth factor (Khan et al., 2011). Furthermore, a 
potent synergistic effect between TGFα and TNFα has been demonstrated to enhance the 
MSC-derived VEGF and HGF production that may be essential for cell survival, migration 
and angiogenesis (Herrmann et al., 2010a; Wang et al., 2008b; Wang et al., 2009b). 
4.4 Anaesthetics 
Anaesthetics, routinely administered in patients during surgery, are widely recognised to have 
preconditioning properties protecting the heart and many other organs against ischaemia and 
reperfusion injury in laboratory settings as well as in humans with coronary heart diseases 
(Huffmyer & Raphael, 2009; Yellon & Downey, 2003). The efficacy of anaesthetic-induced 
preconditioning has been shown to be similar to IPC in terms of infarct size reduction, 
increased collateral blood flow and attenuated inflammatory responses during ischaemia. 
Although the mechanisms underlying the protective effect of anaesthetic-induced 
preconditioning have been shown to resemble those responsible for IPC (Zaugg et al., 2003), 
Mullenheim et al showed that administration of sevoflurane combined with IPC can 
synergistically protect rabbit hearts against myocardial infarction indicating the existence of 
parallel protective mechanisms (Mullenheim et al., 2003). In ESC-derived cardiomyocytes, 
brief exposure to the commonly used volatile anaesthetic, isoflurane, significantly attenuated 
cell death against oxidative stress through opening of mitoKATP channels, production of 
signalling ROS and inhibition of mPTP opening (Sepac et al., 2010). Other benefits include 
enhanced cell growth capacity and increased expression of pro-angiogenic VEGF as 
demonstrated in human EPCs preconditioned with sevoflurane (Lucchinetti et al., 2009). 
4.5 Cyclosporin-A (CsA) 
The mPTP is a non-specific channel of the inner mitochondrial membrane, whose opening at 
the onset of reperfusion is a critical mediator of lethal myocardial ischaemia-reperfusion 
injury. IPC exerts its cardioprotective effect by inhibiting the opening of the mPTP and 
pharmacological inhibition of mPTP with CsA has been shown to confer cytoprotection both in 
vitro and in vivo (Hausenloy & Yellon, 2003; Lim et al., 2007). In addition to inhibiting mPTP 
opening, CsA can also inhibit calcineurin-mediated dephosphorylation of the apoptogenic 
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protein BAD and uncouple the mitochondrial respiratory chain, which might, in itself, result in 
protection (Wilkins et al., 2004). Interestingly, mPTP can also open reversibly under basal 
conditions without causing cell death. This form of reversible non-pathological mPTP opening 
has been noted to contribute to the cardioprotection elicited by IPC through the mitochondrial 
generation of signalling ROS and the subsequent activation of the pro-survival kinases Akt 
and ERK1/2 (Hausenloy et al., 2010). In stem cells, pre-treatment with CsA has been shown to 
protect MSCs from hypoxia-reoxygenation induced apoptosis through stabilizing 
mitochondrial membrane potential and promoting Bcl-2 and phosphorylated BAD protein 
expression (Wang et al., 2008a). In line with this study, we recently showed that pre-treatment 
with 0.2 μM of CsA for 30 minutes effectively increased the resistance of human ASCs to 
subsequent simulated ischaemia-induced cell death (Figure 2, unpublished data). 
 
 
Fig. 2. Preconditioning with CsA confers cytoprotection in stem cells. Pre-treatment with 
CsA (0.2 μM, 30 min) reduced cell death (determined by propidium iodide staining, arrow 
heads) in hASCs subjected to 15 hours of simulated ischaemia (<1% O2 and ischaemic buffer 
as described previously (Lim et al., 2008)) from 58.5±2.6% to 42.5±1.8% (n=4-5, P < 0.05). 
4.6 Lipopolysaccharide 
LPS is an antigenic component of the outer membrane of gram-negative bacteria and an 
agonist of Toll-like receptor-4 (TLR4) capable of eliciting immune responses in animals. The 
cardioprotective effect of LPS preconditioning was previously demonstrated in an in vivo 
murine model of myocardial ischaemia-reperfusion injury (Ha et al., 2008). Evidence 
supporting the pro-survival effect of LPS preconditioning in MSCs was recently provided 
by Wang and colleagues. The authors reported that activation of Toll-like receptor-4 (TLR4) 
with low dose of LPS can prevent MSCs from apoptotic cell death induced by oxidative 
stress and serum deprivation through PI3K/Akt- and NFκB-dependent mechanisms (Wang 
et al., 2009c). Furthermore, transplantation of these LPS-preconditioned MSCs into infarcted 
rat hearts significantly improved cardiac function, reduced apoptosis and fibrosis, and 
enhanced angiogenesis (Yao et al., 2009).  
4.7 Other agents 
Other drugs and hormones have also been employed as preconditioning agents to promote 
stem and progenitor cell survival and function. For example, pre-treatment with the pineal 
hormone melatonin can improve the therapeutic effectiveness of MSCs in the setting of 
acute renal ischemia-reperfusion injury by potentiating their survival and paracrine activity 
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(Mias et al., 2008). Trimetazidine is a cytoprotective anti-ischaemic agent that acts to reduce 
ischaemia-induced metabolic damage by shifting the energy substrate preference from fatty 
acid oxidation to glucose oxidation. It has been employed recently to precondition MSCs 
and showed increased cell survival and enhanced therapeutic potential in reducing 
myocardial ischaemic injury (Wisel et al., 2009). Fucoidan, a high molecular weight 
sulphated polysaccharide, also favourably enhanced the migratory potential of pre-treated 
EPCs in vitro. Although alone it did not promote angiogenesis, treatment with fucoidan 
potentiated the angiogenenic effect of bFGF in EPCs (Zemani et al., 2005). Du et al. 
preconditioned skeletal myoblasts with lithium chloride and showed enhanced cell 
survival and increased gap-junctional coupling with co-cultured neonatal cardiomyocytes, a 
result of increased Cx43 expression (Du et al., 2009). Similarly, pre-treatment with the 
endogenous phospholipid signalling molecule, lysophosphatidic acid (LPA), can improve 
MSC survival in vivo in ischaemic myocardium and enhance their angiogenic effects (Liu et 
al., 2009). Interestingly, an in vitro study by the same group indicated that LPA failed to 
precondition MSCs (Chen et al., 2008). In this study, the anti-apoptotic effect of LPA was 
only evident when the drug was present throughout the hypoxia and serum deprivation 
insult but not when LPA was removed after the pre-treatment period. Nevertheless, the 
cytoprotective effect of LPA was demonstrated to be dependent on the activation of LPA 
receptor-1, and pertussis toxin-sensitive PI3K/Akt and ERK pathways (Chen et al., 2008).  
Heat shock proteins (HSP) are known protective mediators of preconditioning induced by 
ischaemia, hypoxia, heat stress and oxidative stress (Das & Maulik, 2006) (Table 1). In MSCs, 
preconditioning with recombinant human HSP90α produced an anti-apoptotic effect via 
activation of PI3K/Akt and ERK signalling pathways (Gao et al., 2010). Prior to this study, 
genetic modification to over-express HSP20 had been shown to enhance the survival of 
MSCs against oxidative stress and improve their therapeutic potential in ischaemic rat heart 
(Wang et al., 2009a). Therefore, it is not surprising that drugs capable of increasing HSP 
expression are potential preconditioning agents. Indeed, short-term exposure to β-
mercaptoethanol has been shown to protect MSCs from oxidative injury, a cytoprotective 
effect associated with an elevation of HSP72 expression (Cizkova et al., 2006).  
The haematopoietic cytokine erythropoietin (EPO) also exerts cardioprotection in both 
animal and clinical studies with many intracellular signalling pathways implicated, 
including PI3K/Akt, ERK1/2, p38 MAPK, PKC, eNOS and guanylyl cyclase and the 
opening of mitochondrial KATP channels (Riksen et al., 2008). In MSCs (Hu et al., 2008; Theus 
et al., 2008) and embryonic stem cell-derived neural progenitor cells (NPCs) (Francis & Wei, 
2010; Theus et al., 2008), EPO is already involved in the cytoprotective effect of HPC. As a 
preconditioning agent, recombinant human EPO mimicked the cytoprotective effect of HPC 
in protecting mouse NPCs against serum deprivation-induced apoptotic cell death (Theus et 
al., 2008). Similarly, ESC-derived cardiomyocytes survived better in the infarcted mouse 
hearts when they were preconditioned with carbamylated EPO prior to implantation (Robey 
et al., 2008). The hydroxyl-methylglutaryl coenzyme A reductase inhibitors, also known as 
statins, are effective for lowering serum cholesterol and have been widely prescribed for 
patients with coronary heart diseases as the primary and secondary preventive treatment of 
cardiovascular events. In addition to lipid-lowering effects, statins have been shown to exert 
multiple pleiotropic effects including protection from MI, improved endothelial function 
and reduced platelet adhesion and atherosclerotic plaque rupture (Ludman et al., 2009). In 
MSCs, treatment with lovastatin has been shown to improve cell survival when challenged 
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with hypoxia and serum deprivation, a protection mediated by PI3K/Akt and ERK1/2 
pathways (Xu et al., 2008). Similarly, human EPCs pre-treated with simvastatin also exhibit 
higher resistance against TNFα induced apoptotic cell death (Henrich et al., 2007).  
5. Ischaemic or hypoxic preconditioning in vivo mobilises endogenous stem 
and progenitor cells 
Endogenous stem and progenitor cells can be mobilized from their niches in various organs 
and tissues, including bone marrow, skeletal muscle, heart, brain, skin, liver, adipose, blood 
vessels and others, and then home to target tissues. This property of stem and progenitor 
cells has fuelled investigations of potential clinically adaptable strategies to actively recruit 
endogenous stem and progenitor cells to serve as integrated participants in regenerating the 
injured tissues through stem cell trans-diffentiation and/or as supportive players via 
pleiotropic paracrine effects (Chen et al., 2011; Krankel et al., 2011). By subjecting rats to 3 
weeks of chronic hypoxia, Rochefort et al have unveiled the potential of HPC in mobilising 
endogenous MSCs. In this study, circulating MSCs were higher in rats subjected to chronic 
hypoxia compared to the control normoxic cohort (Rochefort et al., 2006) (Table 4). 
Interestingly, this hypoxic condition did not affect the circulating level of haematopoietic 
stem cells (HSCs) indicating a possible cell-type specific effect of HPC (Rochefort et al., 
2006). In line with this study, rats preconditioned with 6 hours of hypoxia daily for 6 weeks 
also have a higher level of CD34+CXCR4+ cells in their blood circulation and in the infarcted 
hearts with concomitant reduction in acute myocardial ischaemia-reperfusion injury (Lin et 
al., 2008). Using a relatively more invasive preconditioning protocol of transient coronary 
artery occlusion and reperfusion, Ii and colleagues have showed that IPC modulates 
endogenous EPC kinetic and increases their recruitment to the infarcted myocardium (Ii et 
al., 2005). This observation was associated with infarct size limitation, increased 
angiogenesis and cardiac function improvement, beneficial effects that were shown to be 
strongly dependent on the iNOS and eNOS activities of the EPCs (Ii et al., 2005). The 
mobilizing and homing effect of IPC was subsequently illustrated on other cell types such as 
MSCs and HSCs using a clinically relevant porcine myocardial ischaemia-reperfusion injury 
experimental model (Gyongyosi et al., 2010). Excitingly, Kamota et al showed that 
preconditioning applied on the abdominal aorta can also increase the accumulation of bone 
marrow-derived sca-1+ and c-kit+ stem cells in infarcted hearts through a SDF-1/CXCR4-
dependent mechanism, thus protecting the hearts against injury (Kamota et al., 2009). This 
finding is clinically important as it supported the translation of the non-invasive strategy of 
remote IPC into clinical practise. Remote IPC is a clinically amenable strategy which can be 
induced by simple transient limb ischaemia. This cardioprotective strategy has been 
extensively trialled in patients undergoing cardiac surgeries such as coronary angioplasty 
and coronary artery bypass surgery, and has thus far showed tangible beneficial effects in 
reducing myocardial injury with no known adverse risks (Hausenloy & Yellon, 2008). 
Although the precise molecular and cellular mechanisms governing the homing effect of 
ischaemic/hypoxic preconditioning on endogenous stem and progenitor cells remain to be 
fully addressed, evidence of a role for the chemokine axis SDF-1/CXCR4 (Kamota et al.,  
2009; Lin et al., 2008) and EPO (Lin et al., 2008) has been found in recent studies. Other 
possible stem cell homing factors include VEGF, colony-stimulating factor, monocyte  
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PC stimulus Models End points Mechanisms References 
Hypoxia; 
24 h of 50kPa O2 
daily for 3 weeks
Rat, Sham ↑ circulating MSCs - Rochefort et al., 2006 
Hypoxia; 
6 h of 10% O2 daily 
for 6 weeks 
Rat, MI 
↑ circulating & heart 
CD43+CXCR4+ cells; ↓ 




Lin et al., 
2008 
Ischaemia; 




↑ circulating & heart EPCs;




VEGF Ii et al., 2005 
Ischaemia; 




↑ circulating HSCs; 
↑ heart MSCs & HSCs; 
↓ infarct size & apoptosis;










↑ circulating CD43+flk-1+ 
cells; ↑ heart Sca-1+ & c-kit+ 
BMSCs; ↓ infarct size & 
apoptosis; ↑ LV function 
SDF-1/CXCR4; 
VEGF 
Kamota et al., 
2009 
Ischaemia; 
25 min/7 d renal 
artery O/R 
Mouse, RI ↑ renal EPCs - Patschan et al., 2006 
Table 4. Effect of in vivo ischaemic/hypoxic preconditioning on endogenous stem and 
progenitor cells. BMSCs (bone marrow stem cells), O/R (occlusion/reperfusion), RI (renal 
ischaemia). 
chemotactic protein-3, HGF, IGF-1, IL-8/growth regulated oncogene-1, stem cell factor, 
TGF-β3, Wnt antagonist and other chemokines (Krankel et al., 2011; Binger et al., 2009; Chen 
et al., 2011). However, whether these navigational factors govern the homing effect of in vivo 
IPC warrants further investigation. In perspective, a living body appears to host a great 
reservoir of various stem and progenitor cells ready to be recruited for regeneration and 
repair, and can be catalysed by external stimuli such as IPC. This is of great clinical 
importance because in vivo IPC can be readily and non-invasively achieved in patients. 
However, given the fact that majority of ischaemic disease sufferers are elderly patients, and 
endogenous stem and progenitor populations and functions are known to decline with age 
and are negatively affected by other co-morbidity such as diabetes and hypertension 
(Krankel et al., 2011), it is important to determine whether there are sufficient populations of 
functionally competent resident stem and progenitor cells to be mobilised and recruited to 
the target tissues to exert significant repair in older patient cohorts. Otherwise, a 
combination of exogenously administered cells and potent homing factors might be utilised 
to supplement the endogenous reservoirs for effective cell-based therapy. Therefore, 
detailed characterisation of various endogenous stem cell niches and deciphering the 
mechanisms governing endogenous stem cell repopulation, mobilisation and homing to 
target tissues are pivotal to the future development of clinically sound pharmacological 
interventions to harness fully the host’s innate regenerative capacity. 
 




Based on the existing literature, it is undeniable that non-genetic approaches of 
preconditioning techniques offer much promise as cytoprotective strategies for stem cell 
therapy, without the long-term concern of genetic manipulation. These pro-survival 
strategies are therefore well suited to clinical translation. Collectively, preconditioning of 
stem and progenitor cells elicits multiple beneficial effects including (1) promotion of cell 
survival in the hostile ischaemic environment, (2) enhancement of paracrine activity to 
create a supportive environment that is rich in trophic and angiogenic factors, (3) increase of 
cell motility and trafficking, (4) increase of cell proliferative potential, (5) promotion of cell 
differentiation allowing functional integration, and (6) enhancement of therapeutic efficacy 
in ischaemic tissues in vivo.  
In cell based therapy for ischaemic diseases, the ability of preconditioning ex vivo to enhance 
stem and progenitor cell survival and function means more implanted cells will be available 
for tissue repair and thus fewer donor cells may be needed to achieve the same functional 
outcome. In parallel, in vivo preconditioning is capable of harnessing the host’s inherent 
regeneration mechanisms through activation of various paracrine signalling cascades, and 
mobilizing and recruiting resident stem and progenitor cells for effective therapeutics 
(Figure 3). Therefore, it will be of great therapeutic interest to determine whether there is an 
additive or synergistic effect of ex vivo preconditioning of implanted cells and in vivo 
preconditioning of host tissues, which may provide an optimal regenerative environment 





Fig. 3. Potential additive effect of ex vivo preconditioning (transplanted exogenous stem 
cells) and in vivo preconditioning (patients) to enhance tissue repair and tissue engineering 
with stem cells.  
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1. Introduction 
The human retina is a complex, layered tissue responsible for the perception of the visual 
stimuli coming from the external environment. Since the visual inputs account for about 
30% of our sensory stimulations, it is not surprising that partial or complete blindness 
results in a strong decrease of life quality. Several diseases affect the retina, often leading to 
degeneration of one or several cell types. The damage induced by these diseases is often 
irreversible, thus leading to a permanent loss of the visual ability. 
Over the last decades significant progress has been made to elucidate the molecular basis of 
retinal degenerative diseases. This knowledge is necessary in order to design valid 
approaches for the treatment of retinopathies. However, the extreme genetic heterogeneity 
of these diseases, combined with the complex molecular nature of the underlying 
degenerative processes, has hampered the design of definitive therapies. Indeed, 
pharmacological treatments are only partially effective and tend to treat the effect of the 
disease, not the underlying cause. Furthermore, despite the recent technical advances, drug 
delivery into the retina may reveal challenging (reviewed in Yasukawa et al., 2011). On the 
other hand, gene therapy reveals as a promising alternative approach for inherited 
retinopathies. However, although significant progress has been achieved in treating 
recessive forms of retinopathies, dominant or multi-factorial forms are more difficult to 
treat, revealing the current limits of gene-based therapies (Farrar et al., 2010). 
Thus, other strategies are needed to treat these diseases. One interesting approach, which 
will not be covered in this review, is the stem cell-based therapy, where stem cells can be 
differentiated in vitro and then transplanted to replace dead cells (for a review see Bull and 
Martin, 2011; Dahlmann-Noor et al., 2010; Locker et al., 2010). Another promising strategy is 
to promote the regeneration in vivo of the tissues (or organs) affected by the disease. 
Although the field of regenerative medicine is relatively young, the continuous findings on 
the mechanisms regulating regeneration in model organisms is improving our knowledge 
on the regenerative phenomena, and in some cases this information can be used to induce or 
increase regeneration in particular contexts (reviewed in Stoick-Cooper et al., 2007). 
In the first part of this review, we will introduce some of the most common retina 
degenerative diseases that affect people worldwide, namely retinitis pigmentosa (RP) and 
age-related macular degeneration (AMD), providing the reader with a general description 
of these retinopathies. In the second part, we will discuss some of the animal models used 
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to mimic particular features of retinal diseases, useful to understand the molecular 
mechanisms underlying retina degeneration. The information gathered from these models 
will be instrumental for the design of accurate and effective therapies. In the final part of 
this chapter we will present animal models, like transgenic frogs or fishes, capable of 
regenerating their damaged retinas. The use of these models is generating important and 
promising knowledge on the molecular pathways regulating neural repair, which could 
one day be used to stimulate retinal regeneration in humans. Thus, we will also review 
the cellular sources and molecular components playing a fundamental role in in vivo 
regeneration. Recent studies, aimed at stimulating regeneration processes in vivo by 
genetic or pharmacological manipulation of signaling pathways, will also be covered in 
this part. 
2. Retinal diseases 
Retinopathy is a generic term regarding non-inflammatory diseases affecting the retina. The 
damage usually affects severely the vision ability, especially when the macula (the region of 
human retina where cone photoreceptors concentrate) or the optic nerve are concerned. 
Retinopathies can arise as a consequence of other disorders, for example diabetes, or as a 
consequence of aging. The degeneration process is generally progressive, resulting in severe 
sight impairment in older patients. Furthermore, although the pathology affects primarily a 
given cell type, secondary events can arise extending the degeneration to other cell types. In 
some cases, genetic mutations are the underlying causes of the pathology, which can 
manifest alone or as a part of a syndromic disease. Due to their prevalence and to the highly 
debilitating loss of sight they cause, RP and AMD gained much attention in medical and 
clinical research.   
2.1 Retinitis pigmentosa  
RP is a group of inherited genetic diseases with a worldwide prevalence of 1 on 4000 
individuals in the industrialized world. RP was first described around 1855 by the Dutch 
ophthalmologist Franciscus C. Donders, while observing pigmented speckles in a patient’s 
degenerating retina. In the most typical form of RP, rod photoreceptors undergo a gradual 
degeneration, eventually leading to their death which occurs either by apoptotic or non-
apoptotic mechanisms (reviewed in Berson, 1993; Chang et al., 1993; Hartong et al., 2006; 
Sancho-Pelluz et al., 2008). As a result, the loss of rods compromises the peripheral and 
night vision, as evidenced by the restriction of visual field (tunnel vision) and night 
blindness in RP patients. 
As the disease progresses, the cones residing in the macula are also affected, degenerating 
after the rod photoreceptor death. As a consequence, other symptoms are manifested like 
color-blindness and loss of the central vision, resulting in total visual impairment (Berson, 
1993; Hartong et al., 2006). The onset of RP symptoms is variable: some patients develop 
visual impairments during childhood, while others remain asymptomatic until mid-
adulthood. There is no treatment to cure patients with RP, who usually become legally blind 
by the 40th year of age, because of a severe constriction of the visual field. Retinas of patients 
affected by RP undergo dramatic changes, as can be observed by fundus examination. 
Besides accumulation of pigmented deposits, retina atrophy, attenuation of retinal vessels 
and reactive gliosis are also associated with RP (reviewed in Hamel, 2006). 
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The pattern of inheritance of RP is complex and depends on the gene being affected. 
Generally, RP presents as a monogenic disease that can be inherited as autosomal dominant 
(24% of the cases), recessive (41%), or X-linked (22%). However, the remaining of the cases 
are considered to result from non-Mendelian inheritance or environmental factors (reviewed 
in Wright et al., 2010). So far, more than 45 genes have been shown to be involved in RP 
(http://www.sph.uth.tmc.edu/retnet/), which highlights the high genetic heterogeneity of 
the disease. Nonetheless, the significance of gene mutations in RP, as well as the molecular 
mechanisms leading to photoreceptors degeneration, is still poorly understood. 
2.2 Age-related macular degeneration  
AMD is a group of conditions that affect the central retina, particularly the macula. AMD 
represents the leading cause of vision loss in individuals above the 60th year of age, with a 
prevalence of 30% among people older than 75. Among these patients, about 10% show 
signs of advanced AMD, which is characterized by an extensive deterioration of central 
vision, with a tremendous impact on normal daily activities such as reading or 
deambulating (reviewed in Prasad et al., 2010). Age is one of the risk factors for this disease. 
It is estimated that, since the life expectancy is increasing, with an escalation of people 
reaching the age of 70 or greater, the prevalence of AMD in 2020 will double (for reviews, 
see Liutkeviciene et al., 2010; Prasad et al., 2010). Besides age, other factors such as oxidative 
stress and genetics are known to play a major role in the onset of the disease. However, it is 
important to note that the precise causes of AMD remain still unclear. Although AMD 
affects mainly elderly people, young may also be affected in the context of genetic 
(monogenic) disorders characterized by early onset, affecting people younger than 40 
(reviewed in Rattner and Nathans, 2006). 
Initially, AMD is characterized by the presence of large and poorly demarcated “drusen”, 
aggregates of lipids and proteins which accumulate between the retinal pigmented 
epithelium (RPE) and the Bruch’s membrane. RPE underlying these drusen displays some 
abnormalities such as hypo-pigmentation. Although at this stage there is no significant 
impairment on visual acuity, there is a high risk of progression to more severe forms of 
AMD, or late AMD. Late AMD is characterized by localized degeneration of RPE 
(geographic atrophy or dry - non exudative – AMD). Eventually, new blood vessels from the 
choroid above the RPE can grow into the macula, leading to the so-called exudative (or wet) 
AMD. These blood vessels are very fragile and may result in local bleeding, leading to 
blurry vision and visual distortion. Ultimately, these lesions can form a fibrous scar, which 
typically result in irreversible loss of central vision (Prasad et al., 2010; Rattner and Nathans, 
2006). It is important to note that, although RPE cells are primarily affected by AMD, it is the 
subsequent loss of photoreceptors that accounts for vision loss. 
As stated above, genetics play also a role in macular degeneration. In particular, some 
inherited forms are known, characterized by early (or juvenile) onset. For example, Best 
Vitelliform Macular Degeneration (BVMD) and Stargardt-like disease are both dominant 
inherited juvenile forms of macular degeneration (reviewed in Vasireddy et al., 2010; Xiao et 
al., 2010). These diseases are characterized by extensive accumulation of lipofuscin, yellow 
granules containing lipids, atrophy of the RPE and loss of the central vision, all clinical 
features shared by several forms of age-related macular degeneration. However, clinical 
profiles of inherited macular degeneration may vary among patients, indicating the 
intervention of other factors in modelling the disease. One of such factors could be oxidative 
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stress. Interestingly, susceptibility to the onset of macular degeneration is increased by 
oxidative damage that leads to cumulative mutations in mitochondrial DNA of retina cells 
(reviewed in Jarrett et al., 2010). 
3. Animal models for retinopathies 
Because animals develop retinal diseases with similar traits as in humans, they are 
commonly used to improve our understanding of the molecular pathogenesis of hereditary 
retinal degeneration. Animal models can also serve to screen compounds for therapeutic 
use. Different species such as mice, rats, dogs, cats and even pigs have contributed to the 
study of retinal degeneration (reviewed in Fletcher et al., 2011; Rivas and Vecino, 2009). 
Describing all these different models is beyond the aims of this review. Thus, in this section 
we will focus on some models mimicking retina degeneration, which greatly contributed to 
the elucidation of molecular pathways underlying the different retinopathies. 
3.1 Mouse models for retina degeneration 
Natural mutant mice or knock-out animals allowed to identify several important genetic 
factors involved in retina degeneration. Importantly, these genes share analogous mutations 
in human. In addition, the effects on retinal structure and function of gene mutations 
associated with retinal diseases can also be tested by means of transgenesis. In many cases 
the proteins encoded by these genetic factors were shown to be sensible targets for 
pharmacological treatments or gene therapy, giving important results in terms of clinical 
and medical investigation. Below, we will give a brief overview of the different mouse 
models used to mimic RP or AMD, describing the degenerative mechanisms they 
contributed to elucidate (see also Table 1). 
3.1.1 Mouse models for RP: Mutations in rhodopsin 
The rod visual pigment rhodopsin, a G-protein coupled receptor that initiates the visual 
transduction cascade, was the first protein found to be mutated in RP. Rhodopsin mutations 
are responsible for 30–40% of autosomal dominant forms of RP (reviewed in Fletcher et al., 
2011; Wang et al., 2005). One of the most common mutation in human rhodopsin is the 
substitution of proline for histidine in position 23 (P23H) (Dryja et al., 1990). Mice 
expressing such mutated rhodopsin develop significant photoreceptor degeneration, with a 
consequent decrease in visual function (Olsson et al., 1992). Importantly, photoreceptor 
degeneration was also observed in control transgenic mice overexpressing wild type 
rhodopsin. Together, these data suggested that the expression levels of either normal or 
aberrant rhodopsin may play a role in triggering cell death (Olsson et al., 1992). Based on 
cell culture and transgenic mice, it was shown that most rhodopsin mutants interfere with 
the folding, the stability and/or the transport to the membrane of rhodopsin protein 
(Kaushal et al., 1994; Roof et al., 1994; Wang et al., 2005). However, since different results are 
obtained in various animal models, the exact mechanisms underlying rhodopsin-dependant 
photoreceptor cell degeneration is still not well understood and remains controversial. 
Therefore, generating additional, more appropriate, animal models is still an issue. Along 
this line, a knock-in mice model expressing P23H rhodopsin was recently reported and 
highlighted defective glycosilation and rapid degradation of the mutant protein, in addition 
to disorganization of the rod outer segments, which may account for photoreceptor 
degeneration (Sakami et al., 2011). 
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3.1.2 Mouse models for RP: Mutations affecting phototransduction pathway 
Among the genes involved in phototransduction cascade, phosphodiesterase 6 (PDE6) genes 
are the most studied. Phosphodiesterase 6 is a hetero-tetrameric enzyme consisting of one α, 
one ß and two γ subunits, involved in cGMP (cyclic guanosine monophosphate) breakdown. 
Mutations in any of the three subunits give rise to recessive forms of RP. Most of the 
knowledge on the molecular mechanisms concerning this specific form of RP comes from 
studies on one mouse strain, known as Retinal degeneration 1 (rd1), where the PDE6B gene, 
encoding the ß subunit, is mutated. The corresponding mutation in humans accounts for 
about 5% of the recessive forms of RP (http://www.sph.uth.tmc.edu/retnet/). These 
animals are natural loss of function mutants closely mimicking the human disorder. In these 
mice, non-functional PDE6B protein leads to accumulation of high levels of cGMP in the 
rods (Paquet-Durand et al., 2009). Thus, the sustained levels of cations contribute to 
constantly depolarize rod photoreceptors, eventually causing these cells to die. More 
recently, it has been shown that cyclic nucleotide-gated ion channels (CNGs) play a pivotal 
role in the PDE6B-dependent cell death mechanism (Paquet-Durand et al., 2011). These 
channels allow the influx of Na+ and Ca2+ inside the cells in a cGMP-dependent manner, and 
increased levels of cGMP are correlated with excessive intracellular concentration of Ca2+ 
ions. Indeed, as a confirmation of these results, knock-out mice for Cngb1 gene (lacking rod 
CNGs) in a rd1 mutant background, show a substantial rescue of rod and cone cell-
morphology and function, compared to single rd1 mutants. These double mutant mice show 
also an increased rate of photoreceptor survival compared to the single mutant rd1 (Paquet-
Durand et al., 2011). Thus, the results reported here argue for a major role of CNGs and 
calcium in triggering rod degeneration. 
3.1.3 Mouse models for RP: Mutations affecting photoreceptor structural proteins 
Photoreceptor outer segments are continuously renewed to replace proteins and lipids that 
are damaged by light and highly oxidative environment. Maintenance of the integrity and 
renewal of the outer segment disk membranes is thus critical for correct photoreceptor 
function. Peripherin is an integral membrane protein that localizes to the rim of 
photoreceptor outer segments and was proposed to act as a structural element for the outer 
segment membranes (Connell and Molday, 1990; Molday et al., 1987). Mutations in 
Peripherin (PRPH) are a common cause for autosomal dominant RP, accounting for about 5% 
of the cases (reviewed in Boon et al., 2008). Retina degeneration slow (rds) mice are 
naturally occurring homozygous mutants, carrying a mutation in the Peripherin gene 
(Connell et al., 1991; Travis et al., 1989). These mice are characterized by photoreceptor 
degeneration and abnormal morphological features in the outer segment discs. Transgenic 
mice, carrying an aminoacid substitution (P216L) in the Peripherin protein were generated 
(Kedzierski et al., 1997). These mice exhibited photoreceptor loss proportional to the level of 
transgene expression. Importantly, photoreceptor outer segments displayed abnormal 
shortening and central lacunae, confirming the hypothesized role for Peripherin in the 
stabilization of outer segment architecture and thereby in the viability of photoreceptors. 
The underlying mechanisms remain however to be further explored for the future 
development of therapeutic strategies. 
3.1.4 Mouse models for RP: Mutations affecting ciliary proteins 
The photoreceptor connecting cilium, a structure that connects the inner (having the 
metabolic machinery) with the outer segment (containing phototransduction proteins), 
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mediates trafficking of factors involved in phototransduction. It is therefore not surprising 
that mutations in photoreceptor cilium proteins have been reported to cause RP, and in 
particular X-linked RP, which is the most severe form in terms of age onset and progression 
(reviewed in Hosch et al., 2011; Murga-Zamalloa et al., 2009). Mutations in retinitis 
pigmentosa GTPase regulator (RPGR) and retinitis pigmentosa GTPase regulator interacting 
protein (RPGRIP) genes account for about 70% of X-linked RP (Vervoort et al., 2000). RPGR 
protein localizes to the connecting cilium, and mice knock-out for this protein exhibit 
progressive photoreceptor degeneration. Notably, basal disc membranes were strongly 
disorganized in these mice, and opsin mislocalization or reduction was observed (Hong et 
al., 2000). Even though RPGR is a ciliary protein, the cilium structure seems to be well 
preserved in knock-out mice. This may indicate that RPGR regulates activities like protein 
transport along the cilium, more than its biogenesis/maintenance. Consistent with this, it 
was recently reported that RPGR interacts with RAB8A, which is a critical GTPase involved 
in photoreceptor protein trafficking, and that this interaction may account for photoreceptor 
degeneration in patients with RPGR mutations (Murga-Zamalloa et al., 2010). RPGRIP 
knock-out mice also show photoreceptor degeneration and outer segment discs appear 
oversized and disorganized (Zhao et al., 2003). Importantly, in these mice RPGR protein 
appears mislocalized, indicating that RPGRIP is involved in tethering RPGR to the 
connecting cilium. RP1 is another ciliary factor, a photoreceptor-specific microtubule-
associated protein, whose mutation gives rise to common forms of autosomal dominant RP 
(5-10% of the cases). Mice expressing C-terminal truncation of this protein (resembling 
human disease-associated mutations) were created (Liu et al., 2003). These mice developed 
significant photoreceptor degeneration. Analysis of the phenotype indicated that RP1 could 
play a fundamental role in the organization of the outer segment discs. Given the important 
phenotype heterogeneity observed in patients with cilium associated RP, it is critical to 
further characterize animal models carrying mutations in cilium proteins to better 
understand the pathogenesis of these RP diseases. 
3.1.5 Mouse models for age-related macular degeneration 
Due to its complex genetic components and to the role played by environmental factors, 
AMD is more difficult to be modelled in mice. Furthermore, mice do not possess a well-
defined macula, which is particularly affected in human AMD. Notwithstanding, it is 
possible to mimic some forms of AMD, as well as juvenile inherited forms of macular 
degeneration, using knock-out or transgenic mouse models (reviewed in Elizabeth Rakoczy 
et al., 2006; Fletcher et al., 2011). Stargardt’s disease is a juvenile inherited form of macular 
degeneration, where defects in lipid biosynthesis and transport occur (reviewed in Molday 
and Zhang, 2010). ABCR (a member of ABC transporter family) null mice are used to mimic 
recessive form of Stargardt’s disease while transgenic mice expressing the human mutant 
form of ELOVL4 (an enzyme that catalyzes the elongation of very long-chain fatty acids) 
mimic the autosomal dominant Stargardt-like disease (Karan et al., 2005; Weng et al., 1999). 
In both the mutant mice, accumulation of lipofuscin granules in RPE is observed and is 
correlated with photoreceptor loss. Indeed, lipofuscin accumulation is one of the hallmarks 
of several forms of macular degeneration. The studies of these mice allowed to hypothesize 
that accumulation of lipofuscin (and its main component, the fluorophore A2E) into RPE 
cells would result in toxicity and death of these cells, with deleterious secondary 
consequences on photoreceptors. 
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Knock-in mice expressing a mutated form (W93C) of Bestrophin anion channel revealed to 
be a good model of the inherited form of macular degeneration, BVMD (Best vitelliform 
macular dystrophy, Zhang et al., 2010). The aminoacid substitution present in this mutated 
protein exerts a dominant negative effect on the channel activity. Indeed, these mice 
developed several features typical of BVMD, like retinal detachment in central region of the 
eye, accumulation of debris like shed outer segment, lipofuscin and lipid droplets. 
Furthermore, calcium signalling was suppressed in the transgenic mice. Such findings 
suggest that calcium may play a pivotal role in the pathogenesis of BVMD. Furthermore, 
since BVMD is the second cause of juvenile inherited macular degeneration (following 
Stargardt’s disease), their use is thought to generate important data for therapeutical 
approaches. Other models, like mice lacking monocyte chemoattractant protein-1 (Ccl-2) or 
its cognate C-C chemokine receptor-2 (Ccr-2) also develop characteristic features of AMD, 
like drusen, lipofuscin accumulation and choroidal neo-vascularization (CNV), as well as 
photoreceptor degeneration (Ambati et al., 2003). Importantly, choroidal macrophage 
recruitment was impaired in Ccl-2-/- and Ccr-2-/-, leading to accumulation of complement 
C5a and IgG proteins. This accumulation, in turn, leads to overexpression of vascular 
endothelial growth factor (VEGF) by RPE, likely mediating the CNV phenotype. Other 
interesting factors have been shown to play a role in RPE degeneration and development of 
particular forms of AMD. Mice lacking functional Dicer1 in the RPE, for example, develop  
 
Mouse models for RP 
Affected proteins Affected genes Inheritance Phenotype 
Rod visual pigment Rhodopsin Autosomal dominant 
Defects in Rhodopsin sorting, glycosilation 
and/or folding, resulting in cell toxicity 
Phototransduction 
proteins PDE6B Recessive 
High cGMP and calcium levels, determining 
cell death 
Structural proteins PRPH Autosomal dominant 
Rod outer discs abnormalities, leading to 
photoreceptor death 
Ciliary proteins RPGR, RPGRIP     RP1 
X-linked              
Autosomal 
dominant 
Defects in disc membrane organization and 
protein sorting/localization, leading to cell 
death 
 
Mouse models for AMD 
Disease category Affected genes Phenotype 
Juvenile inherited forms 




Lipofuscin accumulation, resulting in RPE degeneration 
Dry AMD (geographic 
atrophy) Dicer1 
Accumulation of Alu RNAs, which results in RPE cell 
dismorphology and death 
AMD (general features) Ccl-2, Ccr-2   Accumulation of drusen and lipofuscin, choroidal neo-vascularization, leading to cell death 
Table 1. Main mouse models for RP or AMD, discussed in the present manuscript. 
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RPE dysmorphology similar to those observed in humans affected by geographic atrophy 
(or dry AMD) and RPE degeneration (Kaneko et al., 2011). Importantly, Dicer1 depletion in 
RPE results in increased levels of Alu RNAs, which are responsible for the cell death. Thus, 
a variety of different mechanisms appear to be involved in different steps, or forms, of 
AMD. 
3.1.6 Mouse models and therapies for retina degeneration  
The plethora of data obtained from the studies on mouse models has provided potential 
targets of pharmaceutical interest. Some Ca2+ channel blockers were found to efficiently 
protect photoreceptor of rd1 mice from degeneration. For example D-cis-diltiazem, a cGMP-
gated channel blocker used to treat cardiac disfunctions, was shown to slow down 
photoreceptor degeneration and to preserve visual function in rd1 mice (Frasson et al., 1999). 
More recently, similar observations were extended to other calcium channel blockers, able to 
preserve photoreceptor viability in mouse models for retinal degeneration (Takano et al., 
2004). These results confirm cGMP-gated channels as important pharmacological targets for 
treating some forms of RP, like PDE6B recessive RP. Other factors play an important role in 
preserving photoreceptor viability. For example, cytotoxicity in P23H mutant mice was 
exacerbated by lack of 11-cis-retinal chromophore, thus indicating an important role for this 
molecule in protecting from P23H-induced cell death(Sakami et al., 2011). Indeed, 
pharmacological replacement of 11-cis-retinal (as well as other retinoids) showed beneficial 
effects in the treatment of several forms of retina degeneration (Palczewski, 2010). Proteins 
may be also used to treat retina degeneration. It was shown that injection of rod-derived 
cone viability factor (RdCVF), a protein secreted by rod cells, is able to protect cone cells 
from death in rd1 mice (Leveillard et al., 2004). This observation is particularly important, 
since cones affection in late stages of RP is responsible for legal blindness. Thus, due to its 
ability to maintain cones viable and to preserve their function, future therapeutic strategies 
in humans should consider the possibility to deliver RdCVF protein in the patients’ retina, 
or to promote its expression from unaffected cells (Leveillard and Sahel, 2010). Besides 
RdCVF, systemic administration of Insulin in rd1 mice increased the rate of cone survival 
(Punzo et al., 2009). It is evident that different therapeutic strategies are becoming available 
to promote photoreceptor maintenance. 
However, drug or molecule treatment is not the only strategy that can be used for this aim. 
Gene therapy, for example, showed promising results in treating some forms of RP in 
mouse models. Indeed, adeno-associated virus serotype 5 (AAV5) has been recently used to 
deliver mouse rhodopsin in P23H transgenic mice (Mao et al., 2011). These mice (which 
mimic autosomal dominant RP) showed significant rescue of photoreceptor function 
(assessed by electroretinogram recording) as well as photoreceptor viability. Although it is 
still not known how wild type rhodopsin rescues the dominant effect of mutated rhodopsin, 
this result is encouraging in the view of gene therapy treatment of human RP. Several 
clinical trials have shown to be effective in improving visual function in patients affected by 
Leber’s congenital amaurosis (a recessive retinal degeneration) (Bainbridge et al., 2008; 
Simonelli et al., 2010). Thus, delivery of functional rhodopsin could represent a valid option 
for treating RP. However, since high rhodopsin levels can result in toxicity for rod cells, 
much work is still required to optimize these therapies in humans. Recently, adeno-
associated vectors were used to deliver human RPGRIP1 gene in mouse models of Leber’s 
congenital amaurosis (Pawlyk et al., 2010). Expression of RPGRIP1 was able to improve rod 
and cone survival in the retina of these mice. 
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Different approaches have been designed to treat also AMD. Importantly, many of these 
approaches have been designed to target wet (exudative) AMD (reviewed in Querques et 
al., 2011). As we have seen, one of the hallmarks of wet AMD is the process of 
neovascularization, which is correlated to severe visual loss. To this regard, several 
strategies aim to block the process of blood vessel formation, to minimize the effects of 
macular degeneration. Indeed, antibodies against the angiogenic factor VEGF, like 
Ranibizumab, have demonstrated successful in blocking VEGF-dependent angiogenesis in 
patients affected by AMD, improving their visual functions (for a review, see Lien and 
Lowman, 2008). Not all the antibodies against VEGF are able to efficiently penetrate the 
retina, and some of them show important side-effects. Thus, AAV-assisted gene therapy 
seems to be a valid alternative to this approach. In particular, AAV2-mediated intravitreal 
delivery of chimeric forms of VEGF receptor Flt-1 showed promising results in mouse 
models (Pechan et al., 2009). In these oxygen-induced retinopathy models, the AAV-
delivered chimeric proteins were able to inhibit efficiently angiogenesis, showing no 
detectable signs of toxicity. Thus, these results show promising candidate molecules for the 
treatment of human AMD by gene therapy. 
Despite the abundance of strategies to target wet AMD, no therapies are available for 
treating dry or atrophic AMD (Querques et al., 2011). However, a recent study shows a 
potential and important therapeutic target. As seen above, Alu RNAs were shown to induce 
cytotoxicity in murine RPE cells, which developed a degeneration phenotype similar to 
atrophic AMD (Kaneko et al., 2011). Notably, subretinal administration of antisense 
oligonucleotides, which targeted and reduced Alu RNAs, inhibited efficiently the 
degeneration phenotype in vivo (Kaneko et al., 2011). Thus, this study reveals a promising 
target for blocking RPE degeneration typical of AMD. Inherited forms of macular 
degeneration are also current targets of therapeutic treatment. For example, administration 
of vitamin A to murine models of Stargardt’s disease was shown to efficiently decrease the 
accumulation of lipofuscin, and to improve visual function (Ma et al., 2010). In a different 
approach, lentiviral-mediated delivery of human ABCA4 gene in Abca4-/- mice showed 
effective reduction in the accumulation of the lipofuscin pigment A2E (Kong et al., 2008). 
Thus, gene therapy could also be used to treat genetic forms of macular degeneration. 
3.2 Alternative models for retina degeneration 
Besides the mouse models reported above, other mammalian animal models are used to get 
insights into the pathogenesis of inherited retina degeneration, such as rat, dog or pig. 
However, because the development of the retina and its morphology are remarkably 
conserved in all vertebrates, non-mammalian species have also emerged during the last 
decade as alternative valuable models. In particular, zebrafish, which is well suited for 
large-scale genetic screens, revealed to be very informative in the elucidation of the 
processes underlying retina degeneration (reviewed in Bibliowicz et al., 2011; Brockerhoff 
and Fadool, 2011; Li et al., 2010). Its importance is strengthened by the fact that not all the 
murine models are suitable to mimic a particular pathological feature or for the 
development of pharmacological therapies. In zebrafish, a dozen different genetic lesions 
have been identified leading to photoreceptor cell death, belonging to different functional 
classes. For example, mutation in the gene encoding the cone specific phosphodiesterase c 6 
(pde6c) was shown to induce cone cell death, similarly to pde6b-induced rod cell death in 
mouse models (Stearns et al., 2007). Importantly, some rod cells also died in these mutant 
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fish, primarily in areas where rod density was low. This result suggests an important 
correlation between secondary cell death and cell density. Another recent study taking 
advantage of zebrafish as a model system provided novel insights into the pathogenic 
potential of disease-associated mutations in RPGR (Ghosh et al., 2010). 
The frog Xenopus laevis also recently revealed important in deciphering the mechanisms 
underlying photoreceptor degeneration (Tam and Moritz, 2006; Tam and Moritz, 2007; Tam 
and Moritz, 2009; Tam et al., 2006; Zhang et al., 2008). For example, transgenic frogs 
expressing different glycosylation-deficient forms of rhodopsin showed rod degeneration 
when rhodopsin glycosylation was inhibited in position N15 (Tam and Moritz, 2009). 
Strikingly, the photoreceptor degeneration was exacerbated when the frogs were exposed to 
light, while was attenuated in dark-reared animals. This result suggests that glycosylation is 
involved in rhodopsin stabilization, particularly after its activation by light. Studies on 
Xenopus also showed that the localization of rhodopsin is important for photoreceptor 
viability. In fact, in transgenic frogs expressing a rhodopsin bearing C-terminal truncation 
(Q350Ter), mutant rhodopsin (but not wild type endogenous rhodopsin) failed to correctly 
localize and induced a severe form of photoreceptor degeneration (Tam et al., 2006). 
Importantly, in this case degeneration occurred even in the dark, indicating that the toxic 
effects of mislocalized rhodopsin were independent from its activation. Additionally, since 
Xenopus retina contains numerous cone cells (differently from mice) this system would 
allow to examine more easily the secondary effects of rod death on cone viability. 
4. Studying retina regeneration in vivo 
The animal models described so far have greatly contributed to the understanding of 
mechanistic processes of retina degeneration. Furthermore, as we have seen, this knowledge 
has revealed instrumental in the excogitation of valid medical approaches. However, even 
though the available therapies lead to amelioration of the degeneration, these treatments 
cannot compensate for the cells that have been already lost, often limiting their efficacy to 
the early steps of the pathology. In order to compensate for this limitation, regenerative 
medicine aims at developing treatments that improve, or even induce, regeneration of lost 
cells, a process that involves formation of newly born cells, which then differentiate to 
replace dead cells. 
In order to identify mechanisms and molecules that mediate retina regeneration, it is 
opportune to work with suitable animal models. The mouse models reported in the last 
section are not appropriate for deep examination of regenerative processes. One reason is 
that higher vertebrates show little regenerative potential. Moreover, the transgenic, knock-
out or natural mutant models presented above do not offer the possibility to control 
experimentally the duration of degeneration. Such a requisite is essential to observe the 
mechanisms acting during regeneration: first, one would induce degeneration of a particular 
retinal cell type; then, by blocking the degenerative processes, it would be possible to allow 
the regeneration to occur. This system would offer the possibility to study genes and 
pathways regulating regeneration. 
Thus, the first problematic is the choice of the animal model. Amphibians such as frogs and 
salamanders, and fishes show a strong regenerative potential, maintained for a great part of 
their life. Importantly, it seems that part of the regenerative program active in lower 
vertebrates is still present in higher vertebrates like birds and mammalian, which  show a 
limited and short regenerative response upon injuries (reviewed in Karl and Reh, 2010). 
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Thus, the complete understanding of the regenerative program in fish and frogs would 
provide a basis in designing effective strategies able to stimulate or enhance this process in 
humans affected by degenerative retinopathies. 
The second problematic is how to induce and to reverse the process of retina degeneration. 
Several methods can be employed to this aim: for example, it is possible to induce the death 
of photoreceptor (both rods and cones) by exposing dark-adapted animals to strong white 
light (Reme et al., 1995; Vihtelic and Hyde, 2000), or by using laser to mediate cell ablation 
(Wu et al., 2001). Small molecules can also be used to destroy retina cell types: mature 
photoreceptors are particular sensitive to N-Methyl-N-nitrosourea (MNU) (Tsubura et al., 
2011), while exposure to high level of glutamate can induce death of retinal ganglion cells 
(RGCs), a finding that has been linked to several cases of glaucoma (Dreyer et al., 1996). 
Neurotoxins like ouabain can also be used to damage RGCs and cells of the inner nuclear 
layer (Fimbel et al., 2007; Sherpa et al., 2008). Logically, removing the drug or switching off 
the light source would block the degenerative event, allowing the system to recover and to 
regenerate. Finally, surgical methods can also be employed to remove small part of the 
retina, for example by cutting a portion of retina with a surgical blade or by pricking it with 
a needle (Cameron, 2000; Fausett and Goldman, 2006; Goldsmith and Harris, 2003; Vergara 
and Del Rio-Tsonis, 2009; Yoshii et al., 2007). 
Although these strategies do not resemble generally a particular pathway occurring during 
human retina degenerative diseases, they offer the important advantage of controlling the 
timing and duration of degenerative treatment. However, the systems here described 
present also a limitation: for example light can be used to kill only photoreceptors, while 
chemicals or physical damage may lack enough specificity, affecting more than a particular 
cell type. Thus, in the recent years more elegant and fine tuned systems have been 
developed, like transgenic animals expressing an inducible and reversible cytotoxic gene 
under control of a retina specific promoter. Below, we will give examples of transgenic 
animal models which are thought to bring great contribution to the study of regeneration.  
4.1 Transgenic models for regeneration studies 
Transgenic animals offer the unique possibility to selectively induce cell death (provided 
that a cell or tissue specific promoter is available) through the use of a cytotoxic gene whose 
activity is inducible and reversible. One powerful and elegant system to induce specific cell 
ablation in fish and frogs, in an inducible and reversible fashion, is the 
nitroreductase/metronidazole (NTR/mtz) system (Figure 1). Bacterial NTR is a flavoprotein 
enzyme able to reduce nitro group-containing substrates. When a non-toxic molecule like 
mtz (prodrug), is reduced by NTR, it is converted into a powerful DNA cross-linker agent 
leading to cell death by apoptotic mechanisms. Thus, mtz can be added into the water of 
animals expressing NTR under the regulation of a cell-specific promoter to induce cell death 
only in those cells expressing the enzyme. Cells not expressing NTR are not directly affected 
by the prodrug mtz, validating the high specificity of the system. Subsequently, mtz can be 
removed by washing the transgenic animals in mtz-free water, allowing the study of the 
cellular and molecular processes of regeneration (Curado et al., 2007; Curado et al., 2008; 
Davison et al., 2007; Pisharath, 2007; Pisharath et al., 2007).  
In the context of the retina, NTR/mtz system has been used to induce cell death successfully 
in different retina cells of zebrafish and Xenopus laevis, using enhancer traps or specific 
promoters (Choi et al., 2011; Montgomery et al., 2010; Zhao et al., 2009). In particular, 
 




A: Schematic diagram representing a chimeric GFP-tagged NTR under the control of a specific 
promoter. This construct is used to create transgenic frogs. B: Ventral view of a stage 41 transgenic 
tadpole carrying a GFP-NTR transgene under the control of the rod specific Xop promoter. C: 
Magnification of the onset shown in B, showing GFP fluorescence in the eye. D-F: Transversal retinal 
section of such a transgenic tadpole, following anti-GFP (green, D) and anti-rhodopsin (red, E) 
immunostaining. The merge image (F) confirms the rod specificity of expression. G: magnification of 
the onset shown in F. l = lens; nr = neural retina. Scale bar in B=2 mm, scale bar in D=20 µm.  
Fig. 1. The NTR/mtz transgenic system in frogs.  
transgenic Xenopus frogs were obtained, expressing NTR under the control of rhodopsin 
promoter (Xop::NTR). This model is of particular importance, since it mimics human RP. 
Indeed, when tadpoles at stage 50 were exposed to mtz, their rods started to die soon after 
the treatment. Furthermore, when mtz treatment was prolonged, cone degeneration was 
also observed following rod cell death, a characteristic of RP (Choi et al., 2011). Importantly, 
upon mtz removal, newly born rods were observed in a time-range of thirty days, indicating 
successful regeneration of death cells. Regeneration studies were conducted also in zebrafish 
retina, where rod or bipolar cells were targeted for ablation. Again, treatment with mtz 
induced specific ablation of NTR-expressing cells, while removal of the prodrug allowed 
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regeneration of rods and bipolar interneurons in a short period (Montgomery et al., 2010; 
Zhao et al., 2009). Altogether, these data show that the NTR/mtz system is a powerful tool 
to induce cell-death in a specific and reversible fashion, which can be applied to animals 
with regenerative capacity to investigate the molecular pathways governing the 
phenomenon of regeneration. 
Other cytotoxic genes can also be used to achieve retinal cell death. For example, an 
inducible form of caspase-9 (iCasp9) was expressed in Xenopus rod photoreceptors by using 
rhodopsin promoter (Hamm et al., 2009). This inducible caspase is activated by the drug 
AP20187, added to the tadpoles’ medium, thus leading to death of rod cells. Similarly to 
mtz, AP20187 can be removed at any time, thus switching off the stimulus for rod death. 
These frogs developed abnormalities in the function of cone cells, assessed by 
electroretinogram. Importantly, cone functionality was restored 6 months after the 
treatment, confirming the reversibility of this model. However, differently from the 
Xop::NTR Xenopus model, no clear signs of cone apoptosis were observed, although the 
reasons of this difference are not known. In conclusion, different systems can be employed 
to induce death of specific cell types, enabling the study of their regeneration and the 
secondary consequences related to their death on neighbouring tissues. 
4.2 Sources of regeneration 
In order to understand the retina regenerative process, the first question to answer is which 
cells are able to set off the regeneration? Although mammals are devoid of a regenerative 
capacity, they possess cells with stemness features in the ciliary body, a structure derived 
from the optic cup, lying between the retina and the iris. Although these cells remain 
mitotically quiescent in vivo, they are able to clonally expand in vitro (Ahmad et al., 2000; 
Coles et al., 2004; Tropepe et al., 2000). Although the proliferative and differentiation 
potential of such ciliary body-derived cells towards the photoreceptor lineage is 
controversial (Cicero et al., 2009; reviewed in Locker et al., 2010), this raises the question 
whether and how it is possible to stimulate the proliferative and differentiation ability of 
these cells in vivo, to regenerate injured cells. Lower vertebrates on the other hand possess a 
region, adjacent to ciliary body, called ciliary marginal zone (CMZ), where active 
proliferating retinal stem and progenitor cells reside. These cells, capable of generating all 
types of retinal neuron and glial cells, contribute to the perpetually expanding retina of 
these animals, which grow throughout life (reviewed in Otteson and Hitchcock, 2003; Wetts 
and Fraser, 1988; Wetts et al., 1989). CMZ cells were shown to contribute to the replacement 
of retinal cells after injury (reviewed in Locker et al., 2009; Locker et al., 2010; Moshiri et al., 
2004). However, it seems that the origin of regenerating cells can be species-specific and 
changes according to the developmental stage.  
4.2.1 CMZ and RPE as a source of retina regeneration 
If retina is surgically removed in urodele amphibians, like salamanders, RPE cells respond 
to injury by re-entering the cell cycle. These cells undergo a process of transdifferentiation, 
loosing features of differentiated RPE like their pigmentation, and form a new (inner) layer 
which will give rise to a complete retina, with normal lamination and apparently functional 
(Araki, 2007). In the anuran amphibian Xenopus, both stem cells of the CMZ and cells 
constituting the RPE are able to regenerate the injured retina. The contribution of CMZ in 
Xenopus retina regeneration was already known since 1982 (Mitashov and Maliovanova, 
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1982). When neural retina was removed, partial regeneration of neural retina was observed 
by proliferating stem cells normally present in the CMZ. However, it was also shown that, 
upon surgical retinectomy, cells of RPE delaminated and migrate toward the retinal vascular 
membrane (RVM), forming a new layer (Yoshii et al., 2007). The cells of this layer 
transdifferentiate, as assessed by expression of neural retina markers. Importantly, the 
pigmented cells were intermingled with other cells deriving from the CMZ, which also 
contributed to the newly formed neural retina. This study suggested also a role for RVM in 
the process of regeneration, which could be fundamental. Although the molecular nature of 
RVM contribution in regeneration remains still elusive, it could act likely through the 
secretion of particular growth factors into extracellular matrix. Indeed a possible role for this 
tissue in retina regeneration was observed already in 1987 in a study on the amphibian Rana 
catesbienna, where close contact between RVM and delaminated RPE was observed (Reh and 
Nagy, 1987). Its importance is also underlined by the fact that, when absent, the neural 
retina is not able to regenerate. When neural retina was surgically removed, together with 
the RVM, no regeneration occurred in tadpoles, unless specific growth factors were added 
to the operated eyes (Vergara and Del Rio-Tsonis, 2009). Further work is required in order to 
fully elucidate the modalities through which RVM act during regeneration. It is important to 
note, at this point, that the mechanisms of regeneration observed in amphibians are also 
present in higher vertebrates such as chicken, although this potential is limited to a short 
temporal window. The hatched chicken retina indeed also possesses a CMZ, although with 
a more limited potential compared to that of fish and amphibians (Fischer and Reh, 2000). 
Thus, both RPE and stem cells residing in the ciliary body/CMZ are able to contribute to 
retinal regeneration, until approximately embryonic day 4.5 (E4.5) (reviewed in Spence et 
al., 2007b). 
4.2.2 Müller glia as a source of retina regeneration 
RPE and CMZ are not the only origin of regeneration. Müller glia were also shown to 
display neurogenic capacity and to contribute to the regenerative process following retinal 
injury in diverse vertebrate retinas (Bernardos et al., 2007; Das et al., 2006; Fausett and 
Goldman, 2006; Fischer and Reh, 2001; Fischer and Reh, 2003; Monnin et al., 2007; Yurco and 
Cameron, 2005). For instance, upon photoreceptor cell death in transgenic zebrafish 
expressing NTR in rod cells, Müller cells were observed to re-enter the cell cycle. This 
yielded clusters of neural progenitor cells, which later on differentiated in rod cells 
(Montgomery et al., 2010). It is important to note, however, that Müller glia was mobilized 
only when the damage to rod cells was extensive: when mosaic transgenic lines, expressing 
NTR only in a small subset of rods, were treated with mtz to induce cell death, only 
specialized Müller glia-derived progenitors committed to rod lineage (known as rod 
precursor cells) were activated for regeneration. This result demonstrates that factors, like 
the extent of damage, can influence the source of regeneration. The role of Müller glia in 
regeneration has been observed in other studies. Upon light damage in zebrafish, Müller 
glia cells re-enter the cell cycle and de-differentiate, as judged by the loss of specific 
differentiation markers such as GFAP (glial fibrillary acidic protein) and Glutamine 
Synthetase. Successively, these cells start to express neural marker such as Pax6, and form 
neurogenic clusters that migrate toward the outer nuclear layer, where photoreceptors 
reside (Thummel et al., 2008a). In particular, ability of glial cells to re-enter the cell cycle is 
fundamental for the regeneration. Indeed, inhibition of Müller glia division, by knock-down 
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of PCNA (proliferating cell nuclear antigen), inhibited proliferation and expression of neural 
markers such as Pax6 (Thummel et al., 2008b). This resulted in failure to regenerate 
photoreceptors in zebrafish light-damaged retinas confirming that Müller glia, upon 
proliferation, can serve as a major source of retinal regeneration. Importantly, lineage 
tracing experiments indicate that Müller glia can regenerate all retinal cell types, 
demonstrating the high plasticity of these cells (Ramachandran et al., 2010b). However, the 
neurogenic potential of activated Müller glia seems to be limited, as particular mature 
retinal cell types are rarely or never regenerated following injury (Fischer and Reh, 2001; 
Ooto et al., 2004). Nonetheless, this can be experimentally overcome by treatment with 
specific soluble factors (Ooto et al., 2004; Osakada et al., 2007) raising the possibility that 
Müller glia could be stimulated to produce specific retinal cell types, provided exogenous 
supply of endogenously limiting factors. 
What initiates the regenerative response of Müller glia? This question remains still largely 
unanswered, however a fascinating hypothesis points to its role in phagocytosis of dead 
photoreceptors. Interestingly, it was observed that Müller cells were able to engulf apoptotic 
bodies derived from light-damaged photoreceptors. Upon phagocytosis of dead cells, it was 
reported that Müller glia started to proliferate, as assessed by PCNA immunolabelling, and 
successively regenerated dead cells (Bailey et al., 2010). On the other hand, when 
phagocytosis was blocked by means of inhibitors, the process of regeneration failed to occur. 
In mammalian retina, Müller glia can be activated in response to injury, becoming 
hypertrophic. However, very few cells enter the cell cycle (Bringmann et al., 2009). Thus, 
understanding the signals that activate these cells toward a regeneration program is a 
necessary step to successfully induce retinal regeneration in mammals. 
4.3 Candidate genes and signaling pathways involved in regeneration 
In the previous section, we have discussed about the sources of regeneration in lower 
vertebrates, identifying the RPE, the CMZ and the Müller glia as the main generator of 
regeneration. What are the molecular signals that activate these cells in response to retina 
injury? To date, a network of different genes and signaling has been shown to act during 
regeneration. An important goal of regenerative medicine is to characterize the network in 
fine details, so that this knowledge can be used to promote retinal regeneration in patients 
affected by retinopathies. 
4.3.1 Transcription factors promoting regeneration 
Several transcription factors involved in early retinogenesis were shown to be essential for 
regeneration to occur. It has been recently reported in Xenopus tadpoles that the 
transcription factor Rx1, a paired like homeobox gene fundamental for early eye field 
specification, plays a central role in retinal regeneration (Martinez-De Luna et al., 2011). 
When retina was physically damaged, retinal progenitor cells were found to migrate near 
the site of wound and to initiate regeneration of the entire damaged retina. However, when 
Rx1 was knocked-down by means of small hairpin RNA (shRNA), defects in morphology of 
progenitor cells were observed, together with a reduced expression of progenitor markers. 
Examples of transcription factors acting during Müller glia-dependant regeneration come 
from studies in zebrafish. Indeed, the proneural transcription factor Ascl1 is essential for the 
regeneration process in the fish (Ramachandran et al., 2010a). Ascl1 mRNA is rapidly 
induced in dedifferentiating Müller glia, and it is necessary for the transcription of the 
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pluripotency RNA binding protein Lin-28. Lin-28, on its turn, inhibits the biogenesis of Let-7, 
a miRNA associated with the repression of regeneration-associated genes including Ascl1 
itself, hspd1 and Pax6b. Thus, while normally Let-7 is implicated in maintaining the 
differentiation status of Müller glia, its Ascl1/Lin28-mediated downregulation in response to 
injury is a pre-requisite for the re-entry in the cell cycle and dedifferentiation of the glial 
cells. The activity of Pax6a and Pax6b transcription factors is also essential for the division of 
the glia-derived neuronal progenitors. Both genes are expressed in Müller glia soon after the 
retinal damage (Raymond et al., 2006). Their knockdown in zebrafish reduced the number of 
inner nuclear layer proliferating neuronal progenitors, resulting in a corresponding loss of 
regenerated photoreceptors (Thummel et al., 2010). Pax6 was also shown to be sufficient, 
upon ectopic expression, to promote transdifferentiation of the RPE in the chick retina both 
during development (Azuma et al., 2005) and during the regenerative process (Spence et al., 
2007c). Due to their involvement in early retinal development, where such transcription 
factors regulate proliferation and specification of early retinal progenitors, it is plausible that 
they play an analogous role on the regenerating cells during the process of regeneration. 
However, such hypothesis remains to be tested and the details by which these factors act 
remain to be identified.  
4.3.2 Signaling molecules involved in regeneration 
To discover novel factors involved in retina regeneration, transcriptional profiles of injury-
activated Müller glial cells were generated from adult zebrafish, at the early stages of 
photoreceptor regeneration (Qin et al., 2009). The chaperone hspd1 and the mitotic 
checkpoint kinase mps1 were shown to be up-regulated in these cells. Subsequent functional 
analyses indicated that both factors are required for cone regeneration, at different steps of 
the process (Qin et al., 2009). Although the mutation in these genes was shown to inhibit 
neurogenic cluster formation and neuronal progenitor proliferation, the exact mechanisms 
underlying their activities remain unknown. Such genes, activated during regeneration play 
an obvious important role, yet they represent a downstream response to the initial event 
that damages the retina. This implies that there must be one or more signals that initiate the 
regeneration process. So far, several signaling molecules have been identified, which might 
play such a role. It is long known that the FGF (fibroblast growth factor) pathway is a critical 
inductive cue for retinal regeneration. Basic FGF-2 was indeed shown to induce RPE 
transdifferentiation in chick (Park and Hollenberg, 1989; Park and Hollenberg, 1991) and 
Xenopus (Sakaguchi et al., 1997). The importance of FGF-2 in Xenopus regeneration was 
confirmed also recently. Indeed, administration of FGF-2 was able to stimulate regeneration 
of a new entire retina in Xenopus tadpoles, where complete neural retina (and vascular 
membrane) was surgically removed (Vergara and Del Rio-Tsonis, 2009). Inhibition of the 
MAPK pathway reduced significantly the regeneration, highlighting its importance in retina 
regeneration. MAPK may regulate retina regeneration also in birds. For instance, over-
expression of a constitutively active form of MAPK (Mek-1) in the chick embryonic retina 
induced RPE transdifferentiation into neural retina, an event correlated with down-
regulation of the RPE-specific marker Mitf, and overexpression of Pax6 (Galy et al., 2002; 
Spence et al., 2007c). Among other critical factors, CNTF (ciliary neurotrophic tactor) was 
observed to stimulate Müller glia proliferation in zebrafish (Kassen et al., 2009) and BMP 
signaling was shown to regulate regeneration from the ciliary margin in chick, through 
Smad activation and upregulation of FGF/MAPK pathway (Haynes et al., 2007). Besides, 
Sonic hedgehog (Shh) also plays a key role in chick retina regeneration. In particular, 
 
Degeneration and Regeneration in the Vertebrate Retina 
 
135 
exogenous activation of Shh in cooperation with FGF activation induces regeneration from 
the ciliary body, by stimulating the proliferation of the cells residing in this region (Spence 
et al., 2007a; Spence et al., 2004). More importantly, it was observed that activation of 
analogous pathways were able to initiate retina regeneration even in mammals. The 
mammalian optic nerve does not regenerate when injured. However, significant 
regeneration can be achieved through exogenous administration of various growth factors. 
For example, intravitreous injections of CTNF strongly induced optic nerve regeneration in 
rats where the optic nerve was cut (axotomy). This effect was shown to strongly rely on 
MAPK activity, since inhibition of MAPK compromised the effects of CNTF on neurite 
outgrowth (Muller et al., 2009). Similarly, simultaneous administration of CNTF and 
inhibition of Rho kinase (Rock) promoted retinal ganglion cell survival and regeneration 
upon axotomy (Lingor et al., 2008). Hedgehog signaling could also represent a potential 
candidate pathway to stimulate mouse retina regeneration. Activation of Shh pathway in 
patched+/- (ptc+/-) mice results in persistent proliferating progenitors at the ciliary margin, 
resembling the CMZ of lower vertebrates. Importantly, such patched mutation in P23H mice 
was able to promote a partial rescue of the retina degeneration (Moshiri et al., 2004). 
The factors shown here are only some of the many known to be involved or stimulate retina 
regeneration. Although the list of these factors is in continuous expansion, our knowledge 
about their in vivo function modalities is still modest. The most important point emerging 
from the present data is that the mechanisms regulating regeneration seem to be conserved 
among vertebrates. In particular, there are some evidences that factors normally regulating 
regeneration in lower vertebrates can be successfully used to improve regeneration in higher 
vertebrates like birds and mammals. Thus, an interesting scenario emerges from these 
results: once a particular factor is identified to have a role during retina regeneration in 
animals showing regeneration, then it is important to test whether this factor is conserved in 
mammals and whether it has any ability to stimulate retina regeneration.  
5. Conclusion 
The promise of regenerative medicine is to induce regeneration of damaged tissues or entire 
complex structures in situ. Although mammalian possess a natural regenerative capacity, 
this is very limited and restricted to a few tissues, such as the liver and the skin. On the 
other hand, amphibians and fishes have extensive regenerative capacity. Concerning the 
retina, they are able to regenerate all the neurons and the glia of this fundamental tissue. 
Understanding precisely all the molecules and genes involved in this process, as well as the 
network of interactions that these form in vivo will be fundamental for a rationale screening 
of pharmacological drugs, able to trigger the precise regenerative process. Furthermore, the 
lower vertebrates adopt mechanisms, such as transdifferentiation and dedifferentiation, 
which mammalian does not seem to possess. In the next future, it will be important to 
determine exactly how Müller glia or RPE exploit these processes to regenerate damaged 
tissues, so that we could use them to initiate regeneration directly in vivo, in patients affected 
by degenerative retinopathies. 
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1. Introduction 
There are millions of patients suffering from fatal liver disease in the world. Whole-organ 
transplantation of the liver, such as orthotopic liver transplantation (OLT), improves the 
survival rate of these patients (Benten et al., 2009). However, the traditional OLT is still 
limited due to the serious want of viable livers available for organ transplantation. 
Therefore, cell therapies for the treatment of end-stage hepatic diseases are currently under 
investigation all over the world (Ito et al., 2009). The simplest method for cell therapies is by 
transplantation of primary hepatocytes isolated from the donor. Experimental studies on 
animals have shown that transplanted primary hepatocytes into the spleen or portal vein of 
host animals repopulated in the liver, suggesting that the primary hepatocyte 
transplantation may be successful as an alternative to organ transplantation for patients 
with liver failure (Sutherland et al., 1977; Makowka L et al., 1980; Demetrious et al., 1986; 
Arkadopoulos et al., 1998; Ribeiro et al., 1992; Ito et al., 2007; Nagata et al., 2003; Kobayashi 
et al., 2000). However, success in clinical use is limited (Fox et al., 1998; Platt, 1998) and 
donor human livers to isolate the hepatocytes for hepatocyte transplantations are also 
limited, since these organs are needed to use in organ transplantation. Furthermore, the 
primary hepatocytes are cultured in vitro with very limited success due to their slow growth 
and instability of hepatic phenotype tending to lose differentiation character (Clayton & 
Darnell, 1983). Thus, although the human primary hepatocytes are ideal cells for cell 
therapies, an unlimited source of hepatocytes is required. There are two ways to prepare an 
unlimited supply of hepatocytes: 1) induction of differentiation from pluripotent stem cells, 
such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) and 2) 
production of hepatocytes from somatic cells by reactivation of mature hepatocytes 
themselves or reprogramming the somatic cells other than hepatocytes into hepatocytes.  
ESC and iPSC are expected to be a promising alternative resources for cell therapy because 
they are pluripotent, making it possible to produce any type of tissue from a single resource 
and they are also an infinite resource expanding continuously in the undifferentiated state 
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under appropriate conditions (Hanna et al., 2010). A lot of studies have reported the 
successful induction of hepatic differentiation from ESCs and iPSCs (reviewed in Andersson 
& Lendahl, 2009; Behbahan et al., 2011; Greenbaum, 2010; Kung & Forbes, 2009). However, 
undifferentiated pluripotent stem cells possess intrinsic property of teratoma formation in 
the host after transplantation (Fong et al., 2010; Blum & Benvenisty, 2009; Knoepfler, 2009) 
and their induction efficiency of hepatocellular differentiation was still not enough so that 
various types of cells, including undifferentiated pluripotent stem cells, remained at 
different stages of differentiation (Sasaki et al., 2009; Shiraki et al., 2008; Teratani et al., 2005; 
Yoshie et al., 2010). Thus, improvement of the induction method for the hepatocellular 
differentiation to the efficiency of almost 100% and/or development of an efficient selection 
method for differentiated hepatocytes are needed.  
Several strategies for isolation of ES cell-derived hepatic cells have been proposed in the last 
decade (Basma et al., 2009; Duan et al., 2007; Gouon-Evans et al., 2006; Heo et al., 2006; Li et 
al., 2010; Soto-Gutierrez et al., 2006; Suzuki et al., 2000; Yin et al., 2002). The method of 
isolation is based on the sorting system, such as fluorescence-activated cell sorting (FACS) 
or magnetic-activated cell sorting (MACS) devices and utilizes fluorescent markers or 
antibodies specific for hepatic cells. To realize enough quality and quantity, we propose in 
this paper a dual selection method; first the proliferative immature hepatocytes are isolated 
with a cell surface marker Liv2 antigen and after growing fully in the culture, differentiated 
mature hepatocytes are purified with indocyanine green (ICG) which is an organic anion 
that is specifically taken by mature hepatocytes. We suggest that in surface markers only 
Liv2 antigen is used in the specific isolation of immature hepatocytes from pluripotent stem 
cells (Takashimizu et al., 2009). Purification with ICG has the two major benefits of being 
both safe and inexpensive, since the ICG system that we are developing is non-immune 
based and a non-genetically engineered method for selection of differentiated hepatocytes 
by using flow cytometry with a newly developed laser beam suitable for excitation of ICG.  
Except for cell therapy, human hepatocytes are also useful and necessary for drug 
development (Greenhough et al., 2010). The liver is the central site of drug metabolism and 
detoxication and thus liver based toxicological tests for developing drugs are necessary. 
However, preclinical studies of model animals are inadequate to fully evaluate toxicity due 
to species variation of hepatic functions, such as cytochrome P450 induction (Lake, 2009). 
This remark is also true for food development. Therefore, the strategy described here is 
applicable to a wide area of health science.  
2. How to obtain hepatocytes 
2.1 Hepatocyte induction by differentiating from pluripotent stem cells (ESCs or 
iPSCs) 
Induction of differentiation from pluripotent stem cells into hepatocytes was performed by 
mimicking the hepatocyte differentiation during embryonic development. During 
embryonic development, hepatocytes are differentiated from the definitive endoderm and 
the definitive endoderm is generated from the mesendoderm, which is induced under the 
influence of Nodal, a transforming growth factor beta (TGF-beta) family gene product 
(Zaret, 2000; Zaret & Grompe, 2008). The hepatocyte differentiation from the definitive 
endoderm or mesendoderm is induced by FGF signalling from the cardiac mesoderm and 
BMP-4 signalling from the septum transversum mesenchyme (Duncan, 2003; Si-Tayeb et al., 
2010; Zaret, 2001). Thus, the procedure for induction of hepatocyte differentiation from 
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pluripotent stem cells consists of two steps: the first is definitive endoderm induction by 
activin, which acts in a similar way to Nodal, the second is hepatocyte induction by FGF and 
BMP-4. However, because the cells induced with this procedure are not fully maturated, we 
further induce maturation with serum-free Lanford medium, which is developed for 
maintaining human hepatocytes in vitro (Sasaki et al., 2009; Yoshie et al., 2010). 
2.1.1 Induction of hepatocyte differentiation from mouse ESCs 
Although, in most studies, the differentiation-inducing experiments were performed under 
serum-containing conditions (e.g. Ishii et al., 2005), the hepatocytes induced using these 
conditions have inevitable risks, such as viral infection advising against use in possible 
future clinical applications. Therefore, we propose a simple two-step induction method 
under serum-free conditions as below (Yoshie et al., 2010). 
 
 
Fig. 1. Experimental design for the induction of hepatocytes from mouse ESCs. 
As a first step, the mesendoderm was induced by activin as shown in Fig. 1. The expression 
of the mesendodermal marker goosecoid and the primary endoderm marker Foxa2 were 
increased approximately twofold under serum-free conditions than under serum-containing 
conditions at 100 ng/ml of activin which mimics the role of Nodal signals (Kubo et al., 
2004), suggesting that unknown serum factors inhibited hepatic differentiation. 
Next, as a second step, hepatocytes were induced from the mesendoderm with serum-free 
Lanford medium, which has been developed for maintaining human hepatocytes (Lanford 
et al., 1989). Once immersed in the Lanford medium, the embryoid bodies (EBs) began to 
show typical hepatic features by day 17, including the expression of hepatic lineage markers 
albumin (ALB), alpha fetoprotein (AFP), transthyretin (TTR) and α1-anti-trypsin (AAT) 
detected by RT-PCR, and ALB, AFP and cytokeratin-18 (CK18) detected by immunostaining. 
On day 22, these cells seemed to have become mature, functional hepatocytes characterized 
by the expression of metabolizing enzymes, including DPPIV/UDP-glucuronosyl 
transferase (Ugt1a1), Slcola4, cyp3a11, cyp2b10 and cyp7a1 detected by real-time PCR, a 50-
fold greater cyp3A11 response than the control with 100uM dexamethasone stimulation. 
These results indicate that this simple two-step induction method under serum-free 
conditions induces high quality hepatic lineage cells directly from mouse embryonic stem 
(ES) cell-derived mesendoderm.  
2.1.2 Induction of hepatocyte differentiation from human ESCs or iPSCs 
From embryonic events we learn how to differentiate hepatocytes from pluripotent stem 
cells. Put simply, FGF produced from cardiac mesoderm triggers hepatic buds from the 
endoderm-originated tube, BMP-4 from septum transversum promotes differentiation and 
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proliferation, cytokine, such as OSM, leads them to the final stage (Duncan, 2003). Many 
methods to differentiate have been developed and practiced (Cai et al., 2007; Hu et al., 2003; 
Ishii et al., 2008; Pei et al., 2009; Soto-Gutierrez et al., 2006; Teratani et al., 2005). Curiously, 
however, they deleted BMP-4 produced from septum transversum, which is an 
indispensible factor for hepatic development. So we have developed a new protocol to 
differentiate EB prepared from H1,khES1,2,3 ES lines into hepatocytes (Sasaki et al., 2009): 
25 ng/ml acidic fibroblast growth factor (aFGF) and 25ng/ml basic fibroblast growth factor 
(bFGF for the first 3 days; 20 ng/ml BMP-4and 20 ng/ml hepatocyte growth factor (HGF) 
for the next 3 days, and 20 ng/ml oncostatin M (OSM) and 20 ng/ml vascular endothelial  
 
 
Fig. 2. Induction of hepatocyte differentiation from human ESCs . a. RT-PCR analysis of gene 
expressions associated with hepatic differentiation. Prox1 is definitely recognized in the OSM 
stage. Albumin is definite in the Lanford stage. G6P appears from the BMP-4 stage. b. The 
cluster of large cells with binucleate (arrows). c. Fine structures of the cytoplasm of 
differentiated hepatocytes. rER are layered (arrow). d. The junctional areas show bile canaliculi 
with microvilli (white arrow). Round mitochondria are rich in the cytoplasm (black arrow). 
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growth factor (VEGF) for the third set of 3 days; the modified Lanford medium for an 
additional 2 weeks. RT-PCR showed switch-on to hepatocyte maturation in the BMP-4 stage 
(Fig.2a), but it was quickly recognized that Lanford medium was a powerful promoter for  
cellular maturation. Therefore, Lanford medium was developed to maintain primary 
hepatocytes without serum. The contents contain growth factors and hormone, including EGF, 
LCGF, prolactin insulin and glucagon (Lanford et al., 1989). It remains unknown which factors 
are more effective, but it is true that some of them, or all, progress maturation powerfully 
(Sasaki et al., 2009; Yoshie et al., 2010). Drastic morphological changes had not been recognized 
during the periods from FGF stage to OMS, though gene expression showed signs of 
hepatocyte differentiation. However, several days later in the Lanford medium, the cells 
enlarged, took polyhedral forms and formed hepatocyte-like colonies with two-nuclei and 
large cytoplasm (Fig.2b). As described in our paper, they showed many gene expressions seen 
in mature hepatocytes, ICG uptake and albumin production. However, it was the TEM images 
that made us confirm that they were hepatocytes. They contained all the features with which 
morphologists determine that they are hepatocytes (Fig.2c, d). But this method, as well as 
other methods, has fatal defects. It is complicated, has no ability to produce a large number of 
hepatocytes at the final differentiation stage and requires high cost to use many growth 
factors. For clinical application, a simpler method has to be developed.  
2.2 Hepatocyte reactivation or transdifferentiation from somatic cells 
Although the liver is well known to have remarkable regenerative potential, the 
pathological liver has a limited ability to regenerate and the hepatocytes isolated from the 
living liver do not proliferate with ease in vitro (Clayton et al., 1983). However, by using 
gene transfer techniques similar to that used in the production of iPSC, reactivation of the 
hepatocytes or reprogramming of the somatic cells to hepatocytes is possible. It has been 
reported that rat primary hepatocytes, immortalized with oncogenic simian virus 40 T 
antigen (SV40Tag) could grow in vitro and maintain differentiated hepatic phenotype (Cai 
et al., 2000, 2002; Schumacher et al., 1996; Tada et al., 1998). Additionally, following 
transplantation into host rodents with liver failure, these immortalized hepatocytes function 
as well as primary hepatocytes and improve survival. However, although the SV40 T 
antigen can be excised by genetic engineering (e.g. Cre/lox recombination), the 
reprogramming to proliferative state by SV40Tag is thought not to be physiological as SV40 
T antigen is a virus gene. We found some endogenous genes which when expressed in the 
proliferative hepatic cells could stimulate the growth of rat primary hepatocytes, following 
gene transfer, in vitro (unpublished data), so we expect that hepatocytes can be reactivated 
physiologically by these methods. However, to prevent immune rejection in cell therapy, 
these hepatocyte reactivation strategies have to utilize primary hepatocytes from the patient 
with end-stage liver pathologies or transfer the gene(s) into the patient’s liver. Recently, it 
was reported that functional hepatocyte-like (iHep) cells could be induced directly from 
mouse tail-tip fibroblasts by gene transfer of Gata4, Hnf1a and Foxa3 (Huang et al., 2011). 
The transplanted iHep cells repopulated the livers of mice deficient in fumarylacetoacetate 
hydrolase (Fah) gene, restored liver functions and rescued almost half of recipients. 
Moreover, recently, we showed gene transfer unmediated transdifferentiation between 
hepatocytes and pancreatic cells (Kanoh et al., 2011). Thus, in addition to the induction from 
pluripotent stem cells, the strategy of direct induction from somatic cells will provide 
promising methods to prepare functional hepatocytes for regenerative medicine and 
toxicological tests. 
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3. Applicative aspects of the prepared hepatocytes 
3.1 Research for realization of the cell replacement therapy 
The major problems concerning realization of the hepatic cell therapy are: (i) existence of 
undifferentiated cells in the induced hepatocyte sample and (ii) difficulty in the 
establishment and functioning of transplanted hepatocytes. To solve the first problem, we 
are trying to establish two selection techniques: 1) isolation of immature hepatocytes with a 
cell surface marker Liv2 antigen and 2) purification of differentiated hepatocytes with 
indocyanine green (ICG). The immature hepatocytes isolated with Liv2 antigen retain 
proliferative capacity and therefore the collection of immature hepatocytes can be amplified 
in this step. Although the maturation to functional hepatocyte is usually difficult, the flow 
cytometry with laser beam for ICG could specifically purify functional hepatocytes, because 
uptake of ICG is hepatocyte-specific function and ICG is incorporated by only functional 
hepatocytes. The second problem could be partly solved by improving the transplant 
method. Because the liver with cirrhosis cannot accept transplanted cells, we are examining 
the transplant method that plants hepatocytes into the submucosa of the duodenum as 
mentioned in the last section of this chapter. In this way, the bile produced by the 
hepatocyte may be flowed into the lumen of the duodenum appropriately. 
3.1.2 Isolation of immature hepatocytes with Liv2 antibody  
Although various cytoplasmic markers, such as ALB, AFP and glucose-6-phosphatase (G6P), 
have been reported as useful for identifying immature and mature hepatocytes, these are not 
surface markers, so it is impossible to isolate only living hepatocytes using the fluorescence-
activated cell sorting (FACS) or magnetic-activated cell sorting (MACS) method. An isolating 
method using several surface antigens of hematopoietic markers to select hepatocytes has been 
reported (Suzuki et al., 2000), but the method is insufficient due to inaccurate cell counts and 
contamination of other types of cells in addition to hematopoietic cells and hepatocytes. Liv2, 
which was first reported by Watanabe et al. (Watanabe et al., 2002) is selectively detected in 
the cell surface of fetal mouse liver cells of embryonic day E9.5 to E12, so it can be used as a 
surface marker to isolate immature hepatocytes. 
We have performed immunocytochemical analysis to verify the presence of Liv2 in 
immature hepatocytes derived from ES cells (Takashimizu et al., 2009) and we found 
clusters of Liv2-positive cells in EB outgrowth with the same patterns as the 
immunoreactivity seen in the E9.5 immature hepatocytes. In addition, we analyzed 
microlocalization of the Liv2 antigen by immuno-TEM (ImmunoGold) and confirmed 
definitely that Liv2 is a surface antigen. Next, we analyzed the property of Liv2-positive 
cells isolated by MACS. Cell counting and MTT assay revealed that Liv2-positive cells 
isolated by MACS from the primary hepatocytes obtained from the fetal livers of E12 mouse 
embryos have moderate proliferative potential (Figure 3).  
Double-Immunostaining of the isolated cells of 1 day after Liv2-MACS showed that all of 
Liv2-positive cells analyzed express Prox1, AFP and ALB (Figure 4). Both Prox1 and AFP 
are markers of immature hepatocytes and not express in the adult liver cells. Thus, it was 
demonstrated that in the cells obtained from E12 fetal livers, only immature hepatocytes 
were positive for Liv2. 
Further cultivation of the isolated cells confirmed that these Liv2-positive cells were 
progenitors of mature hepatocytes and could differentiate into mature hepatic cells. 
Immunocytochemical analysis showed that although population of Liv2-positive cells was 
decreased 5 days after culture, positive cells for AFP and ALB increased (Figure 4).  
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Fig. 3. Proliferation of Liv2-positive cells isolated by MACS. a: cell counting. b: MTT assay.  
 
 
Fig. 4. Immunocytochemical analysis of cultured cells isolated by MACS with Liv2 antibody. 
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RT-PCR analysis revealed that the expression of mature hepatocyte markers CYP7A1, G6P, 
TAT and TTR was initially very low or absent and increased gradually afterward (Figure 
5A). Moreover, the expression of CK7, a maker of bile duct cells, was extremely low on the 
first day and drastically up-regulated on day 5 (Figure 5b), suggesting that the Liv2-positive 
cells were bipotential progenitors capable of producing both hepatocytes and bile duct cells.  
 
 
Fig. 5. Analysis of gene expression of mature hepatocyte makers in Liv2 positive cells 
cultured with Lanford medium. a; RT-PCR，b; Real-Time RT-PCR. 
Taken together, these data strongly suggest that Liv2-positive cells are immature 
hepatocytes normally contributing to embryonic development and that anti-Liv2 antibody 
can be used to isolate immature hepatocytes derived from ESCs. 
There is only one report adopting a similar strategy by purifying hepatic progenitor cells 
rather than mature hepatic cells with surface antigens (Li et al., 2010). They successfully 
isolated hepatic progenitors by FACS with c-Kit and EpCAM antibody, and demonstrated 
that these c-Kit-negative, EpCAM-positive cells could undergo long-term expansion with 
sustained hepatoblast-like characteristics. Moreover, they cloned the hepatoblast-like cells 
and showed these clones repopulated in the host livers without inducing tumorigenesis. 
Although EpCAM expressed in hepatic progenitor cells rather than adult hepatocytes, 
EpCAM also expressed in many other cells such as undifferentiated ESCs and definitive 
endoderm cells. Therefore, they complemented EpCAM in positive selection with c-Kit in 
negative selection since c-Kit is only expressed on ESCs, definitive endoderm cells and some 
mesoderm cells, but not hepatic cells. However, there may be other cells with c-Kit-negative 
and EpCAM-positive other than hepatic progenitor and the success of their strategy is 
thought to depend on their efficient induction of definitive endoderm from mouse ESCs. On 
the other hand, to isolate immature hepatocytes, we use single antibody (Liv2) highly 
specific to immature hepatocytes. Although anti-Liv2 antibody specifically recognizes 
rodent Liv2 antigen, but not human and gene encoding, its Liv2 antigen is still unclear, 
however, a human counterpart must exist considering the evolutionary relationship 
between rodent and human. Developing tools for biochemical analysis, such as mass 
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spectrometry, are expected to reveal the Liv2 gene. Thus, we expect the development of an 
isolating system for human immature hepatocytes with anti-Liv2 antibody recognizing 
human Liv2 in the future.  
3.1.3 Isolation of mature hepatocytes with ICG 
There are a lot of protocols for generating hepatocytes from ESCs or iPSCs in vitro, but 
purifying mature hepatocytes is still difficult and many different cell types remain. Several 
studies have used ESC lines transfected with the green fluorescent protein reporter gene 
controlled by promoters of hepatic genes, such as Foxa2 (Gouon-Evans et al., 2006), Afp (Yin 
et al., 2002), ALB (Heo et al., 2006; Soto-Gutierrez et al., 2006) and a1-antitrypsin (Aat) (Duan 
et al., 2007). However, these strategies need genetic manipulation that is not suited to the 
future therapeutic applications and GFP is known to have slight toxicity to cells. Moreover, 
mature hepatocytes rather than immature hepatocytes are known to be unstable in vitro. 
Thus, a particularly safe method is required for selecting mature hepatocytes derived from 
ESCs or iPSCs. 
Indocyanine green (ICG) is a nontoxic organic anion that is eliminated exclusively by 
hepatocytes and is clinically used as a test substance to evaluate liver function (Berk & 
Stremmel, 1986). The uptake and release of ICG are frequently used to identify and/or 
evaluate ESC-derived hepatocytes (Agarwal et al., 2008; Farzaneh et al., 2010; Yamada et al., 
2002). The fluorescence of ICG can be observed at 800-900 nm with appropriate excitation of 
near 780 nm. Therefore, we developed a flow cytometer equipped with an excitation laser of 
785 nm to detect ICG-positive cells (Yoshie et al., manuscript in preparation). We 
determined optimal concentration and incubation time for detection of ICG uptake and 
showed that rat primary hepatocytes and ESC-derived hepatocytes selectively took up ICG. 
Although irradiation of ICG with a laser at 100 J/cm2 was reported to generate singlet 
oxygen (1O2), which is damaging to cells (Hirano et al., 2007), the power of our laser 
(FISHMAN-R) was 5 mJ/cm2 and much less likely to generate singlet oxygen. In fact, in 
analysis with trypan blue exclusion, the analyzed cells were not damaged by FISHMAN-R 
laser flow cytometry. 
Similar sorting methods of hepatocytes or hepatocyte-like cells by use of antibodies are 
frequently reported, e.g. isolation of mature hepatocyte-like cells by FACS with 
sialoglycoprotein-receptor (Basma et al., 2009). However, because the purification of mature 
hepatocytes is thought to be a final step and the mature hepatocytes have limited 
proliferative potential, this purification step must be massive i.e. sorting a lot of hepatocytes. 
Therefore, use of antibodies in this step is inadequate in the cost performance, as the 
antibodies are expensive. Our detection system which relies on the selective uptake by 
hepatocytes of ICG, a stable and inexpensive fluorescent chemical compound, overcomes 
this problem and will lead to the development of an effective system for purifying 
hepatocytes derived from ESCs, iPSCs or somatic cells.  
3.2 Use of hepatocytes for toxicology and drug development 
The liver is centre of metabolism and the hepatocytes are responsible for metabolizing most 
compounds in vivo. Therefore, the cultured hepatocyte can be used to predict how drugs 
are metabolized and to what extent they may be toxic. These tests include use of primary 
rodent hepatocytes and human immortalised hepatocyte cell lines, such as HepG2 (Rudzok 
et al., 2010). However, the rodent hepatocytes have species-specific differences in 
metabolizing function from human (Lake, 2009) and immortalised hepatocytes have poor 
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hepatic function and sometimes have an abnormal karyotype (Wong et al., 2000). Thus, 
human primary hepatocytes have become a standard tool for evaluating hepatic drug 
metabolism in vitro. However, to do so demands a lot of functional hepatocytes and the 
utility of the human primary hepatocyte is seriously limited. Our induction and selection 
methods will be helpful to meet the demand of these examination systems as an alternative 
to primary human hepatocytes. Particularly, dual selection strategies mentioned above are 
suited for scalable production of human hepatocytes. Immature hepatocytes isolated with 
Liv2 were suggested to have unlimited proliferative potential (Figure 3) and could serve the 
scalable production. Although expanded immature hepatocytes have to differentiate into 
mature hepatocytes, our protocol could efficiently induce maturation with Lanford medium 
and the functional, mature hepatocytes that must be in large amounts could be purified 
inexpensively by FACS with ICG. 
4. Further problems 
4.1 In vitro tissue formation using induced hepatocytes 
Besides immature hepatocytes being acceptable in some cases of hepatocyte transplantation 
due to hepatic maturation after transplantation, immature hepatocytes are absolutely 
unacceptable for use in evaluating hepatic drug metabolism in vitro. The mature functional 
hepatocytes are required in drug tests. However, in vitro induction of hepatic maturation or 
terminal differentiation has not been achieved enough. Realization of fully functional 
hepatocytes may require tissue organization similar to that of the liver in the living body. 
There is a dilemma in this problem: although the purification of hepatocytes is necessary for 
the improvement of the quality of induced hepatocytes, fully functional liver tissue requires 
various types of cells other than hepatic parenchymal cells. To solve this problem, we have 
three options: (i) selecting several types of cells and organizing them into tissue structure, 
(ii) selecting the precursor cells for histogenesis of liver, inducing differentiation and 
prompting self-organization and (iii) constructing artificial culture microenvironments 
mimicking native environments of liver. The culture microenvironments, such as microwell 
architecture (Mori et al., 2008), are well known to improve the function of cells, including 
hepatocytes (Sharma et al., 2010).  
Previously, we showed the induction of retinal cells by co-culturing with ESC-derived RPE 
cells (Yue et al., 2010). Now, we try to apply a combination of these co-culture and 
microwell methods to induce mature function of hepatocytes.  
4.2 Hepatocytes transplantation: Where or how are hepatocytes transplanted? 
Purified pluripotent stem cell-derived hepatocytes are transplanted into patients with fatal 
hepatic disease, in whom hepatic tissue structures are newly developed and function. Thus, 
a new therapy for incurable hepatic disease substituting liver transplantation is established, 
which is a final goal of regenerative medicine.  
The problems to overcome for successful regenerative medicine are to determine the 
appropriate sites for effective cellular survival and function, and the effective way, i.e. 
which should be selected for transplantation, cell type or tissue type. The best way still 
remains unknown. Most experimental studies show injection of pluripotent stem cell-
derived hepatocytes through the vein or directly into the liver as cell type. Mouse ESC-
derived hepatocytes were injected into the liver through the portal vein (Yamada et al., 
2002). HGF-treated bone marrow mesenchymal cells were transplanted through the caudal 
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vein into the liver of CCl4-injured rats and this was effective against liver damage (Oyagi et 
al., 2006). After multipotent progenitor cells derived from human umbilical cord blood were 
transplanted into the left lateral lobe of the liver of the CCl4-injured rats or through the 
portal vein, they differentiated into the hepatocyte-like cells and were useful in treating the 
injury (Moon et al., 2009). 
But there is extreme pessimism about these ideas, methods and practices because fatally 
damaged livers provide poor and severe environments, such as extreme fibrosis in cirrhosis, 
rapid cellular necrosis in liver failure etc. for transplanted fresh hepatocytes. It is more 
reasonable to transplant hepatocytes into good conditions with a rich blood supply 
ectopically. In fact, the first transplanted site performed in a human patient with cirrhosis 
was the spleen (Mito et al., 1992). According to their report, a part of the cirrhotic liver was 
resected, from which intact hepatocytes were isolated and were injected into the spleen; 
afterwards, the survival was confirmed. Their experimental reports using rats indicated that 
6 months later splenic tissues were substituted by the hepatic tissues consisting of hepatic 
cords and hepatic sinus (Kusano & Mito, 1982; Mito et al., 1979). Except the spleen, fat 
tissues are good sites for breeding hepatocytes and their survival has been shown in fat pads 
(Jirtle & Chalopoulos, 1965). One of the authors transplanted rat primary hepatocytes into 
the rat mesenteric fat tissues and confirmed their survival and tissue structure (Sasaki et al., 
1983) (Figure 6a). But ectopic transplantation has a significant problem: it has no way and 
route to discharge bile juice. Any definite answers have not been given yet, but we have 
some hints that might help to resolve the problem. For example, glands e.g. duodenal 
glands or pancreatic tissues are found in the submucosa of the intestine (Fig.6b, c). Clinically 
ectopic tissues e.g. pancreatic or stomach tissues are recognized. In evolution, primitive 
hepatic tissues are incorporated into the midintestine in the earth worm as chloragocytes with 
varied functions, including a storing function of endogenous substances, such as glycogen and 
lipids, and metals (Ireland & Richards, 1977) and intensive DAB reactivity (Fischer & Horvath,  
 
 
Fig. 6. Strategy of ectopic transplantation. a. The survival hepatocyte cluster in the rat intra-
mesenterium (arrow). b. The duodenal gland in the submucosa of the rat duodenum 
(arrow). c. The pancreatic tissue in the submucosa of the small intestine (arrow). 
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1978). The next function in shipworms is midgut glands consisting of large cells with 
binucleate (Strunk, 1959) and enhanced hepatic function in crabs and lobsters as 
hepatopancreas (James, 1989). In mammalian embryonic development, it is well-known that 
hepatic buds grow from the duodenum described above. Therefore, our idea is to transplant 
hepatocytes into the submucosa and return them into the mother site, the intestine.  
Our first trial was to confirm whether human ES cell-derived embryo bodies, which were 
treated with the previous cocktail (Takashimizu et al., 2009) and containing ICG-positive 
cells (Fig.7a), survived in the submucosa or in the intestine. Injection was insecure in that it 
was difficult to confirm where it was injected or whether hepatocytes or EBs remained there. 
Then, we have established a new technique for transplantation. The peritoneum and muscle 
layer of the nude rat was cut by an electronic scalpel and separated (Fig.7b), in whose shallow 
furrow EBs were arranged in order (Fig.7c). After the wound was closed (Fig.7d), one or two 
weeks later, the transplanted site was prepared for histological investigation. In the 
submucosa, unique tissues including duct like structures were found (fig.7e). The vascular  
 
 
Fig. 7. Transplantation of human ESC-derived hepatocyte-like cells into a rat duodenum. a. 
Human EB containing ICG positive cells (green). b. The linear cut line performed on the 
surface of the nude rat duodenum (arrow). c. EBs (arrow) are arranged in the shallow 
furrow. d. The wound was closed with 7-0 nylon. e. Histology of the treated duodenum. EB 
survives in the submucosa along with duct formation (arrows). f. Vascular supply is 
confirmed (arrow), but is not sinusoid-like. 
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supply did not penetrate the cell cluster, but rounded the periphery (Fig.7f). Hepatic sinus 
did not appear to be differentiated yet. We recognized transplanted cell clusters survived in 
this method, but did not confirm that they differentiated into functional hepatocytes from 
EBs containing ICG-positive cells. At that time, we did not have the method to purify 
pluripotent stem cell-derived hepatocytes from mixed varied cell types yet. As the ICG-
selection method has been established, as described above, purified hepatocytes will be 
transplanted and be confirmed to function and discharge bile juice into the intestine. 
Further, for clinical trials, we provide a new technique, fibre scope transplantation. To cut 
the muscular layer is to subject patients to opening the abdomen, whereas if hepatocytes 
were injected into the submucosa, patients’ discomfort would significantly decrease. But it 
remains unknown how hepatocytes are injected into the submucosa with the fibre scope, as 
fibre scope has not yet been developed for rats. The scope with the smallest diameter for use 
on a dog was tried through the stomach to attain the duodenum (Fig.8a). It was very 
difficult to inject into the mucosa on the same side, but was successful in swelling the 
mucosa on the opposite side (Fig.8b). Fibre scope transplantation will be an effective tool for 
endoderm-derived differentiated cells in addition to hepatocytes. 
 
 
Fig. 8. Fibre scope transplantation. a. The interior of the nude rat duodenum. The red 
mucosa and the needle for injection of the fibre scope (arrow) are recognized. White circle is 
the mark for the needle to insert. b. The needle is inserted into the mucosa. The mucosa 
swells after fluid injection (arrow). 
On the other hand, another problem is whether cell transplantation or tissue transplantation 
is better, more effective or reasonable. It will take a long time to determine this, or each 
method may be used according to varied conditions, such as kinds of disease, its progress 
and permitted transplanted site. But in conclusion we prefer tissue transplantation, because 
effective function is due to cell-to-cell interaction and tissue organization. Kikuchi et al. have 
developed a unique in site cell micropatterning system (Kikuchi et al., 2009). A 
photoresponsive cell culture surface was geometrically processed in situ with the UV 
irradiation to increase the cell adhesiveness of HepG2. After confirmation of HepG2 
adhesion to the first dot pattern, fibroblast, which adhered easily to the plate without the 
UV irradiation were introduced to fill gaps among the HepG2 dot pattern. This simple 
 
Advances in Regenerative Medicine 158 
geometric pattern caused a 50-fold increase of CYP3A than conventionally cultured HepG2. 
Cell transplantation breaks once-established cell-to-cell interaction and requires 
reorganization in vivo, which creates double the work.  
But three methods to complete tissue transplantation have to be established, the in vitro 
method of tissue organization, which geometric patterning described above helps, the 
technique to transport in vitro established tissue into in vivo without destruction and the 
method to acquire rapid blood supply after transplantation. 
Scaffold-engineering may be essential to tissue transplantation, because it is easily 
transported in intact conditions and is processed for drug delivery systems e.g. slow 
releasing angiogenic factors (Hou et al., 2011). Collagen or modified collagen sponges were 
conventionally used as cell carriers in many labs, as well as in ours (Imamura et al., 2004; 
Kanematsu et al., 2004; Takimoto et al., 2003). The above collagen-based scaffold is not 
complete, because cells did not expand rapidly within the sponge in vitro. After 
transplantation, the carrier was bounded on the periphery by the non-penetrating host 
tissue. Moreover, function, such as urea synthetic rate, decreased below the control level 
(Hasirci et al., 2001). In addition to collagen-based materials, many other materials and 
methods are proposed (Kano et al., 2008; Katsuda et al., 2010; Torok et al., 2011), which will 
steadily improve tissue transplantation techniques. In the future it is expected that simpler, 
easier, more effective and more practical transplantation techniques will be developed. 
5. Conclusion 
In this chapter, we described the production and selection of hepatocytes and show a 
strategy for regenerative medicine using pluripotent-derived hepatocytes. There are two 
sources to obtain hepatocytes: (i) somatic cells, such as mature hepatocytes themselves and 
(ii) multi- or pluripotent stem cells, such as embryonic stem cells (ESCs) and induced 
pluripotent stem cells (iPSCs). We have reported the methods for induction of 
differentiation from pluripotent stem cells. Our protocols for induction of differentiation 
from pluripotent stem cells mimic the hepatocellular differentiation during embryonic 
development.  
One important problem of the differentiation-mediated preparation of hepatocytes is how to 
exclude undifferentiated cells, while a lot of hepatocytes are produced. Additionally, it is 
impossible to improve the efficiency of hepatocellular differentiation to 100% and the 
remaining undifferentiated cells have the potential to cause teratoma after being 
transplanted into the host. To isolate hepatocytes, we proposed a dual selection method. The 
first is isolation of immature hepatocytes by cell sorting with Liv2, which specifically detects 
immature hepatocytes. The second is purification of mature hepatocytes by low cost sorting 
with ICG, following massive expansion of immature hepatocytes and induction of 
differentiation into mature hepatocytes with Lanford medium. The flow of our method is as 
below: 
i. Induction of immature hepatocytes from pluripotent stem cells  
ii. Isolation of proliferative immature hepatocytes with anti-Liv2 antibody 
iii. Large scale culture expanding the immature hepatocytes and induction of 
differentiation into mature hepatocytes 
iv. Low cost and safe purification of functional mature hepatocytes by FACS with ICG 
The next step is in vitro and in vivo tissue formation. The culture condition mimicking 
tissue organization improves the function of cells, including hepatocytes. Moreover, to 
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realize the therapy for patients with incurable hepatic disease, it is necessary to promote 
tissue organization artificially in vivo. We propose that for the artificial organization of 
hepatic tissue, heterotropic transplantation into submucosa of the duodenum is most 
suitable, since the liver with incurable disease does not accept the transplanted hepatocytes 
easily.  
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1. Introduction  
In recent past, the potential use of stem cells and the advancement in stem cell research for 
Regenerative Medicine is considered as an alternative therapeutic strategy for a broad range 
of genetic and acquired diseases.   
The interest in stem cells has been increasing over the past years, since their discovery in the 
early ’90s, and they might represent a promising tool for regenerative purposes because of 
their capability to become almost any cell of an adult organism.  
Despite the discoveries and the promising results, many are the controversies raised by stem 
cells. Feasibility of their use for human therapeutic purposes is regulated by many 
requirements such as safety, accessibility to a source that can provide an adequate amount 
of cells for in vitro expansion, absence of ethical issues and repeatability of the results. 
Different lines of stem cells are investigated for understanding the basic mechanism of 
cellular differentiation and the potential for regenerative medicine purposes. However, to 
overcome safety and ethical issues, scientists are still looking for alternative sources that 
may provide easy and safe access to a cell population that may be used for cellular therapy. 
Amniotic fluid, due to its contact with the fetus, has been considered an interesting source 
for undifferentiated or partially differentiated cells.  
More recently, interest has been rising on more committed cell lines that may possibly 
provide new, more specific, tools for tissue regeneration. In particular, the isolation of cells 
already committed to a specific fate has been performed for kidney, pancreas and other 
organs and the study of these novel cell populations may give us an insight on cellular 
development and provide a more precise way of driving cell differentiation into a mature 
cell type.   
Nevertheless, our knowledge of amniotic fluid cellular composition is still incomplete and 
only in the last few years some studies have been published describing the different cell 
types that can be retrieved. As long as new discoveries are shared and new insights are 
given on amniotic fluid cellular composition and cell differentiation we can gain a better 
understanding of the mechanism underlying development. The main goal of this chapter is 
to provide the readers with a broad knowledge regarding the work that has been done until 
now to undisclose the heterogeneous amniotic fluid cellular composition and their use for 
regenerative medicine purposes. 
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2. Amniotic fluid 
Amniotic fluid is a clear, fluid that fills the amniotic cavity. It provides an ideal and 
protective environment in which floats the developing embryo and later on the fetus. It also 
helps to regulate the temperature of the fetus during the pregnancy. 
2.1 Origin and molecular composition 
During embryogenesis, maternal plasma is the main protagonist of amniotic fluid volume 
increase and water flows osmotically through fetal membranes, and, later on, through the 
placental membrane. The volume and the composition change during pregnancy following 
the physiological variations of the developing fetus (Fig. 1).  
 
 
Amniotic fluid composition and volume are the result of exchanges and interaction with many different sources, 
either fetal or maternal. the above figure shows a schematic representation of the most important overall 
contributions to amniotic fluid. 
Fig. 1. Amniotic fluid origin and composition 
During the first weeks of gestation, the composition is comparable to the fetal plasma and its 
volume increases from 25 ml at 10 weeks to about 400 ml at 20 weeks (Underwood et al., 
2005). By 8 weeks of gestation the fetal kidney begins fluid production that rapidly increases 
in volume during the second trimester.  The exchange of fluids through the skin is present 
until keratinisation that occurs between 20 and 24 weeks of gestation. The molecular 
composition and the presence of nutritive substances have been shown to play a key role, in 
animals, in the proliferation and differentiation of various intestinal cell types such as 
epithelial and mucosa cells (Underwood et al., 2005).  
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2.2 Amniotic fluid in diagnostic  
The use of amniotic fluid to determine the status of health of the fetus has been an important 
diagnostic tool for many years. Back in the 60s, it was considered an invaluable source of 
information for the diagnosis of fetal distress, haemolytic disease and fetal maturity (Horger 
et al., 1969), neural tube defects and lung maturity (Underwood et al., 2005).  Over the years, 
the diagnostic techniques have been greatly improved and new fields of investigation have 
tried to tie various conditions with preterm labour, infective processes and embryo diseases.  
In particular, it has been used as a safe and reliable screening tool for genetic and congenital 
diseases in the fetus.  
2.3 Isolation, expansion and characterization of amniotic fluid cells 
The possibility of using amniotic fluid derived pluripotent and multipotent stem cells has 
been found appealing due to the relative easiness and safe procedure required to retrieve 
the cells from its source. Furthermore, the use of multipotent progenitors has been 
considered an attractive alternative to the use of pluripotent cells due to their already 
committed phenotype. Cells can be isolated from the liquid collected by amniocentesis. 
Briefly, prior to amniocentesis an ultrasound is performed to confirm fetal viability, 
gestational age, number of fetuses, placental location, volume, fetal anatomical survey, 
uterine cavity abnormalities and to evaluate the best needle insertion site.  
A 20 cc syringe is used to aspirate the liquid.  The first 2 cc collected should be discharged 
and then using another syringe and then, using another syringe, additional 15 to 20cc are 
aspirated.. Removal of the fluid generally takes less than 1 minute. After collection the cells 
are seeded with specific culture media and the adherent fraction is expanded. 
Contact between amniotic fluid and compartments of the developing fetus, such as lung and 
gastrointestinal tract can explain the presence of different types of cells (Fig. 2).  Moreover, 
cells detaching from the forming kidney or exfoliating from the fetal skin may contribute 
significantly to cellular composition. In particular, the presence of mature cell lines derived 
from all three germ layers has been identified (Hoehn et al., 1982; Gosden et al., 1983).  
Mesenchymal and hematopoetic progenitor cells have also been shown to exist before the 
12th week of gestation in humans (Torricelli et al., 1993) together with cells expressing 
proteins and various genetic markers from specific tissue types including brain, heart, and 
pancreas have all been discovered (Tsangaris et al., 2004, Bossolasco et al., 2006; McLaughlin 
et al., 2006; Da Sacco et al., 2010).  
Fauza et al. reported the successful isolation and expansion of unfractioned mesenchymal 
stem cells (AFMC) from human samples between 20 and 37 weeks of gestation, confirming 
the presence of a multipotent mesenchymal cell types over the progression of gestation 
(Kunisaki et al., 2007).  A fully characterization of amniotic fluid pluripotent cell population 
has first been reported by Atala in 2007 (De Coppi et al., 2007).  This newly isolated stem cell 
population (AFSC) is characterized by expression of c-kit, a surface marker expressed by 
stem cells of mesenchymal origin. AFSC  express some surface markers and transcription 
factors distinctive of ESC such us OCT-4 and  SSEA-4 indicating they can actually posses 
some important characteristics that also ESC have, showing their pluripotential capability. 
They stained positively for a number of surface markers characteristic of mesenchymal 
and/or neural stem cells, including CD29, CD44 (hyaluronan receptor), CD73, CD90 and 
CD105 (De Coppi et al., 2007). 
 






Amniotic fluid cells can be easily collected and expanded in vitro and exhibit a heterogeneous morphology with a 
preponderance of fibroblastoid, mesenchymal like cell shape (Unpublished Picture, Da Sacco et al.) 
 
Fig. 2. Amniotic fluid cells morphology 
However, a comprehensive analysis of amniotic fluid cellular composition has been 
missing and only in 2010 Da Sacco et al. for the first time demonstrated that the cellular 
composition varies in a timely fashion (Fig.3). Expression of markers for cells belonging to 
early endodermal and mesodermal germ layer differentiation pathway is predominant in 
the earlier weeks of gestation and constantly decreases over time to disappear at 17-18 
weeks of gestation. Ectodermal markers, probably because of the exfoliating fetal skin, 
maintain a stable expression in all the samples analyzed. Interesting, it is shown that 
concurrent with the decrease of germ layers markers there is a noticeable increase of 
organ specific progenitor cell marker expression. Proteins expressed during lung, liver, 
heart and kidney differentiation are highly expressed starting form 17-18 weeks while 
expression of pluripotent markers such as OCT-4 and c-kit was found stable over time in 
all the samples analyzed, suggesting that, at least in the time range analyzed, the 
pluripotent cells are undergoing self renewal. Furthermore, mesenchymal marker CD90 is 
present in all the samples analyzed while hematopoietic marker CD34 decreased its 
expression over time. 
 




Mesodermal and endodermal cellular markers decrease over time and are not detectable after 17-18 weeks of 
gestation while various organ progenitor cell markers concentration rise after 17-18 weeks. Pluripotent markers 
OCT-4 and c-kit remain unchanged, as well as ectodermal markers, probably because of skin exfoliation. CD34 
cellular marker rises after 18 weeks of gestation.  
Fig. 3. Schematic representation of changes in composition within amniotic fluid between 15 
and 20 weeks of gestation. (Da Sacco et al., 2010) 
3. Amniotic fluid cells and organ specific regenerative medicine 
Due to an easy and safe collection procedure, amniotic fluid has quickly gained interest as a 
potential source of pluripotent/multipotent cells for regenerative medicine purposes. 
Amniotic fluid stem cells have been shown to be easily cultured and expanded upon 
collection and isolation De Coppi et al., 2007, Perin et al., 2007, Da Sacco et al., 2010, 
Kunisaki et al., 2007). De Coppi et al. (De Coppi et al., 2007) and Arnhold et al. (Arnhold et 
al. 2011) proved that after c-kit selection these cells are still exhibiting optimal growth rate. 
Their potential for differentiation has been proved in many published works and cells can 
be retrieved from different species like humansDe Coppi et al. 2007, Perin et al., 2007, Da 
Sacco et al., 2010), pigs (Zheng et al., 2010), goat (He et al., 2011; Zheng et al., 2011 ), mouse 
(De Coppi et al., 2007 ) and buffalo (Yadav et al., 2010).  
A recent report following a comparative analysis of AFSC and BM-MSC cells on 
proliferative potential and immunogenicity analysis showed the AFSC are less 
immunogenic and harbor a higher proliferation rate than BM-MSC (Mirebella et al., 2011). 
3.1 Amniotic fluid cells and kidney 
The complexity of the kidney and the multiple functions of the renal compartment are a 
great challenge to a successful therapeutic approach for its recovery and the regeneration. 
Beside the use of endogenous stem cells and other traditional and advanced therapies, the 
administration of exogenous stem cells, including AFSC has been proposed (Perin et al., 
2011).  
In the recent past, Perin et al. showed the capability of AFSC to participate in vitro to the 
development of embryonic kidneys. In particular, cells labeled with the surface marker CM-
Dil were shown able to integrate within the structures of the developing kidney. Integration 
into the metanephric structures was additionally confirmed by the migration of the injected 
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cells to the periphery of the embryonic kidney. This data strongly correlates to the 
centrifugal pattern of induction, morphogenesis and differentiation of the metanephros, 
proceeding from the center to the periphery of the embryonic organ (Perin et al., 2007).  
Moving into an in vivo model, the same group for the first time proved the potential of 
human AFSC to participate to the regeneration of kidneys undergoing acute tubular 
necrosis (Perin et al., 2010). After intra renal injection, cells were showed to survive, 
integrate into renal structures, and differentiate into tubular cells expressing proximal as 
well as distal epithelial tubular markers and persist over the long term.  
However, as the Authors highlight in their study, the main mechanism of action seems to lie 
into the ability of AFSC to modulate the immune response by lowering pro-inflammatory 
cytokines while stimulating the expression of anti inflammatory molecules, and by lowering 
apoptosis and increasing endogenous proliferation.  
On a different model of acute renal injury, Camussi’s research group confirmed the positive 
results and the comparable efficacy between BM-MSC and AFSC (Hauser et al., 2010).  
Beside the use of pluripotent cells, in 2010, we reported the isolation and characterization of 
more committed Amniotic Fluid derived Kidney Progenitor Cells (AFKPC) (Da Sacco et al., 
2010). Cells expressing both CD24 and OB-Cadherin were sorted and characterized for a wide 
range of kidney markers such as PAX-2, LIM-1, GDNF, ZO-1. Additional selections were 
performed on the CD24+OB-cadherin+ cells to isolate cells committed to mesangial 
differentiation, podocyte differentiation, mesenchymal to epithelial transition cells and 
vascular progenitors. Characterization of marker expression for these subpopulations showed 
significant differences in gene expression, confirming their different commitment to renal fate.  
3.2 Amniotic fluid cells and lung 
In uterus, the developing lungs of the fetus are filled with fetal lung liquid which is actively 
secreted into the amniotic fluid.  In the late gestational period, surfactant produced by the 
fetal lungs contributes to the composition of amniotic fluid and can be measured to 
determine the developmental stage of the surfactant system within the organ.  Contact 
between the developing lung and the fluid make it a possible important reservoir for cells to 
be used in lung regenerative medicine. In fact, AFSC were shown able to integrate and 
proliferate into mouse embryonic lung and express human lung epithelial cell markers 
(Carraro et al., 2008).  
Following hyperoxia injury, a tail vein injection of cells into nude mice showed localization 
in the distal lung with expression of both TTF1 and type II pneumocyte marker surfactant 
protein C. In the same work, specific Clara cells damage through naphthalene injury was 
followed by integration and differentiation of AFSC at the bronchioalveolar and bronchial 
positions with expression of specific Clara cell 10-kDa protein  (Carraro et al., 2008). The 
positive results obtained by Warburton’s research group were the first to prove the use of 
AFSC for in vivo organ regeneration. However, as underlined by the author, the number of 
cells homing and integrating within the lung was considerably low and the effects on tissue 
regeneration may be due on mechanisms different from integration and proliferation. 
However, our knowledge on this field is still lacking and more studies should be performed 
to clarify molecular pathways and suggest a plausible mechanism of action.  
3.3 Amniotic fluid cells and heart 
Heart failure remains one of the major causes of mortality in the United States (Honold et 
al., 2004). Stem cells have been proposed as an alternative, innovative approach for the 
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treatment of heart disease and cardiac differentiation. AFSC have been tested in the past 
years for their potential of becoming functional cardiomyocytes. 
Hoerstrup’s research group used amniotic fluid derived cells to successfully repopulate 
heart valves. After isolation, CD133- and CD133+ cells were isolated, characterized and 
subsequently seeded onto tissue engineered scaffolds. Feasible heart valve leaflets were 
obtained in vitro with the use of both fibroblast-like and endothelial like cells (Schmidt et al., 
2007). However, Chiavegato et al., in 2007 showed that injections of human AFSC into a rat 
normal or ischemic myocardium was ineffective and cells were targeted by the immune 
response with consequent rejection of the xenotransplanted cells. On the other hand, the use 
of a xenotransplantation model, even when cells were injected in immunodeficient animals, 
may not be ideal for immunogenicity studies. 
New insights on the cardiomyogenic potential of amniotic fluid cells have been published in 
2010 by Soker et al. showing the in vitro capability of AFSC to be differentiated into cardiac 
cells when co-cultured with rat cardiomyocytes (Guan et al., 2010). Along with this work, 
Sung’s research group reported the differentiation of AFMC into cardiomyocytes and 
endothelial cells (Yeh et al., 2010). Bollini et al. in two different works demonstrated the 
potential of AFSC to differentiate into cardiomyocytes both in vitro (Bollini et al., June 2011) 
and in vivo showing their cardioprotective effect following acute myocardial infarction 
(Bollini et al., May 2011).  
In summary, the results obtained with amniotic fluid derived stem cells for cardiomyocyte 
differentiation are contrasting, mostly due to the lack of a specific model and the use of 
different species and differentiation protocols. More studies should be performed in order to 
truly confirm their capability to provide an effective tool for cardiovascular regenerative 
medicine.  
3.4 Amniotic fluid cells and hematopoietic system 
C-kit positive/ Lin – cells derived from both human and mouse, have been shown to have 
hematopoietic potential (Ditadi et al., 2009). These cells were capable of differentiating into 
erythroid, myeloid, and lymphoid lineages in vitro as well as in vivo, in the peripheral 
blood of irradiated mice. Furthermore, single cells analysis was able to assess the expression 
of several genes important during different stages of hematopoietic differentiation.  
3.5 Amniotic fluid cells and pancreas 
The occurrence of pancreatic damage and diabetes has dramatically increased in the last 
years. The rise of this emergency has strongly encouraged physicians and scientist to search 
for alternative therapeutic approaches. In 2009 was suggested that stem cells derived from 
amniotic fluid could be of use for pancreatic regeneration (Furth et al., 2009).  
However, the first attempts to differentiate amniotic fluid cells into functional pancreatic 
cells were unsuccessful. In fact, the use of obestatin, a molecule proven to efficiently increase 
expression of pancreatic beta cell genes, was unable to stimulate pdx-1 expression these cells 
(Trovato et al., 2009).  
A better knowledge of developmental pathways and gene cascades involved in pancreatic 
specification brought, a year later, to a growing number of successes. In fact, differentiation 
into pancreatic cells was proven using a variety of different procedures. In particular, 
transfection with the PDX-1 gene was able to induce pancreatic features on cells from AFMC 
(Gage et al., 2010).  
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With an interesting approach, Li et al. were able to prove differentiation into insulin 
producing cells by silencing several neuronal genes by use of small interference NRSF RNA. 
This was shown as crucial for pancreatic differentiation and for the expression of pancreatic 
markers including Pdx1, Hnf4α, Isl-1, Nkx6.1, Insulin, and Glut (Li et al., 2010).  A different 
approach was taken by Zou et al.  Knowing that the expression of particular surface markers 
can identify cell populations with specific traits and defined commitment, a CD44+/CD105+ 
population was isolated and successfully differentiated into pancreatic cells expressing 
PDX-1 (Zou et al., 2011). The increasing number of studies reported in the last two years 
suggests that the interest for amniotic fluid cells for beta cell differentiation is a growing 
research subject. Moreover, differentiation into pancreatic beta cells is been proven as 
possible in vitro settings. However, no in vivo studies have been published reporting their 
potential in acute and chronic pancreatic diseases. 
3.6 Amniotic fluid cells and brain 
The differentiation of pluripotent and multipotent cells into neural cells has been considered 
fundamental for understanding brain differentiation and for the establishment of innovative 
approaches for the healing of brain injuries. Many different studies have been performed on 
amniotic fluid cells and their expression of neuronal markers. However, their ability to 
differentiate into functional brain cells has being highly debated.  
First reports on amniotic fluid progenitor cells commitment to neuronal cell lineage were 
published in 2006. In fact, McLaughlin’s research group reported the ability to isolate and 
expand them in culture. Their studies showed that these novel progenitors are committed to 
mesencephalic dopaminergic neurons (McLaughlin et al., 2006). AFMC  were shown to be 
able to differentiate into brain cells both in vitro (Prusa et al., 2004, Tsai et al., 2004; Tsai et 
al., 2007; Jiang et al., 2010, Mareschi et al., 2009)  and in vivo (Cheng et al., 2010). Selection of 
specific cell population based on specific surface marker expression didn’t show to really 
improve the neuronal potential of amniotic fluid cells. Cells isolated by use of different 
surface markers like c-kit, (De Coppi et al., 2007),  sox-2 (Jezierski et al., 2010)  were shown 
able to differentiate into neuronal like cells.  However, in 2009 was reported the inability of 
AFSC to differentiate into dopamine neurons both in vitro and in vivo assays (Donaldson et 
al., 2009). An interesting recent study, investigated the impact of extracellular signals on 
neural differentiation, where it was confirmed that extracellular matrix has an essential role 
on neurogenic differentiation and therefore regulates its efficiency (Orciani et al., 2011).  
While many studies seems to prove that differentiation of amniotic fluid stem cells, either 
AFSC or AFMC, into neural cell types, there are still too many open questions about 
functionality of the differentiation, ideal cell population and best differentiation cocktail. 
While the current status of the research gives great hope for the future, to confirm of deny 
the possible use of amniotic fluid cells for brain regeneration more in vitro and in vivo data 
are certainly required.   
3.7 Amniotic fluid cells and liver 
Only a few studies have been reported that investigate the potential of amniotic fluid 
derived cells for hepatocyte differentiation. Zheng et al. in their work, claimed that AFSC 
had a better response to the differentiation when compared with BM-MSC under the same 
conditions (Zheng et al., 2008). Later on, differentiation into the hepatic lineage was 
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successfully obtained by Gasbarrini research group (Saulnier et al., 2009) that showed the 
equal potential of adult and fetal derived cells, including AFSC, for liver regeneration. 
However, beside these encouraging results, more studies are required prior to confirm the 
suitability of amniotic fluid stem cells for liver therapy.  
3.8 Amniotic fluid cells and bone  
In 2010, it was reported a positive effect of transient ethanol exposure during early 
differentiation of AFSC into osteoblasts (Hipp et al., 2010).  
Papaccio’s research group showed the ability of AFMC to differentiate into bone cells when 
co-cultured with dental pulp cells proving potential for bone engineering (De Rosa et al., 
2010).  
Osteogenic progenitors have been found within amniotic fluid (Antonucci et al., February 
2009).  In this work, they were able to obtain calcium mineralization and osteogenic 
differentiation of AFMC. Expression of various osteogenic markers after 30 days in culture 
was demonstrated. Similar results were obtained by two other research groups (Antonucci  
et al., October 2009, Steigman et al., 2009 and Sun et al., 2010).  
Peister in 2011 showed that AFSC  were capable of a greater differentiation potential 
compared to mesenchymal stem cells although the latter response to the differentiative 
cocktail was occurring at earlier times (Peister et al., 2011). However, in vivo data are still 
lacking and the osteogenic potential of amniotic fluid cells in a complex environment should 
be undisclosed. 
3.9 Amniotic fluid cells and chondrocytes, adipose tissue and skeletal muscular 
cellular differentiation 
3.9.1 Chondrocytes  
The regenerative capacity of the cartilage is limited. The ability to differentiate stem cells 
into cartilage may provide a better alternative to primary culture of chondrocytes that in 
vitro dedifferentiate losing their characteristics (Kramer et al., 2008). 
Fauza’s research group demonstrated the ability of ovine AFMC to successfully differentiate 
into chondrocytes on 3D scaffolds expressing several markers of cartilage (Kunisaki et al., 
2006). Atala’s group showed the ability of AFSC to differentiate into chondrocytes (De 
Coppi et al., 2007). However, no functional studies were performed to confirm the possible 
use of these amniotic fluid derived cartilage cells.  
3.9.2 Adipocytes 
Adipocyte differentiation was proven in 2007 for AFSC when these cells were first 
characterized and tested for their pluripotentiality (De Coppi et al., 2007). 
In addition,  adipogenic differentiation for goat derived AFMC was shown in 2011 (He et al., 
2011) proving their differentiative potential.  
3.9.3 Myocytes 
Muscular tissue is well known to harbour endogenous stem cells that help recovering the 
tissue after an injury. However, the differentiation potential of these pluripotent stem cells 
and when the extent of the injury, due to an acute or chronic insult, is too heavy, muscular 
degeneration occurs with loss of motility and impaired function. The study of cells feasible 
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for muscular differentiation and regeneration has been considered essential for a successful 
therapeutic approach.  
Amniotic fluid cells have been studied for their capability to differentiate into functional 
muscular cells. In particular,  Streubel  reported using non-hematopoetic AFMC for the 
conversion of amniocytes into myocytes. (Streubel et al., 1996). De Coppi  showed the ability 
of AFSC to differentiate into myocites in vitro by expression of markers expressed by the 
differentiating and mature muscle fibers (De Coppi et al., 2007) and the results were later 
confirmed by studies both in vitro and in vivo on scid mice (Gekas et al., 2010) 
4. Amniotic fluid derived cells and their role as cytokine modulators 
In the last years new evidences have been found that correlates the administration of stem 
cells with the modulation of inflammatory and fibrotic processes through cytokine mediated 
cross-talk between the pluripotent cells and the surrounding environment. New studies 
have highlighted the possibility that the same mechanism of action can be used to explain 
the effect of amniotic fluid stem cells in many diseases.  In particular, Perin showed that in a 
murine model of acute tubular necrosis, the expression of inflammatory cytokines is 
strongly regulated after injection of AFSC (Perin et al., 2010). Down regulation of pro-
inflammatory molecules and up-regulation of pro-regenerative and anti-flogistic cytokines 
resulted in a faster regeneration of the damaged tissue with higher proliferation rate, lower 
apoptosis and an overall better physiological profile of different renal parameters. A broad 
study performed by Yoon (Yoon et al., 2010) investigated the in vitro production of 
cytokines by AFMC in the cultured media. Presence of several inflammatory molecules was 
reported such as IL-8, IL-6, TGF-β, TNFRI, VEGF, and EGF and other molecules involved in 
the TGFB/SMAD2 pathway. The conditioned culture media proved to be useful for 
enhancing wound healing in an in vivo murine model. While studying the angiogenic 
potential of AFSC, Teodolinda et al. (Teodolinda et al., 2011) reported the ability of the cells 
to produce and release several cytokines and chemoattractant molecules that are able to 
modulate not only the vessel growth but also the activity of macrophages/monocytes and 
other cells involved in inflammation and  immunoresponse.  
5. Conclusions 
In the last few years, an increasing number of studies have been performed on amniotic 
fluid derived stem cells and progenitor cells. Exciting results have been reported on 
amniotic fluid cell population characterization of composition, growth kinetics and potential 
for specific organ regeneration.  However, further investigation is still required to 
completely categorize cells according to origin and function.  Improving the efficiency and 
specificity of differentiation into various mature and functional cell types to prevent their 
attrition towards unrelated cell types would be an important factor to control in 
regenerative medicine applications. In this very same direction, the establishment of 
protocols and differentiative media will better allow us to compare the different populations 
and understand their mechanism of action. In addition, knowledge about how the different 
compartments of the developing fetus are contributing to the cellular composition may 
undisclose important information about the development and the amniotic fluid 
composition.  
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1. Introduction 
The normal cell is confined by its genetic program to a rather narrow range of 
morphofunctional characteristics within which it is nevertheless able to handle normal 
physiological demands (Kumar et al., 2011). A single cell, placed in an appropriate 
environment, contains, enclosed in its genome, sufficient information to generate a variety 
of differentiated cell types, whose spatial and temporal dynamics interact to form detailed 
morphological patterns (Geard and Wiles, 2005). Similarly, in multicellular organisms, it is 
the genetic program that establishes networks basics -including differentiation, 
functional hierarchy and interaction patterns- with each level in the system representing 
an increase in organizational complexity. Indeed the emergence from a single or few stem 
cells of multicellular organisms with a complex organization must be seen as a necessity in 
evolution since it alone can ensure an optimal use of resources (Furusawa and Kaneko, 
2000). From such evolutionary perspective, the development of a cardiovascular system in 
complex organisms fulfills the need for transport of nourishment, oxygen and metabolic 
waste as well as the need for communication between distant districts. 
All closed biological systems facing the external environment, whatever their level of 
complexity, are characterized by the ability to maintain a stable, constant condition by 
regulating themselves and the internal environment. In the early 19th century Cannon 
(Cannon, 1926) defined this property “homeostasis”, from the Greek: ὅμοιος, hómoios, "similar" 
and στάσις, stásis, "standing still". This condition of relative equilibrium grants the biological 
system a certain degree of independence from the environment and enables what we call life. 
Any change, either decremental or incremental, in the internal/external environment of the 
cell/organism such that it requires an active response from the cell/organism can be termed 
demand. In the case of complex organisms demands are met by the functional reserve of the 
cell/tissue/organ. The functional reserve is involved in the process of adaptation by which a 
cell/organism acquires morphofunctional features that allow it to better fit in with the 
changed environment and thus attain a new equilibrium (Figure 1). Adaptation is driven by 
the genetic program, via the activation of appropriate subsets of genes, and is influenced by 
the qualitative and quantitative characteristics of the demand such as its nature, intensity and 
duration. Adaptation can be considered to include both plasticity and adaptability. Plasticity is 
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the ability to express a broad variety of phenotypes in response to environmental changes and 
is at a maximum during embryogenesis and early extrauterine life. The term adaptability 
could instead be applied to the (more limited) process of adaptation which occurs in adult life 
and varies between organs and species. In complex organisms two points deserve particular 
mention. First, it should be remarked that, since complex organisms possess cognitive 
functions, demands can be not only physical but also mental or emotional, and that no line can 
be drawn between body and mind. Second, the functional hierarchy of complex organisms is 
paramount in allocating functional reserve where it is needed so that priorities can be 
established in the distribution of the available resources. 
 
 
Fig. 1. Genetic programming and functional hierarchy 
Schematic representation of the interplay between environmental demands and the genetic-
driven adaptation process in adult life. In complex organisms genetic programming is 
paramount in allocating functional reserve where it is needed. Adaptation is the response to 
environmental demands and involves the acquisition by a cell/organism of 
morphofunctional features that allow it to better fit in with the changed environment. 
Adaptation includes plasticity and adaptability. During development plasticity is 
progressively replaced by adaptability. 
Inflammation-Angiogenesis Cross-Talk and Endothelial  
Progenitor Cells: A Crucial Axis in Regenerating Vessels 
 
183 
Thus, the adaptation process –whether be it grounded in plasticity or adaptability– is 
determined by the genetic program. Since the genetic program is finite so is also the 
functional reserve, and there is necessarily an intrinsic limit to adaptation. However, this 
limit is extremely variable from subject to subject because each organism possesses a 
peculiar genotype and thus a unique functional reserve.  
It must be underscored that there is a lifelong interplay between genome and environment, 
i.e. the genome-driven adaptation process is continuously called upon to buffer 
environmental changes throughout the life of an individual. What happens then when the 
functional reserve is inadequate per se and/or in relation to the characteristics of the 
demand? There arises a condition which is currently classified as stress and appears to be 
more common than is generally believed, although it is not formally considered a disease. In 
fact stress may cause cell injury but a disease can be recognized as such only when cell 
injury leads to functional deficits in the organism and to the occurrence of signs and/or 
symptoms. Hence, the notion of disease has very much to do with communication. It can be 
conceived as communication at multiple levels of complexity: from cell to neighbouring 
cells, from organs to organism and, finally from organism to organism. The latter is the apex 
of the communication process and corresponds to what is normally witnessed in everyday 
life when the patient attends the doctor’s office.  
In summary, it is the balance between genetically-determined functional reserve and 
environmental changes that delineates the fuzzy boundary between physiology and 
pathology, between what we define a current and an extra demand and, ultimately, between 
what we define health and disease. In complex organisms with an evolved circulatory 
system, the role of the circulation as a dynamic interface between blood and tissues 
implies that it is continuously challenged by noxious stimuli of different kinds 
(mechanical, chemical, biological). Thus the circulatory system plays a key role in 
communicating stress at a distance and in responding to it through the vascular changes 
that characterize inflammation, even by replacing its own damaged endothelial cells. This 
is the conceptual basis of vascular homeostasis and the reason why in organisms with a 
circulatory system inflammation acts as a bridge between environment (demand) and 
genome (response). 
2. The circulation of blood and its constituents: an evolved system of 
transport and communication  
There are about 100 trillion cells in the human body, a number that is about ten thousand 
times greater than the number of human beings on Earth. Even though they are an awesome 
multitude all these cells can communicate directly or indirectly with each other. Every single 
cell needs to receive nourishment, replenish oxygen and remove waste in order to survive 
and work properly. It must also be able to inform other cells about its fate, the changes it 
experiences, the answers it provides to stimuli and, in general, the actions it intends to take. 
Successful cell functioning therefore requires the existence of an excellent 
“communication route” that enables cells to exchange information with the external 
environment, and with distant cells via humoral signaling. This route is the circulatory 
system, which is a perfect model of a dynamic and well-organized highway. Consistently 
with its function, it is composed of an extensive network of vessels: De Witt (2005) has 
calculated that blood vessels from an adult would circle the earth twice if placed end to end 
(DeWitt, 2005). Busy but efficient, the circulatory system consists of two basic elements: the 
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vessels (composed by endothelium and connective tissue) and the blood. It is a highly 
dynamic system which is always “turned on” and ready to respond to the changing 
demands of the organism. Given the dynamic nature of the vascular system, vascular 
injury requires rapid repair and this means that “spare parts” must be readily available. 
Later in this chapter we will see which are the main players in vascular turnover and which 
are the cellular and molecular processes involved in the repair of vascular damage. 
2.1 Open and closed circulatory systems 
With very few exceptions, all coelomates (by the broadest definition, every organism with a 
fluid-filled cavity) possess a circulatory system (Ruppert and Carle, 1983). The walls of the 
blood vessels are made of a layer of epithelial cells which in most invertebrates forms part of 
the coelomic lining (called mesothelium or peritoneum); the mesothelium lining the blood 
vessels contains myofibrils (myo-epithelium) whose contractility determines the flow of 
blood. In vertebrates and some invertebrates, blood vessels are lined by a non-muscular 
endothelium and are surrounded by a separate muscle cell layer. Blood vessels can form 
two different types of circulatory systems: closed, e.g. in chordates and annelids, or open at 
both ends, e.g. in arthropods such as insects, and mollusks. In the former case, the body 
fluid is contained within two separate compartments, one inside the lumen of the 
circulatory system (blood), the other inside the coelom (coelomic fluid). In the latter case, 
there is a single compartment filled with a body fluid called hemolymph. Blood, coelomic 
fluid and hemolymph contain dispersed cells, generally termed blood cells or hemocytes 
(Ratcliffe and Rowley, 1979). Contractile blood vessels, such as the dorsal vessel/heart in 
insects, are suspended within the hemolymphatic space and cause a streaming motion of the 
hemolymph by means of rhythmic contractions. Evolution well illustrates how an increase 
in complexity is always paralleled by an increase in needs and thus requires the 
establishment of appropriate structures to support them. A closed vascular system, under 
neural control, is consistent with the functional hierarchy of complex organisms, since it 
allows a fine-tuned modulation of the blood flow to allocate resources (nutrients, oxygen) 
to the body districts that most  require them.  
2.2 Embryo vasculogenesis 
The development of the circulatory system is a key event during embryogenesis in many 
animal species. The process of vasculogenesis involves the differentiation of local 
mesodermal precursors into vascular and endothelial cells (ECs). These are clustered in 
blood islands whose growth and fusion leads to the formation of  a primary vascular plexus 
(Carmeliet, 2000; Risau and Flamme, 1995; Timmermans et al., 2009). After the onset of the 
blood circulation, the yolk sac capillary network differentiates into an arteriovenous 
vascular system (Risau et al., 1988). The integral relationship between the elements that 
circulate in the vascular system (the blood cells) and the cells that are mainly responsible for 
the vessels themselves (the endothelial cells) is reflected by the composition of the 
embryonic blood islands. In fact the cells which are destined to generate hematopoietic cells 
are located in the center of the blood islands and are termed hematopoietic stem cells 
(HSCs) while endothelial progenitor cells (EPCs), or angioblasts, can be found at the 
periphery of the blood islands. In addition to this spatial association, HSCs and EPCs share 
certain antigenic markers, including Flk-1, Tie-2, Sca-1 and CD34, which will be discussed 
later in greater detail. On the basis of such embryological and molecular data there is 
evidence for a close developmental relationship between these two types of progenitor cells, 
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thus EPCs and HSCs have been considered to derive from a putative common precursor, 
termed hemangioblast (Choi et al., 1998; Flamme and Risau, 1992; Weiss and Orkin, 1996). 
For a long time the existence of a common precursor for both hematopoietic and endothelial 
cells was believed to be restricted to embryonic development but recent studies have 
identified a postnatal hemangioblast. Over recent years, much attention has focused on bone 
marrow (BM) stem cell potentiality. It has been reported that the bone marrow contains cells 
termed multipotent adult progenitor cells (MAPCs), which, at a single-cell level, can 
differentiate into a large number of cell types, including endothelial cells (Reyes et al., 2002). 
Bone marrow–derived EPCs originate from CD34+ stem cells, which are able to differentiate 
via separate pathways not only in endothelial cells but also in erythrocytes, thrombocytes 
and various lineages of leukocytes. 
It is possible that circulating EPCs mobilized from the bone marrow are in fact progenitor or 
stem cells with a broader differentiation potential which is directed towards the formation 
of endothelial cells at sites of neovascularization, where the microenvironment is adequate 
for such process to occur (Asahara et al., 1997; Peichev et al., 2000). Indeed, a decade ago, 
two groups reported that human CD34+ cells isolated from circulating peripheral blood 
(PB), umbilical cord blood (UCB) and BM, could differentiate into ECs in vitro and in vivo in 
mouse models, thereby contributing to neoendothelialization and neovascularization in the 
adult organism (Asahara et al., 1997; Shi et al., 1998). 
2.3 Stemness and the hemangioblast  
As we have seen, stem cells have a key role in the setting of both embryonic and postnatal 
vasculogenesis. The two main players on stage are the hemangioblast and the EPC. The 
hemoangioblast is a pluripotent stem cell that is able to differentiate into cells belonging to 
the hemopoietic lineage and into EPCs.  The EPC is a multipotent stem cell that can 
differentiate into various cell types including vessel-lining endothelial cells. Hemoangioblast 
and EPC are distinguished on the basis of a number of characteristics, including the 
developmental stage in which they are identified, their tissue localization, their molecular 
profile and their properties in vitro. Still, as new information is acquired and as 
experimental techniques are refined, the classification of stem cells is becoming less clear-cut 
and much more complex. Indeed a review by Blau and colleagues (Blau et al., 2001) 
endorses the pioneering view that a stem cell should not be considered a specific cellular 
entity but rather a biological function which can be taken on by numerous cell types 
expressing different genes. Traditionally, stem cells have been regarded as 
undifferentiated cells capable of self-renewal and production of a large number of 
differentiated progeny, with a sharp distinction being made between embryonic and 
adult stem cells. According to a large body of in vitro and in vivo evidence only embryonic 
stem cells (ES) were believed to be pluripotent –i.e. capable of differentiating into a wide 
range of cell types. Their high degree of plasticity fitted in well with the notion that 
maximum “flexibility” is required during the early stages of development, when a variety of 
body tissues are in the process of being formed. Adult stem cells were thought to exhibit a 
limited differentiative potential- i.e. to be able to differentiate exclusively into cells of the 
specific tissue in which they resided. This idea was supported by several examples of tissue-
specific regeneration: the proliferation of liver cells after surgical removal of part of the liver, 
the production of blood elements by transplanted hematopoietic stem cells after chemo- or 
radio-induced BM ablation, the existence of satellite cells that repair damaged skeletal 
muscles, the participation of keratinocyte precursors in the healing of skin wounds. 
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However, it is increasingly recognized that adult stem cells have a broader regenerative 
potential than was originally supposed, and that it is probably involved not only in the 
response to tissue injury but also in physiological tissue homeostasis. BM-derived cells have 
been reported to yield not only blood cells but also cells belonging to the brain, liver and 
heart. Stromal cells in the BM, other than HSC, have been found to give rise to a number of 
different cell types. Going one step further, even highly specialized cells such as muscle cells 
and central nervous system cells have been shown to be able to contribute to the 
replenishment of the blood. It is therefore speculated that adult stem cells possess a 
significant amount of plasticity which can be channelled along diverse differentiation 
pathways by the interactions they establish with the environment. Indeed, resorting once 
again to the “highway” metaphor, the circulatory system can be envisioned as the route 
through which stem cells gain access to all districts of the body. It has been documented 
experimentally that BM-derived cells enter different organs such as the heart, brain, skeletal 
muscle, and liver (Bittner et al., 1999; Brazelton et al., 2000; Ciulla et al., 2007c; Gussoni et al., 
1999; Jackson et al., 1999; Krause et al., 2001; Lagasse et al., 2000; Mezey et al., 2000). The 
recruitment of stem cells from the circulation into a specific organ would be brought about 
by homing signals, as has been described for the homing of leukocytes (Butcher, 1991). 
Likewise, the behavior of the stem cells - in terms of generative potential- would then be 
determined by the surrounding microenvironment, including the extracellular matrix (Hay, 
1991), the local milieu (Studer et al., 2000) as well as growth and differentiation factors. Stem 
cells would thus be stimulated to assume morphologies and functions typical of the new 
environment in which they have migrated. Therefore, stem cell plasticity coupled with the 
availability of a route connecting different compartments of the organism, explains how 
stem cells residing in one tissue would be able to contribute to the regeneration of distal 
tissues.  
In summary, the concept of stemness should be conceived as a highly dynamic one, with no 
fixed tissue-specific boundary either in the localization or in the differentiation of stem cells. 
2.3.1 The hemangioblast  
It has already been mentioned that the formation of blood islands in the extraembyronic 
yolk sac marks the onset of hematopoiesis and vasculogenesis in the developing embryo. 
These blood islands derive from aggregates of mesodermal cells that colonize the 
presumptive yolk sac. In about 12 hours, the central cells within these clusters give rise to 
embryonic hematopoietic cells while the peripheral cells differentiate into endothelial cells 
which form the first vascular structures that surround the inner blood cells (Wagner, 1980). 
The close developmental association of the hematopoietic and endothelial lineages within 
the blood islands has led to speculate that they arise from a common precursor, the 
hemangioblast (Murray, 1932; Sabin, 1920; Wagner, 1980). This hypothesis has gained most 
support from the observation that the hematopoietic and endothelial lineages share the 
expression of a number of different genes (Anagnostou et al., 1994; Asahara et al., 1997; Fina 
et al., 1990; Kabrun et al., 1997; Kallianpur et al., 1994; Millauer et al., 1993; Yamaguchi et al., 
1993; Young et al., 1995). Moreover, recent gene-targeting experiments demonstrating that a 
functional Flk-1 receptor tyrosine kinase is required for the development of the blood 
islands are consistent with the notion that these lineages derive from a common precursor 
(Shalaby et al., 1997; Shalaby et al., 1995). However, there is still no definite proof of the 
existence of the hemoangioblast. Past studies aimed at identifying and characterizing the 
putative hemangioblast have been hampered by difficulties in accessing the embryo prior to 
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the establishment of the blood islands and by the limited number of cells present at this 
stage of development. Differentiation of embryonic stem (ES) cells to hematopoietic and 
endothelial cells in culture provides an alternative approach for investigating these early 
commitment steps since both cellular and molecular analyses have documented that the 
sequence of events giving rise to these lineages is similar in vitro and in the normal mouse 
embyo (Keller et al., 1993; Keller, 1995; Nakano et al., 1994; Risau et al., 1988; Vittet et al., 
1996; Wiles and Keller, 1991). Indeed, using this in vitro model, it has recently been shown 
that embryoid bodies (EBs) generated from ES cells allowed to differentiate for 3-3.5 days 
contain a unique precursor population with both primitive and definitive hematopoietic 
potential (Kennedy et al., 1997). When cultured in the presence of vascular endothelial 
growth factor (VEGF), c-kit ligand (KL) and conditioned medium from an endothelial cell 
line, D4T, these precursors form colonies consisting of immature or blast-like cells that 
express a number of genes common to both the hematopoietic and endothelial lineages, 
including tal-1/SCL, CD34 and the VEGF receptor, flk-1 (Kennedy et al., 1997). The 
responsiveness to VEGF of these embryonic precursors together with the gene expression 
pattern of their blast cell progeny suggests that this population could have the potential to 
generate cells of the endothelial lineage in addition to hematopoietic precursors (Choi et al., 
1998). 
3. Cellular identity, a dynamic concept 
Until a few decades ago, many dogmas of cell biology had not yet been dismantled; among 
them was the idea that cells might not have an alternative fate after maturation according to 
their specific identity. 
The effects of nuclear transfer to enucleated oocytes in adult cells (Gurdon, 1960) have 
experimentally shown that the mechanisms that regulate cell identity follow rules, bound to 
processes of genetic reprogramming, which are still unclear today. There are two well-known 
processes by which cells are able to turn into other cell types:  transdifferentiation, i.e. the 
direct conversion from one cell type to another, and dedifferentiation, i.e. the reversion to a 
less-differentiated cell type and the subsequent maturation to a different lineage. 
After Dolly the sheep (Campbell et al., 1996), cell biology moved under the spotlight and 
there arose within the scientific community questions which have still not found exhaustive 
answers. Cell identity, which had so far been considered a rigid and durable characteristic 
involving a one-way process from precursor to mature cell, was shown to exhibit not only 
intrinsic plasticity (Scadden, 2007) but also a large degree of adaptation depending on the 
interplay between genome and microenvironment.  
In fact it was demonstrated that mature cells are able to switch not only their functional 
phenotype but also their gene expression profile into that of stem cells, thereby acquiring 
pluripotent plasticity. Such findings yielded several questions: can all somatic cells 
dedifferentiate? What kind of epigenetic events are able to reverse the fate of a cell which is 
already committed and in what order can they do so? Factors that can reverse the fate of the 
cells are only endogenous or can they be exogenous too? As far as regenerative medicine is 
concerned, the latter question is the most important, since the application of potential drug 
treatments that can revert a pool of cells into stem cells capable of regenerating damaged 
tissues in the setting of injury or disease holds great promise.  
In the field of regenerating vessels the central issue is: what kind of cells are able to repair 
vascular damage? The answer to this apparently straightforward question – i.e. EPCs - leads 
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us into a topic fraught with controversy. In fact the identity of EPCs from both a molecular 
and technical standpoint is still open to discussion and experimentation. It would therefore 
be helpful to find biological markers of progenitor cells in order to validate a reproducible 
method for the enumeration and distinction of EPCs from circulating endothelial cells 
(CECs). Different approaches have been used to detect these cells, including in vitro culture, 
magnetic bead separation and fluorescence microscopy, immunocytochemistry and flow 
cytometry (Bull et al., 2003; Del Papa et al., 2004; George et al., 1993; Goon et al., 2006; 
Mancuso et al., 2001; Mutunga et al., 2001; Nakatani et al., 2003), each having specific 
strengths and limitations. 
3.1 EPC Identity 
Numerous markers of EPC lineage have been proposed in the literature, subcategorized into 
stem cell makers (such as CD34, CD133, CD45, and c-kit) and endothelial-like markers (such 
as VEGF receptor (VEGFR), CD31, CD146, and von Willebrand factor) (Hristov et al., 2003a; 
Timmermans et al., 2009). However, the precise definition of what constitutes an EPC is the 
subject of an extensive debate (Asosingh et al., 2009; Diller et al., 2008). At present, the only 
EPC phenotype based on surface antigenic markers that provides strong and reproducible 
correlations across multiple studies on vascular damage and cardiovascular risk is 
CD34+/VEGFR+ (Fadini et al., 2008). An additional phenotype that has recently been 
employed in the literature involves the inclusion of CD133 as a secondary stem cell marker 
(Friedrich et al., 2006); however, Timmermans et al. have recently questioned its utility as an 
EPC marker (Timmermans et al., 2009; Timmermans et al., 2007). Notably, the intersection of 
the CD34+/CD133+ and CD34+/ VEGFR+ cell phenotypes (i.e., CD34+/CD133+/ VEGFR+ 
cells) is known to be extremely rare (Fadini et al., 2008).  
Many investigators have identified or designated putative circulating EPCs (CEPCs) with 
flow cytometry using a single surface marker such as CD34 or CD133, or various 
combinations of surface markers, which has actually resulted in a complicated list of 
putative CEPC immunophenotypes both in humans and mice. Most of the surface marker 
combinations used in flow cytometry studies included the marker CD34 and VEGFR-2, 
because initial studies in the field had reported that CD34+ and VEGFR-2+ cells purified 
from various sources like UCB, PB and BM were able to generate ECs in vitro, suggesting 
that CD34+ cells contain CEPCs (Asahara et al., 1997; Bompais et al., 2004; Shi et al., 1998). 
One specific subset of CD34+ cells, designated as CD34+VEGFR-2+CD133+ cells, is widely 
accepted to correspond to ‘true CEPCs’ in humans but yet these cells were never directly 
tested for their ability to generate new ECs in vitro or in vivo, which is essential to validate 
CD34+VEGFR-2+CD133+ cells as true CEPCs (Bertolini et al., 2006; Kondo et al., 2004; 
Peichev et al., 2000). Recently, however, Case et al. , using in vitro hematopoiesis assays, 
reported for the first time that isolated human UCB or mobilized adult PB CD34+VEGFR-
2+CD133+ cells in fact represent an enriched population of CD45+ hematopoietic 
precursors, but that CD34+VEGFR-2+CD133+ did not contribute to the formation of ECs in 
vitro (Case et al., 2007). Similarly, CD34+CD45+CD146+ cells previously considered to be 
CEPCs, were not directly assayed in vitro, nor in vivo for their ability to contribute to newly 
formed endothelium, and thus, it is difficult to know whether this cell type acts as a true 
CEPC (Delorme et al., 2005). Therefore, the scientific foundation for using CD34+ plus 
variable combinations of surface markers remains elusive. Moreover, the use of these 
diverse combinations to define a singular entity (the CEPC), makes the significance of flow 
cytometry studies difficult to interpret, creates obstacles to the direct comparison of data 
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between laboratories, and may result in discrepancies in the interpretations of study results 
among different laboratories. Therefore, investigators should strongly consider that any 
‘putative’ CEPC, whatever its phenotype, be carefully assessed by validating its postnatal 
endothelial differentiation capacity in vitro and in vivo. An effective way of doing so is to 
test the ability of CEPCs to form endothelial colonies in vitro (Ciulla et al., 2006) or actual 
vessels in vivo (Ciulla et al., 2007b; Ciulla et al., 2007c). However, even the latter approaches 
pose a series of challenges because they involve a number of variables such as the exact 
combination of growth factors to which the cells are exposed in vitro and, in vivo, the type 
of animal model used, its genetic background and the nature of the angiogenic stimulus 
applied. Furthermore, a potential limitation of single-cell clonal assays is that a cell may 
behave differently according to whether it is isolated or in the presence of other cells, and 
thus transplanting or culturing a single cell may not be an appropriate EPC assay, and the 
presence of supportive cells with a different phenotype or function may be required. 
In summary, one of the greatest problems to date in the field of EPC biology is the lack of 
a unique marker, or combination of markers, that solely identifies the rare CEPCs in 
humans (between 0.01% and 0.0001% of peripheral mononuclear cells) (Shaffer et al., 
2006). As Blau and colleagues (Blau et al., 2001) very appropriately point out, this obstacle 
may be technical or  indeed purely biological- i.e. specific molecular markers for stem cells 
are not available either because they have not yet been discovered or because they simply 
do not exist. 
4. The endothelium: More than a lining 
The endothelium is a key component of the vascular system, being strategically located to 
provide a physical interface between blood and tissues. Far from being an inert layer of 
“nucleated cellophane” (Chen et al., 2008; Cines et al., 1998; Galley and Webster, 2004) it 
participates in a number of physiological processes such as the transfer of biologically active 
molecules to the underlying interstitium and cells, the selective transmigration of cells in 
and out of the bloodstream, the modulation of vasomotor tone and the regulation of 
hemostasis/coagulation (Chen et al., 2008; Cines et al., 1998; Galley and Webster, 2004; 
Hunting et al., 2005; Mikirova et al., 2009). In an average adult it contains ten trillion (1013) 
cells, weighs about 1 kg and covers a surface area of approximately 7 m2 (Cines et al., 1998; 
Galley and Webster, 2004; Lin et al., 2000). It has traditionally been considered a rather static 
structure with little turnover (0.1% replications per day) (Cines et al., 1998), but over the last 
two decades its highly dynamic nature is being increasingly recognized (Dignat-George and 
Sampol, 2000; Mikirova et al., 2009). Indeed the endothelium is continuously exposed to 
different kinds of noxious stimuli (mechanical, chemical, biological) that damage endothelial 
cells and injured endothelial cells need to be replaced in order to guarantee 
structural/functional vascular integrity and prevent atherosclerotic disease. Initially 
endothelial repair was believed to occur exclusively through the proliferation and migration 
of mature endothelial cells surrounding the lesion. However, these are terminally 
differentiated cells with low proliferative potential (Caplan and Schwartz, 1973; 
Haudenschild and Studer, 1971; Haudenschild and Schwartz, 1979; Hristov et al., 2003a; Jujo 
et al., 2008; Kunz et al., 1978; Malczak and Buck, 1977; Schwartz et al., 1980; Schwartz et al., 
1981; Schwartz et al., 1975; Taylor and Lewis, 1986; Tongers et al., 2010) and it was 
reasonable to suppose that an alternative mechanism would be required for efficient 
endothelial regeneration. Research conducted along this line provided growing evidence 
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that a crucial role in endothelial turnover is played by EPCs (Asahara et al., 1999; Asahara et 
al., 1997; George et al., 2011; Hristov et al., 2003a; Hunting et al., 2005; Jujo et al., 2008; 
Mikirova et al., 2009; Peichev et al., 2000; Tongers et al., 2010). These are BM-derived cells 
that can be found in the peripheral blood and have properties similar to those of embryonic 
hemangioblasts, being able to circulate, proliferate and differentiate into mature endothelial 
cells (Asahara et al., 1999; Asahara et al., 1997; Dignat-George and Sampol, 2000; George et 
al., 2011; Hristov et al., 2003b; Jujo et al., 2008; Peichev et al., 2000). In particular, they are 
mobilized from the BM into the circulation, travel to the site of vessel damage (a process 
known as recruitment or homing) and integrate into the endothelial monolayer to substitute 
damaged cells (Asahara et al., 1999; Asahara et al., 1997; George et al., 2011; Hristov et al., 
2003b; Hunting et al., 2005; Jujo et al., 2008; Tongers et al., 2010). It is also becoming clear 
that EPCs do not merely have a direct, structural function –producing the “hardware” of the 
vessel –but also an important indirect, paracrine role, behaving as “cytokine factories”- i.e. 
they secrete proteins (growth factors, chemokines, cytokines) that have a variety of 
proangiogenic actions including the recruitment of additional EPCs and the suppression of 
apoptosis as well as the activation of “resident” EPCs (George et al., 2011; Jujo et al., 2008; 
Rehman et al., 2003; Tongers et al., 2010). As far as the latter are concerned, emerging data 
points to the presence of in situ EPCs, embedded within the vessel wall, that may aid in 
vascular repair, although their existence is still a matter of controversy (Ingram et al., 2005; 
Jujo et al., 2008; Torsney and Xu, 2011).  
Animal studies have extensively demonstrated the involvement of BM cells in tissue 
regeneration after vascular damage. In a rat model of myocardial cryodamage it has been 
shown that labelled donor rat BM mononuclear cells (BM-MC) injected peripherally through 
the femoral vein were found after one week in the injured myocardium (Ciulla et al., 2003) 
in a number proportional to the size of the infarcted area (Ciulla et al., 2004) and were 
located within small early-stage vessels (Ciulla et al., 2007b). Similarly, in a rat model of 
myocardial ischemia induced by coronary artery ligation, human CD34+ cells injected 
intravenously were reported to infiltrate the infarcted zone within 48 hours and form 
capillaries of human origin after two weeks, improving echocardiographically-assessed left 
ventricular function (Kocher et al., 2001). Asahara and colleagues described the 
incorporation of BM-derived EPCs into sites of active angiogenesis one week after 
surgically-induced hindlimb and myocardial ischemia in a seminal work on BM transplant 
(BMT) murine models (Asahara et al., 1999; Asahara et al., 1997). Likewise, in a mouse 
model of hindlimb ischemia intravenous human EPCs were integrated into limb vessels at 
two weeks, significantly increasing blood flow at a Doppler evaluation. “Urbich C, 
Heeschen C, Aicher A, Dernbach E, Zeiher AM, Dimmeler S (2003) Relevance of monocytic 
features for neovascularization capacity of circulating endothelial  progenitor cells. 
Circulation 2003 18;108(20):2511-6.” In murine models of wire-induced arterial injury (carotid 
and femoral artery denudation), EPCs from donor mice were detected within the 
neoendothelium after two weeks (Ii et al., 2006; Urao et al., 2006). In a canine BMT model it 
was reported that a synthetic graft of the descending thoracic aorta was coated with 
endothelial cells derived from the donor three months post-angioplasty (Shi et al., 1998). 
With regard to humans, Lin and colleagues (Lin et al., 2000) investigated BMT recipients 
who had received gender-mismatched transplants and identified in the peripheral blood a 
small population of highly proliferative donor-derived cells, expanding more than a 1000-
fold after one month in culture. 
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5. Inflammation-angiogenesis cross-talk 
Inflammation is the body’s protective response to noxious stimuli of different kinds 
(mechanical, chemical, biological). It has the purpose to dilute, circumscribe or destroy the 
injurious agent, and to promote the healing process. In complex organisms with a 
circulatory system, the distinctive feature of inflammation is a vascular reaction 
characterized by changes in the caliber and permeability of blood vessels (Kumar et al., 
2011). Angiogenesis is closely related to inflammation and the endothelial cell lies at the 
very core of this association (Rajashekhar et al., 2006). In fact, activated inflammatory cells 
(macrophages, T cells) secrete Interleukin-1 (IL-1) and Tumoral Necrosis Factor  and   
(TNF) which stimulate the production of VEGF from the endothelium (Naldini and Carraro, 
2005). VEGF, in turn, is a major proangiogenic factor with a number of effects on endothelial 
cells. Originally discovered as a potent and rapid inducer of vascular permeability (Vascular 
Permeability Factor, VPF) (Senger et al., 1983), it was then found to have a modest mitogenic 
effect on mature endothelial cells (Keck et al., 1989; Leung et al., 1989; Plouet et al., 1989) and 
finally it was shown to be an important participant in the regulation of EPC kinetics 
(Asahara et al., 1999; Olsson et al., 2006). Specifically, VEGF is believed to promote the 
mobilization of EPCs from the BM into the circulation by a) stimulating BM EPC 
proliferation b) providing a chemoattractive gradient for EPC migration towards the site of 
injury and c) modulating the BM-blood barrier, by increasing its permeability and 
modifying the expression of adhesion molecules (Asahara et al., 1999). VEGF is a dimeric 
glycoprotein of approximately 40 kDa whose actions on vascular and progenitor endothelial 
cells are mainly mediated by the VEGFR-2 (Homsi and Daud, 2007; Olsson et al., 2006; 
Schabbauer et al., 2007). This is a tyrosine kinase containing in its cytoplasmic domain 19 
tyrosine residues which are in part phosphorylated upon activation by receptor ligands and 
function as specific docking sites for molecules that initiate cytoplasmic signaling cascades 
(Olsson et al., 2006; Schabbauer et al., 2007). In particular, it has been shown that both Early 
Growth Response Protein-1 (EGR-1) and Nuclear Factor of Activated T cells (NFAT) are 
transcription factors involved in VEGF-mediated gene induction in endothelial cells 
(Schabbauer et al., 2007; Schweighofer et al., 2007). Matrix metalloproteinases (MMPs), a 
group of proteolytic enzymes which degrade the extracellular matrix (ECM), also appear to 
be involved in the mobilization of EPCs. Recently, a cross-talk between VEGF and MMPs 
has been suggested, with VEGF activating MMPs to favor the release of EPCs from the BM 
stroma and MMPs rendering available VEFG sequestered in the ECM (Ebrahem et al., 2010). 
VEGF is likewise produced by inflammatory cells (macrophages, neutrophils, T cells), 
consistently with the known redundancy of the cytokine system.  It has been proposed that 
VEGF from different sources (endothelial and non-endothelial) may have different 
functional significance: endothelial VEGF seems to take part in an autocrine loop that 
conveys survival signals to the endothelium while paracrine VEGF is considered the main 
contributor to the angiogenic cascade (Lee et al., 2007).  
Finally, it is important to remark that VEGF also acts on inflammatory cells: it is capable of 
recruiting macrophages, drive T cell differentiation towards a proinflammatory Th1 
phenotype, and stimulate the production of IL-1 and TNF by peripheral blood mononuclear 
cells (Angelo and Kurzrock, 2007; Mor et al., 2004; Naldini and Carraro, 2005; Noonan et al., 
2008). Thus the inflammatory process is marked by an extensive bidirectional 
communication between the endothelium and inflammatory cells, via cytokines and 
growth factors, which establishes an inflammation-angiogenesis cross-talk. 
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5.1 Effects of C reactive protein on EPCs 
Within the scenario of inflammation-angiogenesis the role of C Reactive Protein (CRP) on 
EPCs remains as yet uncertain and deserves a brief discussion. CRP has long been 
recognized as an acute phase protein whose plasma levels increase significantly (up to 1000-
fold) during systemic inflammation (Calabro et al., 2009). In such context it is synthesized by 
the liver in response to IL-6, IL-1 and TNF, and is a key component of innate immunity 
(Calabro et al., 2009; Li and Fang, 2004; Slevin and Krupinski, 2009). However, it is now 
acknowledged that CRP is also produced within the vascular wall at the site of 
inflammation. In vitro models have demonstrated that CRP is secreted by human coronary 
artery muscle cells after stimulation with cytokines (Calabro et al., 2003), by human aortic 
endothelial cells after stimulation with macrophage-conditioned medium (Venugopal et al., 
2005) and by human brain endothelial microvessel cells following oxygen-glucose 
deprivation (Slevin et al., 2010). An in vivo study in patients with coronary artery disease 
(CAD) undergoing percutaneous coronary intervention (PCI) showed that CRP levels distal 
to the target lesion were higher than proximal levels and that CRP levels in coronary sinus 
blood increased in a time-dependent manner after stenting, consistently with the hypothesis 
of a local production of CRP (Inoue et al., 2005).  
Moreover, it was found that CRP levels were higher in patients with unstable than stable 
angina and that the transcardiac CRP gradient at 48 hours after PCI was predictive of late-
lumen loss due to neointimal thickening (Inoue et al., 2005). Similarly, elevated 
preprocedural plasma CRP predicted restenosis after stenting (Hong et al., 2005) in one 
study and ergovine-induced coronary vasospasm during coronary angiography in another 
(Hung et al., 2005). Taken together these data provide evidence that CRP is a useful index of 
the “activity” of the atherosclerotic process. In fact atherosclerosis is no longer considered a 
mere lipid storage disease, stemming from the passive accumulation of lipids within the 
artery wall, but a chronic inflammatory disease which involves inflammation at all stages, 
from initiation to progression and, eventually, plaque rupture (Calabro et al., 2009; Paoletti 
et al., 2004). This is the reason why high-sensitivity CRP (hs-CRP)– i.e. the low CRP 
concentrations found in the peripheral blood in the absence of overt inflammation – has 
gained ample consensus in the evaluation of cardiovascular risk. Indeed hs-CRP is a 
stronger predictor of cardiovascular events – such as CAD, stroke, PAD and sudden cardiac 
death- than LDL cholesterol, and it adds prognostic value to the Framingham score (Ridker, 
2001; Slevin and Krupinski, 2009). 
It seems therefore established that there is a relationship between CRP and atherogenesis, 
but the role of CRP as an innocent bystander or active participant is still an unsettled and 
highly debated question (Calabro et al., 2009; Genest, 2010; Kushner et al., 2010; Lee et al., 
2007; Slevin and Krupinski, 2009; Verma et al., 2004). According to several authors, CRP has 
a direct proatherogenic effect by exercising a wide spectrum of detrimental actions on both 
vessel wall cells and EPCs (Calabro et al., 2009; Li and Fang, 2004; Slevin and Krupinski, 
2009; Verma et al., 2004). As far as mature endothelial cells are concerned it would a) 
decrease the expression and activity of nitric oxide synthase, causing endothelial 
dysfunction, b) increase the expression of surface adhesion molecules such as Vascular Cell 
Adhesion Molecule-1 (VCAM-1), Intercellular Adhesion Molecule-1 (ICAM-1) and selectins, 
favouring the recruitment of mononuclear cells, and c) induce the expression of oxidized 
LDL receptor, promoting lipid accumulation (Calabro et al., 2009; Verma et al., 2004). 
Macrophages and vascular smooth muscle cells (VSMCs) would also be involved, the 
former being stimulated to phagocyte oxidized low density lipoproteins (LDLs), the latter 
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being induced to proliferate and migrate towards the intima (Calabro et al., 2009; Verma et 
al., 2004). With regard to EPCs, CRP has been shown to reduce their survival, differentiation 
and migration, thus impairing a crucial component of vascular integrity and regeneration 
(Verma et al., 2004).   
However, when healthy subjects with no cardiovascular risk factors are considered the 
picture seems to change. We found evidence of a possible CRP-enhanced functioning of 
EPCs, by demonstrating that endothelial colony-forming capacity is related to CRP levels in 
healthy subjects (Ciulla et al., 2006). In order to investigate the burden of angiogenesis in 
physiological conditions we enrolled 37 subjects who were carefully selected for the lack of 
cardiovascular risk factors, had low hs-CRP (< 1 mg/L), normal Echocardiogram and 
carotid Doppler examinations and were not on pharmacological treatment. We found that 
15 subjects (40.5% of the sample) formed endothelial cell colonies from peripheral blood and 
that, relative to the non-colony formers, they had higher levels of hs-CRP as well as of 
VEGF. These results suggest that CRP may directly increase the clonogenic potential of 
EPCs, yet it may also be that higher hs-CRP is merely a marker of more active 
microinflammation - due to minimal endothelial stress- and greater VEGF production. 
Although the association between hs-CRP and EPC clonogenic capacity appears in contrast 
with reports from other investigators (Verma et al., 2004), it must be emphasized that we 
focused on a physiological setting and that the effect of CRP on EPCs may be influenced by 
different factors such as the concentration and conformation of CRP. For instance, the hs-
CRP levels in our study were markedly lower (<0.1 mg/L) than those used for the in vitro 
demonstration of EPC inhibition (>10 mg/L) (Verma et al., 2004). Indeed Turu and 
colleagues subsequently showed that CRP at concentrations of 1-5 mg/L had a strong 
proangiogenic effect on bovine aortic and human coronary artery endothelial cells and that 
this was in part mediated by the expression of the VEGF receptor (Turu et al., 2008). Also, it 
is increasingly acknowledged that CRP exists in two distinct conformations, native 
circulating CRP and monomeric tissue-associated CRP, and that it is the latter which is 
responsible for the proangiogenic actions of CRP (Schwedler et al., 2006; Slevin and 
Krupinski, 2009; Slevin et al., 2010). Whatever the interpretation, the finding of colony-
forming potential in healthy individuals underscores the notion that vascular integrity is a 
“round-the-clock” process characterized by a continuous balance between endothelial 
injury and regeneration- i.e. between environmental challenges and genetically-determined 
functional reserve. In this perspective cardiovascular disease can be viewed as the result of a 
disruption of this balance, with the threshold between physiology and pathology being 
specific for each single individual.   
6. Current and extra demands on the endothelium, the tip of the iceberg 
The endothelial cells lining the blood vessels are continuously exposed to different kinds of 
stimuli consisting in changes in the physicochemical characteristics of blood. These reflect 
the interplay between the internal and external environments, are transmitted by the 
pulsatile blood flow generated by the pressure gradient produced by the heart, and can 
trigger inflammation. We have already seen that environmental changes requiring an 
active response from the cell can be called demands. Demands can be further classified in 
current or extra according to the efficiency with which they can be handled by the 
homeostatic machinery. Current demands can be adequately dealt with in a physiological 
context, even though some degree of cell injury can still occur. Extra demands cannot be 
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sufficiently buffered and lead to functional impairment and, eventually, disease. Since 
the circulation of blood is a highly dynamic phenomenon it can be argued that current 
demands represent the bulk of all demands while extra demands are more often 
occasional. If we use the iceberg metaphor, current demands represent the huge part of the 
iceberg below the water while extra demands causing disease are only the tip of the iceberg.  
The water line is the boundary between health and overt disease, which varies from 
individual to individual according to the genetic program. Between overt disease and health 
we must conceive a grey zone (subclinical disease) in which disease may be unrecognized 
due to lack of knowledge or appropriate communication (Figure 2). 
In the following paragraphs we will discuss the effect on the endothelium of blood pressure 
(BP) and high altitude (real or simulated) – taken as instances of current demands- as well as 
of ischemia, exemplifying an extra demand. 
 
 
Fig. 2. The iceberg of disease 
Pictorial representation of the iceberg metaphor, illustrating the boundary between health 
(as a result of individual adaptability) and disease. The tip of the iceberg corresponds to 
overt disease; the huge part below the water line is where individual adaptability 
successfully buffers environmental demands; just below the surface is the grey zone of 
subclinical disease. Demands are defined as current or extra according to how efficiently 
they can be handled by the single organism. 
6.1 Blood pressure as a mechanical stimulus 
BP is a highly dynamic phenomenon, whose profile is characterized by a series of peaks and 
nadirs, and it is one of the most important mechanical stimuli acting on vessels. Thus the 
endothelium is constantly exposed to enormous shear stress (Lu and Kassab, 2011), defined 
as the component of stress coplanar with a material cross-section and tending to cause a 
deformation of the material by slippage along  this plane. Although it has been shown that 
exercise can increase circulating EPCs in mice (Cheng et al., 2010; Laufs et al., 2004) and 
humans (Rehman et al., 2004) and that shear stress promotes endothelial differentiation of 
EPCs in vitro (Ye et al., 2008) there is scant information on the specific effect of BP on 
endothelial turnover in healthy subjects.  In order to address this issue we enrolled 12 
normotensive volunteers who underwent a cycloergometer stress test (Bruce protocol) with 
BP monitoring (Ciulla et al., 2009). Samples of peripheral blood were obtained immediately 
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before and after the test to determine the number of EPCs and circulating endothelial cells 
(CECs). The latter are mature endothelial cells that are dislodged from the endothelium by 
injurious stimuli via different mechanisms of cell detachment, including apoptosis and 
cytokine-mediated proteolysis of the ECM (Dignat-George and Sampol, 2000; Hunting et al., 
2005; Mikirova et al., 2009). They can be considered a marker of vascular injury and their 
levels are generally proportional to those of EPCs (Hunting et al., 2005). We found that the 
number of CECs increased significantly (1.5-fold) with exercise and that such increase was 
directly associated with the value of peak systolic BP. The number of EPCs also increased, 
albeit not in a statistically significant way, probably because their mobilization from the BM 
requires a longer time. It can therefore be speculated that in physiological conditions BP 
fluctuations contribute to the renewal of the endothelium by a “mechanical clean-up” 
process, with systolic BP peaks removing damaged endothelial cells, just like the wind 
blows away the withered leaves from a tree. On the contrary, in hypertensive subjects, in 
whom BP levels are constantly elevated with frequent peaks, BP and shear stress can cause 
damage to the endothelium (Figure 3). 
 
 
Fig. 3. Effect of blood pressure on the endothelium 
Schematic illustration of the effects of shear stress on endothelial turnover. In healthy 
subjects systolic blood pressure peaks are responsible for a “mechanical clean up” process 
by dislodging damaged cells, thereby increasing the number of CECs. Concurrently, EPCs 
are moblized from the bone marrow into the circulation to replace detached cells. In 
hypertensives, BP may cause direct damage to the endothelium. 
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6.2 Hypoxia: a common cause of cell damage 
Hypoxia is defined as a decrease in the normal level of tissue oxygen tension and can be 
classified as hypoxic or ischemic based on the underlying pathophysiological mechanism. 
Hypoxic hypoxia is characterized by a low partial pressure of oxygen in arterial blood 
(PaO2) while in ischemic hypoxia PaO2 is normal, and so is the oxygen content of blood, but 
oxygen delivery to tissues is impaired because of a reduction in blood flow (Kumar et al., 
2011). 
It is widely acknowledged that hypoxia and inflammation are closely intertwined: hypoxia 
stimulates the production of proinflammatory cytokines and inflammation is associated 
with tissue hypoxia due to the increased metabolic demands of cells (Eltzschig and 
Carmeliet, 2011; Frede et al., 2007). The link to angiogenesis is established via VEGF which is 
expressed in response to both hypoxia and proinflammatory cytokines (IL-1, TNF) (Homsi 
and Daud, 2007; Naldini and Carraro, 2005). At a molecular level, hypoxia and cytokines 
mainly rely on two distinct signaling pathways in which upregulation of the VEGF gene is 
brought about by Hypoxia Inducible Factor-1 (HIF-1) (Dehne and Brune, 2009; Eltzschig and 
Carmeliet, 2011; Harris, 2002; Jewell et al., 2001) and Nuclear Factor kappa-B (NFkB) 
respectively (Hofer and Schweighofer, 2007; Huang et al., 2000; Sprague and Khalil, 2009; 
Winsauer and de Martin, 2007). HIF is a heterodimeric transcription factor composed of a 
PaO2-sensitive subunit (HIF-1 ) and a constitutive subunit (HIF-1 ). The enzyme prolyl 
hydroxylase (PHD) acts as an oxygen sensor within the cell since in normoxic conditions it is 
activated and hydroxylates proline residues on the HIF-1  subunit, thus creating a binding 
site for the Von Hippel Lindau protein (VHL). The interaction with VHL then causes HIF-1 
 to become ubiquitylated and targeted to the proteosome for degradation. Conversely, in 
hypoxic conditions PHD is inactive, HIF-1 is stabilized and translocates to the nucleus 
where it binds to hypoxia-responsive elements (HRE) in oxygen-responsive genes such as 
VEGF. NFkB is a heterodimeric transcription factor consisting of the p50 and p65 subunits. 
Normally it is associated to an inhibitory protein (IĸBα) which retains it in the cytoplasm. 
Upon stimulation by IL-1 and TNF, IĸBα is phosphorylated on two serine residues by a 
specific kinase (IKK) and undergoes ubiquitylation and proteosomal degradation. This 
allows translocation of NFkB to the nucleus where it binds to the promoter regions of genes 
encoding a number of biologically active molecules such as VEGF and proinflammatory 
cytokines. It must however be emphasized that the hypoxia and cytokine signaling 
pathways intersect at multiple points, consistently with the notion of an extensive cross-talk 
between hypoxia and inflammation. For instance, IL-1 and TNF are both able to activate 
HIF-1 (Dehne and Brune, 2009; Frede et al., 2007); HIF can stimulate the transcription of 
NFkB and NFkB can do the same with HIF (Angelo and Kurzrock, 2007; Eltzschig and 
Carmeliet, 2011); hypoxia leads to the formation of hydrogen peroxide which directly 
activates NFkB (Angelo and Kurzrock, 2007).  
Although VEGF is the key player in angiogenesis, other proangiogenic factors deserve a 
brief mention, namely Hepatocte Growth Factor (HGF), Erythropoietin (Epo) and Stromal 
Cell Derived Factor-1 (SDF-1). HFG, also known as Scatter Factor (SF), is a large 
multidomain protein similar to plasminogen which is produced by cells of mesenchymal 
origin (such as vascular smooth muscle cells, pericytes and fibroblasts) and acts in a 
paracrine way on neighbouring endothelial cells via its receptor, a transmembrane tyrosine 
kinase encoded by the Met proto-oncogene (Abounader and Laterra, 2005; Desiderio, 2007; 
Ding et al., 2003; Schroder et al., 2010). It has been shown to be a powerful stimulator of 
angiogenesis, mobilizing EPCs from the BM into the circulation, either directly or by 
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promoting the expression of VEGF (Desiderio, 2007; Schroder et al., 2010; Zhang et al., 2005; 
Zhu et al., 2010). Epo, better known for its effects on the hematopoietic system, has also 
gained recognition as an enhancer of endothelial cell functions, especially for its ability to 
mobilize EPCs from the BM (Bahlmann et al., 2004; Heeschen et al., 2003; Schroder et al., 
2010). The chemokine SDF-1/CXCL12 and its receptor CXCR4 have been found to regulate 
the mobilization of EPCs from the BM and their homing to sites of tissue injury (Shen et al., 
2011; Walter et al., 2005). Remarkably, also HGF, Epo and SDF-1 are involved in the HIF-1 
signaling pathway: the former can induce HIF-1  (Desiderio, 2007), the latter (and CRXR4) 
are activated by HIF-1 (Dehne and Brune, 2009; Harris, 2002). 
Several studies have investigated the effect of hypoxic hypoxia on EPCs, both in vitro and in 
vivo. In vitro, it has been shown that rat EPCs exposed for 48 hours to 5% O2 improved their 
ability to proliferate, migrate and express VEGF (Wang et al., 2010). Similarly, human 
peripheral blood mononuclear cells (PB-MC) cultured for one week in hypoxic conditions 
were stimulated to differentiate into EPCs and express VEGF (Akita et al., 2003), and human 
EPCs cultured in 1% O2 were found to accumulate HIF-1 and upregulate VEGF (Abaci et al., 
2010). In vivo, hypoxic hypoxia can be obtained either by exposure to a low fraction of inspired 
oxygen (FiO2) – i.e. normobaric hypoxia– or to a low atmospheric pressure – i.e. hypobaric 
hypoxia. In a mouse model of normobaric hypoxia a significant increase in circulating EPCs 
was observed after exposure to a 10% FiO2 for four days (Schroder et al., 2009). In healthy 
subjects we demonstrated that breathing through a hypoxicator an oxygen mixture at 11.2 % 
(corresponding to a simulated altitude of 4850 m above sea level) for one hour resulted in a 
marked increase in the number of PB-EPCs, which then normalized after one week, and that 
the percentage increase in EPCs from baseline was inversely correlated with the baseline PaO2 
(Ciulla et al., 2007a). In keeping with the underlying molecular mechanisms, we also found 
that such brief standardized hypoxia was associated with an increase in the serum levels of 
HGF and Epo as well in the expression of HIF-1 within EPCs (Ciulla et al., 2007a). In a healthy 
individual undergoing a trek in the Himalayas at a mean altitude of 3900 m we described a 
significant increase in the number and clonogenic activity of EPCs one day after the trek, 
returning to normal after 45 days at sea level (Ciulla et al., 2005). A recent study conducted on 
healthy volunteers participating in a one-week hiking program on the Austrian Alps at 1700 m 
reported an increase in circulating EPCs (Schobersberger et al., 2010). It must however be 
remarked that in the case of these high- and moderate-altitude studies it is not possible to 
dissociate the effects of hypoxia from those of physical activity which is also a powerful 
stimulus for EPC upregulation (Cheng et al., 2010; Laufs et al., 2004).  
With regard to ischemic hypoxia there is a wealth of evidence from animal and human 
studies that acute ischemic conditions are marked by an increase in plasma levels of VEGF 
and in the number of EPCs in the PB. In rabbit and murine models of hindlimb ischemia 
(Takahashi et al., 1999) an increase in the frequency of circulating EPCs, reaching a 
maximum 1 week after the onset of ischemia, has been described. In a murine model of soft 
tissue ischemia (Tepper et al., 2005) VEGF levels were found to be increased by 2.5-fold after 
one week and correlated with the levels of circulating EPCs. As far as human studies are 
concerned, researchers have mainly investigated vascular diseases such as myocardial 
infarction (MI), ischemic stroke (IS) and peripheral artery disease (PAD). In the first study 
carried out on patients with acute MI (Shintani et al., 2001), the levels of VEGF and EPCs in 
the peripheral blood were significantly increased relative to controls the first day after the 
event and peaked at one week. Moreover, they were closely correlated, supporting the 
notion that VEGF induces EPC mobilization from the BM. Subsequent studies demonstrated 
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an increase in the number of EPCs, peaking on admission, in patients with recent ST-
elevation MI (<12 hours) (Wojakowski et al., 2004), and elevated levels of EPCs in patients 
with acute MI as early as 3 hours from the onset of symptoms (Massa et al., 2009). Over the 
last years several studies on patients with acute IS stroke have also been conducted, 
showing that EPCs are mobilized in response to cerebral ischemia and that the extent of 
such mobilization appears to have a prognostic value in terms of the likelihood of recovery. 
In patients with acute IS a two-fold mean increase in peripheral blood mononuclear CD34+ 
cells has been found when compared to healthy controls and it has been demonstrated that 
neurological and functional outcomes at one and three months were significantly improved 
in those defined as “high mobilizers”(count > 15000 cells/ml) (Dunac et al., 2007). In a 
similar study (Sobrino et al., 2007), patients with a greater EPC rise during the first week 
after a first-ever nonlacunar IS had better outcomes at three months according to the 
National Institutes of Health Stroke Scale (NIHSS) and the Rankin Scale (RS). In a larger 
sample of patients with IS (Yip et al., 2008), circulating levels of EPCs were about twice 
higher in subjects with IS than in controls matched for risk factors, and low ECP levels were 
predictive of both severe concurrent neurological impairment at the NIHSS and combined 
major adverse outcomes at three months. Finally, Sandri and colleagues (Sandri et al., 2005; 
Sandri et al., 2011) investigated the acute and chronic effects of exercise-induced peripheral 
limb ischemia in subjects with PAD. After four weeks of ischemic treadmill training PAD 
patients exhibited a 3-fold increase in VEGF levels and a four-fold increase in EPCs (Sandri 
et al., 2005). After a single maximal treadmill test, VEGF levels increased more than four-
fold after one day and EPCs rose three-fold at one to two days (Sandri et al., 2011). 
7. Enumerating ECPs: a tricky question 
CD34+VEGFR-2+CD133+ cells are more similar to hematopoietic-derived cells, which may 
contribute to vascular repair and homeostasis in an indirect manner. In fact cells belonging 
to the hematopoietic lineage can be recruited to injured or angiogenic sites and secrete 
regulatory cytokines that promote vessel homeostasis and repair by local cells, including 
local vessel wall ECs. It is possible that cardiovascular risk factors and established 
cardiovascular disease decrease the circulating number and properties of the hematopoietic-
derived cells. Hence, low levels of these circulating cells might correlate with adverse 
cardiovascular outcomes. However, this concept is entirely different from the notion of EPC 
which was proposed 10 years ago, when EPCs were suggested to function as a structural 
backup from the BM (Asahara et al., 1997). Mature hematopoietic cells include red blood 
cells, platelets, myeloid cells such as monocytes/macrophages and granulocytes, dendritic 
cells and lymphoid cells including B cells, T cells, NK cells and NKT cells. Hematopoietic 
cells derive from HSCs and hematopoietic progenitor cells (HPCs) that reside within the 
BM. Importantly, hematopoietic-derived cells such as monocytes, granulocytes, platelets 
and even HSCs/HPCs have been shown to be involved in vascular repair (Heil et al., 2006; 
Langer et al., 2006). However, because both endothelial lineage cells and hematopoietic cells 
are present at sites of neovascularization and co-express a host of similar surface markers, it 
can be difficult to discriminate them from each other at sites of vascular repair, and 
appreciate their individual contribution to the healing or regenerative process. Therefore, 
the diverse cell types now known to be recruited at sites of neo- vascularization are highly 
likely to have previously been lumped into the single term ‘EPC’ in many early studies of 
postnatal vasculogenesis, explaining some of the apparent controversy in the field. 
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One of the models that has been used to directly investigate donor cell differentiation into 
ECs in vivo has been a transgenic mouse whose cells express a fluorescent marker (e.g. 
green fluorescent protein (GFP)) only in the presence of an endothelium-specific gene, such 
as Tie-2 (Schlaeger et al., 1997). Therefore, transplantation of BM cells from transgenic mice 
into wild-type mice allows the tracking of the cells of interest, and of their fate during 
mobilization from the BM into sites of vascular injury, and discriminates them from other 
cell types and from the host cells involved in vascular repair and regeneration. However, 
even these sophisticated approaches have often yielded contradictory results, probably 
because the expression of Tie-2 is not entirely restricted to the endothelial lineage, but is also 
found in pericytes and hematopoietic (derived) cells such as monocytes, that also migrate to 
sites of vascular repair (De Palma et al., 2003). 
On the other hand, it has been argued that the failure to retrieve genetically labelled BM-
derived Tie-2+ ECs in the work by De Palma et al. might be due to the fact that the 
exogenous Tie-2 promoter used may not mark all mature ECs, or that during the random 
genetic manipulation of cells the CEPC population might not have been targeted with the 
viral Tie-2 vector (Nolan et al., 2007). Also, it is possible that the failure to detect few, if any, 
BM-derived ECs in the neovasculature of experimental models may be related to poor 
engraftment of the EPC compartment following its transplantation (De Palma et al., 2003; 
Gothert et al., 2005). Although the latter pitfall can be circumvented by the use of a 
parabiosis model (where two mice are surgically connected and share a common circulatory 
system allowing exchange of circulating cells), conflicting results have also been reported in 
the parabiosis model (Purhonen et al., 2008). 
In order to definitely demonstrate in vivo that the EPC-derived progeny in the newly 
formed vasculature is truly endothelial in nature, a more direct or convincing approach 
would be to extract the putative EPC progeny from tissues (by means of a genetic tracer 
such as GFP) and FACS-analyze these cells (with or without previous culturing) using a 
wide panel of antigens (CD11, CD45, VE-Cadherin, CD146, CD31, CD13, CD105, etc.) so as 
to be able to discriminate them from other cell lineages, especially the hematopoietic one. In 
addition, these extracted cells could also be tested functionally by evaluating their 
proliferative or tube-forming capacity. So far, only one group has used such a FACS-based 
strategy to identify EPC progeny in vivo (Nolan et al., 2007), but the combination of markers 
used (CD31+Lectin+GFP+) does not allow a clear discrimination from hematopoietic 
(derived) cells that also display the same functional abilities (Nolan et al., 2007; Yoder et al., 
2007). 
Other methodological issues - such as the number of tissue sites sampled, the time frame of 
the study intervals, and the microscopic technique employed in tissue analysis - may 
explain why in different animal models different findings were obtained with regard to the 
extent of EPC contribution to neovascularization. For instance, while the use of confocal 
microscopy may permit a complete volumetric 3-dimensional rendering of donor cell 
contribution to new blood vessels in a damaged tissue, the use of light microscopy can make 
it difficult to discriminate whether cells are are integrated within the endothelial layer, or 
merely located at periluminal sites, just beneath the endothelial layer (De Palma et al., 2003; 
Galimi et al., 2005). Thus, differences in the microscopic technique, and/or in the method of 
image analysis, may also account for the huge variability in the rate of EPC incorporation 
into repairing vessels that has been reported in the literature, ranging from 0 to 90%. 
Furthermore, it remains uncertain how many of the ‘luminal integrated cells’ (e.g. 
monocytes, that phenotypically overlap with ECs) are in fact passenger cells participating in 
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an inflammatory reaction to vascular injury, or cells in the process of transmigrating deeper 
into the vessel wall and interstitial tissues. Thus, whenever possible, the use of 3-
dimensional imaging, coupled with antibodies which are specific and validated for the 
identification of cells and subcellular organelles as well as extracellular structures, provides 
the most sensitive and specific information on the location and contribution of donor cells to 
tissues under repair. 
As it is increasingly recognized that cell fate changes are a property of stem cells (Blau et al., 
2001) there arises the need to adopt more stringent criteria to determine if a cell fate 
transition has taken place. Blau and colleagues (Blau et al., 2001) propose a set of such 
criteria. The first criterion is the demonstration that the cell expresses a previously silent 
gene specific for the new cell type. This can be accomplished by investigating protein 
expression via antibodies and FACS analysis. Of course, in vivo evaluation must be 
considered superior to in vitro evaluation. The second criterion is the demonstration that the 
cell is well integrated into the tissue and has acquired morphological characteristics 
identical to those of neighbouring resident cells. The third –and most important– criterion is 
the demonstration, by means of a functional assay, that the cell is able to perform tissue-
specific functions. For instance, using appropriate genetically-modified animal models it can 
be shown that it produces de novo an organ-specific molecule which is essential for survival 
or improvement of disease-associated deficits. With reference to the cardiovascular domain, 
convincing evidence of a cell fate transition in BM-derived cells could be obtained by 
verifying that these cells not only produce myocardium-specific proteins but are also able to 
contract in synchrony with the cardiac syncytia.  
8. Conclusion 
The circulatory system is involved in the transport of a wide variety of biological molecules 
and cells and can be considered the body's basic communication system. It consists of an 
intricate network of vessels lined by endothelium. Although the endothelium has long been 
viewed as an inert layer of  “nucleated cellophane” its highly dynamic nature is being 
increasingly recognized. Endothelial cells are exposed round the clock to proinflammatory 
stimuli of different kinds (mechanical, chemical, biological), even in healthy individuals, 
and vascular homeostasis is ensured by a continuous balance between injury and repair- 
i.e. between environmental challenges and genetically-determined functional reserve. A 
disruption of this balance leads to endothelial dysfunction and atherosclerotic disease, with 
the threshold between physiology (current demands) and pathology (extra demands) being 
different and specific for each individual, as unique as is the genome.  
There is growing evidence that EPCs are a major player in the process of vessel 
regeneration, being mobilized from the BM into the PB and homing to sites of injury 
where they are incorporated into the neoendothelium to serve a structural and paracrine 
role. Indeed we demonstrated, in an animal model of myocardial cryodamage, that 
peripherally injected BM mononuclear cells are able to target the site of damage and form 
early-stage small vessels. 
Since 1997, when Asahara and colleagues isolated EPCs from human PB by means of 
magnetic beads, the identity and characterization of EPCs have been the subject of heated 
debate. However, it is generally accepted that progenitor cells similar to embryonic 
hemangioblasts participate in adult angiogenesis, thus establishing the notion of postnatal 
vasculogenesis.  
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In complex organisms inflammation and angiogenesis are closely related and the 
endothelial cell lies at the very core of this association. Inflammatory cells secrete 
cytokines (IL-1 and TNF) which elicit VEGF production from the endothelium. VEGF, in 
turn, is a powerful proangiogenic factor which regulates EPC kinetics and stimulates 
inflammatory cells. Such extensive communication between endothelial and inflammatory 
cells is the basis of the inflammation-angiogenesis cross-talk.  
There is a wealth of evidence from animal and human studies that ischemia enhances the 
number and functions of circulating EPCs. Less information is available on the effect of 
physiological stimuli on EPCs or CECs in healthy subjects. Our group showed that blood 
pressure-induced shear stress increases the number of CECs, that hypoxia (normo- and 
hypobaric) increases the number and/or clonogenic capacity of EPCs, and that hs-CRP 
levels are higher in colony-formers. 
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1. Introduction 
Cells encounter many internal and external stimuli, some of which may induce stresses, 
when they are a part of a normal tissue or when they grow in a culture. These stresses 
trigger responses which may change cellular responses to subsequent environmental signals 
or even cause cell death. Exposure to stress over time may cause the accumulation of 
damage to DNA, proteins and lipids. If not repaired, this will enhance susceptibility to 
aging associated illnesses, like neurodegenerative diseases, diabetes, heart diseases, etc., and 
to cancer. The cellular stress responses must be taken into account when the cells are used in 
cell therapies and in regenerative medicine. 
The cellular stress response is a reaction to changes or fluctuations of extracellular 
conditions, which damage the structure and function of macromolecules (Kültz, 2003). 
Depending on the severity and duration of stress encountered, cells either re-establish 
cellular homeostasis to the former state or adopt an altered state in the new environment. 
Therefore, different stressors and different intensities of stresses trigger different cellular 
responses: (1) induce cell repair mechanisms; these use considerable amounts of available 
resources and often result in recovery of normal cells, (2) induce cell responses that result in 
temporary adaptation to some stressors, (3) induce autophagy or (4) trigger cell death. Some 
important mechanisms of cell adaptation to stress and their inducers will be described in 
this chapter. 
1.1 Cell repair mechanisms 
1.1.1 Altered gene expression  
Stressors can damage intracellular macromolecules, including proteins, DNA, RNAs and 
lipids. The stress responses are mediated through induction of molecular chaperones 
(Buchberger et al., 2010), clearance of damaged macromolecules (Kroemer et al., 2010), 
growth arrest and changed gene expression patterns (Spriggs et al., 2010), etc. First we shall 
describe some examples of altered transcription. 
1.1.1.1 Modulation of transcription upon stress 
The changes in gene expression are often mediated by micro ribonucleic acids (miRNAs, 
reviewed in Leung and Sharp, 2010), which are short noncoding RNAs of about 22 
nucleotides. There were about 950 miRNA discovered by April 2010, which could target 
about 60% of mammalian mRNAs. The stress responses modify the synthesis of miRNAs 
and the activities of miRNA-protein complexes, consequently the expression of their mRNA 
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targets. miRNAs bind to mRNAs and either accelerate the degradation or inhibit the 
translation of mRNA, i.e. modulate the stability and/or translational potential of their 
targets.  
The transcription factor, transformation-related protein 53 (p53, chapter 1.1.3.2) regulates 
the expression of miRNA at the levels of transcription and processing. p53 was found to 
induce the transcription of the primary transcripts miR-34a, miR-34b and miR-34c upon 
DNA damage. These repress some target genes to promote growth arrest and apoptosis. The 
expression of p53 itself must be precisely regulated. A miRNA (miR-125b) was found, which 
keeps the expression of p53 low in humans. The repression of miR-125b is reversed upon 
DNA damage with the activation of p53 through a protein kinase cascade (Leung and Sharp, 
2010). 
The level of target gene repression depends on the relative concentrations of target genes 
and miRNAs. For example, MICA and MICB are extracellular ligands of an immune 
activating receptor (NKG2D) of natural killer cells (NK) and T cells. MICA and MICB are 
induced by several types of cells under stress, like heat shock, viral infection, oxidative 
stress and DNA-damage. Their translation is inhibited by miRNAs in normal cells, however, 
upon stress the transcription of MICA and MICB is upregulated, while the levels of 
appropriate inhibiting miRNAs remain unchanged. It seems that the levels of mRNA exceed 
the quantity that can be inhibited by miRNA; consequently MICA and MICB are expressed. 
Their binding to the receptor NKG2D, which is expressed on natural killer cells and T cells 
helps to eliminate the virus-infected cells.   Interactions in the cells are more complex, as the 
level of miRNA-mediated repression depends also on the expression amount of other 
mRNAs of the transcriptome, which are targeted by the same miRNA. The outcome of 
miRNA repression depends also on interactions with other stress proteins that can modulate 
the activity of miRNA protein complexes, e.g. by inhibiting the access to target mRNA.  
The subcellular location of miRNA can change as a consequence of stress. Most of miRNA 
are diffused in the cytoplasm; they have to associate with the member of Argonaute protein 
family for activity. After a maturation process at Argonaute protein, mature miRNA guide 
the Argonaute-containing complexes to target sites in mRNAs that are partially 
complementary to the miRNA sequence, and induce repression of gene expression at the 
level of mRNA stability or translation. Upon stress some of miRNAs, mRNAs and 
Argonaute are in stress granules.  
Sometimes, miRNA can time the stress response. Timing is important in acute stress 
responses, such as during inflammation. Then nuclear factor-B (NF-B, chapter 1.1.3.3) 
upregulates the transcription of miRNAs along with other inflammatory responsive genes 
through a cascade of reactions in macrophages. RNAs are synthesized as pre-RNAs; all pre-
RNAs, including miRNA, are synthesized in about 2 hours. The processed mature miRNA 
peak about 24 hours later; therefore, the action of miRNA is delayed. 
1.1.1.2 Translational regulation of gene expression during stress 
Nutrient stress, temperature shock, DNA damage and hypoxia can lead to changes in gene 
expression patterns caused by shutdown and reprogramming of protein synthesis through 
selective recruitment of ribosomes to mRNAs (Spriggs et al., 2010). This is regulated by 
elements in 5’ and 3’ untranslated regions of mRNAs, like internal ribosome entry segments, 
upstream open reading frames and miRNA target sites.  
In eukaryotes, the initiation of translation is inhibited often by phosphorylation of the 
eukaryotic initiation factor 2 (eIF2), which is a part of the so called ternary complex. The 
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ternary complex is composed of eIF2, initiator tRNA (tRNAi) and GTP and is loaded onto a 
small ribosome subunit, which binds mRNA and recognizes the start of translation, codon 
AUG. This triggers the hydrolysis of GTP, uncoupling of tRNAi from eIF2, release of 
initiation factors and start of translation (Spriggs et al., 2010). In mammalian cells, four 
stress-related kinases phosphorylate eIF2, which lead to reduction in initiation codon 
recognition. A second mechanism for nonspecifically reducing levels of protein synthesis is 
by preventing recruitment of the translational machinery to the mRNA. This is done by 
interfering with m7G cap recognition, which is a modified base at the extreme 5’ end of the 
mRNA. mRNAs for stress response proteins evade global repression of translation by 
several mechanisms. For example, a cap-dependent recruitment of mRNA may be bypassed, 
by the internal ribosome entry sites (IRES). IRES were originally detected in viruses and are 
parts of RNA, which facilitate binding of mRNAs to 40S ribosomal subunits (Spriggs et al., 
2010). This involves cofactors IRES trans-acting factors (ITAF). Changes in the abundance or 
activity of ITAFs influences the degree of IRES mediated translation; this is often used 
during stress conditions. 
Heat shock factors (HSF) are inducible transcriptional regulators of genes encoding stress 
proteins, like molecular chaperones and others. HSF1 is the most important regulator of 
expression of heat shock proteins (Hsp, chapter 1.1.2.1) in vertebrates (Akerfelt et al., 2010). 
Hsp are molecular chaperones and among others assist proteins in folding or prevent and 
reverse protein missfolding and aggregation. HSF1 is converted from monomer to trimer in 
response to temperature shock and oxidative stress. Monomeric HSF1 is a phosphorylated 
protein and is interacting with Hsp90. On stress, HSF1 dissociates from Hsp90, which 
enables its trimerization and binding to heat shock elements of Hsp genes. To enable a 
versatile regulation, these processes are more complex. HSF1 interacts with different HSP at 
different phases of its activation cycle. Trimeric HSF1 is inactive when bound to multimeric 
chaperon complex composed of Hsp90, co-chaperone p23 and immunophilin FK506-binding 
protein 5 (FKBP52, also FKBP4, Akerfelt et al., 2010). Elevated levels of both, Hsp90 and 
Hsp70, prevent trimer formation of HSF1. Activated HSF1 can bind to Hsp70 and Hsp40. 
There seem to be activation-attenuation cycles of HSF1, during which there are extensive 
posttranslational modifications of HSF1, including acetylation, phosphorylation and 
sumoylation. HSF1 is phosphorylated also under non-stress conditions, while 
phosphorylation-mediated sumoylation of a Lys residue of the regulatory domain occurs on 
exposure to heat shock. SUMO stands for small ubiquitin-related modifier. This are small 
proteins that are covalently attached to and detached from other proteins to modify their 
function. While stress-induced sumoylation is rapid after the heat shock, acetylation is 
delayed, as it is regulated by the balance of acetylation by p300-CBP (CREB-binding protein) 
and deacetylation by nicotinamide adenine dinucleotide dependent histone deacetylase 
sirtuin 1, SIRT1. Increased expression of SIRT1 was reported to enhance and prolong the 
DNA-binding activity of HSF1 at the promoter of HSP70.1. Therefore SIRT1 maintains HSF1 
in a state which enables DNA binding, while the acetylated form can not. Sirtuins are a 
family of NAD+ (nicotinamide adenine dinucleotide) dependent histone deacetylases, which 
influence gene transcription, metabolism, DNA repair and organism life span (Majmundar 
et al., 2010). Sirtuins are sensors of the cellular redox state, as they respond to the changes of 
ratios of oxidized/reduced forms of NAD+. 
Other HSF, like HSF2 also bind to the promoters of HSP genes. Upon stress-induced 
transcription of HSP genes, both, HSF1 and HSF2 accumulate into nuclear stress bodies. 
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Nuclear stress bodies are thought to participate in rapid, transient, and global 
reprogramming of gene expression through different types of mechanisms including 
chromatin remodeling and trapping of transcription and splicing factors (Biamonti & 
Vourc’h, 2010). 
1.1.2 Protein quality control and repair 
Proteins have numerous functions in cells: enzymatic, transport, structural, for molecular 
recognition, signal transduction, etc. They are often damaged as a consequence of stress; 
even their normal biogenesis is an error-prone process and may lead to stress. For example, 
truncated polypeptides that result from incomplete translation, misfolded intermediates, 
and unassembled subunits of protein complexes have exposed hydrophobic regions, which 
may facilitate aggregation (Buchberger et al., 2010). Failure to clear aggregated proteins 
leads to cell stress common to many disorders, especially to neurodegenerative diseases. 
The environmental stress triggers can induce nonnative posttraslational modifications and 
damage proteins in other ways and consequently induce cell stress as well. 
Some degree of protein damage occur normally in every cell, however, the extent of protein 
damage increases by adverse intrinsic and environmental conditions, like unbalanced 
protein synthesis, oxidative stress, metabolic stress, some environmental toxins and 
pollutants, elevated temperature, high-energy radiation, etc. To cope with considerable 
extent of protein damage, the damaged proteins are either repaired by molecular 
chaperones or degraded by the ubiquitin proteasome system or autophagy (Buchberger et 
al., 2010). Ubiquitin is a protein of 76 kDa, which marks the proteins for degradation by the 
protease, 26S proteasome. The attachment of ubiquitin (ubiquination or ubiquitinylation) is 
an ATP-consuming process by the cascade of enzymes: ubiquitin-activating enzyme (E1), 
ubiquitin-conjugating enzyme (E2) and ubiquitin protein ligase (E3). E2 and E3 enzymes 
cooperate with molecular chaperones. Polyubiquinated substrates are transferred to the 
proteasome for degradation. Aggregated proteins, which are degraded by selective 
autophagy, are also ubiquinated.  
Some types of protein damage are prevalent in specific organelles of eukaryotic cells 
(Buchberger et al., 2010). The errors in glycosylation, disulphide bond formation and 
membrane insertion are more frequent in the endoplasmic reticulum (ER) and secretory 
pathway, while these proteins are generally thermodynamically more stable, therefore less 
sensitive to heat stress compared to cytosolic proteins. 
1.1.2.1 Stress repair and stress response 
The stress repair mechanisms enable cells to survive the stress induced damage. Chaperones 
are a family of proteins that assist the non-covalent folding or unfolding of proteins and the 
assembly or disassembly of multimeric macromolecular structures, but do not occur in these 
structures during their normal biological functions when these are in correctly folded state. 
There are different classes (families) of chaperones, which serve different functions, 
including folding of newly made proteins, the repair of the damage caused by misfolding, 
membrane transport, keeping the protein precursor in translocation-competent state, 
assistance in protein degradation, etc. Chaperons are efficient quality control components 
for proteins. Many chaperons were discovered as their expression was elevated after the 
heat shock, thus they were named heat shock proteins (Hsp). Chaperons of Hsp70 family 
interact with short extended peptide stretches of hydrophobic and basic amino acid residues 
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of unfolded, natively folded or aggregated proteins (Buchberger et al., 2010). The binding of 
Hsp70 prevents aggregation of these proteins and can even induce conformational changes. 
The rounds of Hsp70 binding and release to protein substrates can promote the 
disaggregation of proteins. This is enhanced by cooperation with Hsp100 family chaperones. 
The cells have several Hsp40 chaperones (J domain containing chaperones), which provide 
substrate specificity of Hsp70, stabilize Hsp70-substrate interactions and trigger ATP 
hydrolysis by Hsp70. Nucleotide exchange factors, like Hsp110 are also required for ADP 
release and rebuilding of ATP at Hsp70. 
Chaperon Hsp90 is thought to bind and stabilize partially folded but inactive conformations 
of its substrates; some of the substrates may be recognized in extended conformations. It 
hydrolyzes ATP like Hsp70; it interacts with a large number of co-chaperones. Its substrates 
are proteins involved in signal transduction, like protein kinases and transcription factors 
(Buchberger et al., 2010). Chaperones Hsp90 and Hsp70 can cooperate; then they are 
physically coupled by co-chaperone Hop. 
An Hsp60 family member in eukaryotic cytosol is TRiC (TCP-1 Ring Complex or chaperonin 
containing TCP-1; CCT). Like other Hsp60 family members, TRiC is a barrel shaped protein 
complex that encapsulates substrates into protected folding environment. Its substrats are 
subunits of oligomers, with beta sheet secondary structures (Buchberger et al., 2010) and 
possibly late folding intermediates or misfolded proteins. There are also other small heat 
shock protein family members in the cytosol. ATP-independent small heat shock proteins 
(sHsp) bind misfolded proteins to prevent their aggregation and may loosen aggregates by 
coagreggation therefore facilitating subsequent re-folding by Hsp70. Hsp70 and Hsp40 
present aggregated proteins to Hsp100. The solubilized protein can re-enter chaperone-
mediated folding cycles or degradation by ubiquitin-proteasome system; this is implied by 
the presence of ubiquinated proteins within aggregates, colocalization of 26S proteasome, 
and the increased aggregate formation and delayed removal of aggregates upon inhibition 
of proteasome. However, ubiquitin proteasome system is not the only pathway for 
aggregate removal, especially as 26S proteasome can become inhibited by the aggregate 
formation. Irreversibly aggregated proteins in aggresomes are degraded primarily by 
selective autophagy. This autophagy requires ubiquitin-binding proteins; perhaps 
ubiquination is important for this degradation as well. 
Stressed cells attempt to repair or degrade acutely damaged proteins and may undergo 
adaptive responses to reduce protein damage by decreasing global protein translation and 
increasing the molecular chaperones and proteins of proteolytic system. The well known 
adaptive responses in eukaryotic cells are the heat shock response (HSR) and unfolded 
protein response, which is the response to an accumulation of unfolded or misfolded 
proteins in the endoplasmic reticulum (UPR, Buchberger et al., 2010). Expression of genes, 
which are upregulated by HSR, are under the control of HSF1 (chapter 1.1.1.2, Akerfelt et al., 
2010). Under non stress conditions, the monomeric HSF1 is in the cytosol bound by Hsp90, 
perhaps also Hsp70/40. These chaperones are tugged away under heat stress, which enables 
trimerization of HSF1, the activation of HSF1 trimer and expression of HSR target genes.  
The ability to respond to ER stress is critical for cell survival, as chronic or unresolved ER 
stress can lead to apoptosis. Increases of protein synthesis or protein missfolding rates that 
exceed the capacity of chaperones, changes in calcium concentration in the ER lumen, 
oxidative stress and disturbances of the redox balance in the ER lumen contribute to 
development of ER stress (Tabas & Ron, 2011). In eukaryotic cells, the ER stress is sensed by 
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three upstream signaling proteins that start cascades of corrective reactions. The activities of 
these three pathways are collectively called unfolded protein response. All ER stress 
response pathways are activated when there is imbalance of unfolded proteins and 
chaperones. The evolutionary oldest pathway is triggered by activation of IRE1 (inositol-
requiring protein-1). In mammalian cells there are two isoforms: IRE1 in all cells, and 
IRE1 in gastrointestinal and respiratory tracts. IRE1 is likely activated by dissociation of 
BiP and binding of unfolded proteins. ER stress induces the dimerization of the IRE1 
luminal domains and positions the cytosolic domains close for trans-autophosphorylation of 
the kinase activation loop. Phosphorylated IRE1 is the specific endonuclease which cleaves 
the mRNA of X-box binding protein 1 (XBP-1), which is then translated into a transcription 
factor, which induces the expression of many genes involved in UPR. The second pathway 
of UPR is initiated by activation of kinase PERK (protein kinase RNA (PKR)-like ER kinase). 
Similarly to IRE1, PERK is autophosphorylated and undergo homomultimerization upon 
stress. Then it phosphorylates the -subunit of the translation initiation factor eIF2 
(eukaryotic translation initiation factor-2), which results in attenuation of global translation 
initiation. Translation of the gene encoding the transcription factor ATF4 (activating 
transcription factor-4) is favored by limiting amounts of eIF2. It enables the expression of 
CHOP (C/EBP-homologous protein, GADD153, gene name Ddit3), which through 
interaction with other transcriptional regulators induces and suppresses numerous genes, 
which repair the ER stress. CHOP induces also the transcription of GADD34 (growth arrest 
and DNA damage-inducible protein-34), which dephosphorylates phosphorylated eIF2 
and restores global protein translation. 
A third pathway is mediated through transcriptional factor ATF6 (activating transcription 
factor-6, Buchberger et al., 2010). In unstressed cells ATF6 is bound to BiP in the ER. Upon 
ER stress, BiP dissociates to allow transport of ATF6 to Golgi, where it is processed and its 
fragment is released to cytosol for the subsequent activation of genes in the nucleus. The 
three pathways can be activated by any type of ER stress; there is different timing of 
activation (Tabas & Ron, 2011).  IRE1, ATF6 and PERK pathways are sequentially activated 
upon the prolonged ER stress. Prolonged IRE1 and CHOP activation can trigger apoptosis.  
Molecular chaperones seem to have also other biological functions, which are not connected 
with protein folding (Henderson, 2010). Such proteins are called moonlighting proteins. 
Based on the extreme sequence conservation between the chaperone members within 
families, the researchers have long assumed that they have the same functions. However, it 
appears that they may have different moonlighting activities despite of close sequence 
similarities. Some molecular chaperones act as receptors in the plasma membrane and have 
signaling functions in the extracellular fluid. The latter may be important in stress response. 
Circulating molecular chaperones may be a danger signal, as stress is a danger to all 
organisms and needs to be integrated into the homeostatic regulation.  
1.1.3 Signaling pathways 
1.1.3.1 mTOR pathway 
Protein mTOR (mammalian target of rapamycin, also FK506 binding protein 12-rapamycin 
associated protein 1; FRAP1) is a serine/threonine protein kinase, which regulates growth 
by maintaining the balance between anabolic processes, like macromolecular synthesis, and 
catabolic processes, such as autophagy. It is involved in cell cycle progression, DNA 
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recombination, and DNA damage detection. mTOR functions in regulatory pathways that 
control ribosome biogenesis and cell growth when nutrient concentrations change 
(particularly the levels of essential amino acids), like in a hypoxic environment of solid 
tumors (OMIM, 2011).  
mTOR is the catalytic subunit of two complexes, mTORC1 and mTORC2 (Sengupta et al., 
2010). mTORC1 is a homodimer, composed of mTOR and regulatory-associated protein of 
mTOR (raptor), mammalian lethal with Sec13 protein 8 (mLST8), proline-rich AKT substrate 
40 kDa (PRAS40), and DEP-domain-containing mTOR-interacting protein (Deptor). 
mTORC2 is composed of Rictor (RPTOR-independent companion of mTOR), mLST8, 
Deptor, mammalian stress-activated protein kinase interacting protein (mSIN1) and protein 
observed with Rictor-1 (Protor-1, also PRR5). Rictor is required for mTORC2 catalytic 
activity; it is proposed to recruit substrates to mTORC2. 
The upstream signals that regulate the activity of mTORC1 are growth factors, amino acids, 
glucose, oxygen levels (Sengupta et al., 2010). The downstream actions of mTORC1 include 
protein synthesis, autophagy and many metabolic pathways. mTORC1 is a critical mediator 
of the cellular response to many types of stress, such as DNA damage, drops in the level of 
energy, oxygen, amino acids and glucose. It is therefore involved in many stress responses 
in physiological and pathophysiological states, possibly in aiding the resistance of tumor 
cells to conventional therapy. 
1.1.3.2 p53  
Transformation-related protein 53 (p53) is a transcription factor, which  responds to many 
types of cellular stress, such as DNA damage, hypoxia and oncogene activation. It regulates 
target genes that induce cell cycle arrest, apoptosis, senescence, DNA repair or changes in 
metabolism (Speidel, 2010). In addition to its functions as a transcription factor in the nuclei, 
cytoplasmic p53 has transcription independent activities. Both, transcription dependent and 
transcription independent activities of p53 may lead to apoptosis. There are accounts when 
transcription independent mechanisms are essential for the full apoptotic response (Speidel, 
2010). p53 is also a BH3 domain protein and can interact with some members of BCL2 family 
(chapter 1.4.1.3). The apoptotic stimuli will induce transcription dependent and 
transcription independent activities of p53 in most cases; the two complement each other. A 
few connections of the two signaling pathways have been identified by demonstrating the 
roles of p53 transcription targets Puma, Mdm2, IGFBP1 in transcription-independent 
apoptosis. 
p53 is kept inactive in unstressed cells. The concentration and activity of p53 are regulated 
mostly on the posttranslational level. The half life of p53 protein in normal, unstressed cells, 
is about 6 to 20 minutes, while it can be hours under stress. Post-translational modifications 
are selectively activated by different stress signals. p53 is then modified by phosphorylation, 
methylation, monoubiquination, sumoylation, neddylation and glycosylation (Ak & Levine, 
2010). p53 is polyubiquinated under non-stressed conditions by mouse double minute 2 
homolog (MDM-2, E3 ubiquitin ligase, chapter 1.1.2), which speeds up its degradation on 
the proteasome. On the other hand, MDM-2 is transcriptionally regulated by p53, so there is 
an autoregulatory loop. MDM-2 functions as a heterodimer with MDM4. There is another 
autoregulatory loop between MDM-2 and MDM-4, as MDM-2 ubiquinates MDM-4. Further, 
MDM-2/MDM-4  and MDM-2/p53 complexes are regulated by protein kinases CHK-1/2 
and ATM (Ak & Levine, 2010). DNA damage activates the ATM kinase (ataxia-telangiectasia 
mutated gene), which inhibits MDM-2 and activates p53. The members of calcium 
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calmodulin kinase superfamily, CHK-1/2 kinases, phosphorylate MDM-2, which dissociates 
from MDM-4 resulting in increased levels of p53. The failure to polyubiquinate p53 results 
in its high intracellular levels. Ubiquitin proteases, HAUSP (herpesvirus-associated 
ubiquitin-specific protease, also ubiquitin-specific protease 7; USP7) and USP42 remove 
ubiquitin from p53 and stabilize it. Stress signal results in higher levels of p53, which leads 
to transcription of selected genes and cell cycle arrest, apoptosis or the cells loose the ability 
to divide (are senescent). Different stress signals result in different post-translational 
modifications of p53 and transcription of different sets of genes. 
p53 regulates the expression of miRNA (chapter 1.1.1.1) at the levels of transcription and 
processing. Most p53 mutations found in cancers are in a domain required for miRNA 
processing and transcription (Leung & Sharp, 2010). p53 enhances the processing of a 
population of pre-miRNA in cancer cells. Therefore loss of p53 function in transcription and 
processing might contribute to tumor progression.  
The interruption of ribosomal biogenesis during the cell replication cycle results in an 
increase in free ribosomal proteins; some of them bind to MDM-2 and inhibit its 
polyubiquination, which stabilizes and activates p53 (Ak & Levine, 2010). Mutations in 
some tumor suppressor genes, e.g. retinoblastoma protein, free the transcription factor E2F-
1, which transcribes ARF tumor suppressor gene. ARF is transcribed from an alternative 
reading frame of the cyclin-dependent kinase inhibitor 2A gene (CDKN2A). ARF protein 
binds and inhibits MDM-2 and raises levels of p53 within the cells. Similarly, the mutations 
that activate oncogenes Ras and myc increase ARF levels. In this way ARF acts as tumor 
suppressor by initiating p53-dependent responses. Activity of p53 is ubiquitously lost in 
human cancer either by mutation of the p53 gene itself or by loss of cell signaling upstream 
or downstream of p53 (Toledo & Wahl, 2006). 
p53 responds to the intrinsic stress. There is another transcription factor, nuclear factor-B 
complex (NF-B), which responds to extrinsic stress (chapter 1.1.3.3, K10). p53 and NF-B 
cannot function at the same time in the same cell. On activation of one, the other is 
inactivated. 
1.1.3.3 NF-B 
NF-B has been detected in many cell types, which express cytokines, chemokines, growth 
factors, cell adhesion molecules, and some acute phase proteins in health and in various 
disease states. It is activated by different stimuli, like cytokines, free radicals, ultraviolet 
irradiation, and bacterial or viral products. Inappropriate activation of NF-B leeds to 
inflammatory events associated with autoimmune arthritis, asthma, septic shock, lung 
fibrosis, glomerulonephritis, atherosclerosis, and AIDS, while its persistent inhibition may 
result in apoptosis, inappropriate immune cell development, and delayed cell growth (Chen 
et al., 1999). 
NF-kB is a complex; a heterodimer from the protein of Rel family (p65, Rel A, Rel B, c-Rel) 
and from the p50/p52 set of proteins (Ak & Levine, 2010). NF-B is in the cytosol associated 
with the inhibitor IB in the absence of stress signals. IB is phosphorylated upon stress by 
IB kinase (IKK), then ubiquinated and degraded by a proteasome. NF-B shifts to the 
nucleus resulting in transcription of genes with NF-B response elements. The activation of 
these genes results in cellular replication, inflammatory responses mediated by tumor 
necrosis factor, and cell survival signals. NF-B transcribes the gene of IB-, which is one 
of its negative regulators. The result is the autoregulatory loop of the transcribed IB- with 
NF-B, which alternatively activates and shuts down the transcription of IB-  
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1.2 Adaptation to stress 
Acclimation and physiological adjustments that lead to tolerance to a certain degree of 
stress is a well known and proved concept, which enables the organisms to survive in 
different environmental conditions. Some experimental proofs are emerging that the same 
concept is true at the cellular level; i.e. that the cells can adapt to environmental stress to a 
certain degree and this makes them more resilient to environmental stresses. In 2010 our 
group has shown that a mild stress can inhibit triggering of apoptosis through the 
intrinsic pathway (chapter 1.4.1.1) in the primary liver cells (hepatocytes; Nipic et al., 
2010). This is the first evidence to our knowledge of apoptotic pathway shut down caused 
as a consequence of mild stress. The state of the cells after encountering the mild stress, 
was named preapoptotic cell stress response. This state is temporary, since the cells revert 
to a normal state in a few days in the absence of further stressors (Nipic et al., 2010, Banic 
et al., 2011). Despite the inactivation of apoptosis triggering by caspase-9 through the 
intrinsic pathway, apoptosis can be triggered when the inducer is strong enough, 
however, the apoptosis executing enzymes caspase-3 and -7 are activated to a lesser 
degree than when the cells are in the normal state. This seems like a mechanism of an 
adaptive response in the stressed cells. 
Adaptations to sublethal stress, which result in greater stress tolerance, were observed also 
in mouse blastocysts, where applying hydrostatic pressure improved their survival after 
freezing and in suboptimal culture conditions (Pribenszky et al., 2005). Similar results were 
obtained also in bovine blastocysts (Pribenszky & Vajta, 2011). Also, signals from DNA 
damage can facilitate osmotic stress adaptation (Kültz, 2005).  
The phenomenon that a sublethal stress induces a resistance to mild stress, was observed 
from bacteria to multicellular organisms and humans. Some cells have to tolerate large 
changes in the environment because of their position in the organism. The cells in papilla of 
mammalian kidney have to tolerate varying degrees of hyperosmotic stress during urine 
concentration; the degree of hyperosmolarity depends also on the organism’s hydration 
state. These cells are adapted to ever changing environment. The proteomic approach was 
used to compare the expression in hyperosmotic renal papilla and an adjacent iso-osmotic 
region, the cortex (Gabert & Kültz, 2011). Of 1877 proteins that were common to both 
regions, there were 212 comparably overexpressed in the cortex and 80 proteins in the 
papilla. In response to tonicity changes in papilla, protein expression altered significantly, 
mainly that of metabolic enzymes, molecular chaperones, proteins involved in redox 
balance, transport and transcription. During antidiuresis 15 different proteins changed 
significantly, while 18 different proteins changed significantly during diuresis relatively to 
normally hydrated controls. Proteins significantly altered by diuretic state are structure 
proteins (actin, tubulin), signaling (Rho GDP dissociation inhibitor, abhydrolase domain-
containing protein 14B), chaperones (Hsp beta-1, B crystallin, T complex protein-1) and 
those with anti-oxidant functions (-enolase, GAPDH, LDH). Therefore, many genes, which 
are commonly overexpressed in stress, have been identified to be induced as a result to 
environmental changes in the kidney papilla. The possible pathways of adaptation remain 
to be determined. 
Discovering the mechanisms of adaptation to stress may prove tremendously important, 
also because it is conceivable that the cells, during the process of malignant transformation 
and the resulting tumor cells, undergo adaptations, which enable them to resist the signals 
that would trigger cell death in their normal state. 
 




Autophagy is an intracellular lysosomal (vacuolar) degradation process characterized by the 
formation of double-membrane vesicles, autophagosomes, which sequester cytoplasm. It is 
involved in growth, survival, development and death of cells. Autophagy is a term used for 
several processes: (1) macroautophagy, (2) microautophagy and (3) chaperone-mediated 
autophagy (Funderburk et al., 2010). (1) In macroautophagy, the cytoplasmic material is 
engulfed by a double-membrane, which fuses subsequently to the lysosome. Sequestered 
material is indiscriminately removed. (2) Lysosomes engulf a portion of cytosol in 
microautophagy. (3) Chaperone-mediated autophagy is a way for removal of selected 
proteins. These proteins can be modified, e.g. ubiquinated. As macroautophagy is the most 
prevalent form, it is often referred to as autophagy; this term shall be used in such manner 
below. Autophagy starts by formation of an isolation membrane (phagophore) around the 
portion of cytosol. The membrane elongates and seals on itself to form a double membrane 
vacuoles autophagosomes. These then fuse with lysosomes where the entrapped 
components are degraded.  
Autophagy is conserved among eukaryotic cells and occurs at a basal rate in most cells. It is a 
mechanism for quality control to eliminate protein aggregates and damaged organelles, like 
mitochondria (Scarlatti et al., 2009). During cell stress, autophagy is a process through which 
the cells can reuse the resources. For example, the starvation-induced autophagy helps to 
recycle the amino acids for protein synthesis and produce the substrates for oxidative 
phosphorylation when the supplies of nutrients are limited. Degradation of whole regions of 
cytoplasm therefore generates free amino acids, which can be metabolized to meet energy 
demand during periods of stress. Autophagy may be the last attempt to rescue the cells from 
dying. As the intracellular processes are complex and intertwined, autophagy may have a role 
in some cases of cell death, too. While this was shown during the development of Drosophilla 
and Dictyostelium discoideum, there is no evidence for such process in mammals so far. 
However, autophagy can be involved in cell death in cultured mammalian cells and can occur 
upstream of, alongside to or during the final stages of apoptosis. It is often challenging to 
determine the role of autophagy in cell death, as observing autophagic structures is not 
sufficient to demonstrate the involvement of autophagy in cell death.  
Apoptosis and autophagy may be co-regulated in the same directions, as the anti-apoptotic 
Bcl-2 and Bcl-xL proteins negatively regulate autophagy by binding to Beclin 1 (mammalian 
Atg6, see below), and pro-apoptotic BH3-only proteins may reverse this effect by displacing 
these interactions. Apoptosis can also suppress autophagy (Luo & Rubinsztein, 2010). The 
interplay between autophagy and apoptosis is currently a fast developing field of research. 
The signaling of autophagy is mainly through serine/threonine kinase mTOR (chapter 
1.1.3.1). Amino acid deprivation inhibits mTORC1, which leads to induction of autophagy 
(Sengupta et al., 2010). The autophagic process liberates amino acids, which reactivate 
mTORC1 and the replacement of lysosomes consumed during autophagy. Another main 
regulator of autophagy is a protein Beclin 1 (Bcl-2-interacting protein, reviewed in Scarlatti 
et al., 2009, Funderburk et al., 2010). Beclin 1 was discovered first as the interacting partner 
of the anti-apoptotic protein Bcl-2 through its BH3 domain (chapter 1.4.1.3). Subsequent 
studies have indicated that the endogenous Bcl-2 regulates Beclin 1. Also, it was found out 
that Beclin 1 interacts with many different proteins; however, the physiological roles of 
many of these interactions are not fully understood. In mammals, the core autophagy 
complex is thought to form by binding of Beclin 1 to the class III phosphatidylinositol 3-
kinase VPS34 and protein VPS15 (Funderburk et al., 2010). This is based also on the 
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similarity with the autophagy complex of its yeast counterparts Atg6 and Vps34. The 
association of Beclin 1 with additional sets of proteins implies that Beclin 1 may be a 
connection point between autophagy, endocytic and cell death pathways. Elucidating its 
diverse roles may uncover its involvement in heart disease, pathogen infection, 
development and neurodegeneration. 
1.4 Cell death 
There are many pathways for a cell to die; the best known are necrosis, apoptosis and in 
some circumstances autophagy. 
1.4.1 Apoptosis 
The term apoptosis was first used by Kerr and coworkers (1972) to describe a cell death with 
several of typical morphological manifestations (Kroemer et al., 2009): rounding up of the 
cell, reduction of cellular volume, chromatin condensation, nuclear fragmentation, little or 
no ultrastructural modifications of organelles, plasma membrane blebbing, maintenance of 
plasma membrane integrity until the final stages of the process, phagocytosis of remains of 
the cells. There is no inflammation in tissue as the consequence of apoptosis (Savill & Fadok, 
2000; Kurosaka et al., 2003). 
There are biochemical and functional heterogeneities, as apoptosis is triggered through 
different biochemical pathways. The cysteine proteases caspases are central to triggering 
apoptosis (caspase-dependent triggering), although the apoptosis triggering can be caspase-
independent, too. These and some of the main apoptosis regulators shall be described in the 
following chapters. 
1.4.1.1 Caspases 
The term caspases (cysteine-dependent aspartate-specific protease) describes a family of 
proteolytic enzymes with cystein in the active site, which cleave the substrates after the 
aspartate residue (Denault & Salvesen, 2002). Caspases -1, - 4, -5, -11 and -12  are important 
in development of cytokines, like interleukines 1ß and 18. The caspases -2, -3, -6, -7, -8, -9 
and -10 are important in apoptosis signaling. In normal cells, they are inactive zymogens 
(procaspases), which are activated through dimerization and proteolytic cleavage upon the 
apoptotic stimuli (Denault & Salvesen, 2002). Caspases can trigger and execute apoptosis 
through cascades of reactions. Caspases -2, -8, -9 and -10 are initiating caspases, i.e. activate 
the executioner caspases, -3, -6 and -7. These activate other proteins, whose action result in 
apoptosis morphology.  
There are several molecular pathways of triggering apoptosis; however the central two 
involve proteases caspases. These are (1) the extrinsic pathway, which originates from the 
cell surface, and involves activation of caspase-8 and (2) the intrinsic or mitochondrial 
pathway originating through the activation of caspase-9 (Salvesen & Dixit, 1997). The two 
pathways converge to activate caspase-3, which is the best understood executioner caspase. 
The extrinsic pathway is important in immune responses. The intrinsic or mitochondrial 
pathway can be activated by many stress stimuli,  including DNA damage or extensive 
perturbation of mitochondrial membrane potential. It is also activated through caspase-3; it 
then enhances apoptosis.  
Although not all caspases are involved in the regulation of apoptosis, the overexpression of 
any one of them culminates in cell death (Norberg et al., 2010). Knockout of any of caspases 
results in higher cell numbers. 
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1.4.1.2 Caspase – independent pathways 
Many apoptosis regulators are associated with mitochondrial membranes and are released 
into the cytosol upon apoptotic stimuli. One of the better known pathways of caspase-
independent triggering of apoptosis involves apoptosis-inducing factor (AIF, Norberg et al., 
2010). It is anchored with its N-terminal into the mitochondrial inner membrane. AIF is 
triggered by increased calcium or early lysosomal permeabilization; these are frequent in 
cell death signalling after ischaemia/reperfusion injury and treatment with cytotoxic drugs. 
AIF can be cleaved by calpain I, which has a mitochondrial localization signal and needs M 
amounts of Ca2+ for activation. Then cleaved AIF is released from mitochondria upon the 
mitochondrial permeabilization. It is transported into the nucleus, where it contributes to a 
large scale DNA fragmentation and chromatin condensation. Several studies detected that 
antioxidants can inhibit AIF-induced cell death and intracellular ROS levels may regulate 
AIF cleavage and release. 
AIF has to be cleaved from the membrane in order to be released from mitochondria. Unless 
it is cleaved before the permeabilization of the mitochondrial outer membrane, it would be 
reasonable to expect that other soluble mitochondrial proteins, e.g. cytochrome c, would be 
released first and would activate apoptosis through caspase-dependent mechanisms 
(Norberg et al., 2010). The elimination of AIF does not protect the cells from apoptosis 
induced by most drugs. 
1.4.1.3 Apoptosis regulators - BCL2 family proteins 
The proteins of BCL2 family (B cell lymphoma-2) are important regulators of apoptosis; 
some of them are pro-apoptotic, others are anti-apoptotic. All family members share 
characteristic BCL2 homology domains (BH). The anti-apoptotic members, like BCL-2 and 
BCL-xl (BCL-2-related gene, long isoform) have four BH domains (BH1-BH4). Some pro-
apoptotic BCL2 members have three (effector domains), others one BH domains (BH3-only 
proteins). BAX (BCL-2-associated x protein) and BAK (BCL-2 antagonist killer 1) have three 
BH domains (BH1-BH3), while e.g. BID (BCL-2-interacting domain death agonist), BIM 
(BCL-2-interacting mediator of cell death), Puma (p53-upregulated modulator of apoptosis) 
and Noxa have a single BH domain (BH3). Anti-apoptotic BCL2 proteins control the 
integrity of the mitochondrial outer membrane in mammals by inhibiting pro-apoptotic 
members (Chipuk et al., 2010). Upon activation, the effector pro-apoptotic proteins homo-
oligomerize into pores in the outer mitochondrial membrane and promote its 
permeabilization. This releases apoptosis regulators, among others cytochrome c, which 
binds to APAF-1 (apoptotic protease activating factor-1) and procaspase-9 in the cytosol to 
oligomerize and form a complex named apoptosome. This activates procaspase-9, therefore 
turns on the intrinsic apoptotic pathway (chapter 1.4.1.1). 
The BH3-only proteins are activated in response to cellular stress. Some of them (at least BID 
and BIM) are called direct activators, as they can promote the oligomerization of BAX and 
BAK. For example, the stress activated BID may be sequestered by an anti-apoptotic 
member, which prevents apoptosis. In the case of the further stress, other BH3-only protein 
can replace the BID, so it may activate BAX or BAK. Cellular stress can cause also 
transcriptional regulation of the BCL-2 family. The newly synthesized BH3-only proteins 
can interact with anti-apoptotic proteins and lower the threshold for BAK and BAX 
activation. For example, if BCL-2 is associated with PUMA, any future induction of BIM is 
not inhibited and results in the permeabilization of mitochondrial outer membrane. 
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Therefore the progression of stress to apoptosis is determined through complex interactions 
between the BCL-2 family proteins. 
1.5 Cellular stress responses in regenerative medicine 
As it was described above, the cellular responses to stress result in reparation of damage, 
cell death or in adaptation to mild stress that prevents excessive apoptosis. The processes of 
cellular adaptation to stress, i.e. the acquired resilience of cells to apoptosis by mild stress 
may be of value in regenerative medicine. There are indications that modulation of stress 
mechanisms is useful to improve the outcome of transplantations. For example, cold 
ischaemia pretreatment correlates with increased regeneration of epithelial cells 
immediately after the transplantation of kidney allografts (Naesens, 2011). Also, the 
adaptations to increased hydrostatic pressure improve the survival of murine and bovine 
blastocysts after freezing or in suboptimal culture conditions (Pribenszky & Vajta, 2011, 
chapter 1.2). On the other hand, it was observed that deterioration of mechanisms of cellular 
adaptation to stress result in lesser survival of kidney grafts. Old donor age decreases the 
chances of successful kidney transplantation (Naesens, 2011). Namely, many processes 
associated with aging are general pathways involved in tissue damage and stress responses; 
examples are the changes in mitochondrial physiology, increased susceptibility to apoptosis, 
impaired regeneration and repair, replicative senescence (when the cells become senescent 
as the result of breaks in DNA), etc. 
There are examples of pre-treatments of cells to manipulate stress response pathways that 
minimise cellular damage and improve the transplantation outcome. Preconditioning of 
model cells of retinal pigment epithelium with non-lethal oxidative stress protects these cells 
from cell death induced by oxidative-stress (Sharma et al., 2009). The cell line ARPE-19 was 
used to mimick the conditions of oxidative stress, which is encountered by retinal cells 
transplanted for repairing the age-related macular degeneration.  
The application of moderate shear stress on liver tissue slices was better than no shear or 
high shear stress, with the conclusion, that perioperative flow management is needed to 
regulate shear stress, i.e. to avoid the excessive shear stress on liver tissue upon a massive 
liver resection (Torii et al., 2005). Interestingly, the absence of shear stress also resulted in 
destruction of sinusoidal structures, which supports the need for constant perfusion of 
donor liver. 
Targeting specific proteins involved in stress response was shown to increase the stress 
resistence of grafts in several cases. Increased synthesis of heme oxygenase-1, which is 
known to increase the cellular resistance against oxidative injury, improved liver graft 
viability in Lewis rats (Uchida et al., 2003). Other stress proteins, like heat shock proteins, 
are protective in models of transplantation; however, there is a need to develop strategies 
for their upregulation in clinical practice. Overexpression of heat shock protein 90-binding 
agent geldanamycin and some of its analogs protected renal cells from oxidative stress and 
reduced kidney ischaemia-reperfusion injury in a mouse model (Harrison et al., 2008). Rat 
mesenchymal stem cells engineered to overexpress Hsp20 were resistant to oxidative stress; 
this increased their survival after transplantation into infarcted heart by about twofold 
(Wang et al., 2009). A further example of targeting the stress responses is the protection of  
cells by inhibition of iNOS (Hynes et al., 2011). Transplanted  cells fail because of specific 
autoimmune reactions and also due to non-specific inflammatory reactions. Proinflamatory 
cytokines, like interleukin 1 can induce  cell destruction in a nitric oxide-dependent 
manner, as it stimulates inducible nitric oxide synthase iNOS, which produces NO cytotoxic 
 
Advances in Regenerative Medicine 
 
228 
to  cells. Lentiviral-based strategy was used to inhibit iNOS expression through short 
hairpin interfering RNA; this improved protection of  cells (Hynes et al., 2011). 
Pharmacological preconditioning may improve the survival of grafted cells as well. For 
example, trimetazidine (1-[2,3,4-trimethoxybenzyl]piperazine, TMZ) is a widely used anti-
ischaemic drug for treating angina in cardiac patients. The stem cells were preconditioned 
with TMZ and used in an in vivo rat model of myocardial infarction (Wisel et al., 2009). A 
significant increase in the recovery of myocardial function and up-regulation of Akt and 
BCL-2 levels were observed in hearts transplanted with TMZ-preconditioned cells. 
Similarly, the treatment of ventromesencephalic grafts with the p53 inhibitor, pifithrin- 
enhanced the survival of dopamine cell transplants and augmented behavioral recovery in 
Parkinsonian rats (Chou et al., 2011).  
Clearly, using cells’ ability to adapt to stress conditions or manipulating the stress response 
mechanisms to improve the cellular adaptation to stress betters the survival of cells and the 
transplantation outcome in experimental models. The challenge remaining is the finetuning 
of experimental techniques to suit the needs of regenerative medicine. 
1.6 From triggers to consequences of stress responses 
Any deviation from the ideal environment could be a stressor for cells, i.e. the stress is 
caused by too much or too little of an agent, stimulus or other environmental condition. 
Heat or cold, modification of pH, hyper- or hypo- osmolarity, the increased concentrations 
of reactive oxygen species, etc., all result in cellular stress. 
Stressors can trigger two types of cellular responses, from within cells and by the immune 
system. The stress responses of non-immune cells, are described sometimes as an intrinsic 
stress, while the stress responses of the immune system are called extrinsic stress (Ak & 
Levine, 2010). The latter functions by signaling with cytokines and clonal selection of cells. 
The transcription of many of the genes that participate in immune response is regulated by 
NF-B (chapter 1.1.3.3), which is a growth and division-promoting factor and can thus turn 
into an oncogene. The intrinsic stresses can be DNA damage, hypoxia, low levels of glucose 
and amino acids, interference with mitochondrial and ribosomal biogenesis, the action of 
some toxins, etc. The protein p53 responds to such stressors (chapter 1.1.3.2). p53 also 
regulates many genes that prevent DNA damage or help in the DNA repair. Hypoxia, 
glucose levels and mitochondrial and ribosomal biogenesis are regulated by the interactions 
of the p53 pathway genes with the insulin-like growth factor 1 (IGF-1)/mTOR pathways 
and the regulation of the endosomal compartment by p53-induced genes (Sengupta et al., 
2010).  The activation of p53 or NF-B including pathways are mutually exclusive within the 
cells. The activation of p53 results in slowing glycolysis and restoring oxidative 
phosphorylation, while the activation of NF-B pathway activates cell division and utilizes 
large amounts of glucose and predominant use of glycolysis (Ak & Levine, 2010). 
Encountering the stressors is the normal consequence of living in a fluctuating environment, 
therefore, the cells have developed mechanisms to ameliorate the stress or to adapt to it.  
This is achieved through the repair of damage, adaptation, reuse of resources and a limited 
cell death. As living with stressors is unavoidable in the life of organisms and cells, does the 
stress matter? The cells have to divert at least some of their resources from other pathways, 
to deal with stressors, as it is described throughout this chapter. Our cells are well adapted 
to a mild stress for a short time, however, there are potentially serious consequences of the 
long term stress. 
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One of the recently established hallmarks of cancer is the presence of stress phenotypes (Leung 
& Sharp, 2010). The expression of microRNA is often aberrant in cancer; also, microRNA 
expression patterns often correlate with clinically relevant tumor characteristics. Several 
microRNAs regulate genes that control proliferation, apoptosis, differentiation, tumor 
invasion or tumor metastases, and are therefore directly involved in cancer initiation and 
progression. MicroRNAs are also important in regulating the development of immune cells 
and in modulating innate and adaptive immune responses (Stern-Ginossar et al., 2008). 
The connection of prolonged stress to the development or deterioration of various pathologies 
is clearly seen in the consequences of aggregated proteins accumulation, which is a hallmark 
of many neurodegenerative diseases (Petrozzi et al., 2007). Cell stress and stress proteins have 
a profound effect in triggering/developing the cardiovascular diseases, too. It was first 
observed in 1970's that the patients infected with Mycobacterium tuberculosis or M. leprae have 
antibodies to an antigen, which was later identified as Hsp60 (chapter 1.1.2.1). It is now 
confirmed that Hsp60 and other chaperones, like Hsp10, Hsp70 and Hsp90 family members 
are strong imunogens and imunomodulators in experimental models of arthritis, diabetes and 
atherosclerosis (Shamaei-Tousi et al., 2007). The reason for this may be that many chaperones 
are potent activators of immune cells and may act as adjuvants and as immunogens, possibly 
as the latter in the case of Mycobacterial infection. Atherogenesis may be driven by 
crossreactive immunity to bacterial Hsp60 proteins. Namely, the host Hsp60 are expressed on 
the stressed endothelial cells. Endogenous chaperones may protect ischaemic myocardium. 
Hsp70 members inhibit some caspase-dependent and independent apoptosis. Hsp27 was 
shown also to inhibit cytochrome c-dependent activation of apoptosis and to stablize 
cytoskeletal structures. The major cytoskeletal lesions of myocardium may occur during 
ischemic injury, therefore, the stabilization of these structures could be important for cell 
survival (Haigs & Yankner, 2010). 
Accumulation of damaged macromolecular structures over time was long recognized to 
lead to aging. The rate of aging and the appearance of age-related signs are modulated by 
stress responses (Haigs & Yankner, 2010). Central to it are protein and DNA damage repair 
mechanisms and mitochondrial respiratory metabolism. These are controlled by 
insulin/IGF-1, mTOR, sirtuin and AMPK (AMP-activated protein kinase) pathways. The 
coordinated action of these pathways are central to maintaining homeostasis in normal and 
stress conditions through the regulation of nutrient sensing and stress response pathways. 
There are many studies, which link the decline in the effectiveness and integration of stress 
responses to ageing and the development of age-related diseases. Modulation of 
mitochondrial and metabolic functions and mobilization of macromolecular maintenance 
and repair leads to life extension in modeling organisms. 
Cellular stress can at least contribute to, or even trigger, many diseases and malignant 
transformations and has an important role in aging. To ameliorate or repair these processes 
the cells are being used in cell therapies and regenerative medicine. For maximal therapeutic 
success it is important to use the cells in the best condition possible or those adapted to 
stress as described in chapter 1.5. Discovering the detailed mechanisms of stress responses, 
some of which were described in this chapter, will improve the assessment of the condition 
of transplanted cells and to better their handling and transplant survival rates. 
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1. Introduction 
Tissue engineering and regenerative medicine (TE/RM) represents a broad spectrum of cell 
and biomaterial based approaches aiming to repair, augment and regenerate diseased 
tissues and organs. The successful recent clinical implantation of tissue engineered trachea, 
bladder and bladder derivative (Neo-Urinary ConduitTM) has highlighted the emergence of 
common methodological frameworks for the development of TE/RM approaches that may 
be broadly applicable towards the regeneration of multiple, disparate tubular organs.  
Similarly, recent progress towards regeneration of heart, kidney, liver, pancreas, spleen and 
central nervous system is identifying shared methodologies that may underlie the 
development of foundational platform technologies broadly applicable towards the 
regeneration of multiple solid organ systems. Central themes emerging for both tubular and 
solid neo-organs include the application of a biodegradable scaffold to provide structural 
support for developing neo-organs and the role of committed or progenitor cell populations 
in establishing the regenerative micro-environment of key secreted growth factors and 
extra-cellular matrix critical for catalyzing de novo organogenesis.  
However, aspects of these strategies currently under active development for tissue 
engineering of tubular and solid neo-organs may not be relevant for successful 
commercialization of neo-organs as novel TE/RM products for clinical application. For 
example, difficulties in large scale sourcing and quality control of biomaterials derived from 
decellularization of cadaveric organs imply that such biomaterials may be less suitable for 
incorporation into TE/RM products when compared to biomaterials of synthetic origin. 
Similarly, TE/RM technologies that attempt to leverage populations of stem and progenitor 
cells are less likely than platforms focused on committed cell populations or acellular 
biomaterials to facilitate rapid development of viable products.  
In this chapter, we will present our experience in the development of the Neo-Bladder 
AugmentTM, Neo-Urinary ConduitTM and Neo-Kidney AugmentTM to identify elements of 
this foundational organ regeneration technology platform that may be broadly applicable 
towards the design and development of additional tubular neo-organ products, including the 
esophagus and small intestine, the lung, the vasculature and the male or female genito-
urinary tract as well as additional solid neo-organs. We will focus specifically on 
highlighting aspects of these neo-organ regenerative platforms conducive to the commercial 
viability of such technologies.  
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2. Tissue engineering of tubular organs 
Two significant recent studies have brought the concept of de novo regeneration of tubular 
organs within humans towards proof-of-practice in the clinic. In the first example, seeding 
of tubular, biodegradable scaffolds with autologous urothelial and smooth muscle cells was 
shown to catalyze regeneration of a complete bladder with laminarly organized histology 
and associated urologic functionality upon implantation within seven pediatric patients 
(Atala et al., 2006). In the second example, a tissue engineered, functional human trachea 
was created using a decellularized, cadaveric tracheal segment as scaffold and seeded with 
autologous respiratory epithelial cells and chondrocytes generated by the directed 
differentiation of the patient’s own bone marrow cells (Asnaghi et al., 2009; Macchiarini et 
al., 2008).  
Both studies leveraged a scaffold seeded with autologous cells to trigger a regenerative 
response within the patient, ultimately leading to complementation of organ functionality 
with concomitant histogenesis of laminarly organized tissue structures. These approaches 
have focused on the regeneration of tubular organs and, taken together with additional 
recent developments in the regeneration of additional hollow organs, provide perspective 
into overlapping technology platforms and insight into key methodological differences that 
may impact the commercial feasibility of tubular organ engineering. In the following section 
(based on Basu & Ludlow, 2010), we discuss recent developments in tissue engineering of 
tubular organs.  
2.1 A Platform technology for tubular organ regeneration 
Organ regeneration technologies aim to restore the original structure and functionality of a 
diseased organ. Typically, healing responses within mammals are characterized by fibrosis 
and scar tissue formation, not regeneration. Tubular organ regeneration involves a specific, 
temporal sequence of cellular infiltration, vasculogenesis, neurogenesis and the defined 
differentiation of mucosal, stromal and parenchymal laminar tissue architectures (reviewed 
by Basu & Ludlow, 2010). Strategies for organ and tissue regeneration must therefore 
achieve the dual objectives of triggering a true regenerative response while ameliorating any 
tendency towards fibrotic repair. The methodology first pioneered for regeneration of the 
bladder (illustrated in Figure 1) may serve as a foundational platform for the regeneration of 
any tubular organ.  
 
 
Fig. 1. Tengion Neo-Bladder AugmentTM (NBA). Dome shaped biodegradable bladder 
scaffold (left panel) is placed in a support prior to seeding with cells and incubated in a 
bioreactor. The bioreactor is transported to the clinical site and the supported seeded 
scaffold removed (middle panel) and positioned for patient implantation (right panel).  
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Examination of the temporal sequence of neo-bladder regeneration in dogs illustrates the 
dichotomy in outcomes between implantation of acellular and cellularized scaffolds. This 
distinction is a principal theme of most studies describing the regeneration of tubular 
organs. Cell seeded scaffolds mediated a regenerative response within one month post-
implantation, characterized by induction of heavily vascularized, smooth muscle-like 
parenchyma. In contrast, acellular scaffolds triggered a principally fibrotic, reparative 
outcome characterized by randomly organized collagen fibers with minimal 
vascularization. 
Baseline urodynamics were reconstituted within four months of implantation with cell 
seeded scaffold, whereas the urodynamic profile of animals implanted with acellular 
scaffold remained abnormal throughout the trial period (Jayo et al., 2008a).  
In a related dog study, restoration of tri-laminar bladder wall architecture occurred within 
three months post-implantation and normal compliance characteristics of a urinary bladder 
wall developed by 12 months. Regenerated bladders were functionally and structurally 
stable for up to two years post-implantation. Importantly, although the construct volume 
was constant at implantation within variably sized dogs, the ratio of the regenerated 
bladder’s volume to host body weight adapted to the recipient animal’s size, demonstrating 
that the neo-organ responds to homeostatic mechanisms regulating organ volume (Jayo et 
al., 2008b).  
Although these canine studies utilized both bladder-derived urothelial and smooth muscle 
cells, urothelial cells have been shown to not be essential for bladder regeneration, thereby 
greatly facilitating process development and commercialization (Jack et al., 2009). However, 
use of bladder-derived smooth muscle cells is problematic in patients presenting with 
bladder related malignancies. Therefore, a number of alternate sources of smooth muscle 
cells have been investigated. Such alternate cell sources may have broad application in the 
regeneration of additional, laminarly organized tubular organs.  
One possible alternate source of smooth muscle cells may be the directed differentiation of 
mesenchymal stem cells (MSC) with recombinant, inductive cytokines such as transforming 
growth factor  (TGF-). Such MSC may be procured from bone marrow or adipose (Tian et 
al, 2010a,b; Sakuma et al., 2009). Additionally, autologous smooth muscle cells may be 
isolated from the vasculature of omentum or other adipose tissue as well as directly from 
the mononuclear fraction of peripheral blood (Basu et al., 2011a; Toyoda et al., 2009; Lin et 
al., 2008; Metharom et al., 2008).  
Although the use of MSC or other stem cell populations (adult-derived, embryonic or iPS 
(induced pluripotent stem cell)) for organ regeneration is informative as proof-of-concept, 
from a process development perspective focused on eventual manufacturing and product 
release, the requirements to monitor and control stem cell potential and directed 
differentiation towards a smooth muscle lineage substantially complicates efforts to 
streamline, standardize and assure quality, as well as leading to significant increases in cost 
of goods. To simplify bioprocessing procedures, enhance product consistency, reduce the 
risk of immune rejection and to ensure a robust supply of cellular raw material, we are 
focused on developing classes of committed smooth muscle cells for tubular organ 
regeneration (Basu et al., 2011a). 
An alternative platform technology for regeneration of bladder and related tubular organs 
including vas deferens and uterus is based around application of the peritoneal cavity as a 
living bioreactor to trigger the encapsulation of a tubular scaffold with myofibroblasts, as 
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demonstrated in rabbit and rat models (Campbell et al., 2008). Two to three weeks after 
implantation, tubular constructs were observed to be heavily encapsulated with 
myofibroblasts. These tissue engineered composites were anastamosed to the native organ 
and allowed to mature in vivo for up to 14 months. Histological analysis of regenerated 
tissue was performed together with evaluation of organ functionality. Bladder function was 
confirmed by normal urine flow, vas deferens function by ejaculation and uterine function 
by the ability to sustain pregnancy.  
With all three organ systems, an epithelial layer and laminarly organized musculature was 
observed with minimal evidence of inflammation. However, this approach may be 
impractical for widespread clinical application, as the cell encapsulation protocol represents 
an additional major surgical event. In vitro scaffold cell seeding is a simple and 
straightforward methodology sufficient to induce neo-organ regeneration in vivo. Use of 
alternate, non-bladder sources of smooth muscle-like cells will likely eliminate any 
requirement for peritoneal cavity based tissue engineering of bladder or bladder-like 
derivatives.  
2.2 Trachea 
Tissue engineered trachea illustrates another iteration of the foundational, bladder-based 
platform for tubular organ regeneration. Here, a decellularized, cadaveric tracheal 
segment was used as a scaffold. The recipient’s own epithelial cells seeded the luminal 
surface, while MSC derived from the recipient’s bone marrow was differentiated towards 
a chondrocytic lineage with recombinant cytokines prior to application on the abluminal 
surface. Although the patient showed reconstitution of pulmonary function within four 
months, detailed histological examination of the regenerated organ was not possible 
(Macchiarini et al., 2008).  
However, in a swine model of this tissue engineered trachea, both the chondrocytes derived 
from differentiated MSC as well as the epithelial cells were needed for host survival (Go et al., 
2010). While this methodology is valuable as proof of concept, it is clearly not amenable to 
large-scale process development. Decellularization of cadaveric scaffolds is an uncontrolled 
methodology that may not entirely alleviate immune response (Kasimir et al., 2006; Zhou et al., 
2010), as well as increasing cost of goods by the requirement to stringently monitor the 
decellularization protocol. Broader application requires synthetic biodegradable scaffold 
materials, facilitating reproducible manufacturability at large scale with defined chemical and 
physical properties. Furthermore, the application of directed differentiation strategies on cells 
destined for patient implantation may trigger additional regulatory hurdles, further 
complicating commercialization efforts. To this end, chondrocytes derived from autologous 
tracheal explants may be leveraged (Komura et al., 2008 a,b).  
2.3 Gastro-intestinal tract (GI) 
Individual components of the GI represent locally specialized iterative variations of 
essentially the same laminarly organized tubular histologic architecture as the bladder. 
However, from a commercial perspective, the small intestine represents by far the most 
pressing current clinical need, with small bowel transplantation being an unsatisfactory 
current standard of care for pediatric small bowel syndrome (SBS) 
(http://digestive.niddk.nih.gov/ddiseases/pubs/shortbowel/). Esophageal replacement 
for esophageal cancer may also be commercially viable.  
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The intestinal epithelium is the most highly regenerative tissue within adult mammals and 
may therefore be expected to be highly amenable towards tissue engineering or regenerative 
medicine methodologies. In one such study, in vivo derived organoid units, formed from 
incompletely disassembled clusters of epithelial and mesenchymal cells generated through 
partial digestion of intestinal epithelium (and therefore likely incorporating resident 
intestinal stem cells) were used to seed PLLA scaffold tubes that were subsequently 
matured within the peritoneal cavity of pigs. Seven weeks post-implantation, this tissue-
engineered small intestine recapitulated the gross overall laminar organization of native 
small intestine (SI) (Sala et al., 2009).  
Significantly, acellular scaffolds did not result in the regeneration of tissue engineered 
gastrointestinal structures. These data notwithstanding, anastamosis of these tissue 
engineered small intestines to host SI within a large animal model remains to be 
demonstrated. Additionally, up to 10cm of host SI was harvested to derive donor organoids 
that are not readily expandable in vitro. Whether organoid units capable of seeding a 
scaffold structure may be isolated from diseased human intestine, and how much diseased 
donor material may be needed, remain factors yet to be elucidated. The requirement to 
leverage the peritoneal cavity as a bioreactor for tissue engineering may also impede 
widespread application of this approach.  
The bladder-derived organ regeneration platform of biopolymeric scaffold seeded with 
smooth muscle cells may be applicable for regeneration of SI. To this end, stomach derived 
smooth muscle cells were used to seed a collagen-based scaffold prior to implantation 
within surgically isolated ileal loops of dogs for eight weeks, prior to re-anastamosis to the 
native intestine. Acellular collagen scaffold was used as a control. By 12 weeks post- 
surgery, macroscopic analysis of the cell seeded scaffold implantation site demonstrated 
regeneration of neo-mucosa resembling native mucosa. However, in animals containing an 
acellular scaffold, the implant site remained ulcerated up to 12 weeks post-implantation. 
Additional histological data showed significantly enhanced vascularization, 
epithelialization and organization of the circular muscle layer at the cell seeded scaffold 
defect site relative to acellular control (Nakase et al., 2006).  
Increasing the number of smooth muscle cells seeded onto the scaffold increased the area of 
regenerated SI tissue, although no concomitant increase in the thickness of the smooth 
muscle layer was observed (Nakase et al., 2007). Nevertheless, these data suggest that a 
simple regenerative platform composed of biodegradable scaffold nucleated with smooth 
muscle cells may be adequate to facilitate SI regeneration. Although this approach must be 
reproduced using a directly anastamosed tubular scaffold and alternate sources of smooth 
muscle cells, if successful, this methodology represents the most straightforward, clinically 
relevant and commercially viable strategy for regeneration of the SI.  
This organ regeneration platform technology may also be leveraged for regeneration of the 
esophagus. In one such example, patch defects were created in the abdominal esophagus of 
27 female rats, subsequently implanted with gastric acellular matrix (GAM). Of the 24 
survivors, none showed evidence of regeneration of the lamina muscularis mucosa even 18 
months post-implantation (Urita et al., 2007).  
In contrast, a study of a canine model of esophageal resection and replacement 
demonstrated that PGA tubes seeded with a mixture of keratinocytes and fibroblasts 
triggered regeneration of smooth muscle laminar organization similar to native esophagus 
within 3 weeks post-implantation, whereas acellular PGA tubes formed esophageal 
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strictures associated with near complete obstruction within two to three weeks (Nakase et 
al., 2008).  
In another dog study, cervical esophageal defects were patched with either small intestinal 
submucosa (SIS) alone, or SIS seeded with autologous oral mucosal epithelial cells. After four 
weeks, dogs implanted with cell seeded SIS showed almost complete re-epithelialization and 
minimal evidence of inflammation and, by eight weeks post surgery, regeneration of the 
underlying smooth muscle layer. Acellular SIS grafted animals presented only partial re-
epithelialization and a more extensive inflammatory response by four weeks, and no muscular 
regeneration by eight weeks post-implantation. Attempts to introduce an acellular SIS tubular 
construct into the cervical esophagus of piglets were also unsuccessful, demonstrating 
scarification and a minimal regenerative response (Doede et al., 2009). 
Progress has also been made in efforts to tissue engineer the stomach. Stomach derived 
organoid units, (analogous to the SI organoids used to tissue engineer the SI) upon seeding 
of a biopolymeric scaffold, triggered reconstitution of the gastric and muscularis mucosa in 
stomach tissue engineered within the peritoneal cavities of swine (Sala et al., 2009). In 
another study, circular defects were created in the stomach of seven dogs and a composite 
biodegradable scaffold (“New-sheet”), soaked with either autologous peripheral blood or 
bone marrow aspirate, was sutured over the defect. By 16 weeks post implantation, the 
defect site had formed regenerated stomach with evidence of re-epithelialization, formation 
of villi, vascularization and fibrosis within the submucosal layer. However, minimal 
regeneration of the smooth muscle layer was observed, as shown by expression of smooth 
muscle -actin, without expression of calponin, a marker of mature smooth muscle cells 
(Araki et al., 2009). 
Though strictly not a tubular organ, the anal sphincter is a component of the gastrointestinal 
tract and is critical in regulating patency of the large intestine. Recent efforts to engineer the 
anal sphincter leverage the same general platform used to catalyze bladder regeneration. To 
this end, smooth muscle cells isolated from human internal anal sphincter were seeded onto 
fibrin gels poured around a central mold. Cell mediated contraction of the gel around the 
mold resulted in the formation of a three-dimensional cylindrical tube of sphincteric smooth 
muscle tissue. Although in vivo anastamosis remains to be demonstrated, this bio-
engineered anal sphincter demonstrated contractile properties and response to defined 
neurotransmitters consistent with the functionality of native anal sphincter (Hashish et al., 
2010; Somara et al., 2009). Use of alternatively sourced smooth muscle cells may facilitate the 
transition of engineered sphincter towards commercial production.  
2.4 Neo-vessel 
Neo-blood vessels represent a major commercial opportunity for application of a tubular 
organ platform technology towards patients receiving bypass surgery. In a recently 
published clinical trial of vascular grafts composed of autologous bone marrow aspirate 
seeded onto a PGA/PCL scaffold and implanted into a cohort of 25 patients presenting with 
single ventricle physiology, all patients were asymptomatic 30 days post implantation and 
24/25 patients were alive at one year post-implantation (Hibino et al., 2010).  
Efforts to seed PGA tubular neo-vessel scaffolds with smooth muscle cells derived from the 
directed differentiation of bone marrow or adipose derived MSC with TGF- have also been 
described (Wang et al., 2010; Gong and Niklason, 2008). The requirement to induce directed 
differentiation with TGF- or related agents as well as the prolonged maturation period 
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under pulsatile conditions needed to achieve a mature smooth muscle phenotype will likely 
make this approach impractical for commercial application. A reliable source of committed 
smooth muscle cells (e.g., the vascular fraction of adipose or omentum) may represent a 
more commercially feasible platform. 
2.5 Lung 
Lung may be regarded as a highly specialized tubular organ amenable to regeneration with 
the bladder-based platform outlined above. Evidence to this effect was provided by a study 
examining the regenerative potential of PGA felt sheets seeded with adipose derived 
stromal cells in triggering pulmonary regeneration within a rat lung lobectomy model 
(Shigemura et al., 2006). The cell seeded PGA sheet was sealed onto the remaining lung lobe. 
Alveolar and vascular regeneration was observed within 1 week of implantation, with 
concomitant recovery of pulmonary functionality. Paracrine action by secreted factors 
including VEGF, HGF and FGF was suggested as a possible mechanism of action for 
triggering the regenerative effect.  
In another study, fetal rat lung cells were seeded onto gelfoam sponge-based scaffolds and 
implanted into adult rat lung. Alveolar-like structures with apparent vascular networks 
were observed to regenerate within degrading scaffold by 4 months post-implantation 
(Andrade et al., 2007). Importantly, the formation of these alvelolar like networks was 
observed to be strongly dependant on prior seeding of the scaffold with lung cells. As with 
the previous study, the authors suggest paracrine action of secreted factors from the seeded 
lung cells acting to facilitate regenerative in-growth of lung cells from the surrounding 
native lung tissue as the likely mechanism of action.  
Growth of lung cells in three-dimensions is essential to induce expression of epithelial genes 
related to lung morphogenesis, including FGFR2 (Mondrinos et al., 2006). Appropriate 
combinations of exogenous fibroblast growth factors chosen to target specific receptor 
isoforms may facilitate appropriate lung epithelial and mesenchymal cell behavior 
conducive to tissue regeneration (Mondrinos et al., 2007). Finally, tissue engineered lungs 
created from recellularized scaffolds derived from decellularized lung have also been 
recently characterized (Ott et al., 2010; Petersen et al., 2010; Cortiella et al., 2010). 
2.6 Genito-urinary system 
The recent reports of functional regenerated neo-phallus and neo-vagina within a rabbit 
model illustrate how foundational principles of tubular organ regeneration pioneered for 
bladder may be extrapolated to facilitate organogenesis of functionally distinct tubular 
organs (De Filippo et al., 2008). Decellularized corpora cavernosa was used as a collagen-
based scaffold matrix for seeding autologous corporal smooth muscle and endothelial cells 
in a rabbit model of penile replacement. Implantation of decellularized matrix alone led to 
formation of a non-functional, fibrotic phallus. However, cell seeded scaffolds regenerated 
corporal tissue organization histologically similar to native controls within 3-6 months post-
implantation. Tissue engineered phallus was functional as demonstrated by the ability of 
recipient animals to copulate normally (Chen et al., 2010).  
For the neo-vagina, autologous vaginal epithelial and smooth muscle cells were seeded onto 
the luminal and abluminal surfaces of PGA tubular scaffolds, preconfigured to resemble 
native rabbit vagina. Seeded composites were implanted in place of the native vagina of 
nine rabbits, with unseeded controls introduced into six other animals. As has been 
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observed for multiple organs, unseeded scaffold failed to trigger a regenerative response, 
whereas cell seeded scaffolds generated stage specific histogenesis, vascularization, 
innervation and regeneration of a patent neo-vagina by 6 months post-implantation with a 
defined muscular layer and a luminal invaginated epithelium. Organ functionality was 
confirmed by a graded contractile response of the musculature to electrical stimulation in a 
manner paralleling native tissue (De Filippo et al., 2008). 
2.7 Mechanism of action for tubular organ regeneration 
The lineage of cell populations constituting a regenerated neo-organ remains unclear. What 
is the contribution of the original cell population used to seed the scaffold compared to that 
derived from cellular migration from the surrounding tissue and/or omentum typically 
used to wrap neo-organs at the time of implantation as a source of neo-vascularization? 
Data addressing this issue was provided for the regenerated neo-vagina, where both the 
epithelial and smooth muscle cell populations used to seed the neo-vagina were labeled 
independently with fluorochromes and tracked to three months post-surgery. Labeled cells 
of both types were found to compose over 85% of the regenerated neo-organ (De Filippo et 
al., 2008).  
However, implantation of a human bone marrow derived cell seeded neo-vessel scaffold 
into immuno-deficient mice led to loss of all seeded human cells within days, followed by 
re-population of the scaffold with mouse monocytes and subsequent re-population with 
mouse smooth muscle cells and endothelial cells recruited via the monocyte chemoattractant 
protein MCP-1 (Roh et al, 2010). No direct contribution of the seeded bone marrow cells to 
the regenerated neo-vessel was observed. 
Organ specific mechanistic differences notwithstanding, these and results from other 
tubular organs demonstrate that defined populations of stem and progenitor cells are not 
required to trigger neo-organ formation. Smooth muscle cells and other committed cell 
types appear capable of mechanistically substituting for stem cells, by initiating cellular 
scaffold repopulation and catalyzing a host specific regenerative response that may 
additionally mediate paracrine signaling pathways to modulate recruitment of resident stem 
and progenitor populations, and regulate inflammation, immune response, apoptosis and 
fibrosis (Caplan, 2009). The ability to engineer neo-organs without a requirement for the 
isolation, expansion and manipulation of defined stem cell populations has greatly 
facilitated the commercial viability of this platform technology and will continue to do so in 
the future (Basu and Ludlow, 2010).  
2.8 Role of extracellular matrix (ECM) in regeneration 
An analysis of the bladder submucosal matrix generated by bladder smooth muscle cells 
identified multiple key paracrine signaling factors including VEGF, BMP4, PDGF-, KGF, 
TGF-1, IGF, bFGF, EGF and TGF- as resident components (Chun et al., 2007). This 
observation might suggest that the presence of living cells is entirely superfluous for 
triggering regeneration, which would greatly lower cost-of-goods for neo-organ production. 
A synthetic scaffold may be matured with an autologous, committed cell population to 
facilitate deposition of ECM, decellularized and implanted within the host to induce organ 
regeneration. Alternatively, defined ECM components or growth factors may be introduced 
into the scaffold to recapitulate key aspects of organogenesis (Sahoo et al, 2010). However, 
studies to date confirm that ECM alone in the context of, for example, an acellular matrix 
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such as small intestinal submucosa or bladder mucosa, is insufficient to induce 
organogenesis in vivo (Doede et al., 2009; Dorin et al., 2008). It is likely that living cells are 
required to modulate a more sustained, physiologically relevant regenerative response.  
2.9 Conclusions & clinical outlook 
We may summarize the key factors affecting the commercial viability of any tubular organ 
tissue engineering or regenerative technology platform as follows: 
 A biodegradable, synthetic scaffold based on well-characterized materials (e.g., PGA, 
PLGA) that is reproducibly manufactured with defined characteristics. 
 A population of committed cells (typically smooth muscle cells), easily isolatable and 
expandable, is required for scaffold seeding to trigger regeneration in vivo.  
 A purified population of defined stem cells is neither needed nor desirable. Cost of 
goods increases significantly with the requirements to monitor stem cell potential and 
to control directed differentiation. 
 Engineering an entire organ in vitro or within the peritoneal cavity is neither needed nor 
desirable. Instead, an in vitro cell seeded scaffold is adequate to trigger the body’s 
innate regenerative response, resulting in de novo organogenesis in vivo. 
The outlook for tubular organ regeneration in the clinic is promising. We have seen how the 
foundational technology platform consisting of a biodegradable scaffold nucleated with a 
population of committed smooth muscle cells, first pioneered for the bladder, may be 
applied towards regeneration of multiple, functionally disparate tubular organs. Proof of 
concept studies in human patients have already been successfully completed with neo-
bladder, trachea and vascular grafts. However, the neo-bladder continues to represent the 
pioneering regenerative neo-organ, with Phase 2 clinical trials currently underway 
[www.clinicaltrials.gov/ct2/show/NCT00512148?term=tengion&rank=4;  
www.clinicaltrials.gov/ct2/show/NCT00419120?term=tengion&rank=5]. Additionally, 
clinical trials are underway for the development of a neo-urinary conduit, a bladder 
derivative neo-organ designed to facilitate urinary diversion and developed through 
foundational principles closely resembling those used to engineer the neo-bladder 
replacement [www.clinicaltrials.gov/ct2/show/NCT01087697?term=Tengion&rank=3]. 
3. Tissue engineering of solid organs 
3.1 Introduction 
Though mammalian fetuses are capable of spontaneous regeneration of damaged organs 
and tissues until the third trimester, adult mammals typically respond to trauma by 
initiating reparative healing mechanisms. These are characterized by wound contraction, 
extensive fibrosis and scar tissue formation mediated by the migration and re-organization 
of myo-fibroblasts, as demonstrated during the response of the heart to ischaemic injury 
(Boudoulas and Hatzopoulos, 2009). True organ regeneration as commonly observed in 
certain species of fish and amphibian is associated with an absence of the fibrotic response 
and concomitant reconstitution of the three dimensional laminar or parenchymal 
organization of the regenerating organ, as exemplified by the regeneration of adult 
mammalian liver in response to lobectomy.  
The objective of de novo organ regeneration through tissue engineering or regenerative 
medicine is to use defined combinations of cells and biomaterials to catalyze a principally 
regenerative response towards organ trauma while simultaneously ameliorating any 
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tendency towards fibrotic repair. The de novo regeneration of a complete organ in mammals 
has been demonstrated for laminarly organized, tubular organs including bladder, trachea 
and vessels of the vasculature (Basu and Ludlow, 2010) as well as recently for the small 
intestine (Basu et al., 2011c). However, the regeneration of solid organs presents a unique 
challenge, requiring the organization of highly specialized cell types into complex three 
dimensional micro-architectures within a parenchymal matrix. Additionally, the 
regenerating solid neo-organ must synergize with developing elements of the vasculature, 
lymphatic and nervous systems throughout neo-organ morphogenesis.  
In this section, we will highlight the latest progress towards regeneration of solid organs in 
mammals, with an emphasis on identifying commonalities of methodology that may drive the 
creation of an organ regeneration platform broadly applicable towards multiple solid organ 
systems (Figure 2). We will focus on identifying aspects of the regenerative methodology most 
conducive towards translation into commercial process development and manufacture. 
 
 
Fig. 2. Solid organ systems potentially amenable to commercial tissue engineering strategies. 
From top, clockwise: central nervous system, heart, kidney, pancreas, liver. 
3.2 Kidney 
Kidney provides an excellent illustration of the considerable technical difficulties associated 
with solid organ regeneration. Numerous specialized cell types including podocytes, 
mesangial cells, endothelial cells, fibroblasts, epithelial cells and numerous stem and 
progenitor cell populations are organized across the renal parenchyma into discrete, 
specialized functional units or nephrons, which serve to selectively filter electrolytes from 
the vasculature (Vize et al., 2003; Basu et al., 2010).  
Efforts to trigger regeneration within animal models of ischaemic or chronic renal disease 
have typically centered around the isolation, expansion and re-introduction of defined 
populations of mesenchymal, embryonic or renal stem cells, potentially capable of site-
specific engraftment and directed differentiation along multiple renal lineages as well as 
facilitating the creation of a regenerative micro-environment through paracrine signaling 
mechanisms (reviewed by Sagrinati et al., 2008; Hopkins et al., 2009).  
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Such cell therapy methodologies have had generally mixed results, with little if any 
evidence supporting site specific engraftment and directed differentiation as a mechanism of 
action by exogenously applied stem or progenitor populations. Introduction of stem cells 
within the kidney by direct injection into the renal vasculature or renal parenchyma leads to 
apoptosis or efflux of the majority of applied cells from the target organ within days of 
implantation (Togel et al., 2008). Uncontrolled differentiation of stem cells that actually do 
engraft may also represent a significant technical challenge and potential regulatory obstacle 
against successful commercialization (Kunter et al., 2007).  
Reconstitution of kidney mass, a central prerequisite for true de novo organ regeneration, 
will likely require a cell/biomaterial scaffold composite facilitating the morphogenesis of 
glomeruli and tubules derived from seeded primary renal cell populations, as well as the 
migration and directed differentiation of host derived renal stem and progenitor cells within 
the scaffold framework, followed by progressive vascularization and innervation of the 
developing neo-organ, deposition of extracellular matrix and the reconstitution of a renal 
parenchyma. 
To this end, it may be reasoned that biomaterials derived from the native kidney are best 
suited to retain renal specific elements of the extracellular matrix (ECM) potentially capable 
of modulating renal morphogenesis as well as the three dimensional parenchymal micro-
architecture unique to the kidney. Application of sodium dodecyl-sulphate (SDS) detergent 
to whole rat kidneys in one recent report was shown to facilitate the removal of renal cells 
while maintaining the functional integrity of the ECM as well as the overall three 
dimensional parenchymal organization of the kidney. Murine pluripotent embryonic stem 
(ES) cells were applied to this renal scaffold via the renal artery or ureter, and the cell seeded 
biomaterial composite matured under static or pulsatile culture without the application of 
inductive differentiation agents.  
This approach permitted an evaluation of the specific effect of native renal-derived ECM in 
modulating the directed differentiation of the ES cell population. After arterial seeding, it 
was observed that ES cells localized within the Bowman’s capsule by 4 days post-seeding 
and within the associated vasculature and renal cortex by day 10. Niche specific localization 
of ES cells was accompanied by concomitant acquisition of the renal markers Pax-2 and Ksp-
cadherin as evidenced by histochemical and RT-PCR approaches (Ross et al., 2009). The 
effectiveness of SDS relative to other detergents in preserving components of the ECM as 
well as details of the renal micro-architecture was confirmed independently in comparative 
studies of the effect of decellularization within monkey kidneys with multiple detergent 
agents (Nakayama et al., 2010).  
Although it is not unreasonable to assume that the organ specific ECM and three 
dimensional histo-architecture associated with scaffolds procured by decellularization of 
native organs may be ideally suited to direct the potential regeneration of that specific organ 
type, this strategy may not be appropriate for a commercially viable solid organ 
regeneration platform. Apart from difficulties associated with the procurement of cadaveric 
organs for scaffold assembly, decellularization is a generally uncontrolled process not easily 
subject to scale-up, process development and quality assurance. Monitoring and verification 
of the extent of cell loss will substantially increase cost of goods associated with 
manufacture. Furthermore, native scaffolds retain the potential for immunogenicity despite 
the presumed absence of cells (Zhou et al. 2010). Reliable and reproducible 
manufacturability of solid neo-organs will likely require the application of synthetic 
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biomaterials with defined physical and chemical properties. With these considerations 
granted, progress towards creation of biosynthetic scaffolds appropriate for the regeneration 
of renal architecture was provided by the demonstration that tubular and glomerular 
structures spontaneously self-assembled from primary rat renal cell populations within one 
week of growth in collagen I gels (Joraku et al., 2009). 
The ability to introduce specific biomimetic peptides and defined proteolytic cleavage sites 
within the context of gel based biomaterials raises the intriguing possibility of controlling 
the morphogenesis of tubules, glomeruli or other renal structural units to modulate defined 
functional outcomes. For example, polyethylene glycol (PEG)-based hydrogels engineered 
with protease degradation sites and controlled densities of RGD peptide or laminin 
bioligands have been found to regulate epithelial morphogenesis of cysts derived from 
MDCK cells, such that cysts grown within ligand functionalized gels demonstrated an 
increased frequency of lumen formation and unambiguous baso-lateral polarization 
compared to those grown in unmodified hydrogels (Chung et al., 2008). Therefore, a true 
renal augment designed to trigger regeneration of glomeruli, tubules, EPO secreting 
fibroblasts (Paliege et al., 2010) or other key renal cell populations may potentially be 
envisioned as an injectable hydrogel containing functionalized matrix optimized to catalyze 
this defined regenerative outcome. Such methodologies alleviate potential concerns 
regarding the requirement for major surgical intervention within the diseased organ.  
Alternatively, a neo-kidney augment may be contemplated as a semi-permanent, 
implantable, cell/biomaterial composite that upon introduction within or adjacent to the 
renal parenchyma of a diseased organ, provides a foundational framework for regeneration 
of tubular or other renal superstructures as well as potentially establishing a regenerative 
microenvironment through paracrine mediated recruitment of native stem and progenitor 
populations as well as amelioration of inflammatory, fibrotic and apoptotic cascades 
(Caplan 2009). To this end, certain species of polyester fleeces have demonstrated the 
capacity to facilitate the growth of renal tubules within the context of a fibrous artificial 
interstitium.  
In this system, a heterogenous primary renal cell population incorporating stem and 
progenitor cells was extracted from the sub-capsular space of embryonic rabbit kidneys. The 
isolated cell population was sandwiched between two layers of polyester fleece and 
maintained within a perfusion culture system in the presence of aldosterone, a hormone 
involved in the renin/angiotensin axis (Vize et al., 2003). Spontaneous generation of tubular 
structures was observed with concomitant expression of key functional markers including 
cingulin and Na+/K+ ATPase. The regenerated tubules appeared to interact with the 
polyester fibers within the context of the artificial interstitium.  
The authors speculate that these cell seeded polyester scaffolds may be multiplexed by 
horizontal “tiling” or “paving” as well as vertical “piling” to create renal superstructures 
supporting the continued morphogenesis of renal tubules in vitro. The authors suggest that 
these compounded renal units could potentially form the basis of a true neo-kidney 
augment upon implantation within the sub-capsular space between the renal capsule and 
the renal parenchyma (Roessger et al., 2009; Minuth et al., 2008), although our observations 
of the mechanical properties of the renal capsule associated with diseased, fibrotic human 
kidneys suggest that this approach may not be feasible.  
Nevertheless, this methodology illustrates one key criterion for commercial viability; 
synthetic polyester fleeces are leveraged for regeneration of renal tubular superstructures, 
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without the requirement for extracellular matrix components derived from decellularized 
kidney or from other naturally occurring sources. In addition, the application of a defined, 
serum/BPE (Bovine Pituitary Extract) free media for tubule growth and maintenance 
additionally serves to facilitate large scale process development. Conversely, it remains to be 
ascertained whether cells derived from human kidney tissue in general and from diseased 
human organs in particular, are capable of supporting the spontaneous assembly of tubular 
structures de novo within the context of polyester or other synthetic polymer based 
biomaterial.  
At Tengion, development of the Neo-Kidney Augment (NKATM), a cell/biomaterial 
composite for renal tissue engineering, has focused on step-wise identification of bioactive 
cellular components and biomaterials amenable to implantation within renal parenchyma. 
To this end, we have leveraged principles discussed throughout this chapter, identifying 
lineage committed, primary renal cell populations as therapeutically bioactive agents 
capable of mediating functional rescue of aspects of disease phenotype within small animal 
clinical models of chronic kidney disease (Kelley et al., 2010; Presnell et al., 2010). Similarly, 
our evaluation of biomaterials compatible with renal parenchyma has led us towards 
application of gelatin hydrogels as the best tolerated biomaterial scaffold for renal tissue 
engineering (Basu et al., 2011b). Studies are currently underway to evaluate the ability of 
bioactive, primary renal cell/hydrogel biomaterial composite constructs (NKATM) to 
catalyze functional rescue of disease in small and large animal clinical models of chronic 
kidney disease. 
3.3 Heart 
Mammalian heart provides one of the clearest demonstrations of the inability of most 
mammalian solid organs to regenerate. Cardiac ischemia typically results in extensive 
fibrosis, scarification and loss of function (Boudoulas and Hatzopoulos, 2009). In contrast, 
zebrafish and other non-mammalian vertebrates are capable of complete regeneration and 
reconstitution of function upon removal of up to 20% of the ventricle, leading to speculation 
that an understanding of the mechanism of action underlying regeneration within model 
organisms such as zebrafish may identify analogous mechanisms that may be leveraged 
within mammals to trigger cardiac regeneration. To this end, dedifferentiation and 
proliferation of existing cardiomyocytes was shown to be the principal mechanism of 
regeneration following ventricular amputation within zebrafish (Jopling et al., 2010).  
This modality of action notwithstanding, tissue engineering approaches towards 
construction of functional mammalian heart have generally focused on decellularization of 
cadaveric organs to provide scaffold structures for reseeding and implantation. For 
example, neonatal rat cardiac or aortic endothelial cells were used to seed a decellularized 
cadaveric rat heart. Upon growth within customized bioreactors for 8 days, evidence of 
spontaneous contractility was observed. Pump functionality of up to 2% of adult was 
successfully reconstituted (Ott et al., 2008).  
However, although of interest as proof of concept, the requirement for cadaveric organs as a 
source of biomaterials may ultimately limit the usefulness of this methodology for 
commercial development and application within the clinic. As we have seen with the 
kidney, decellularization is a difficult procedure to monitor during quality assurance 
regimens, and there can be no guarantee that the resultant tissue engineered composite will 
lack immunogenicity upon implantation (Zhou et al. 2010). Furthermore, it remains to be 
 
Advances in Regenerative Medicine 
 
248 
demonstrated whether cardiac cells derived from adult human tissue are capable of 
repopulating a scaffold to regenerate a functional organ. Finally, the requirement for tissue 
maturation within pulsatile bioreactors will likely substantially increase cost of goods for 
tissue engineered cardiac neo-organs.  
These criticisms aside, the engineering of synthetic scaffolds that recapitulate defined 
cardiac structures such as valves and chambers remains technically challenging (Fong et al., 
2008). We speculate that triggering the dedifferentiation and subsequent proliferation of 
existing cardiomyocyte populations by synthetic biomaterial composites containing defined 
biomimetic peptides and/or autologously derived lineage committed cell populations with 
smooth muscle cell-like properties may ultimately prove to be the more commercially 
feasible approach for regeneration of cardiac substructure and ultimately neo-organ 
regeneration.  
Evidence supporting the idea that biomaterial composites seeded with lineage committed 
cell populations may represent a potential solid organ regeneration platform comes from 
studies of biodegradable scaffolds nucleated with human ES cell derived cardiomyocytes 
alone or cardiomyocytes, endothelial cells and embryonic fibroblasts. Upon implantation 
within rat heart, more extensive vascularization was observed from tri-culture seeded 
constructs when compared to scaffolds seeded with ES cell derived cardiomyocytes alone 
(Lesman et al., 2010). In addition, acellular or mesenchymal stem cell (MSC) seeded SIS 
(small intestinal submuscosa) grafts have been implanted on the epicardial surface of a 
rabbit model of myocardial infarct. Resultant ventricular functionality and histopathology 
were significantly more improved in MSC seeded relative to acellular grafts.  
Finally, the use of injectable gels derived from decellularized human or porcine pericardium 
to trigger migration and proliferation of cardiomyocytes and cardiac progenitors has also 
been explored (Seif-Naraghi et al., 2010). Such synthetic hydrogels incorporating biomimetic 
peptides or containing committed smooth muscle, endothelial or other fully differentiated 
cell type may serve as a commercially feasible organ regeneration platform to trigger cardiac 
regeneration. These regenerative platforms most likely leverage paracrine and ECM-based 
signaling to recreate a regenerative micro-environment and thereby facilitate the 
regenerative response.  
3.4 Liver 
The regenerative potential of the liver is unparalleled among mammalian organs. Adult 
liver progenitors are thought to be defined by the population of “oval cells” capable of 
reconstituting both hepatocytes and biliary epithelium upon mobilization by an appropriate 
regenerative signal (Zaret & Grompe, 2008). However, as with the heart, liver regeneration 
does not appear to leverage discrete, organ specific pools of stem and progenitor cells, 
rather, operating through the increased proliferation of existing, mature hepatocytes. 
Unfortunately, this magnified proliferative capacity has not translated into the ready 
expandability of hepatocyte populations in vitro. Mammalian hepatocytes remain 
notoriously difficult to maintain and expand in culture (Underhill et al., 2007). Regardless, 
regenerative medicine and tissue engineering approaches to reconstitute the liver have 
typically focused on the isolation and expansion of mature, adult hepatocytes as a cell 
source for biomaterials seeding or, alternatively, on the directed differentiation of ES, iPS, 
adipose or bone marrow derived MSC towards a hepatic lineage followed by 3D culturing.  
Morphogenesis of the mammalian liver is triggered by induction of the embryonic 
endodermal epithelium by adjacent mesodermal populations (reviewed by Zaret & Grompe, 
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2008). Mimicking these early developmental signaling events through co-culture of 
hepatocytes with mesenchymal cell populations such as bone marrow-derived stem cells 
(BMSC) or even 3T3 fibroblasts results in significant enhancement of hepatic functionality as 
evidenced by prolonged maintenance of hepatocyte specific morphology and enhanced 
secretion of albumin (Nahmias et al., 2006). This observation raises the possibility that 
biomaterials seeded with mesenchymal cell populations may function as a potential solid 
organ regeneration platform, acting to facilitate the proliferation and functionality of 
hepatocytes in vivo.  
Evidence to this effect was provided by studies of Nagase analbuminea rats implanted with 
corraline hyaluronic acid (HA) ceramic disks seeded either with freshly isolated rat 
hepatocytes alone, or rat hepatocytes together with bone marrow derived mononuclear cells 
(Takeda et al., 2005). Hepatocytes cultured in the presence of BMSC secreted significantly 
more albumin into the media during in vitro culture relative to hepatocytes in monoculture. 
These effects were recapitulated in vivo within 4 weeks in analbuminic rats, within which 
HA-based biomaterials seeded with both BMSC and hepatocytes were associated with 
significantly greater blood serum albumin levels relative to monoculture controls. Finally, 
implantation of co-cultured biomaterials within mice presenting chemically induced liver 
damage resulted in complementation of blood serum albumin as well as increased levels of 
serum IL-6.  
This reconstitution of function notwithstanding, no evidence was provided regarding tissue 
regeneration in vivo within the context of the biomaterial, or whether the presence of 
hepatocytes is in fact essential. A clear demonstration of hepatic tissue regeneration and 
functional complementation using synthetic biomaterials seeded with BMSC or some other 
mesenchymal cell population would be of significant commercial interest. As with heart and 
kidney, we speculate that paracrine action by factors released from the seeded mesenchymal 
cells may be adequate to trigger angiogenesis and vascularization of the biomaterials as well 
as to stimulate the proliferation of the resident hepatocyte population. In keeping with the 
suggestion of paracrine mechanisms, it may additionally be possible to leverage the resident 
pluripotent progenitor populations normally resident in the liver by implantation of a 
biomaterial within the canals of Hering to provide additional space for the development of 
regenerated tissue (Zhang et al., 2008).  
Alternate cell sources of hepatocyte like cells may offer a potential substitute for mediating 
catalysis of liver regeneration. Hepatocyte like cells may be derived from bone marrow or 
adipose primary cells through a multi-step directed differentiation regimen attempting to 
phenocopy key signaling events during hepatic morphogenesis through the controlled 
application of recombinant bioactive factors and small molecules including hepatocyte 
growth factor (HGF), basic fibroblast growth factor (bFGF) and oncostatin-M (OMS) (Talens-
Visconti et al., 2006). These pseudo-hepatocytes display a characteristic polygonal 
morphology, demonstrate expression of key hepatocyte associated transcriptional and 
protein markers and secrete albumin into the media.  
Similarly, cells derived from the stromal vascular fraction of adipose can be driven to acquire 
hepatocyte-like characteristics by application of analogous multi-stage differentiation 
protocols. Importantly, both adipose derived hepatocytes as well as undifferentiated adipose 
stromal vascular fraction derived cells are capable of engraftment within chemically damaged 
liver in vivo, where they appear to form cords of tissue within the hepatic parenchyma and 
acquire hepatocyte specific functionality, as demonstrated by the in situ expression of albumin 
(Ruiz et al., 2010). In this study, engraftment by human adipose derived stromal cells within 
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the liver of a SCID mouse recipient was examined, with functionality being monitored through 
the use of antibodies specifically recognizing human albumin. The differentiation of bone 
marrow derived primary cells into hepatocyte-like cell types appears to be facilitated by 
growth in three dimensions, as shown by the enhanced secretion of albumin, urea, transferrin, 
serum glutamic pyruvic transaminase and serum oxaloacetate aminotransferase from 
hepatocyte-like cells grown in three-dimensions on polycaprolactate (PCL) scaffolds relative 
to similar populations maintained in two-dimensional monoculture (Ruiz et al., 2010).  
The trans-differentiation of bone marrow cells towards a hepatic phenotype may also be 
accomplished by leveraging paracrine and ECM mediated signaling mechanisms between 
existing hepatic cells and bone marrow cells. For example, human bone marrow MSC may 
be incubated in plates containing HepG2 derived ECM and HepG2 derived conditioned 
media for up to 30 days to facilitate the acquisition of a hepatocyte-like phenotype (Tai et al., 
2009). These hepatocyte like cells were seeded onto an RGD (arginine-glycine-aspartic acid) 
modified chitosan alginate polyelectrolyte fibrous non-woven scaffold prior to implantation 
within a rat liver lobectomy model presenting with 70% removal of liver mass. Post-
implantation analysis of the cell seeded biomaterials within 1-2 weeks confirmed the 
expression of key hepatic markers. Detection of human albumin within rat serum was also 
demonstrated. No histological evidence for regeneration was provided, although this 
outcome is unlikely over such a short time period. Taken together, these results provide 
evidence for functional complementation without clear demonstration of de novo hepatic 
tissue regeneration.  
An alternative, methodology for regeneration of hepatic tissue is based on the engineering 
of contiguous monolayers of primary hepatocytes through culturing on temperature 
responsive surfaces (Ohashi et al., 2007). The temperature sensitive polymer PIPAAm, upon 
decrease in temperature to below 32ºC, rapidly hydrates triggering the spontaneous 
detachment of cultured hepatocytes in the form of discrete, uniform sheets. Stacking of 
multiple hepatic tissue sheet monolayers within the subcutaneous space of mice resulted in 
the formation of a significant hepatic tissue mass, with histologically meaningful micro-
architecture, vascularization and functionality as assayed by the presence of glycogen. 
Importantly, ectopic engineered hepatic tissue was capable of reacting to a regenerative 
stimulus (2/3 liver resection) by significantly increased levels of proliferative activity. 
Furthermore, hepatocytes organized as stacked monolayer sheets generated significantly 
greater functional neo-organ volume compared to the same number of hepatocytes 
introduced into the subcutaneous cavity within an injectable Matrigel matrix. Such 
injectable hepatocyte matrices have been proposed as alternate regenerative stimuli for liver 
(Fiegel et al., 2009).  
3.5 Pancreas 
Strategies for regeneration of pancreas have focused almost exclusively on the de novo 
regeneration of pancreatic -cell populations. Morphogenesis of the pancreas broadly 
resembles hepatogenesis, with induction of the endodermal epithelium of embryonic foregut 
triggered by adjacent mesenchymal cell populations (Zaret & Grompe, 2008). As a result, 
methodologies developed to mediate the directed differentiation of ES or adult derived stem 
and progenitor cells towards a pancreatic lineage leverage many of the same key 
developmental morphogens as those formulated to mediate acquisition of hepatic phenotype.  
The forced expression of certain pancreatic transcription factors and/or treatment with 
defined growth factors is sufficient to trigger acquisition of insulin transcription within non-
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pancreatic cell populations as well as within pancreatic ductal and acinar cells, though 
typically not at levels comparable to true -cells. Lineage transdifferentiation and 
dedifferentiation towards a progenitor phenotype have been proposed as mechanisms of 
action underlying the observed de novo presentation of -cell specific phenotypes in vitro. 
Evidence is also accumulating that these mechanisms may operate in vivo to modulate true 
pancreatic regeneration (reviewed by Juhl et al., 2010).  
Strategies to specifically target pancreatic ductal and acinar cells for delivery of defined 
transcription factors selected to mediate dedifferentiation and reacquisition of a -cell specific 
phenotype, while useful as proof of concept, may not represent a commercially viable solid 
organ regeneration platform. Similarly, methodologies oriented around the directed 
differentiation of ES or adult stem cells will considerably increase cost of goods, with process 
development and quality assurance issues focused on the evaluation of stem cell potential and 
the extent and completeness of the directed differentiation process (see Table 1). To this end, it 
may be worthwhile exploring whether tissue engineering approaches for regeneration of 
pancreas may be designed to leverage the innate regenerative potential inherent within the 
organ itself. Although not as dramatic as the liver, regeneration of mammalian pancreas has 
been observed under certain circumstances (Cano et al., 2008).  
 
Stem Cells Committed Cells 
Considerable initial variability in 
proliferative capacity and multi-lineage 
differentiation potential 
Expansion in culture leads to loss of 
differentiation potential. Monitoring multi-
lineage differentiation potential is lengthy 
and expensive 
Directed differentiation is an uncontrolled, 
inefficient process. Only a proportion of cell 
population acquires lineage specific 
characteristics 
Requirement for inductive cytokines to 
direct lineage specific differentiation leads to 
significant increase in cost of goods 
Multiple molecular, proteomic and 
functional tests required to evaluate stem 
and differentiation potential. Substantial 
increasein time, cost, labor. Tests may be 
misleading and unreliable (Montzka et al., 
2009) 
Long term effects of inductive cytokines on 
cells implanted in vivo not known. Potential 
for transformation, teratoma formation 
Straightforward, readily isolatable cell 
sources, less subject to donor variability 
Readily expanded in culture without loss 
of lineage specific characteristics 
No requirement to monitor stem cell 
potential or directed differentiation 
No requirement for recombinant 
cytokines, substantially decreasing cost 
of goods 
No regulatory concerns regarding effects 
of recombinant cytokines on cell 
transformation 
Significant reduction in time required to 
expand committed cell population 
Application of committed smooth muscle 
cells (example) for organ regeneration 
demonstrated across multiple organ 
systems within in vivo models 
No possibility of abnormal in vivo 
differentiation or teratoma formation 
 
Table 1. Potential of Stem and Committed Cell Populations for Application in Commercially 
Viable Solid Organ Regeneration Platforms 
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Autologously derived pancreatic islet cells or alternate cell sources presenting a -cell like 
phenotype may be engineered within an appropriate gelatinous matrix or other biosynthetic 
scaffold. Considerable effort is currently being invested in developing pancreatic islet cell 
encapsulation technology, which may be manifested as a vascular device, microcapsule, 
tubular or planar membrane chamber or sheet architecture (reviewed by Sambanis, 2007). 
Encapsulation techniques facilitate the delivery of allogeneic or cadaveric islets cells by 
modulation of the host immune response. Recent developments in encapsulation 
methodologies include the application of bioactive hydrogels with functionalized moieties 
designed to improve -cell survival and secretion of insulin (Lin and Anseth 2009) as well as 
to modulate inflammation (Su et al., 2010). Implantation of PEG tubes containing rat islet 
cultures maintained on acellular pancreatic matrix was observed to lead to partial rescue of 
insulin secretory activity (De Carlo et al., 2010).  
Alternatively, pancreatic islet cells may be expanded through growth over polyglycolic acid 
(PGA) scaffolds. Scaffold seeded cells may then be further matured into tissue engineered 
islets within a thermo-responsive gel prior to harvesting and implantation beneath the 
kidney capsule of streptozotocin (STZ) induced diabetic mice, triggering a subsequent 
return to the normo-glycaemic condition (Kodama et al., 2009). Similarly, transplantation of 
pancreatic islets grown over a biodegradable scaffold composed of a vicryl fleece with 
polydioxanone backing and implanted within a canine total pancreatectomy model resulted 
in normo-glycaemia without the requirement for exogenous insulin injection (n=4), in one 
case up to 5 months post-implantation. In contrast, dogs receiving an equivalent mass of 
islets without scaffold did not become normo-glycaemic at any time (Kin et al., 2008).  
The sheet architecture solid organ regeneration platform pioneered for application in liver 
regeneration (Ohashi et al., 2007) has also been applied towards ectopic regeneration of 
pancreatic tissue (Shimizu et al., 2009). In this study, isolated rat pancreatic islets were 
expanded over laminin 5 coated PIPAAm plates. Implantation of the tissue engineered 
pancreatic sheets within the subcutaneous space of rats led to reconstitution of pancreatic-
like tissue structures within 7 days post-implantation. As with the liver, the authors 
speculate that stacking of pancreatic islet cell sheets may lead to regeneration of an 
increased mass of pancreatic tissue. It is noteworthy that none of these studies have 
examined the regeneration of native pancreas in situ. This may be a function of the 
additional challenges inherent in modulating regeneration in situ, including the requirement 
for vascularization and oxygenation specific to the internal volume of regenerating solid 
organs located deep within the peritoneal cavity. It will be of significant interest to evaluate 
whether islet cells implanted within biomaterials and ligated to lobectomized pancreas are 
capable of catalyzing partial de novo organ regeneration.  
3.6 Spleen 
Although the regeneration of spleen may not be clinically or commercially relevant, the 
principles developed for engineering these organs may have broader implications for solid 
organ regeneration. To this end, progress towards regeneration of spleen has been reported 
through the leveraging of platform technologies successfully applied towards engineering of 
small intestine and stomach, these representing examples of tubular, laminarly organized 
organs with fundamentally distinct micro- and macro-architecture compared to the spleen 
or other solid organs (Grikscheit et al., 2008).  
In this approach, organoid units generated by the incomplete digestion of rat splenic tissue 
were seeded within tubular PGA/PLA (poly-lactic acid) scaffolds, and the resultant 
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composites implanted within the omentum of the peritoneal cavity of splenectomized rats. 
This ectopic tissue engineered spleen demonstrated splenic tissue organization as well as 
providing protection against Pneumococcal induced septicemia. Interestingly, spleen slices 
cultured ectopically within omentum also mediated formation of quasi-spleen like 
structures capable of providing protection against induced septicemia. 
3.7 Central nervous system 
Potentially the best defined examples of a solid organ regeneration platform demonstrating 
evidence of cellular regeneration in situ within a damaged organ and catalyzed by 
implantation of a cell/biomaterial composite at the injury site comes from brain. Tissue 
engineering of brain and spinal cord typically involves the introduction of gel-based 
biomaterials within the brain that may be nucleated with neuronal stem cells and may 
additionally be supplemented with paracrine signaling factors such as vascular endothelial 
growth factor (VEGF), brain derived neurotrophic factor (BDNF) or components of the 
extracellular matrix including laminin and fibronectin.  
For example, a biomimetic hydrogel incorporating matrix metalloproteinase (MMP) 
degradation sites, a laminin derived peptide and the neurotrophic factor BDNF was shown 
to direct the in vitro differentiation of seeded mesenchymal stem cells towards a neuronal 
lineage. Subsequently, this biomimetic hydrogel was introduced into the intrathecal space 
within a rat model of spinal cord injury. Although no histological evidence for neuronal 
regeneration was presented, rats treated with the biomimetic hydrogel showed the greatest 
improvement in tests of locomotion compared to rats treated with non-biomimetic control 
hydrogels (Park et al., 2009). 
In another approach, defined brain defects were created within rat models and subsequently 
implanted with a gelatin based scaffold impregnated with VEGF. Histological evidence was 
provided as evidence for migration of endothelial, astroglial and microglial cells within the 
periphery of the scaffold at 30 days post-implantation (Zhang et al., 2008). This observed 
regenerative effect was found to be dependant on the presence of VEGF. A demonstration of 
the application of a non-gel based scaffold for tissue engineering of brain is the use of poly-
lactic-co-glycolic acid (PLGA) micro-particles in the 50-200 m size range. These neuro-
scaffolds were seeded with neural stem cells and introduced into the brain cavity of stroke 
induced rats by directed injection under magnetic resonance imaging (MRI) guidance. 
Within 7 days post-implantation, the neural stem cells had dispersed within the scaffold, 
and presented as a tightly packed mass at the center of the biomaterial, but with a broader 
distribution resembling a honey-comb like structure towards the periphery. The graft 
displayed a mixed population of neuronal, astrocytic and stem cell specific markers, 
together with evidence of inflammation, but little if any vascularization within the body of 
the biomaterial. No evidence was provided that the tissue engineered brain tissue had any 
functional significance in terms of impact to the rat stroke model (Bible et al., 2009). 
4. Conclusions 
When examined together, platform technologies for regeneration of solid organs remain 
largely as academic proof of concept. Factors needing to be addressed for successful 
commercialization include the following:  
 Synthetic biomaterials, readily manufactured with defined physical and chemical 
properties, approved by FDA for implantation within the human body. 
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 Avoidance of decellularized scaffolds that require cadaveric organ sources and may be 
potentially immunogenic. 
 Use of committed cell types, not stem or progenitor cell populations that require 
extensive monitoring of stem potential and directed differentiation. 
 Autologous cell sources where possible facilitate FDA acceptance of introduction of 
cellular material. 
 Emphasis on a platform approach: cell/biomaterial composites that upon delivery, 
trigger a broad regenerative response within multiple solid organs. 
This is in marked contrast to analogous platform systems developed for tubular organs such 
as bladder and bladder derivatives, which are currently undergoing Phase I/II clinical trials 
(Basu & Ludlow, 2010). As we have seen, there are few published reports documenting the 
in situ regeneration of a solid organ in response to damage as a function of the implantation 
of a cell/biomaterial composite. The majority of published reports have focused on tissue 
engineering approaches towards solid organ regeneration using the peritoneal cavity or the 
subcutaneous space as a living bioreactor to facilitate the vascularization of the regenerating 
composite that is a prerequisite for organogenesis. However, it is our position that such a 
methodology may not be conducive to large scale clinical application, nor does it represent a 
commercially viable developmental strategy.  
In this regard, a comparison with organ regeneration platforms developed for application 
towards the regeneration of laminarly organized tubular organs may be helpful. The use of 
committed smooth muscle cells seeded onto a biodegradable scaffold of synthetic polymer 
such as PGA, PLGA or PCL provides an example of a commercially viable organ 
regeneration platform that has been successfully applied towards regeneration of bladder 
and bladder derivatives. The serial stacking and piling of polyester fleeces nucleated with 
renal primary cell populations (Roessger et al., 2009; Minuth et al., 2008) may represent a 
viable solid organ regeneration platform amenable to process development, large scale 
manufacture and industrial quality assurance regimens, provided the caveats discussed 
earlier are addressed. Similarly, serial stacking of tissue sheets engineered by monolayer 
formation over temperature responsive PIPAAm surfaces as has been demonstrated for liver 
and pancreas may be viable for commercial development beyond proof of concept.  
Regenerative platforms that focus on committed cell populations such as hepatocytes, 
pancreatic islet cells and cells derived from the stromal vascular fraction of adipose instead 
of stem and progenitor cells have the potential to substantially reduce cost of goods by 
avoiding technical challenges associated with the isolation and expansion of stem cell 
populations, maintenance and monitoring of stem cell potential, monitoring and 
characterization of directed differentiation protocols and the costs associated with 
recombinant cytokines required to drive directed differentiation. Furthermore, introduction 
of mesenchymal stem cells within the renal parenchyma of rat models of glomerulonephritis 
has resulted in abnormal differentiation towards glomerular adipocytes, raising the 
potential for additional regulatory headaches. It remains unclear how the potential for mis-
directed differentiation within the solid organ parenchyma may be definitively eliminated 
(Kunter et al., 2007).  
The observation that adipose derived stromal vascular fraction cells are capable of 
engraftment in vivo within liver and present acquisition of hepatic functionality raises the 
possibility that readily isolatable adipose cells implanted within the context of synthetic 
biomaterials or as serially stacked tissue sheets may be capable of stimulating the innate 
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regenerative potential latent within liver, and potentially, additional solid organs. To this 
end, it has been reported that conditioned media from MSC enhance the survival and 
functionality of pancreatic islet cells following transplantation in diabetic rats (Park et al., 
2010).  
There is no evidence to indicate that the stem cell potential of these cell types is directly 
connected to their secretomic profiles: it is likely that fibroblasts or smooth muscle cells 
derived from these “MSC”-like populations may function just as effectively for paracrine 
signaling during the regenerative process. Such a combination of readily isolatable, 
committed cell types complexed with a biomaterial that may be reliably manufactured, has 
defined physical and chemical properties, and is already acceptable to FDA and other 
regulatory agencies for implantation within the human body would represent the ideal 
platform technology for the commercially viable regeneration of solid organs.  
To summarize, factors impacting successful commercialization of solid organ regenerative 
technologies include: 
 Identification of a synthetic scaffold structure that is broadly relevant to solid organ 
parenchyma, regardless of organ type. 
 Committed cell types that may be capable of triggering organ regeneration within the 
context of an implanted scaffold.  
 Alternatively, common approaches for the isolation of organ specific cell populations 
capable of mediating regeneration within the context of an implanted scaffold. For 
example, cell populations may be isolated from multiple solid organs by density 
centrifugation under standard conditions prior to scaffold seeding. 
 Standardized methodologies for combining organ derived or organ independent cell 
populations with biosynthetic scaffolds to create implantable composites, for example, 
stacking or piling of cell sheets. 
 A focus on methodologies that avoid prolonged maturation periods within bioreactors, 
but rely instead on triggering the body’s innate regenerative potential to stimulate neo-
organogenesis. 
 Identification of common mechanisms of action being leveraged across multiple organ 
types through common regeneration platforms. 
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1. Introduction 
The end goal of most efforts in tissue engineering is the production of an artificial tissue or 
organ that is as similar as possible to the corresponding natural structure. So far, most 
approaches to this have involved combining cells with artificially-sculpted, spun or printed 
scaffolds. The approach works well for anatomically-simple, matrix-rich structures such as 
connective tissue, both in culture and in vivo. The visually-striking example of an 
engineered ‘human ear’ on the back of a mouse (Cao et al., 1997) brought much public 
attention to the idea. Scaffold-based tissue engineering has since found valuable clinical use 
in the production of new cartilage (Andereya et al., 2006), ligaments (Vunjak-Novakovic et 
al., 2004), vessels (Lovett et al., 2010), bladder wall (Atala, 2011) and nipple (Cao et al., 1998).  
Some of the most significant clinical requirements for effective tissue engineering concern 
not matrix-rich, simple tissues such as connective tissue, but very intricately-arranged 
complex organs that consist of many cell types, precisely located and in intimate contact 
with one another. Outstanding amongst these, in terms of clinical urgency, is the kidney, a 
fragile organ that regenerates itself very poorly, and which is damaged irreversibly by a 
large range of toxins, including some medicines. The demand for transplantable kidneys far 
exceeds their supply: in the UK alone, there are about 6,500 people on the waiting list, many 
leading fairly miserable lives in which they spend many hours per week hooked up to a 
dialysis machine.  
Being able to engineer organs such as kidney and pancreas promises a very positive impact on 
the lives of many patients, particularly if the engineering could be done from the patient’s own 
stem cells. There are, though, significant problems in extending scaffold-based techniques to 
organs such as these. The kidney, for example, consists of at least sixty-four distinct cell types 
(Little et al., 2007) and these are arranged not haphazardly but in very precise order along 
intricately folded and branched tubules, vessels and stroma (Fig 1). Even if a scaffold could be 
laid down by some highly-developed three-dimensional printing process to pattern accurately 
the basement membranes of each of a hundred thousand nephrons, ten thousand collecting 
ducts and a corresponding number of vessels, it is difficult to see how cells would enter each 
tube in the appropriate order to populate each segment with the correct type of cell. Kidneys 
do not normally develop by cells moving into a pre-made scaffold, so there is no reason to 
suppose that their cells would have evolved the ability to do this even if a scaffold could be 
provided for them. In normal life, there may be some limited movement of cells along tubules 
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as they are replenished from stem cell populations (Lindgren et al., 2011)  but here the 
movement is from a stem cell niche part way along each nephron (at the ‘neck’ of the 
Bowman’s capsule), not from the open end of the ureter, artery and vein, which could be the 























Fig. 1. The basic anatomy of the kidney (in this case mouse: human kidneys have multiple 
segments). The figure on the left shows the gross anatomy of the organ, while the detail 
shows one of the c. 2,000 nephrons of the organ (100,000 – 1,000,000 in human). Many of the 
tissue types present in the nephron include several different types of cells, for example the 
glomerulus contains at least five, and in each case these cell types are organized precisely. 
It may turn out to be possible, one day, to print the cells and the matrix together at the 
required resolution to put everything in the correct location at the time of manufacture. 
There are formidable technical challenges to this endeavour, however, and it is sensible to 
explore alternatives.  
The approach that is most radically different to developing ever more intricate 3-D micro-
fabrication techniques is to minimize the requirement for engineering by making maximal 
use of cells’ inherent abilities to organize themselves. The underlying idea is to work, as far 
as possible, with the flow of normal development; to engineer a system to turn a simple 
suspension of cells, such would be produced by stem cell culture, into a properly-arranged 
early foetal form of the organ in question, and then to engineer an environment that lets that 
“foetal organ” grow and mature in the usual manner. There are three main challenges in 
this; (a) production of the correct type of committed stem cells in the first place, (b) self-
organization of a suspension of these cells into a “foetal organ” and (c) transplant of that 
into a recipient in a way that allows it to grow and mature. Most of this chapter will 
concentrate on step (b), engineering by self-organization, but steps (a) and (c) will be 
discussed briefly towards the end. 
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2. The self-organizing abilities of cells 
The self-organizing abilities of cells arise from two broad classes of mechanism; biophysical 
and developmental (Davies, 2005). Self-organization through simple biophysics makes no 
demands on there being a ‘developmental programme’ or on cells responding to each 
other’s signals; instead it works purely on the current properties of the cells. Different cell 
types bear different types and quantities of molecules that mediate adhesion between cells  
or that mediate adhesion between cells and matrix. As always, if the components of a 
system (cells, in this case) are free to change their relationships, they will tend towards an 
arrangement that minimizes free energy. By definition, unbound adhesion molecules are in 
a state of higher free energy than bound ones (if this were not true, they would not promote 
adhesion because they would not naturally bind), and the difference in free energy is greater 
for higher affinity interactions. Free energy is therefore minimized by a state in which the 
maximum high-affinity binding is able to take place.  
When only one cell type is present, free energy is minimized either by cells sticking together 
as much as possible in an aggregate, as happens when cell-cell affinity is greater than cell-
matrix affinity (Fig 2a), or by cells dispersing themselves so that they are completely 
surrounded by matrix, as happens when cell-matrix affinity is higher (the two-dimensional 
equivalent of this is the spreading of cells on a culture dish to which they are highly 
adhesive). Where cell-cell affinity is higher than cell-matrix affinity, and where two cell 
types are present, differences in the affinity of cells for their own kind and for the other kind 
can drive cell sorting (Steinberg, 1962b). Where each cell type has a higher affinity for its 
own kind than for another, mixtures of cells will spontaneously separate, the cell type with 
the highest mutual affinity being surrounded by their less adhesive neighbours (Fig 2b) 
(Steinberg, 1962a; Foty & Steinberg, 2005). Where each type of cell sticks better to the other 
type and one type is much less common than the other, the resulting arrangement will be a 
‘salt-and-pepper’ mixture in which the less common type is surrounded by the more 
common. Where the numbers are equal, stripes would be predicted to result. 
The situation becomes more complicated still where cells are polarized, as simple epithelia 
are, so that their apical surfaces are barely adhesive, their lateral surfaces are strongly 
adhesive to similar cells and their basal surfaces are most adhesive to matrix. Here, 
epithelial cells tend to produce cysts or tubes in which lateral cell-cell contacts are 
maximized, as are basal cell-matrix interactions. The direction of the apico-basal polarity of 
cells in the walls of these cysts depends on the availability of suitable matrix: if an adhesive 
matrix is available, they will polarize basal side outwards; if it is not, they will polarize basal 
side inwards (Wang et al., 1990). Any mesenchymal cells present will be located on the 
outside of the cysts (Fig 2c). 
It cannot be over-emphasized that the arrangements described above arise from simply 
biophysics and have nothing to do with any ‘developmental programmes’. To emphasize 
this point, it is worth noting that the arrangements emerge in computer simulations that 
model the current state of the cells but include no information whatever about any changes 
in gene expression (Takano et al., 2003; Krupinski et al., 2011; Agarwal, 1995). Of course, a 
‘developmental programme’ may underlie the reason that different cells express different 
adhesion molecules in the first place, but that is as far as it goes: once established, those 
differences are enough to drive cells into specific, predictable arrangements (as long as they 
are free to move). 
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LL>LM                                        DD>LL>DL>(DM,LM)   DD>DL & D is epithelial
a.                                      b.               c.
 
Fig. 2. Adhesion-mediated cell sorting. (a) depicts a group of identical cells, drawn in a light 
colour and called ‘L’ for this reason,  whose mutual adhesion (LL) is greater then their 
adhesion to the matrix (LM): these cells aggregate together to maximize their areas of 
contact and minimize unbound adhesion molecules. (b) depicts a mixture of cells, dark (D) 
and light (L). In this case, the mutual adhesion of dark cells (DD) is stronger than the mutual 
adhesion of light cells (LL), but any cell-cell interactions are stronger than cell-matrix ones. 
Under these circumstances, the cells aggregate, but with the dark cells in the middle. (c) 
Where the dark cells are epithelial, and primed to achieve apico-basal polarization when in 
contact with one another, the result is an epithelial cyst surrounded by mesenchyme. 
References for these effects are given in the main text. 
The second class of self-organizing mechanism is more classically developmental and 
involves cells changing their states over time. In vertebrates, at least, rather little 
developmental change is cell-autonomous. Rather, most is controlled by signals received 
from the environment, which is dominated by the secretions of other cells. The cells of a 
developing organ multiply, die, move and differentiate in response to the signals of other 
cells around them. The behaviours available to a cell are set by its current internal state (eg 
gene expression), but which of these potential behaviours are triggered, how much and 
when, are determined by neighbours. In the kidney, for example, the branching epithelium 
that will become the urine collecting duct system grows only when it receives signals, such 
as glial cell-derived neurotrophic factor (GDNF) (Sainio et al., 1997), from the cap of 
mesenchymal cells that covers each branch tip. The cells of that mesenchymal cap proliferate 
in response to signals, such as Wingless homologue 9b (Wnt9b) (Karner et al., 2011) 
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produced by the developing collecting duct system. At first sight, this mutual 
encouragement has the look of a positive feedback system, and so it is when everything is in 
balance. If the sizes of the tissues happen to be out of balance, however, it can work as 
negative feedback that steers the system back where it should be. If a collecting duct tip has 
branched too early, for example, and there is not enough cap mesenchyme to properly 
service two new branches, there will not be enough of a signal from it to maintain 
proliferation in the new collecting duct tips, and they will therefore be forced to wait until 
proliferation of the cap mesenchyme has caught up. Similarly, if the cap mesenchyme has 
become too large, its further proliferation will have to wait until the branches have caught 
up again.  
Negative feedback processes such as the one outlined above are very common in organ 
development: in the kidney alone, there are similar processes to balance production of 
excretory nephrons and stroma and to balance production of vessels and glomeruli (Davies 
& Fisher, 2002). The self-correcting nature of these systems is an important element of 
natural self-organization of tissues in foetal life, reducing the need for unrealistic accuracy 
and making the growth of very large animals, such as us, possible. Importantly for the 
context of this chapter, they mean that a tissue engineer may not have to produce an 
engineered “foetal organ” that is exactly, 100% identical to what would exist in a real foetus. 
Rather, there is reason to hope that even a rough approximation to an early foetal organ will 
be enough to kick-start the cells’ own abilities to correct errors and converge automatically 
on the normal anatomy.  
This, then, is the theoretical background to a method of tissue engineering that aims to allow 
cells to do almost everything for themselves, with the minimum of human intervention. The 
rest of this chapter will describe the progress we have made in applying these principles to 
the problem of engineering “foetal kidneys”. Given that the approach will work with the 
normal processes of development, it is necessary describe briefly how kidneys normally 
develop in an embryo before considering using this information for engineering purposes. 
3. Normal kidney development 
In its earliest stages, the anatomy of a normal foetal kidney rudiment is very simple: it consists 
of an unbranched epithelial tube, the ureteric bud (itself a side-branch from the Wolffian duct, 
outside the kidney), surrounded by mesenchyme. Over the next few days of normal 
development, the ureteric bud will undergo rounds of branching and growth to produce a 
tree-like collecting duct system. The mesenchyme close to the bud tip will condense to form a 
‘cap’ over the tip. As the tips divide, the cap will tear in two, so that each new tip carries away 
a small cap of its own. Some of the signals that ensure these two components keep pace with 
each other and maintain co-location have been described in the section 2 of this chapter. As 
well as maintaining itself, the cap also sheds groups of cells that will undergo a mesenchyme-
to-epithelial transition: these will become excretory nephrons (Fig 3).  
For much of renal development, roughly two nephrons form for each collecting duct 
branching event, although the first-formed nephrons later disappear. The nephrons form 
first as small cysts, and these then undergo a stereotyped series of morphogenetic events, 
progressing through the so-called ‘comma-shaped’ and ‘S-shaped’ stages. As they do, they 
become segmented into Bowman’s capsule, proximal tubule, Loop of Henle and distal 
tubule. The distal tubule connects to the nearby collecting duct, and the Loop of Henle 
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extends towards the inside, or medulla, of the organ. Within the Bowman’s capsule, cells 
become specialized for urine filtration. As they do so, they secrete vascular endothelial 
growth factor (VEGF), which acts as a chemo-attractant for endothelial cells, bringing 
capillaries to what will become the glomerulus of each nephron (Tufro, 2000). Similar 
chemo-attraction, based on angiopoietin, is thought to attract blood vessels to the Loops of 
Henle (Kolatsi-Joannou et al., 2001).  
 
Cap mesenchyme-
derived signals for 
bud growth 
Bud-derived signals for cap 
mesenchyme proliferation
Bud (stalk)-derived signals 
for nephron differentiation
Cells 'left behind' by 
the cap 
mesenchyme can 
be induced to be 
nephrons




Fig. 3. A very simplified diagram of kidney development, showing how nephrons derive 
from cap mesenchyme, and showing how signalling between the branching ureteric bud/ 
collecting duct tree and the mesenchyme patterns the organ and ensure that the 
compartments proliferate in pace with each other 
If a kidney rudiment is removed from a mouse and maintained in simple organ culture 
conditions, almost all of the above events happen normally, if a little slowly. The exception is 
the formation of a system of blood vessels, probably because they normally enter the kidney as 
a branch from the aorta (as the future renal artery) and from the vena cava (as the future renal 
vein): there is some evidence for an endogenous source of endothelia too (Loughna et al., 1998). 
The fact that a kidney rudiment will mature basically normally in culture is very important to 
the topic of this chapter, because it implies that the few cell types involved ‘know’ everything 
they need to know, without any need for information to be provided by the rest of the embryo. 
All we may need to engineer is the very simple bud-and-mesenchyme combinations from 
which the kidney develops, and then let nature take it course. 
4. Engineering a kidney from a suspension of renogenic cells 
The ultimate goal of this work is the production of clinically-useful kidneys from 
appropriately committed stem cells. In this context, ‘appropriately committed’ means one 
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population identical to the stem cells that maintain the mesenchyme (some of whose 
daughters give rise to nephrons etc) and another population identical to the stem cells in the 
ureteric bud (that give rise to new bud tips and the stalks they lay down behind them). 
There have been some encouraging developments towards directing mouse embryonic stem 
(ES) cells toward a renal fate (Kim & Dressler, 2005), but there is not yet a reliable method 
for producing the required cell states at high efficiency.  
To experiment with ways of engineering “foetal kidneys” from suspensions of stem cells, we 
therefore began not with ES cells, but with cells isolated directly from early foetal kidney 
rudiments, which are therefore known to be in exactly the required state. The stage chosen 
was E10.5-E11.5, when the ureteric bud and mesenchyme are present but no nephrons have 
yet begun to form. Depending on definitions, a kidney rudiment of this stage can be 
considered to consist of either two cell types (metanephrogenic mesenchyme and ureteric 
bud), or of three (metanephrogenic mesenchyme, ureteric bud tip and ureteric bud stalk). 
Given that we have shown ureteric bud tip and stalk cells to be inter-convertible in both 
directions (Sweeney et al., 2008), this chapter will consider there to be just two cell types. We 
begin by using enzymes to disperse cells of kidney rudiments into a simple suspension of 
isolated cells, to simulate a harvest from a culture dish or FACS machine that would be the 
output of a reliable method for programming stem cells to become renogenic, when such a 
method is finally developed.  
The immediate goal is therefore to allow these cells to come together to re-create something 
sufficiently like a real kidney rudiment that it can go on and develop as if it really were one. 
The mesenchymal and epithelial cells are known to express very different sets of adhesion 
molecules (see www.gudmap.org). It is therefore a reasonable assumption that if they are 
simply brought together into a random lump, then biophysical mechanisms might lead to their 
sorting out into epithelial cysts and surrounding mesenchyme. This turns out to be true: if the 
suspension of cells is re-aggregated by simple centrifugation and then cultured on a 
polycarbonate filter (which is not adhesive enough for cells to spread out on it, so they remain 
as a lump), epithelial cells find one another and form one or more cysts, surrounded by 
mesenchyme (Unbekandt & Davies, 2009). There is, though, a very great loss of cells in this 
process, probably because cells separated form their normal cell-cell and cell-matrix contacts 
tend to undergo elective cell death in a process called anoikis (Frisch & Screaton, 2001). 
Inhibition of the Rho-dependent kinase, ROCK, is known to protect some cell types from 
elective cell death (Watanabe et al., 2007). In particular, ROCK inhibitors used to study the 
effect of the Rho-ROCK-myosin pathways on renal tubule morphogenesis also result in 
reduced apoptosis (Meyer et al., 2006). Together, these observations suggest that 
pharmacological inhibitors of ROCK might be effective in preventing the massive death in 
kidney rudiment cell dispersal and re-aggregation experiments. So it proved: inhibition of 
ROCK using the drugs H1152 or Y27632 resulted in very much improved survival, resulting 
in re-aggregates with many epithelial cysts expressing ureteric bud markers, surrounded by 
mesenchyme (Unbekandt & Davies, 2009). This proved beyond reasonable doubt that the 
mixed cells from kidney rudiments are able to organize themselves back into their basic 
tissue types. Unfortunately, the system as described so far has two major defects from the 
point of view of making a more mature kidney: first, the mesenchyme cells fails to form 
nephrons and second, there are many ureteric ‘cysts’ rather than one branched ureteric bud. 
Our studies on the effect of ROCK inhibition on the morphogenesis of renal epithelia had 
already suggested that nephron formation requires normal ROCK function at various 
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critical stages, including the very earliest (Lindstrom and Davies, unpublished). Nephron 
formation does not begin in a normal foetal kidney until about one day later than the stages 
at which kidneys were harvested for the dispersal and reaggregation experiments described 
in the paragraph above. The danger of anoikis would be expected to be highest when cells 
are dispersed, before they have come together again to find suitable neighbours, while the 
danger to nephron formation would be relevant only after cells have found each other well 
enough for the signalling loops that induce nephron formation to be up and running. This 
reasoning suggested that it might be possible to use ROCK inhibition for temporary ‘life 
support’ during the first 24h of the reaggregation experiment, and then to remove it and rely 
on cells’ new contacts to keep them alive and healthy. When this is done, the result is good 
survival and good formation of nephrons. The nephrons go through all of the normal 
morphological stages of development, such as the comma and S-shaped stages, and they 
connect to nearby ureteric bud/ collecting duct ‘cysts’. Furthermore, they express markers 
for Bowman’s capsule, proximal tubule, distal tubule etc at the expected times and in the 
























Fig. 4. The basic method of reconstructing renal tissue by re-aggregation of dispersed 
progenitor cells. The method illustrated here, based on Unbekandt and Davies 2010, has the 
disadvantage that multiple small ureteric bud ‘tree-lets’ are formed: an improved method is 
illustrated in Fig 6. 
Under the conditions just described, many of the small ureteric bud ‘cysts’ form extended 
tubules that branch, each becoming a ‘tree-let’. (Fig 4) This suggests that the basic cell biology 
of ureteric bud/collecting duct morphogenesis is running normally, but the presence of many 
‘tree-lets’ rather than one tree is abnormal and would be functionally useless for two reasons. 
The first is that, in a normal kidney, nephrons drain their urine to the branches of a single 
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collecting duct tree and these branches drain in turn to the original ‘trunk’ of the tree, the 
ureter. Having nephrons connecting to lots of small, isolated ‘tree-lets’ would provide no 
means of egress for urine. The second reason is more subtle, but still critical. The architecture 
of the growing collecting duct tree imposes a large-scale order on the kidney, in particular a 
cortex in which blood-filtering glomeruli are located and a medulla into which the Loops of 
Henle dip, and through which the collecting ducts pass down from the cortex toward the 
ureter. When the kidney is working, the cortical interstitium is of normal salinity but the 
medulla is very salty, and this saltiness is critical to the kidney’s ability to recover water and to 
concentrate urine. If a kidney had its nephrons scattered everywhere, without the clear cortico-
medullary distinction imposed by arrangement around a single collecting duct tree, 
concentration of urine could not take place. 
The fundamental problem with the simple reaggregation system is that small epithelial cysts 
are stable. Once enough epithelial cells have come together to form a small cyst, there is no 
reason for them to leave in favour of moving again to find a larger mass (indeed, the 
biophysics of the situation would prevent them from leaving, which would entail breaking 
energetically-favourable mutual adhesions). This is an example of the well-known physical 
phenomenon of a local minimum: a system that has reached a moderately energetically-
desirable state but cannot reach an even more desirable state, because all possible routes 
between these two states would involve being in a temporarily less desirable one (Fig 5). 
Multiple small aggregates therefore form, and the system is stuck in this state.  
 
 
Fig. 5. The problem of the system being trapped in a local minimum. In re-organizing 
themselves from a random mix into one in which epithelial cells adhere to one another in 
separate small cysts surrounded by mesenchyme, the system succeeds in lowering its free 
energy.  In order to reach the most favourable possible state (lowest on the diagram), 
though, the cells of the cysts would have to let go of one another and travel to join in with 
another cyst. This would mean a temporary move to a less favourable state than they 
initially found. The system therefore becomes trapped into a state that is moderately 
favourable, but not the best possible. 
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The idea of solving this problem by placing only a very few epithelial cells in the culture to 
begin with, although theoretically-possible, is unlikely to be useful because the total volume 
of the culture would have to be very small to allow the epithelial cells to find one another at 
all by random wandering (there is no evidence for long range chemotactic attraction 
between these cells, and no reason to suppose from normal development that such 
attraction should exist). Also, making an extremely small rudiment is not likely to be 
maximally useful from the point of tissue engineering. We have therefore devised a system 
of serial culture, in which multiple cysts are allowed to form in the first culture, and one of 
these is then combined with a fresh suspension of mesenchyme cells for a second culture 
(Ganeva et al., 2011). When this is done, the cyst develops into a branching tubule. The 
overall result is an engineered “foetal kidney” that is arranged, as it should be, around a 
single branched ureteric bud/ collecting duct system (Fig 6) (Ganeva et al., 2011). 
 
Organotypic 'foetal kidney' rudiment












Suspension of fresh 
mesenchyme
 
Fig. 6. An improved method for reconstructing kidney rudiments by re-aggregation from 
progenitors (Ganeva et al. 2011). A conventional re-aggregation is first performed, as in Fig 
4, and then just one ureteric bud cyst is isolated from it and combined with a suspension of 
fresh renal mesenchyme cells free of ureteric bud. Under these circumstances, the result is a 
kidney organized normally around a single ureteric bud/ collecting duct tree. 
5. Connecting to a blood supply 
Like intact foetal kidney rudiments grown in organ culture, the engineered “foetal kidneys” 
produced by the method describe above lack a vascular system. This is a major omission for 
an organ, the main purpose of which is to filter blood and which receives about a fifth of the 
cardiac output. Normal developing kidneys attract endothelial ingrowth by secreting 
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molecules such as VEGF, particularly from specialized cells that will go on to form the 
filtration barrier in the glomeruli (Tufro, 2000). If a mouse kidney rudiment is cultured on 
the chorioallantoic membrane of a bird’s egg, this chemoattraction is sufficiently strong to 
induce ingrowth of blood vessels from this membrane: indeed, the ease with which quail 
cells can be distinguished from those of mouse allowed this system to be used to 
demonstrate that glomerular endothelia arise from ingrowing vessels rather than from the 
nephron itself (Sariola et al., 1983).  
Our preliminary data suggests that self-organized “kidney rudiments” produced by the re-
aggregation method described here can attract blood vessels in a similar way. When they 
are cultured on a chick egg chorioallantoic membrane, the rudiments attract ingrowth of 
vessels that is clearly visible at a gross level and sections of the resulting hybrid tissue show 
the formation of what appear to be glomeruli. 
6. Self-organized organ rudiments in a clinical context 
The production of a tiny analogue of a normal foetal kidney is clearly a long way from the 
functional, adult organ that is actually required. Is effort in this direction therefore a waste 
of time compared with efforts to build an adult organ directly? 
I would argue that it is anything but a waste of time, for several reasons. The first is that we 
know that it is possible for a kidney to build itself from its foetal form, at least in a foetal 
environment, because that is what happens in normal life: enthusiasts for direct engineering 
can only hope that their aim is possible in any environment at all. The second is that we 
already know that it is possible to transplant normal foetal kidney rudiments into an 
immature or adult recipient and have those rudiments grow and become functional. So far, 
function is partial and not enough to sustain life for a long period (Rogers & Hammerman, 
2004; Rogers et al., 1998) , but these are early days and the technique continues to improve. 
Given how well kidneys grow in culture, in isolation from the foetal environment, the 
problems are probably not those of missing signals from the rest of a foetal body. It is more 
probable that they are to do with what is a very immature organ having to stand blood 
pressures and levels of blood oxygenation far in excess of the foetal situation while it is 
growing, and then having too poor a blood supply to function in its ectopic location. These 
problems may be soluble by surgery, possibly moving the graft from place to place as it 
grows, so that it begins its life in a protected site with low blood flow and pressure but ends 
up grafted to the renal artery.  
The third reason is that the time-course of many renal diseases is very slow; in these 
conditions, a child is typically diagnosed before the age of four with a condition that will 
require transplantation only in their teens or twenties. There is therefore plenty of time for a 
transplanted ‘foetal’ kidney to grow to mature function before the host kidney completely 
collapses. Indeed, with even partial function being shared, the host kidney may last a great 
deal longer. 
Formidable challenges certainly remain. There is a pressing need to improve the functional 
maturation of transplanted foetal kidneys, and to test the self-organized rudiments the same 
way. There is also, of course, the need for a method for production of renogenic stem cells 
but even this is probably easier than finding methods for the production of the many 
different cell types that would be needed for direct engineering of an adult organ.  
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7. Potential for application to other organs 
There is every reason to suppose that the techniques that we have applied to the kidney can 
be applied equally well to other visceral organs of the basically glandular type – that is, 
organs that consist of many repetitions of fine-grained anatomy. Lung, pancreas, prostate, 
mammary gland and salivary gland all develop in a very similar way and are organized 
around a branching epithelial tree, while liver and testis development are not wholly 
dissimilar although their tubes form by a hollowing-out process rather than invasive 
branching.  In each case, the organ begins to develop from two cell types, epithelium and 
mesenchyme, that have self-renewing stem cell properties and that differ markedly in their 
expression of adhesion molecules. A suspension of such cells would be expected to sort into 
epithelial ducts surrounded by mesenchyme, and the signal exchange between such tissues 
would be expected to mimic that found in normal development and therefore to organize 
the growth of an engineered ‘foetal organ’. We have indeed shown this to be the case with 
lung (Unbekandt and Davies, 2010). 
Whether the engineering of other ‘foetal organs’, followed by their transplantation to mature 
in situ, is likely to be clinically useful is governed mainly by the likelihood of their being 
able to mature. Kidneys are unusual, in that many renal diseases progress slowly and a 
patient with very weak renal function can be kept alive for very long periods by dialysis, 
allowing time for a transplanted rudiment to mature before any demands are made of it. 
The same may be true of pancreas in the context of diabetes, where the patient’s existing 
pancreas maintains exocrine function and injected insulin substitutes for endocrine function 
until the transplanted rudiment is ready to take over. Similarly, mammary gland function is 
obviously dispensible (being absent in the male half of the population anyway). It is, on the 
other hand, harder to see how the scheme would work for lungs, for which there is no 
adequate long-term substitute. 
Engineering gonads by re-aggregation of dispersed cells offers intriguing possibilities in 
fields other than medicine. At the cell suspension stage it is possible to mix cells from 
different sources: the result is a fine-grained chimaeric organ (Unbekandt and Davies, 2010). 
It is also, in principle, possible to subtract cells from the suspension stage by FACS or 
magnetic sorting. Putting these ideas together, it might be possible to disaggregate the cells 
of an early gonad rudiment from the foetus of a common (domestic) animal, sort away the 
germ cells, replace them with germ cells from a rare, endangered species that does not breed 
well in captivity, and transplant the resulted engineered gonad rudiments back in to a 
domestic host. In this way, the rare genome of a highly-endangered species might be 
propagated in domestic animals which are happy to mate in captive conditions, to produce 
offspring of the endangered species. Placental immunology and other physiological 
considerations will almost certainly impose limits on how different the species involved 
might be before an embryo cannot be carried, but the approach may work between related 
species if there is nothing else to be done. Obviously, conservation of species by protection 
of habitat is a much better course of action, but realistically many habitats are being lost and 
will take a long time to be regenerated even if there is the will. In this interval, a ‘Noah’s 
Ark’ based on propagation of genomes in surrogate domestic animals might provide an 
emergency stop-gap solution.  
8. Conclusion 
In summary, data obtained so far suggests that the idea of using cells’ own abilities for self-
organization to produce an immature organ progenitor, with a view to placing this in a host 
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to mature, is a viable avenue of research. This is especially true for organs whose failure is 
slow enough to allow time for transplanted organs to grow. In making maximal use of cells’ 
own abilities and in deliberately minimizing the requirement for detailed engineering, the 
approach contrasts with many others in this book. Which will win out in the end, or 
whether the techniques will co-exist for different problems, remains to be seen. 
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1. Introduction 
Tissue engineering is a multidisciplinary field that uses engineering materials called 
scaffolds to support cell seeding and biochemical factors with the aim to regenerate 
biological function of a tissue or organ, in this process typically there are involve three main 
components. Biochemical Factors, such as growth factors, proteins that stimulate 
proliferation and differentiation cell. Cells which can perform the appropriate tissue 
functions regenerating the lost or damage tissue, and scaffolds that will act as artificial 
extracellular matrix that provides mechanical support to cells.  
 
 
Fig. 1. Schematic representation of a scaffold loaded with cell, growth factor and other 
molecules for tissue regeneration. 
Tissue engineering scaffolds are traditionally compose of porous polymer materials the 
sustained three-dimensional (3D) growth of cells that is of particular interest in tissue 
engineering because they can be potentially tailored to mimic the natural extracellular 
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matrix (ECM) in terms of the structure, chemical composition, and mechanical properties. 
The scaffolds that play a key role in tissue engineering require certain characteristics as high 
interconnected porosity in order to allow the vascularization process, appropriate 
distribution and pore size according to the tissue to be regenerated, sufficient initial 
mechanical strength, biodegradability and biocompatibility. These materials have to provide 
a suitable environment for the adherence, proliferation and cell differentiation and guide 
tissue development. Although, there are many approaches to obtain scaffolds to fulfill all 
requirements, it still represents a big challenge, because it is not clear what defines an ideal 
scaffold/cell construct, even for a specific tissue type due to its the complexity that include 
material composition, porous architecture like type, size and interconnection of the pores, 
structural mechanics, surface properties, degradation properties, products of degradation,  
biocomopatibility, kinetic of scaffold degradation, etc. This complexity can be appreciated 
schematically in figure 2 (Hutmacher et al., 2008).   
 
 
Fig. 2. Illustration of the complex interdependence of molecular weight loss and mass loss of 
3D scaffold matrix plotted against time frame for tissue engineering transplant.  
Thermally induced phase separation (TIPS) has been explored in order to produce a well 
interconnected porous structure as tissue engineering scaffold (Olivas et al., 2010; Martel et 
al., 2010; Ma P. 2008; Patist et al. 2004; Ahmad et al., 2010). This technique is based on 
changes in thermal energy to induce the de-mixing of a homogeneous polymer solution into 
a multi-phase system domain by a quench route. When the phase separation occurs, the 
homogenous solution separates in a polymer-rich phase and solvent-rich phase either by 
solid–liquid de-mixing or liquid–liquid phase separation mechanism.  After the solvent is 
extracted and depending upon the system and phase separation conditions, different 
morphologies and characteristics of the materials can be obtained: closed or open-pore 
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material, spheres, powders, bead-like morphology, etc. Most of the works for tissue 
engineering seek scaffolds with open pore and well interconnected morphology. 
One of the most attractive characteristics of TIPS over other techniques is the formation of 
not only an intrinsically interconnected polymer network, but also an interconnected porous 
space in one simple process that is scalable, fast and controllable. TIPS is thus a very 
convenient methodology for fabricating porous materials as scaffold architectures that can 
be obtained by means of the manipulation of processing parameters and system properties. 
A variety of polymers scaffolds as Polylactic Acid (Chen J et al., 2010; He L et al., 2009); 
Polyurethane (Guan J et al.,2005; Martinez et al., 2006; Fromstein et al. 2002), 
Polycaprolactone[15] and others have been prepared by TIPS technique, also blends of 
polymers[Martel et al., 2010; Maquet et al., 2001), and composite of polymers with 
nanohydroxyapatite (Liu et al 2009),  Carbon nanotubes (Olivas et al., 2010; Jell et al., 2008) 
and other have been successfully fabricated.  
 
 
     a)                                       b)               c) 
Fig. 3. Pictures of scaffolds prepared via thermally induced phase separation a) Chitosan, b) 
and c) Chitosan-Ag nanoparticles. 
2. Scaffold fabrication 
There are many methods to prepare porous scaffolds, such as electrospinning (Demir M et. 
al., 2002; Lee K et. al. 2003), porogen leaching (Fujimoto K et. al.,1993; Fromstein et. al., 
2002;), phase inversion(Kowligi R et. al., 1998), laser excimer (Doy K et. al. 1996) and 
thermally induced phase separation (TIPS) to mention a few. Each processing technology 
has its advantages and disadvantages, for example electrospinning is a relatively 
inexpensive technique to produce fibers with diameters size of nanometer to few microns 
with enhanced mechanical properties, and also the high aspect ratio would improve the cell 
proliferation. However, it is difficult to make a large volume scaffold. The porogen leaching 
method has the advantage of controlling pore sizes by manipulating the size of the salt 
particulate, also is a relatively inexpensive technique. However, scaffold fabricated by 
porogen leaching can have limited interconnectivity and residual salt, which would affect 
cell proliferation. Phase inversion method can result in low interconnectivity and difficulty 
in controlling the pore size (Kowligi R et. al., 1998). The laser excimer method can make 
scaffolds with well define pores with a size and shape very homogenous but achieving 
connectivity remains a challenge (Doy K et. al. 1996). Thermally induced phase separation 
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method offers the ability to control pore size by varying the preparation conditions and also 
provides means to control pore structure, additionally the scaffold can be molded into a 
range of shapes and sizes (Jianjun G et. al., 2005; Martinez Perez C et. al. 2006). It is beyond 
the scope of this chapter to cover all scaffold fabrication techniques available. Hence the aim 
of this chapter is to provide an overview of the TIPS technique which it has been employed 
to produce a range of scaffolds for tissue engineering. 
2.1 Thermally induced phase separation 
Thermally induced phase separation has gained significant attention from scientific and 
practical point of view that has led TIPS technique to be applied in the fabrication of 
microporous membranes or microcellular foams from medicine and the chemical industry, 
scaffolds for tissue engineering, and as a drug carrier for controlled release. Microporous 
membranes are used in a very wide range of applications. Examples include the use in 
hemodialysis process, kidney artificial (Ulbrich, 2006), the removal of bacteria and viruses 
(Qui & Matsuyama, 2010), the treatment of waste water (Yave et al., 2005), oil-water 
separation (Funk et al, 2008), the use in batteries (Vanegas et al. 2009; Cui et al, 2008), gas 
separation (Funk & Lloyd 2008), etc. Adjusting TIPS parameters, such as types of polymers, 
solvent or no solvent ratio, polymer concentration, thermal quenching could be obtained 
materials with distinctive morphologies according to their applications (Aristéia & 
Felisberti, 2009; Luo et al.,2008). 
TIPS technique is based on changes in thermal energy to induce the de-mixing of a 
homogeneous polymer solution into a two or multi-phase system domain. When the phase 
separation occurs, the homogenous solution separates in a polymer-rich phase and polymer-
poor phase usually by either exposure of the solution to another immiscible solvent or 
cooling the solution below a binodal solubility curve where a liquid–liquid phase separation 
or solid–liquid de-mixing mechanism can be presented.  After that, the solvent is extracted 
by liofilization and depending upon the system and phase separation conditions, different 
morphologies and characteristics of the materials can be obtained. A typical temperature-
composition phase diagram for a binary polymer–solvent system with an upper critical 
solution temperature is presented in Figure 4. As can see there are two curves, the binodal 
that represents the thermodynamic equilibrium of liquid–liquid de-mixing and the spinodal 
curve. When the temperature of a solution is above the binodal curve, the polymer solution 
is homogeneous. A polymer-rich phase and a solvent-reach phase coexist in a solution in the 
L–L demixing region (Vandeweerdt and Berghmans, 1991; Williams and Moore, 1987). The 
maximum point, at which both the binodal and the spinodal curves merge, is the critical 
point of the system. The area under the spinodal curve is the unstable region, and the area 
located in the zone between the binodal and spinodal curves is the metastable region. L–L 
demixing in the metastable region displays a poor connected stringy or beady morphology 
consequence of a nucleation and growth mechanism for polymer concentration lower or 
higher than the critical point concentration, respectively (Matsuyama et al., 2000; Sperling, 
2003). On the other hand, if the system is quenched into the unstable region, the L-L phase 
separation takes place by a spinodal mechanism that results in a well-interconnected porous 
structure. In figure 5 a SEM picture of Polyurethane scaffold prepared in the different region 
of the phase diagram is shown where it can be appreciated the different types of 
morphologies than can be acquired.  
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Fig. 4. A schematic representation of a binary phase diagram of a polymer solution. 
 
 
     50 µm 
 
     200 µm 
 
            a)      b)             c) 
Fig. 5. SEM pictures of PU obtained a) at the metastable zone in the left side of the phase 
diagram, b) at the inestable zone, c) at the metastable zone in the right side of the phase 
diagram.  
The spinodal curve is the line at which the Gibbs free energy of mixing second derivative is 
equal to zero, and it divides the two-phase region into unstable and metastable zones. For 
scaffolds for tissue engineering that require an open and well interconnected porosity it is 
preferable to take the freezing under the spinodal curve where the distribution, shape and 
size pore, interconnectivity can be determined by a delicate balance of several parameters 
such as molecular weight of the polymers, concentration, quenching route, type of solvent 
and additives as nonsolvent composition. 
These parameters have a great influence at the early stage of the phase separation, but in the 
later stage, the coalescence of phase separated droplets continuously proceeds minimizing 
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the interfacial free energy associated with the interfacial area, which is called the coarsening 
process. This effect is induced by a differential interfacial tension exerted between the two 
phase separated domains. It was demonstrated that the coarsening process results in pore 
size enlargement primarily via Ostwald ripening, coalescense, or a hydrodynamic flow 
mechanism (Mooney et al., 1996; Lo et al., 1996). Thus, the coarsening process should be 
carefully considered as a kinetic parameter to control the size and shape of the pore. In order 
to obtain macroporous, it is desirable to work with the coarsening effect; it will induce the 
pore enlargement. The coarsening process, however, concomitantly tends to generate more 
closed pores; thus, it is important to optimize various TIPS parameters to achieve an 
interconnected and open macroporous open structure. Large pore size and well 
interconnected structure are critical parameters for cell seeding and neovascularization 
when implanted in vivo. 
Some researchers have taken advantage of the solid-liquid phase separation induced by the 
solidification of the solvent before the liquid-liquid separation can occur, they have 
prepared microtubular orientantion-structured scaffold like is shown in figure 6. By using 
this technique the orientation structure of the scaffold is guided by solvent crystallization 
under certain temperature gradient. The results of these studies showed that when the 
concentration of polymer solution increased the thickness of the wall of formed 
microtubules scaffold increased and the diameter of microtubules decreased ( see table 1), 
that the diameter of the microtubules scaffolds were reduced as the temperature gradient 
increased, and also the polymer type affect the morphology of the scaffold. It was 
considered that the dependence of the diameter of microtubules on temperature gradient is 
in agreement with the crystallization theory. By using a lower temperature-cooling agent, a 
higher temperature gradient would perform to lead formation of much more crystal nucleus 
with a higher crystallization speed. As result of this, a great number of smaller sized crystals 
had been produced. In Accordance with others studies (Cao Y et al., 2006; Maquet et al., 
2001; Guan et al., 2005) in which open porous and interconnected architecture was obtained, 
and, porosities of 80-96% and pore size of 14 to 250 µm that can be  vary  with the polymer 
concentration, quenching temperature and polymer type. Another study with a binary 
system used two different types of TIPS processes: uniform quench and non uniform 
quench in a model binary polymer solution (Lee et al., 2004). The results showed that the 
spatial concentration profiles and patterns confirm the formation of isotropic morphology  
 
 
Fig. 6. View of a microtubular orientation-structured scaffold. (Yang et al., 2006; Hu et al., 
2008). 
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from a uniform quench while anisotropic morphology forms from non-uniform quench 
and indicate the lower-temperature regions of the spatial temperature gradient containing 
higher droplet density, larger droplets size when the phase separation process was 
allowed to proceed for long period of time, and the morphological analysis of the shape 


















































































Table 1. Morphology of microtubules orientation-structured scaffolds on concentration 
polymer 
3. Polymer scaffolds prepared via TIPS 
As it was mention above that biodegradable polymers are suitable for scaffolds. Synthetic 
and natural biodegradable materials such as Poly (lactide) (PLA), Poly (L-lactic acid) (PLLA), 
Poly (D,L-lactic acid-co-glycolide acid) (PDLG), Poly (D,L-lactide) (PDLLA), Poly (lactide-
co-glycolide) (PLGA), Poly (lactide-co-caprolactone) (PLCL), Poly (ε-caprolactone) (PCL), 
Polyurethane (PU), Poly (ether ester urethane) (PEEUU), collagen, gelatin, and chitosan 
have been used in the fabrication of scaffolds. These have been designed in order to be 
applied in spinal cord regeneration (Maquet et al., 2001), bone and cartilage regeneration 
(Barroca, et al. 2010; Olivas et al., 2009), blood vessel (Hu et al., 2008), incontinence problems 
(Ahmadi et al., 2011), peripheral nerves (Aijun et al., 2005), and perennial fistula repair 
(Heshaw et al., 2010), among others. These had been performance with appropriate 
structural and functional properties, with the goal to mimic the extracellular matrix (ECM) 
of the tissue to be repair. The ECM is a natural scaffold for tissue and organ morphogenesis, 
maintenance, and reconstruction following injury and it is a vital, dynamic and 
indispensable component of all tissue and organs. Therefore, it is a challenge for tissue 
engineering, the construction of artificial structures that lead the constructive remodeling of 
injured or missing tissues or organs, since it regulate cell behavior, such as attachment, 
migration, proliferation, and differentiation. Even more, it must have a controlled 
degradation, interconnected porosity with high porosity, appropriate pore size, and 
mechanical properties the most closely to the tissue to be repaired. 
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Schugens (1996) prepared biodegradable scaffolds of Polylactic Acid (PLA) by the TIPS 
method using dioxane as solvent. Instead of the L-L demixing mechanism, a solid-liquid 
mechanism take place due to the solidification of solvent and it gave a highly anisotropic 
tubular morphology with a ladder-like microporous structure. A porous structure obtained 
in this manner is highly anisotropic with relatively small pores (Yang et al., 2006). Further 
studies have indicated that by introducing water as a non-solvent, L–L de-mixing can be 
realized in the polyester–dioxane–water ternary system, and that macroporous polyester 
scaffolds can be obtained. The morphology of the resulting scaffold is strongly dependent 
on the phase separation behavior of the ternary system.  
By increasing the polymer concentration except when there is no presence of non-solvente 
the temperature of the cloud point and the temperature where the L-L de-mixing take place 
increases considerably, also higher the non-solvent concentration, higher the L-L de-mixing 
temperature (Hua et al., 2002, 2003). The L–L demixing temperature of a crystalline PLLA 
ternary system is higher than that of amorphous PDLLA and PLGA ternary systems. 
However, the effect of the molecular weight of the polymer seems to be less prominent (Hua 
et al., 2003). The phase behavior of the system is also be affected by adding various 
compounds (Hua et al., 2001; Shin et al., 2005). It has been demonstrated that by adding a 
surface active material such as Pluronic F127, a tri-block polymeric surfactant, the interfacial 
energy between two phases can be reduced, effectively stabilizing the porous structure of 
the scaffolds (Nam & Park, 1999). The addition of NaCl can shift the binodal curve to a 
higher temperature and therefore create a larger operable domain for spinodal 
decomposition (Hua et al., 2001). 
Additionally, researchers have introduced non-solvent as water to induce a liquid-liquid 
phase separation having a polymer-solvent-water ternary system. A liquid-liquid phase 
separation occurs when the temperature of polymer solution is decreased and depended of 
the thermal driving force. The cloud-point temperature was highly dependent on water 
content, polymer concentration and the freezing point of the system was nearly independent 
of polymer concentration and water content (Barroca et al., 2010; Chen et al., 2010; Jun et al., 
2003). The cloud point temperature increases as the polymer concentration increases and 
when the molecular weight of the polymer increases because it reduces the polymer-solvent 
interaction.  When a polymer blend is prepared and its polymers have similar solubility 
parameters the phase separation of the polymers behaves similar as they behave by 
themselves. When a semi-crystalline polymer is part of the solution, the phase separation is 
more complicated because the polymer potentially crystallizes involving the gelation 
temperature as another important parameter in the morphology of the scaffolds because 
semicrystalline polymers, generally, form a gel as a result of liquid-liquid phase separation.  
The interlocking of small crystal agglomerates may play a key role for the formation of the 
gel when the solvent is removed a highly porous structured is obtained. The effects of the 
quench route on the phase in a study (PLLA-dioxane-water) by maintaining the demixing 
temperature in the unstable region for a period of time and then quenching to -196ºC, 
researchers have found that the gelation induced by liquid-liquid demixing is essential to 
maintain scaffolds with uniform interconnected macroporous. The porosities of the scaffolds 
decreased with increases of polymer concentration and this occur by the change of the phase 
separation mechanism and by the extent of the coarsening process involved. The effect of 
molecular weight and the aging time on the scaffold morphology is important because the 
morphology with the higher molecular weight polymer was consistently better organized. 
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The less uniform pore structure (lower molecular weight) was likely to be caused by 
coarsening of two separated phases since the viscosity effect is one of the factors responsible 
for a less organized pore structure. On the other hand, with short aging time, a large pore 
size due to the large thermodynamic driving forces obtained. The microporous scaffolds 
have a highly interconnected macroporous range from 20 to 300µm and exhibited isotropic 
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Table 2. Morphology of scaffolds, water content and polymer concentration.   
Collagen is the main component of the ECM in many tissues and the nanofibrous 
architecture of collagen is important for cell adhesion, proliferation and differentiation. . In 
order to obtain various structures of nanofibrous scaffolds  prepared via TIPS process (Fig. 
7), researches have made several modifications to the process and combined it with others 
process such as porogen leaching (Liu et al., 2009), inner layer (Aijun et al., 2005), and 
electrospinning (He et al., 2009). This process involved the dissolution of polymer in solvent, 
phase separation, and polymer gelation at low temperature. However, immunogenicity and 
pathogen transmission associated with collagen is a concern. Therefore, several works have 
been focused in the fabrication of collagen-like nanofibrous scaffolds. In recent work 
nanofibrous gelatin scaffolds were produced by combining the thermally induced phase 
separation and porogen leaching by Liu and collaborators (Liu et al., 2009) .  Gelatin is 
derived from collagen by acidic or basic hydrolysis and by its chemical composition is very 
similar to that of collagen. The gelation depends on the temperature, the solvent, and the 
polymer concentration in the solution. They obtained fiber diameter ranged from 50nm to 
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500nm, which is on the same scale as natural collagen fibers, the average fiber diameter did 
not change with different gelatin concentrations. The scaffolds  prepared with 7.5% (w/v) 
gelatin solution had a low density, 97.51% of porosity and well defined macropores with 
pore size of 250-420µm. During the process water and ethanol solvent mixtures were used to 
dissolve gelatin. The addition of ethanol was a critical step in creating the nanofibrous 
structure because when gelatin was dissolved in water alone, it could only form smooth 
surface structure after phase separation. The addition of certain amount of ethanol in gelatin 
solution resulted in the formation of gelatin structure after phase separation. Furthermore, 
when increased the amount of ethanol in the solvent mixture resulted in poor solubility of 
gelatin. For this reason, the ethanol/water ratio in gelatin solution was very important 
during the fabrication of nanofibrous. The in vitro analysis indicated the gelatin fibrous 
scaffolds enhanced cell adhesion and proliferation. In other study the researchers fabricated 
fiber porous and tubular chitosan scaffolds for guided peripheral nerves and blood vessel 
tissue regeneration by combining inner layer and TIPS. The scaffolds had a biphasic wall 
structure, with fibrous inner layer and semipermeable outer layer. The inner diameter was 
2.5 mm and outer diameter was 4.5mm. In vitro characterization shows that the scaffolds 
have a very good cytocompatibility. 
 
 
Fig. 7. SEM image of nanofibrous structure fabricated by TIPS (Beachley et al. 2010). 
He Liu et. al., prepared PLLA nanofibrous scaffolds with 3D macro and microporous 
structures by liquid-liquid phase separation from PLLA-dioxane-water system showing that 
aging in the gel status was essential for the formation of a nanofibrous network. The 
coalescence of the solvent rich drops also occurred when aging was performed in order to 
reduce the surface tension. This coarsening effect resulted in pore size enlargement. The 
extent of coarsening affected the size and morphologies of macro or micro pores in the 
scaffold. High quenching temperature favors the pore enlargement, due to the formation of 
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larger solvent rich droplets. High water content in the system increase the pore size but also 
can decrease the pore homogeneity. The gradual addition of water as non solvent increase 
the gelation point and generate macropores (up to 300 µm) and micropores with a high 
interconnection. The enlarged pore sizes with the increase of water content is likely due to 
the combined effects of weaker polymer diluents interaction, larger quenching depth, and 
lowered viscosity in the co-solvent system. The formation of nanofibrous structure was 
related to the liquid-liquid phase separation and the crystallization kinetics of polymer 
affected by the cooling rate. 
4. Particulate filled composite scaffolds 
Filled composite scaffolds produced by thermally induced phase separation are other 
alternative materials which exhibit pore anisotropy that it has shown to support migration, 
adhesion, spreading and viability of cells (Blaker et al., 2005; Barroca et. al. 2010;). 
Commonly, these scaffolds consist of biodegradable polymer with inorganic particles, such 
as bioactive glass and hydroxyapatite. The composite has the advantages of the two types of 
material and for example the bioactivity, control degradation kinetics and the mechanical 
properties can be improved. Two polymer-diluent zeolite was reported by Funk (Funk CV 
et. al., 2008) where they showed the that zeolite particle to have a significant effect on the 
droplet growth and final cell size of that microporous membrane which depend on the 
particle loading and processing condition. Nanohydroxyapatite-filled PLGA scaffolds were 
prepared by Huang and collaborators (Huang et al., 2008) by TIPS technique where the 
influence of Nanohydroxyapatite (NHA) content on the microstructure and properties of the 
composite was studied. It was found that the pore size of the PLGA/NHA scaffolds 
decreases with the increase of PLGA concentration and HA content. Also, the mechanical 
properties and water absorption ability of the composite scaffolds were considerably 
improved with the content of NHA. PLGA/NHA scaffolds exhibited significantly higher 
cell growth, alkaline phosphatase activity than PLGA scaffolds, having in their system the 
best results with 10 wt.% NHA. PLLA was prepared via TIPS with the incorporation of 
micro and nanohydroxyapatite, NAH had better results that of micrometric size and 
compare with PLLA scaffolds, NAH/PLLA scaffolds showed highest compressive strength 
(8.67 MPa) with 85.06% porosity which is comparable to the high end of compressive 
strength of cancellous bone (2–10 MPa) ( Nejati et al., 2008). Also it was found that the 
incorporation of NHA, the scaffolds have more regular microarchitecture due to its more 
interfacial area, surface reactivity and ultra-fine structure. This suggests that the developed 
nHAP/PLLA scaffold via TIPS fulfill most of the requirements as a suitable bone substitute 
for bone tissue engineering applications. 
Carbon Nanotubes (CNT) has also been incorporated in scaffolds for tissue engineering (Jell 
et al. 2008; Olivas et al. 2010). Jell and collaborators design a route via TIPS to manufacture 
three-dimensional, highly porous polyurethane containing CNT where the mechanical 
properties were improved significantly with the addition until 5% of CNT, also the 
composite scaffolds were not only found to be non-toxic but also induce phenotypic changes 
that may enhance wound healing and bone formation in vivo. Olivas and coworkers also 
found that the incorporation of small amount of MWCNT will significantly improve the 
mechanical properties of the scaffolds.  
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Fig. 8. Variation of the Young’s modulus of the Chitosan and Chitosan–MWCNT 
Composites. 
In Fig 9a-d shows FE–SEM pictures of Chitosan-MWCNT scaffolds prepared by TIPS 
containing 0, 0.5, 1 and 2 wt% of MWCNT, respectively; a highly porous morphology can 
be appreciated which reach until 92%; the pore size is between 100 and 300 μm. For 
scaffold utility, the pore size, porosity and interconnectivity become important 
parameters for analysis where macroporos between 50 and 300 μm are most useful for cell 
and tissue ingrowth, and smaller pores contribute to solute diffusion. Here, in accordance 
with Nejati (Nejati et al., 2008) where it was found that the incorporation of NHA 
improves the micro architecture of the scaffolds, as the MWCNT concentration is increase 
a better microarchitecture of the chitosan scaffolds can be appreciated. The pores have a 
better circle form than the scaffolds of pure Chitosan that present and more irregular 
morphology. 
The porosity and size pore of the CH–MWCNT composites are in the appropriate range 
for application in tissue engineering. In Fig. 9 FE-SEM pictures of the composites at higher 
magnification are presented. CNTs were embedded at the polymer matrix and appeared 
uniformly distributed throughout the scaffold. Some MWCNT emerge from the pore 
surface, forming a rough, hairy texture. The alignment of the CNTs to certain directions 
into the matrix and in the surface perpendicular to it could be attributed to the  
phase separation during the freeze-drying processes. Even when the CNTs are  
emerging from the surface, they are coated by Chitosan showing the compatibility 
between them. 
The Chitosan-MWCNT scaffolds were evaluated in vitro by seeding osteoblasts in its 
structure, also the composite scaffolds were it was found that these scaffolds promote 
osteoblasts cell proliferation and, also it was observed by SEM the formation of calcium 
phosphate crystals on the scaffolds surface after just a few days of culture. 
Biomineralization of the scaffolds is a good sign that it could be enhance bone formation 
in vivo.     
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          a)                 b) 
 
          c)      d) 
Fig. 9. SEM pictures of Chitosan with MWCNT (a) Chitosan alone b)  0.5 wt% of MWCNT; 
(c) 1% wt% and (d) 2 wt% of MWCNT. 
 
            a)                  b) 
Fig. 10. a Chitosan-0.5% MWCNT composite. b) Chitosa-1% MWCNT composite. 
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           a)                 b) 
 
           c)               d) 
Fig. 11. Scaffolds biomineralization after it has been seeded with osteoblasts. a) Chitosan-
1%MWCNT after 1 week of culture. b) Chitosan-1%MWCNT after 2 weeks of culture; c)  
Chitosan-2%MWCNT after 1 week of culture; d) Chitosan-2%MWCNT after 2 weeks of 
culture 
5. Biomaterials for biomelecules delivery prepared by TIPS 
Porous biodegradable microspheres and spheres for tissue engineering and drug delivery 
applications have been made by TIPS (Blacker et al., 2008; Keshaw et al., 2010). Microporous 
spheres are likely to be advantageous in the application to inaccessible wounds, such as 
fistulae. Highly interconnected porous structure with pore size ranged from 5 to 50 µm in 
diameter will allow efficient packing into the wound cavity whilst their ability to stimulate 
vascularization will promote tissue regeneration. PLGA microspheres produced by TIPS 
using dimethyl carbonate as a solvent and rapid quenching in -196ºC have a characteristic 
morphology of foams formed by liquid-liquid phase separation. These Microspheres have a 
highly anisotropic channel-like morphology and internal ladder structure. The microspheres 
are monodisperse due to the consistent droplet formation. Reducing polymer concentration, 
reduce viscosity and decrease the size of droplets formed. Blacker and collaborators 
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Fig. 12. SEM picture of well-formed PLGA microspheres by TIPS (Blacker J et. al. 2008). 
Also, highly porous poly(D,L-lactic-co-glycolic acid) (PLGA) scaffolds were fabricated by a 
TIPS technique to deliver plasmid DNA in a controlled manner. Plasmid DNA was directly 
loaded into the inner pore region of the scaffold during the TIPS process. By optimizing the 
parameters, PLGA scaffolds releasing plasmid DNA over 21 days were successfully 
fabricated. Plasmid DNA released from the scaffolds fully maintained its structural integrity 
and showed comparable transfection efficiency to native plasmid DNA demonstrating that 
this kind of materials can be used for tissue engineering where a combined gene delivery 
strategy is required (Woo et. al. 2004). On the other hand, Niu and coworkers (Niu et. al., 
2009) prepared a composite via TIPS, porous NHA/collagen/poly(L-lactic acid)/chitosan 
microspheres loaded with BMP-2 derived synthetic peptide with the aim that it can be 
delivered in controlled way. Dioxane was used as the solvent for PLLA. In order to not 
affect the morphology of the scaffolds the containing quantities of chitosan microsphere 
must be remain less than 30%. Also as the other scaffolds that are particulate-filled the 
compressive modulus of the composite scaffolds increased from 15.4 to 25.5 MPa, while the 
compressive strength increased from 1.42 to 1.63 MPa as the microspheres contents 
increased from 0% to 50%. Also, the results indicated that the degradation rate of the 
scaffolds was increased with the enhancement of CMs dosage and finally, it was shown that 
the synthetic peptide is release in a temporally controlled manner, depending on the 
degradation of both incorporated chitosan microspheres and PLLA matrix. In vitro 
bioactivity assay revealed that the encapsulated synthetic peptide was biologically active as 
evidenced by stimulation of rabbit marrow mesenchymal stem cells (MSCs) alkaline 
phosphatase (ALP) activity. 
6. Conclusions 
A key element in tissue engineering is the scaffold since it enables the fabrication of artificial 
tissue that mimic that to be restore or regenerate. Scaffolds give support for cells, growth 
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factors, and other biomolecules that eventually will enhance the formation of new tissue in 
the human body, the scaffold should fulfill several requirements such as nocarcinogenic, 
nontoxic, nonantigenic, it also must be biocompatible, biodegradable, also is preferred to be 
bioactive. Besides the biomaterial issues, the structure and morphology of the scaffolds is 
very important. They should be highly porous, with defined size and shape pore, well 
interconnected porosity to allow vascularization. Thermally induced phase separation is a 
technique that can produced scaffolds with the desired characteristics. It can be fabricate in 
the desired shape and also can be scalable for fabrication of materials with enough quantity 
and quality. The process can be tuned just adjusting some parameters of the process and 
give materials with the appropriate morphology and structure for tissue engineering. In the 
process it can be incorporated another inorganic materials to enhance its properties, even 
can be loaded with growth factors and others biomolecules that make this technique one of 
the most adequate for scaffolds fabrication for tissue engineering.  
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1. Introduction   
Tissue engineering can be defined as an interdisciplinary field applying the principles of 
engineering and life sciences towards the development of biological substitutes that restore, 
maintain, or improve tissue function (Langer & Vacanti, 1993). To accomplish this aim, a 
balanced combination of cell culture growth with supporting biomaterials is required, as 
well as the introduction of bioactive agents able to enhance and direct cell and tissue 
aggregation. Regenerative medicine has been sometimes looked as an extension of tissue 
engineering, but it can be considered nowadays one of the major interdisciplinary scientific 
challenges, aiming at regenerating the soft and hard tissues, organs, and nerves damaged or 
responsible for main human disabilities. The definition given by Kaiser marks the difference 
of such field from others, and its specific link with pathologies care: “a new branch of medicine 
will develop that attempts to change the course of chronic disease and in many instances will 
regenerate tired and failing organ systems” (Kaiser, 1992). The central focus of regenerative 
medicine is represented by human cells. These may be somatic, adult or embryo-derived 
stem cells and, recently, induced-pluripotent stem cells.  
In both tissue engineering and regenerative medicine, the role of scaffolds is predominant, 
constituting the framework for cell attachment, proliferation, and differentiation. 
Biodegradable natural and synthetic polymers, as well as some non-biodegradable polymers 
have been extensively studied and used for the 2D and 3D reconstruction, as well as for the 
healing of different tissue typologies (Jagur-Grodzinski, 2006). Several requirements have 
been identified as crucial for the production of tissue engineering scaffolds: (1) the scaffold 
should possess interconnecting pores of appropriate scale to favour tissue integration and 
vascularisation; (2) it should be made from material with controlled biodegradability or 
bioresorbability, allowing the new forming tissue to replace the scaffold; (3) it should have 
appropriate surface chemistry to favour cellularattachment, proliferation and 
differentiation; (4) it should own adequate mechanical properties to match the intended site 
of implantation and handling; (5) it should not induce any adverse response; (6) it should be 
easy to fabricate into a variety of sizes and shapes (Hutmacher, 2001). Furthermore, it is 
known that the principal objective of a scaffold is to recapitulate extracellular matrix (ECM) 
function in a temporally coordinated and spatially organized structure, and a key issue is to 
encode required biological signals within the scaffold, in order to control the main cellular 
processes (Causa et al., 2007). 
In order to mimick the nanometric organization of biological structures, many attempts 
have been made in the latest years in order to obtain synthetic or natural scaffolds having 
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nanometric-sized cues, able to better direct cell behaviour. Nanotechnologic processes 
paved the way for such challenge, allowing for the preparation of matrices with pores, 
grooves, fibers and other structures in a submicrometric range of sizes. This allowed a broad 
range of new insights, like the investigation of the effect of submicron topography on cell 
adhesion, migration and differentiation, or the evaluation of the differences, in terms of 
protein adsorption and morphology, on materials showing a nanometric roughness in 
comparison with more flat or micrometric-roughness-characterized substrates. Furthermore, 
the introduction of nanocomposites made by bulk materials (e.g., polymers) with 
nanoparticles embedded in their structure, allowed the fabrication of new structured 
nanoscale materials having promising properties for tissue engineering applications. In 
general, the ability to control the assembly of nanoparticles into discrete organized clusters 
inside a polymeric matrix is of broad interest in the field of nanotechnology, as magnetic, 
electronic and optical behaviours of complex, three-dimensional nanocomposites are highly 
dependent on the size of the nanoparticles, as well as on the distance between them (Sanyal 
et al., 2004). Such nanoparticle-mediated properties become biologically interesting when 
integrated into a scaffold for tissue engineering or regenerative purposes; the incorporation 
of nano-sized objects into degradable or not-degradable polymeric networks, in fact, may 
provide a more favourable synthetic microenvironment to more closely mimic natural tissue 
physiology, with the addition of certain physical stimuli.  
In the present chapter, some techniques and preparation methods to obtain nano-doped 
matrices are described, together with the chemical and physical properties of the fabricated 
nanoscale material. The encouraging results obtained by many research groups using 
polymeric scaffolds doped with various nanoparticle typologies are then reported, 
highlighting the specific advantages that the inclusion of such nanoparticles brings to this 
technology. The main aspects regarding protein adsorption, cell adhesion, proliferation and 
differentiation on the described scaffolds are discussed, also trying to envision future 
applications and challenges related to these materials. The conclusion aims at strengthening 
what emerges from recent studies, namely that nano-doped scaffolds can be considered a 
new and promising instrument for cell and tissue growth and regeneration, with the 
possibility to provide tuned and controlled physical stimuli to the biological culture, in 
order to enhance or direct its behaviour.  
2. The importance of “nano” in scaffold design  
Nanomaterials are materials with basic structural units, grains, particles, fibers or other 
constituent components smaller than 100 nm in at least one dimension (Siegel & Fougere, 
1995), and they include nanoparticles, nanoclusters, nanocrystals, nanotubes, nanofibers, 
nanowires, nanorods, nanofilms, etc. The intrigue of nanotechnology relies on the ability to 
control material properties by assembling such materials at the nanoscale, allowing for the 
construction of new devices with peculiar properties. In fact, after decreasing material size 
into the nanoscale, there is a dramatic increase in surface area and surface roughness to 
volume ratios, thus leading towards superior physiochemical (i.e., mechanical, electrical, 
optical, catalytic, magnetic, etc.) properties. 
Several investigators recently came to the conclusion that in order to achieve a breakthrough 
in the fields of tissue engineering and regenerative medicine, it is necessary to mimic the 
natural biological processes (Tu & Tirrell, 2004; Stupp, 2005). From this perspective, the 
importance of nanomaterials becomes clear, since natural tissues or organs are nanometer in 
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dimensions and cells directly interact with nanostructured ECM matrix. Bone, for example, 
is a nanocomposite consisting of a protein based soft hydrogel template (constituted by 
collagen or other non-collagenous proteins (laminin, fibronectin, vitronectin, etc.) and water) 
and hard inorganic components like hydroxyapatite (HA). The bone matrix is composed for 
the 70% of nanocrystalline HA, which is typically 20-80 nm long and 2-5 nm thick (Kaplan et 
al., 1994). Other protein components in the bone ECM have also nanometric size, 
contributing to create a nanoscale environment surrounding and affecting mesenchymal 
stem cell, osteoblast, osteoclast, and fibroblast adhesion, proliferation and differentiation. 
Cartilage is a flexible connective tissue composed of a small cellular component (the 
chondrocytes) and a dense nanostructured ECM rich in collagen fibers, proteoglycans and 
elastin fibers. Cartilage is able to lubricate joints and withstand static and dynamic loads 
remarkably well; such properties can be well understood treating cartilage ECM as a 
composite medium, with a proteoglycans phase exerting swelling pressure and collagen 
phase resisting it (Basser & Horkay, 2005).  
The use of nanomaterials for bone and cartilage regeneration allowed the achievement of 
exciting results, well reviewed in (Zhang & Webster, 2009). This success is due to the 
dimensional similarity of materials to bone/cartilage tissue, but also to their special surface 
properties (topography, surface wettability, and surface energy) due to their greater surface 
area and roughness compared to conventional or micron structured materials. An important 
mechanism underlying the increased cellular response on nanostructured materials relies in 
protein adsorption. As known, cell behaviour is strongly influenced by serum protein 
adsorption on the biomaterials surface; a nanostructuration allows an increased adsorption 
of specific proteins (fibronectin, vitronectin, laminin, etc.) before cells adhere on implants, 
regulating cell behaviour and dictating tissue regeneration. Furthermore, the surface 
topography determines not only the amount of protein adsorbed, but even its functional 
interconnectivity (Fig. 1). 
 
 
Fig. 1. Atomic force microscope of PLGA nanospheres with different dimensions coated 
with fibronectin (5 µg/ml). (A) Phase image of fibronectin adsorbed on PLGA with 500 nm 
surface features, revealing no interconnectivity between proteins. (B) Phase image of 
fibronectin adsorbed on PLGA with 200 nm surface features, revealing significant 
interconnectivity between proteins. Images from (Miller et al., 2007). Reproduced with 
permission from John Wiley and Sons.   
 
Advances in Regenerative Medicine 
 
298 
Collagen in bone and cartilage is a triple helix self-assembled into nanofibers 300 nm in 
length and 1.5 nm in diameter; many recent efforts have been therefore dedicated to 
exploring the influence of novel biomimetic nanofibrous or nanotubular scaffolds on 
regenerative medicine, by following a bottom-up self-assembly process. Carbon 
nanotubes/nanofibers (CNTs/CNFs), for example, due to their superior mechanical and 
electrical properties, are ideal scaffold candidates for bone tissue engineering applications 
(Tran et al., 2009). 
Vascular tissue is a layered structure characterized by several nanostructured feature, due to 
the presence of collagen and elastin in the vascular ECM. Even for this kind of tissue, 
nanomaterials have a strong influence on regeneration performances, like demonstrated by 
(Choudhary et al., 2007), reporting that vascular cell adhesion and proliferation were greatly 
improved on nanostructured Ti compared to conventional Ti.  
Nanomaterials have also demonstrated to be useful for damaged nerves healing. Central 
nervous system (CNS) and peripheral nervous system (PNS) show different repair procedures 
after injury: for the PNS, the damaged axons usually regenerate and recover by means of 
proliferating Schwann cells; for the CNS, it is much more difficult to re-extend and re-
innervate axons, due to the absence of Schwann cells. Moreover, due to the influence of 
astrocytes, meningeal cells and oligodendrocytes, a thick glial scar tissue forms around neural 
biomaterials, preventing proximal axon growth and inhibiting neuron regeneration. To be 
effective in PNS and CNS regeneration, biomaterials should therefore have excellent 
cytocompatibility, mechanical and electrical properties. Nanotechnology allowed in the latest 
years the development of novel and improved neural tissue engineering materials, with the 
design of nanofiber/nanotube scaffolds (Fig. 2) with exceptional cytocompatibility and 
conductivity properties to boost neuron activities (Mattson et al., 2000; Gheith et al., 2005), as 
well as with the introduction of piezoelectric nanoparticles-mediated neuron stimulation, with 
the aim of enhancing neurite outgrowth in treated cells (Ciofani et al., 2010).  
 
 
Fig. 2. a Neonatal hippocampal neurons adhering on purified multi-walled carbon 
nanotubes-coated glass substrates, showing extended neuritis after 8 days of culture; (B) 
single neurite in close contact to carbon nanotubes; (C) PC12 neural cells grown on vertically 
aligned carbon nanotubes coated with polypyrrole. Images from (Zhang & Webster, 2009). 
Reproduced with permission from Elsevier.  
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The regeneration of other tissues and organs, like bladder, muscle, skin, kidney, liver, 
pancreas and immune system has been addressed using nanotechnology approaches 
(Nukavarapu, et al., 2008; Khademhosseini et al., 2008). Nanomaterials more efficiently 
improve such tissues regeneration, for the same reasons mentioned above (biologically 
inspired roughness, increased surface energy, selective protein adsorption, etc.).  
3. Preparation methods and properties of doped matrices 
Composite materials made of nanoparticles in a polymeric matrix have been under 
investigation for at least one decade, not only for biological applications (only recently 
proposed), but also to develop smart devices, like nonlinear optical materials. A study of 
Pavel and MacKay (Pavel & Mackay, 2000) described the production of randomly dispersed 
(and non-aggregated) cadmium sulfide nanoparticles in a transparent polymer matrix of 
poly(methyl metacrylate) (PMMA). The process was based on a reverse micellar system, 
followed by polymerization to produce a solid inorganic/organic composite, and it was the 
first report in the literature of such technique to obtain a “one-system” synthesis of 
nanoparticles dispersed in a polymer matrix.  
In general, the field of polymer matrix-based nanocomposites started to emerge with the 
recognition that exfoliated clays could yield significant mechanical properties advantages as 
a modification of polymeric systems. Clays are naturally occurring minerals, mainly 
aluminosilicates, having a sheet-like (layered) structure, and consisting of silica SiO4 
tetrahedra bonded to alumina AlO6 octahedra in a variety of ways. Nanocomposites can be 
obtained by following different methods, such as in situ polymerization, solution, and latex 
methods. Melt processing has been also recognized an appreciable method, as it is 
considered more economical, more flexible for formulation, and it involves compounding 
and fabrication facilities commonly used in commercial practice (Paul & Robeson, 2008). 
During the fabrication process, a key aspect in the polymer-clay (or organoclay) interaction 
is the affinity that the polymer segments have for the silicate surface. Specific surfactants can 
be used, in order to induce a greater exfoliation; in all cases, the best exfoliation is achieved 
when the structure of the surfactant and the process parameters are optimized (Fig. 3(A)). 
As already mentioned, the most evident effect of clay-based reinforcement is an increase of 
the mechanical properties of the material, that has been demonstrated to be superior if 
compared with microcomposites or bulk materials (Fig. 3(B)). 
Electrophoretic deposition (EDP) is a cost-effecting and efficient processing method to 
produce ceramic nanocomposites and laminates. It can be seen as two combined processes: 
first the migration of charged particles dispersed in a liquid medium (electrophoresis) under 
an applied electric field and secondly the coagulation process of the particles at the 
electrode. Good dispersion and stability of the suspension are essential factors to obtain a 
homogeneous deposition. Cho and co-workers described the co-deposition of carbon 
nanotubes (CNTs) and TiO2 nanoparticles on a stainless steel substrate by EDP (Cho et al., 
2008). During this process, both CNTs and titania particles move towards the deposition 
electrode, once an electrical field is applied, creating a region close to the electrode surface, 
specifically called “infiltration trajectory”. Here, the charge of the deposited CNT films 
influences the motion of the charged particles; under the effect of the repulsive forces due to 
the surrounding CNTs, the particles will follow the path with the fewest possible obstacles 
until reaching the next interstice between adjacent CNTs. The result is a homogeneous 
distribution of CNTs and TiO2 throughout the whole coating thickness, with a high amount 
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of porosity. The authors did not perform quantitative evaluation of physical properties, but 
they envisioned the interesting mechanical, electrical conductivity, and photocatalytic 
properties of these coatings, useful for biomedical applications. 
 
 
Fig. 3. a Mechanism of organoclay dispersion and exfoliation during melt processing; (B) 
comparison of modulus reinforcement (relative to matrix polymer) between nanocomposites 
based on nanoclays and glass fibers (aspect ratio ~20) for a nylon 6 matrix. Images from 
(Paul & Robeson, 2008). Reproduced with permission from Elsevier.  
In order to replicate natural structures on the nano-scale level, electrospinning is a common 
and inexpensive method that allows the easy fabrication of random or ordered nanofibrous 
constructs. A variety of materials can be processed by electrospinning, and a certain level of 
control can be achieved over the desired nano-structures. In the development of bone grafts, 
nanofibrous scaffolds have been used as fillers, and to bridge critical size defects; the 
fabrication of nanofiber-calcium phosphate composites has been a step forward. Since 
minerals in the native bone are predominantly found on the surface, some researchers have 
deposited hydroxyapatite nanoparticles on the surface of electrospun fibers. The most 
commonly used surface mineralization techniques include soaking the scaffold in simulated 
body fluid (SBF) (Wei & Ma, 2006) and the alternating dipping method (Ngiam et al., 2009). 
Of these two techniques, the alternating dipping method has the advantage of significantly 
faster mineral deposition, requiring hours to complete rather than days for the SBF soaking 
technique. 
The mineralization of 3D block nanofibrous scaffolds is different. In fact, 2D membranes 
have most part of their surface exposed to the solution, while 3D block scaffolds require the 
solution to reach the inner core, requiring a modification of the alternating dipping 
technique. Teo and co-workers described the fabrication of 3D electrospun poly(L-lactic 
acid) scaffolds and their mineralization by means of two approaches: the static 
mineralization (soaking the scaffold for 1h in a mineral solution) and the flow 
mineralization (placing the scaffold in a perfusion chamber, and using a circulating 
peristaltic pump to periodically provide the scaffold with the mineral solution) (Teo et al., 
2011). The analysis of mechanical properties revealed that the presence of minerals 
significantly increased both compressive strength and compressive modulus of the 
scaffolds. The compressive strength of the static mineralized scaffolds was 2.4 times greater 
than that of the unmineralized scaffolds, while the modulus was 1.9 times greater. Such 
analysis also revealed that the mineralization technique has a significant influence on the 
mechanical properties of the scaffolds, being the compressive strength and modulus of the 
flow mineralized scaffolds 6.1 times and 2.8 times greater, respectively, than those of the 
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static mineralized scaffolds. Interestingly, these properties are not related to the overall 
mineral content (found to be 43.3% in flow mineralized scaffolds, and 62.3% in static 
mineralized scaffolds), but to the distribution of minerals inside the 3D structure of the 
scaffold. 
The use of nanoparticles (mainly nano-hydroxyapatite), nanofibers and nanotubes in 
polymer or bioceramic matrices in order to produce nanometric features on the surface of 
3D scaffolds has been recently well reviewed (Meng et al., 2010). Table 1 shows advantages 
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Table 1. Methods of fabrication of 3D nanocomposite scaffolds and corresponding 
advantages and disadvantages of each strategy. Table from (Meng et al., 2010). Reproduced 
with permission from John Wiley and Sons.   
The hybrid technique developed by Park and co-workers, based on a combination of direct 
polymer melt deposition (DPMD) and electrospinning (Park et al., 2008) is particularly 
interesting, even if not including nanoparticles but nanofibers in a polymer matrix. The aim 
of the DPMD process was to determine the overall architecture of the 3D scaffold, by 
producing polycaprolactone (PCL) microfibers able to provide mechanical support and 
overall shape of the device; to this aim, a stainless steel syringe with a micronozzle, a 
syringe heating device, a compressed air dispenser and a three-dimensionally moving 
micropositioning system were used. The electrospinning process allowed to obtain PCL and 
PCL/collagen nanometric fibers applying voltage to a 22-gauge needle on a syringe pump 
at an infusion speed of 10 µm/min and using a grounded collector. By combining DPMS 
and electrospinning a hybrid process was proposed, consisting of two-step sequential 
process (Fig. 4(a)). As a woodpile-like structure was fabricated in a layer-by-layer approach, 
the nanofiber matrices were inserted between each layer of the microfibrous structure. 
Subsequent microfiber layers combined with nanofiber matrices were repeatedly laminated 
onto the previously combined layers, in order to fabricate a 3D complex structure. (Fig. 4(B) 
and 4(C)).  
The beauty of this and other similar approaches is the ability to efficiently simulate the 3D 
fibrous extracellular environment, allowing the envisioning of challenging applications in 
tissue engineering and regeneration. 
Another hybrid approach was proposed by Erisken and co-workers, that described a 
methodology integrating a twin screw extrusion process with electrospinning, and allowing 
the dispersion of nanoparticles into polymeric binders and the generation of nanoparticle-
incorporated fibers and nanofibers. In particular, they dispersed β-tricalcium phosphate (β-
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TCP) nanoparticles into PCL matrices, in order to generate biodegradable non-woven 
meshes for tissue engineering applications (Erisken et al., 2008-a). The fiber size was in the 
range 200 – 2000 nm, and mechanical characterization of the scaffolds revealed that the 
ultimate tensile strength at break of the meshes increased from 0.47 to 0.79 upon the 
incorporation of the β-TCP nanoparticles. 
 
 
Fig. 4. (A) The DPMD/electrospinning hybrid process. A 3D structure can be built by 
alternating such processes; (B) and (C) photographs of hybrid layers composed by 
microfibers and electrospun nanofibers. Images from (Park et al., 2008). Reproduced with 
permission from Elsevier.  
More recently, Jack and co-workers reported the fabrication and characterization of nano-
sized hydroxyapatite (HA)/poly(hydroxybutyrate-co-hydroxyvalerate) (PHBV) polymer 
composite scaffolds, developed by means of a modified thermally induced phase-separation 
technique (Jack et al., 2009). The presence of the HA nanoparticles significantly affected the 
thermodynamic state of the polymer-solvent solutions, resulting in a completely different 
porous architecture upon solidification. EDS characterization confirmed that the clusters 
observed in the SEM images were indeed HA particles (Fig. 5(A), (B), and (C)).  
In order to investigate the mineralization ability, the scaffolds were immersed in SBF for an 
overall period of 2 weeks, evaluating the mechanical performances before and after this 
treatment. The results showed that the immersion of the pure PHBV scaffolds in SBF for up 
to 2 weeks does not significantly change their mechanical performances, confirming that the 
polymer matrix does not significantly degrade in such an environment over the observed 
period. In addition, the incorporation of the HA nanoparticles leads to a marked increase in 
both the stiffness and strength of the scaffolds (Fig. 5(D) and (E)). 
 




Fig. 5. (A) SEM image showing the PHBV scaffold doped with HA nanoparticles. The circles 
indicate the approximate regions in the scaffold that the EDS spectra (B) and (C) were 
collected from; compressive moduli (D) and compressive strength (E) of the PHBV (light 
grey) and HA/PHBV (dark grey) scaffolds following 0, 1 and 2 weeks of immersion in SBF. 
*=p<0.05. Images from (Jack et al., 2009). Reproduced with permission from Elsevier.   
As described, biocompatibility and structural stability are two important aspects for 
engineering functional tissues. An interesting grafted collagen scaffold with a collagen 
triple-helix shape was developed and reinforced with Al2O3-ZrO2 nanoparticles, in order to 
strengthen the mechanical properties of the matrix (Cao et al., 2006). Such modification also 
enhanced the thermal stability of the collagen matrix, bringing the authors to envision 
biomedical and bionic applications of this hybrid material. Regarding the influence of 
nanoparticles inclusion on the degradability of a matrix, Liu and co-workers showed that 
titania nanoparticles alter PLGA degradation, when dispersed in the polymeric structure 
(Liu et al., 2006). To produce the scaffolds, PLGA pellets were dissolved in chloroform and 
nanophase titania powder was added to give a 30/70 ceramic/polymer weight ratio. The 
composite mixture was then sonicated using different output power settings (and thus 
obtaining different samples). After sonication, the suspension was cast into a Teflon petri 
dish, evaporate in air at room temperature for 24 h and dried in air vacuum chamber for 48 
h. After incubation in PBS for several days, the weight loss for the doped samples was 
significantly lower than that of pure PLGA samples. Moreover, results showed that the 
nanophase titania dispersed in PLGA can improve the structural stability and buffer the 
harmful pH variations. 
4. Current applications in tissue engineering and regenerative medicine   
The development of innovative materials useful as scaffolds for regenerative medicine and 
tissue engineering purposes tries to address, as we described, the mimicking of natural ECM 
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in terms of structure, chemical composition, and mechanical properties. In the latest decade, 
an intense research on polymeric matrices doped with several kinds of nanoparticles has 
been carried on, trying to focus on the possible in vitro and in vivo biomedical applications of 
these materials. For example, an interesting electrically conductive biodegradable composite 
material made of polypyrrole (PP) nanoparticles and poly(D,L-lactide) (PDLLA) was 
synthesized in 2004 and tested in vitro with human skin fibroblasts (Shi et al., 2004). It is well 
known that electrical stimulation is capable of modifying cellular activities, like cell 
migration, cell adhesion, DNA synthesis, and protein secretion. An electrically conductive 
scaffold is therefore interesting for the regulation of these activities, but it also must satisfy 
other basic features, as biocompatibility and degradability. Such aim was achieved in this 
study, including electrically conductive PP nanoparticles in a biocompatible and degradable 
PDLLA matrix, easy to process and to test with cell cultures. Human skin fibroblasts were 
cultured on the doped scaffolds, applying electrical currents in the range 0-800 µA. Cell 
growth was affected by such stimulation, showing a maximum peak of growth in 
correspondence to a 10 µA current stimulation.  
The development of doped matrices can be useful not only for tissue regeneration, but 
also for the enhancement of materials antimicrobial acitivity. It is the case of the cellulose 
acetate nanofibers containing silver nanoparticles produced by Son and co-workers. They 
demonstrated for the first time that polymer nanofibers containing Ag nanoparticles on 
their surface could be produced by UV irradiation of the elctrospun fibers with small 
amounts of silver nitrate (AgNO3) (Son et al., 2006). The number and size of Ag 
nanoparticle on the matrix surface was found to continuously increase with the 
irradiation time, and that the particles with an average size of 21 nm exhibited a strong 
antimicrobial activity. 
Specific applications for bone tissue engineering were described by some works in 2006 and 
2007, reporting the results obtained by fabricating doped matrices and testing their 
biological activity by immersing them in standard culture media and simulated body fluid 
(SBF), or evaluating their in vitro response with osteoblasts-like cells or with human 
mesenchymal stem cells (hMSCs) (Li et al., 2006; Gerhardt et al., 2007; Sui et al., 2007; Torres 
et al., 2007; Zhang et al., 2007). The first example of Li et al. is constituted by electrospun silk 
fibroin scaffolds containing bone morphogenetic protein 2 (BMP-2) and nanoparticles of 
hydroxyapatite. TEM images confirmed that nHAP particles were successfully embedded in 
the silk fiber scaffold, being well oriented along the fiber axis in some regions, but more 
aggregated in other regions. Human bone marrow-derived MSCs were cultured for up to 31 
days on nHAP- and BMP-2-containing silk scaffolds, on only BMP-2-containing silk 
scaffolds, and on bare silk scaffolds as control,  using an osteogenic medium. The scaffolds 
containing BMP-2 supported higher calcium deposition and enhanced transcript levels of 
bone-specific markers than on the controls; furthermore, the coexistence of BMP-2 and 
nHPA in the scaffold resulted in the highest calcium deposition and up-regulation of the 
transcript levels of the bone-related markers. Gerhardt and co-workers developed PDLLA 
scaffolds filled with 0, 5 and 30 wt% TiO2 nanoparticles by means of solvent casting. They 
showed that the titania nanoparticles were not directly exposed on the composite surface, 
but rather embedded in the PDLLA matrix, without forming agglomerates even at the 
highest concentration. The bioactivity of such scaffolds was evaluated by immersing them in 
supersaturated simulated body fluid for up to 3 weeks and evaluating the formation of 
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hydroxyapatite on the material surface. HA nanocrystals with an average diameter of 40 nm 
were formed on the 30 wt% TiO2 composite films after 2 weeks, while only some traces of 
HA crystals appeared on pure PDLLA and low titania content films after 3 weeks. The effect 
of TiO2 nanoparticles on the metabolic activity of MG-63 osteoblast-like cells was also 
evaluated, finding that particle concentration up to 100 µg/ml had no significant effect on 
MG-63 cell viability. Sui et al. developed PLLA/HA hybrid membranes via electrospinning 
of a PLLA/HA dispersion. The authors found that the inclusion of HA nanoparticles 
implied a considerably increment in the roughness and in the mechanical properties of the 
matrix, as well as a decrease in its degradation rate in water. MG-63 osteoblast-like cells 
were cultured on PLLA and PLLA/HA membranes, finding a higher cell adhesion and 
growth in the latter substrates. A three-dimensional matrix was introduced by Zhang and 
co-workers, that described the fabrication of PLGA hollow fiber membranes using a wet 
phase-inversion approach and doped with HA nanoparticles. The aim was to obtain an 
aligned, bioactive and biodegradable scaffold mimicking the natural histological structure of 
human long bone, and they obtained an anisotropic membrane with a rough outer skin and 
a smooth inner skin (Fig. 6(A)). The structure showed a highly porous morphology with a 
unique asymmetric finger-like macroviod structure ideal to promote neovascularisation 
(Fig. 6(B)). pH values of the culture media at different time-points were evaluated for pure 
PLGA membranes and PLGA/HA membranes, finding that they were closer to neutral for 
the composite matrices; nanoHA powders in the composite structures may facilitate to 
neutralize the culture media. The bioactivity of such 3D scaffolds was also evaluated, by 
immersing them in SBF for several days, finding a significantly higher biomineralization 
rate for the nanodoped matrix in comparison with the pure PLGA scaffold. Finally, Torres et 
al. tested the mechanical properties and bioactivity of porous PLGA/TiO2 nanoparticle-
filled foams produced by thermally induced solid-liquid phase separation (TIPS) and 
subsequent solvent sublimation. By manipulating the parameters of the TIPS process, they 
were able to control the porous architecture, determining the presence of orientated tubular 
macropores (Fig. 6(C), (D), and (E)). The bioactivity of the scaffolds was also demonstrated 
by immersion in SBF for up to 28 days, and confirming the formation of hydroxyapatite 
crystals on the scaffold surface.  
The aim of doped biomaterials is not always to promote an enhancement of cell adhesion 
and proliferation; in some cases, a specific application requires the inhibition of the 
activity of a certain cell population. In the central nervous system (CNS), astroglial cells 
proliferate and produce an ECM protein-rich glial scar to isolate any implant (for example 
a neural electrode) and, in general, regeneration after injury in the CNS is inhibited 
primarily due to astrocytic glial scar formation. It was therefore proposed a novel 
composite material made of polyurethane (PU) and doped with zinc oxide (ZnO) 
nanoparticles as nerve guidance channel material able to significantly reduce astroglial 
cell adhesion and proliferation (Seil & Webster, 2008). Importantly, ZnO nanoparticles 
possess piezoelectric properties, that make them promising for neural regeneration 
applications. Regarding astrocyte behaviour on such materials, the collected data showed 
a reduced ability of these cells to adhere and proliferate on ZnO nanoparticle PU 
composites with higher nanoparticle concentrations. The authors finally proposed that the 
piezoelectric properties of such composites may provide the stimulatory cues necessary to 
promote neural cell function.  
 




Fig. 6. (A), (B): PLGA hollow fiber membrane doped with 30% nanoHA; (C), (D), and (E): 
foam scaffolds made of plain PLGA(C), PLGA + 5 wt% TiO2 (D), and PLGA + 20 wt% TiO2 
(E). Some TiO2 agglomerates are visible in the 20 wt% foam. Images from (Zhang et al., 2007) 
and (Torres et al., 2007). Reproduced with permission from Elsevier    
In the same year, several studies regarding bone tissue engineering were published (Erisken 
et al., 2008-b; Guan et al., 2008; Nejati et al., 2008; Schneider et al., 2008; Duan et al., 2008; Wei 
et al., 2008). An interesting PHB-based scaffold containing nanosized hydroxyapatite was 
developed by Guan and co-workers by gas-jet/electrospinning. Bone marrow stroma cells 
(BMSCs) were tested on the material, finding that both proliferation rate and alkaline 
phosphatase (ALP) activity increased were higher on the nHAP/PHB scaffolds surface than 
on standard tissue culture plates and pure PHB scaffolds surface. Rod-shaped nano-
hydroxyapatite and nHAP/PLA composite scaffolds were developed by Nejati et al. The rod 
shaped nHAP particles (37-65 nm in width and 100-400 nm in length) were similar to 
natural bone apatite in terms of chemical composition and structural morphology and they 
were used to build PLA nanocomposites using thermally induced phase separation method 
(Fig. 7(H), and (I)). Such scaffolds were found to be comparable with cancellous bone in 
terms of microstructure and mechanical strength, making them suitable for bone tissue 
engineering applications. Rat mesenchymal stem cells (MSCs) were tested on the material, 
finding that nHAP/PLA scaffolds appeared biocompatible and non-cytotoxic to the cells. 
Furthermore, after seven days of culture, round shape cells were found on the surface of 
pure PLA scaffolds (Fig. 7(L)), while cells on the nanocomposite scaffolds exhibited spindle 
shaped morphology and migrated through the pores (Fig. 7(M)). A flexible, cotton wool-like 
PLGA/amorphous tricalcium phosphate (ATCP) nanocomposite was prepared by 
Schneider and co-workers by electrospinning. It was shown that ATCP nanoparticles clearly 
influenced the fiber morphology (Fig. 7(A), (B), (C), and (D)), also enhancing the 
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biomineralization of the scaffold after immersion in SBF (Fig. 7(E), and (F)). Human 
mesenchymal stem cells (hMSCs) were cultured on the composite matrix (Fig. 7(G)), finding 
a good proliferation rate and an enhanced production of ALP and osteocalcin in comparison 
with the controls.  
 
 
Fig. 7. (A), (C): SEM images of electrospun pure PLGA scaffold; (B), (D): SEM images of 
electrospun PLGA/ATCP (60/40) nanocomposite; (E), (F): SEM image of extracted 
PLGA/ATCP (60/40) tubes after 45h of immersion in SBF. The high-magnification image 
reveals a wall thickness of ~ 1 µm; (G): hMSCs morphology after 4 weeks of culture on the 
nanocomposite PLGA/ATCP scaffold. In blue: cell nuclei, in green: cytoskeletal actin, in red: 
scaffold architecture; (H): SEM image of pure PLA scaffold; (I): SEM image of nHAP/PLA 
composite scaffold; (L): optical microscope photographs of MSCs attached to the pure PLA 
scaffold; (M): optical microscope photographs of MSCs attached to the nHAP/PLA scaffold. 
Images from (Schneider et al., 2008) and (Nejati et al., 2008). Reproduced with permission 
from John Wiley and Sons and Elsevier.  
A functionally graded non-woven mesh of polycaprolactone incorporated with tricalcium 
phosphate nanoparticles was fabricated by Erisken et al. using a new hybrid twin-screw 
extrusion/electrospinning process. With such method, the concentration of nanoparticles 
could be tailored in a targeted manner, changing the scaffold properties. MC3T3-E1 mouse 
preosteoblast cells were cultured on the matrix, showing a good proliferation and well 
differentiating into osteoblasts, converting the PCL-β-TCP non-woven composite meshes 
into a bone tissue-like constructs. Duan and collegues used the selective laser sintering 
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technology to produce Ca-P nanoparticle filled poly(hydroxybutyrate-co-hydroxyvalerate) 
(PHBV) microspheres, as bioresorbable osteoconductive composite scaffolds. Ca-P particles 
had a plate-like morphology with about 10 µm in length and approximately several 
nanometers in thickness; the composite matrix was prepared by means of emulsion solvent 
evaporation method. Neither in vitro and in vivo experiments were performed, but the 
authors foresaw that, once inside the human body, the Ca-P particles superficially 
embedded on the microspheres could promote the formation of bone-like apatite and 
enhance bone formation, while the internal Ca-P particles could stiffen the composite and 
gradually release calcium and phosphate ions with the degradation on the PHBV matrix. 
Wei et al. used the solvent casting methods to fabricate PDLLA films with 0 and 20 wt% TiO2 
nanoparticles and with 20 wt% TiO2 mixed with 5 wt% micrometer-sized Bioglass® particles. 
In vitro bioactivity studies were carried out using SBF and culturing osteoblast-like MG-63 
cells. The PDLLS films containing different concentrations of TiO2 and Bioglass® particulate 
inclusions showed no effect on cell viability after 7 days of incubation, and they showed 
promising properties of bioactivity, making them attractive for bone tissue engineering. 
A novel injectable scaffold for tissue engineering was developed in 2009 by Huang and 
collegues (Huang et al., 2009). The opportunity to use an injectable scaffold is attractive for in 
vivo perspectives, as it minimizes patient discomfort, risk of infection, scar formation and 
the cost of treatment. The developed substrate was made of nano-hydroxyapatite/collagen 
(nHAC) loaded on chitosan/β-glycerophosphate matrix. Bone-marrow-derived 
mesenchymal stem cells were tested, evaluating their proliferation capability. The composite 
material showed no toxicity and it did not interfere with the proliferation capability of 
MSCs, making it an interesting solution for bone tissue engineering, above all for its 
injectability (ability to flow out totally from a syringe).  
Another matrix for bone regeneration was fabricated by Thein-Han and co-workers (Thein-
Han et al., 2009), using a silicone rubber doped with nanohydroxyapatite and a process 
involving uniform dispersion of nHA via shear mixing and ultrasonication, followed by 
compounding at sub-ambient temperature and high-pressure solidification when the final 
curing reaction occurred. MC3T3-E1 mouse pre-osteoblast cells were cultured on the 
scaffold, finding that the cell density on the composite matrix was significantly higher than 
that on the pure silicone rubber. Furthermore, immunofluorescence staining revealed that 
cells on the composite matrix showed larger vinculin focal contacts with higher expression 
level at the edges, in comparison with the non-doped material. Cytoskeletal actin 
organization was also more prominent on the composite scaffold.  
Regarding liver tissue engineering, titania/chitosan composite scaffolds were prepared by 
Zhao et al. through a freeze-drying technique (Zhao et al., 2009). Doped matrices with 0.3 of 
TiO2/chitosan weight ratio showed the best mechanical performances, maintaining an 
interconnected pore structure. Hepatic immortal cell line HL-7702 was tested on these 
structures, detecting liver-specific functions, such as albumin secretion and urea synthesis. 
No differences were found between the doped scaffold and the pure chitosan matrix, in 
terms of albumin and urea production; FESEM micrographs of cells cultured on the 
different scaffolds revealed an better sustained attachment of hepatocytes on the doped 
matrix, probably thanks to the improved mechanical characteristics, implying the potential 
application of this material in liver tissue engineering.  
Single-walled carbon nanotubes (SWNTs) are unique in structure and function, and they 
have recently received significant attention due to their potential to create nanostructured 
conductive materials. A composite SWNT/collagen material was recently proposed as 
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conductive peripheral nerve regeneration matrix (Tosun & McFetridge, 2010). Neuron-like 
PC12 cells were tested on collagen and SWNT/collagen scaffolds, finding an enhanced 
proliferation rate on the doped matrices, and a normal expression of p53 gene, indicating the 
absence of nanoparticle-induced DNA damage. 
In another study, the influence of nanodoped matrices on cardiac and mesenchymal stem 
cells (CSCs and MSCs) was evaluated, using PLGA films loaded with TiO2 and CeO2 
nanoparticles (Mandoli et al., 2010). The hybrid nanoCeO2/PLGA scaffolds showed a 
parallel surface pattern, with a spacing of about 250 µm between the ridges (Fig. 8(A)). 
Better CSC and MSC proliferate activity was observed for CeO2 composites with respect to 
either TiO2-added on unfilled PLGA films (Fig. 8(E)), together with a clear cell alignment in 
the direction of the ridges (Fig. 8(B), (C), and (D)). 
 
 
Fig. 8. (A): SEM image of parallel-organized 20% CeO2/PLGA composite; (B), (C), and (D): 
CSC seeded on the composite substrates having different nanoparticle concentrations; (E): 
proliferation assay for the CSC culture on the different scaffolds (pure PLGA, CeO2/PLGA 
and TiO2/PLGA). Images from (Mandoli et al., 2010). Reproduced with permission from 
John Wiley and Sons.   
Skeletal muscle tissue engineering was also addressed using a nanodoped matrix-based 
approach (McKeon-Fischer & Freeman, 2010). PLLA and gold (Au) nanoparticles were 
electrospun to create three composite scaffolds: 7% Au-PLLA, 13% Au-PLLA, and 21% Au-
PLLA. Rat primary skeletal muscle cells were cultured on the three scaffolds and on the 
control (pure PLLA matrix), finding that they showed low proliferation capability on the 
doped scaffolds. However, as demonstrated by the authors, this was not due to the 
 
Advances in Regenerative Medicine 
 
312 
nanoparticle toxicity, but to an enhanced cell fusion into myotubes and a higher level of cell 
differentiation. The electrical conductivity of the scaffolds (increasing with the increase of 
nanoparticle concentration) and the good cell behavior on them are promising for skeletal 
muscle regeneration. 
More recently, H9c2 rat cardiomyocytes were cultured on PLGA scaffolds loaded with 
different concentrations of barium titanate nanoparticles (BTNPs) (Ciofani et al., 2011). 
BNTPs have previously proven to be non-toxic even at high concentrations, and they have 
intriguing properties, related to their piezoelectric nature that could influence some cell 
activities. The PLGA/BTNPs were found to have increased mechanical properties in 
comparison with bare PLGA scaffolds, with a Young’s modulus linearly increasing with the 
BNTPs concentration and the surface roughness was also increasing due to the nanoparticle 
presence. H9c2 cells showed an increased proliferation on the doped matrices, probably 
related to the different protein adsorption due to the different surface roughness. The 
authors hypothesize that BNTPs piezoelectricity could also have a role in such cell behavior, 
also envisioning future nanoparticle-mediated scaffold stimulation. 
 
 
Fig. 9. (A) and (B): SEM images of PLLA and PLLA-CNT-μHA, respectively; (C), (D), (E), 
and (F): Overview of the subcutaneous implantation of the scaffolds on the back of the rat; 
(G): schematic overview of the scaffold placement; (H): scintigraphic image of the in vivo 
measurement of released 131I-labelled BMP-2 in rat 14 days after implantation; (I): in vivo 
release profile of 131I-labelled BMP-2 from the scaffolds. Images from (van der Zande et al., 
2011). Reproduced with permission from John Wiley and Sons.  
An interesting nanocomposite for wound dressing applications was fabricated using β-
chitin and silver nanoparticles (Kumar et al., 2010). Such scaffold showed high porosity, 
which increased for the composite matrix. This is due to the inclusion of the nanosilver 
solution with the original β-chitin hydrogel; when the sample was freeze-dried, the water in 
the silver colloid, which got incorporated into the hydrogel, evaporated and the vacant 
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space was left as pores in the scaffold, ultimately resulting in a highly porous composite. 
Antibacterial studies revealed higher susceptibility of Gram-negative bacteria to nanosilver, 
with a bacteria inhibition zone larger for higher nanosilver concentrations. The scaffolds 
were also demonstrated to be cell-friendly, without significant toxicity induced on cultured 
cells. The β-chitin/nanosilver composites were therefore proposed as novel and promising 
wound dressing material. 
A promising in vivo study was carried out by van der Zande and co-workers (van der Zande 
et al., 2011), that fabricated pure PLLA scaffolds (Fig. 9(A)) provided with bone 
morphogenetic protein-2 (BMP-2), to improve bone response. The problem to employ such 
material in vivo is that BMP-2 is clearly almost immediately released from the site of 
implantation by diffusion; to prolonge the retention of BMP-2 into the scaffold, the authors 
fabricated PLLA matrices doped with carbon nanotubes (CNTs) and microhydroxyapatite 
(μHA) (Fig. 9(B)).  
Radiolabelled BMP-2 was loaded onto plain PLLA and composite PLLA-CNT-μ HA 
matrices, and the scaffolds were implanted subcutaneously for 5 weeks in rats (Fig. 9(C), 
(D), (D), and (E)). In contrast with authors’ hypothesis, the in vivo release showed no 
differences between the composite and plain PLLA scaffolds. Nevertheless, although 
incorporated CNTs and μ HA in a PLLA scaffold did not alter the release pattern of BMP-2, 
they could still provide composite scaffolds with several other beneficial characteristics, as 
higher mechanical performances and enhanced bone formation.  
5. Conclusion   
The development of innovative materials useful as scaffolds for the sustained growth of 
cells is of particular interest in regenerative medicine and tissue engineering, because they 
can be potentially tailored to mimic the natural extracellular matrix in terms of structure, 
chemical composition, and mechanical properties. 
In the past decades, an urgent necessity of innovative, “smart” materials for tissue 
engineering raised, in order to obtain constructs able to sustain and promote cell 
proliferation and tissue regeneration, and particular attention was dedicated to 
polymer/ceramics composites, in order to take advantage by the physico-chemical 
properties of these two classes of materials. 
Nanostructured materials have been extensively explored in many biological applications 
because of their intriguing physical and chemical properties. In particular, the intrinsic 
optical, magnetic, and electrical properties owned by nanomaterials can offer remarkable 
opportunities of interaction with complex biological processes for several biomedical 
applications. 
The advent of nanotechnology is set to accelerate development of improved and 
sophisticated smart material technologies. Researchers are now considering the possibilities 
of designing, altering, and controlling material structure at nanoscale levels in order to 
enhance material performance and process efficacy. The advancements in nanomaterials are 
expected to increase product quality and performance, and they are finding acceptance in 
diverse applications such as sensors and electronic devices. Nanosensor particles assist in 
creating tools for analyzing living cells and serve as reporters in industrial process 
monitoring. In the future, smart materials are likely to derive their success from 
nanotechnology that is likely to be instrumental in creating more varied, complex, and 
intelligent systems. 
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The advances and improvements in smart materials allow them to cater to a diverse set of 
applications, especially in the defense, aerospace, healthcare, electronics, and semiconductor 
industries. Although very few of these applications are at present commercially viable, their 
potential for future acceptance is enormous. Smart materials are particularly useful for 
cellular production: with the addition of cellular fluid and by regulating the cell’s shape and 
mechanical conditions, smart materials can mimic these cells’ interactions and exhibit 
effective results. 
In our opinion, the combination of smart and nanomaterials, and the exploitation of their 
impressive chemical and physical properties, will constitute a fundamental step towards 
realistic clinical applications of tissue engineering and regenerative medicine.  
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1. Introduction  
For decades, platelet concentrates have been a standard transfusion component for the 
treatment of clotting disorders. They are prepared from the whole blood within 24 hours 
from collection from voluntary blood donors by means of differential centrifugation of 
platelet rich plasma (PRP) or by the apheresis and stored at room temperature with a 
maximum shelf life of 7 days. They are transfused to the patients who suffer from 
thrombocytopenia or some other platelet disorder in order to sustain the haemostatic 
function. Freezing platelets is feasible but results in poor recovery, although the platelets 
retain their clotting functions after thawing. The use of platelets is permanently increasing, 
due to advanced surgical and other therapies and they are considered vital products in 
blood banking today (Brecher, 2005). 
Apart from their clotting functions, platelets have been shown to possess some other 
evolutionary highly conserved biological functions, such as immune defence, tissue forming 
and regeneration. These properties are now clinically used by the virtue of platelet gel 
preparations. Technically, the clinical precursor of platelet gel has been fibrin glue that was 
composed of two separate solutions - fibrinogen and thrombin. When mixed together, these 
agents were similar to the last stages of the clotting cascade in forming a fibrin clot. 
Fibrinogen has been obtained from pooled allogeneic single-donor plasma units and from 
the autologous blood of the patients and has been usually isolated by the process of 
cryoprecipitation. The additional thrombin component has been generally derived from 
commercial bovine sources. Some investigators have even added calcium chloride and/or 
antifibrinolytics (i.e., aminocaproic acid, aprotinin) to their preparations in order to enhance 
the clot formation. Although fibrin glue has been used in a variety of surgical procedures for 
the prevention of bleeding, it has been especially useful in heparinized patients undergoing 
cardiovascular procedures requiring extracorporeal circulation, as it does not need an intact 
hemostatic system to be effective. Fibrin glue has also been evaluated in the presealing of 
woven or knitted Dacron vascular grafts. The major drawback to its use has been attributed 
to the potential risk of transmitted serological disease from pooled and single-donor blood 
donors, so the patient's own blood was considered to be the safest preparation to prepare 
fibrin glue. Overall, fibrin glue is a useful adjunct to other methods to control bleeding in 
selected surgical patients (Thompson et al., 1988; Lee & Kang, 2011). 
 
Advances in Regenerative Medicine 320 
Autologous platelet rich plasma, which is by the activation of platelets converted to platelet gel 
(PG) was developed in the early 1970s as a by-product of multicomponent apheresis. The first 
published paper relating to the use of platelet-fibrinogen-thrombin mixture as a ˝corneal 
adhesive˝ is dated from 1975 ( Rosenthal et al., 1975). In 1979, a report was published about 
platelet gel ˝gel foam˝ used to obtain sutureless nerve anastomosis (Fischer, 1979). Another 
publication in 1980, described the role of fibrin to drive fibroblast migration and collagen 
deposition and leading to granulation tissue formation (Brandstedt et al., 1980).  
Articles published in the 1990s provided numerous insights into the basic mechanisms of 
the physiologic process of healing after injury had occurred. Some of the results provided by 
these papers were that fibroblasts are recruited at the injury site by soluble factors; that the 
platelet releasate contains a high level of chemotactic factors that recruit fibroblasts in a 
strictly dose-dependent manner, that the fibroblasts migrate along a fibrin-rich matrix; and 
that fibronectin is necessary for such migration to occur since it provides a conduit for 
transmigration. In their migration, fibroblasts adhere to the fibronectin fibres through 
alpha5beta1 and alpha5beta3 receptors. Proteases are necessary for fibroblast transmigration 
through the fibrin-rich matrix (the role of metalloproteases was depicted some years later). 
Interestingly, the fibrin/ fibronectin fibres retain growth factors released from the activated 
platelets within the injured site (Greiling & Clark, 1997). 
In 1996, the physiological relationship between mesenchymal cells, fibrin and growth factors 
was shown to result in the establishment of granulation tissue. It was demonstrated that the 
formation of granulation tissue is strongly enhanced by the platelet releasate. The platelet 
releasate provides continuous stimulation for mesenchyme-derived cells to interact with 
fibrin, thus accelerating the development of granulation tissue (McClain et al., 1996). It is 
now confirmed that the human platelet lysate can induce the expansion of human 
mesenchymal stem cells in vitro, which will by omitting the animal derived albumin, change 
the cell cultivation approaches for regenerative medicine.  
One of the first disciplines that readily accepted the new regenerative capacity of the 
PRP/PG was the maxillofacial surgery (Schallmoser et al., 2007). PRP was introduced to the 
maxillofacial community by Whitman et al. as an alternative to the fibrin glue in 1997 
(Whitman et al., 1997). Marx et al. showed that by combining PRP with autologous bone in 
mandibular continuity defects resulted in significantly faster radiographic maturation and a 
histomorphometrically denser bone regeneration (Marx et al., 1998).  
In 2000 – 2010 authors observed various healing effects of PG, for instance that chronic 
lower extremity ulcers (diabetic, post-traumatic, vascular) reepithelialized faster with the 
course of twice-daily wound treatment with platelet releasate as compared with similar 
wounds treated with a placebo. The supernatant or releasate of the platelet gel was able to 
promote dose-dependent proliferation and changes in gene expression as well as in 
metabolic activities related to protein synthesis (Junger et al., 2000;Valencia et al., 2001; Fang 
& Galiano, 2008; Bernuzzi et al., 2010; Ficarelli et al., 2008; Chen et al., 2010). The platelet 
concentrate was used for healing skin, soft tissue wounds, fractures, surgical injuries, 
diabetic ulcers, dental, oral and maxillofacial settings (Altman et al., 2001; Margolis et al., 
2001; Anderson &Baker, 2003; Castro, 2004; Belli et al., 2005; Burkus, 2005; Carreon et al., 
2005; Sclafani et al., 2005; Trowbridge et al., 2005; Brown et al., 2006; Driver et al., 2006; 
Savarino et al., 2006; Rozman & Bolta, 2007; Borzini & Mazzucco 2007; Smrke et al., 2007; 
Cieslik-Bielecka et al., 2008;). 
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Novel strategies of platelet gel application in cardiology were under investigation in the 
year 2004. Studies evaluated the use of platelet gel in the case of myocardial injury, in order 
to promote remodelling through the regeneration of myocytes, the induction of 
angiogenesis and the restoration of a normal extracellular matrix composition (Mogan & 
Larson, 2004; Balbo et al., 2010;). 
PG/PRP was further intensively studied. Human umbilical vein endothelial cells (HUVECs) 
were isolated from umbilical cord veins and grown in appropriate conditions in vitro. The 
platelet gel-released supernatant was able to induce proliferation and to stimulate motility 
and the invasiveness of HUVECs. Higher concentrations of PG induced a reversion of the 
stimulatory processes. It became clear that different concentrations of the platelet growth 
factors do not have the same efficacy in inducing these processes: excessively high 
concentrations can have an inhibitory effect on the processes. Further studies are necessary 
to reach a better understanding of these complex biological processes (Rughetti et al., 2008). 
PG treatment in 2008 revealed a unique capacity of articulating a pro-inflammatory and pro-
angiogenic cytokine profile in human peripheral blood mononuclear cells, co-cultured with 
PG, which may partially explain the clinical success of PG application in a wide range of 
diseases (Naldini et al., 2008). 
A 1-year retrospective review of a cardiac surgery patient in 2008 showed that the treatment 
group with PG significantly shortened the duration of intensive care and decreased the total 
length of stays as well as decreased postoperative blood loss, compared with the control 
group. In addition, the treatment group had no reported incisional wound infections 
(Englert et al., 2008; Gunaydin et al., 2008). 
2. Platelet structure and physiology 
Platelets are not ˝real˝ cells but rather non-nuclear cellular fragments derived from the 
megakaryocytes in the bone marrow through controlled cellular fragmentation, 
followed by their release into circulation (Jurk & Kehrel, 2005). A healthy adult aged 
between 30 and 70, weighing 70 kg, has in total about 1,300-1,500 grams of platelets 
(thrombocytes); 40% of them in the spinal bone marrow, 25% in the ribs and sternum, 
15% in the pelvis, 10% in the skull, and 10% in other bones. Progenitor cells of the 
thrombocytic lineage develop in the same way as other immature cells of bloodlines in 
the bone marrow, originating from the common hematopoietic stem cell. When 
immature cells differentiate into directed stem cells they are morphologically 
recognizable as the progenitor cells of thrombocytic lineage. The progenitor cell is the 
megakaryoblast, with 21-50 mm diameter, which develops from the common myeloid 
progenitor named CFU-GEMM. The megakaryoblast gives rise to the promegakaryocyte 
and then the megakaryocyte - the largest cell in the bone marrow with 70-100 mm in 
diameter. Several growth factors are involved in the platelet differentiation, among 
which the thrombopoietin plays the most decisive role, inducing thrombopoiesis in a 
negative loop fashion by binding to the thrombocytes when they are present in 
sufficient numbers, thus decreasing their production from the HSCs in the bone marrow 
(See Figure 1). 
There are 1/3 immature and 2/3 mature elements of megakaryocyte lineage in the bone 
marrow. Thrombocytes are formed by the breaking off of small fragments of the 
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megakaryocyte cytoplasm. Each megakaryocyte gives rise to 2,000 to 4,000 thrombocytes. 
The development of the megakaryocyte from the megakaryoblast takes 4-5 days, and the 
life-span of a thrombocyte is 7-10 days. The number of thrombocytes in the peripheral blood 
is 150-350 x 10E9/L. If functionally classified, platelets consist of various molecules: 
membrane proteins 3%, signalling proteins 24%, cytoskeletal 15%, vesicular 6%, 
extracellular 4%, mitochondrial 7%, protein processing 22%, metabolic enzymes 6%, 




Fig. 1. Thrombopoiesis in the bone marrow 
As mentioned previously, platelets are primarily specialized secretory cells that release the 
contents of their intracellular granules in response to activation. Beside their well known 
function in haemostasis where they prevent blood loss at the sites of vascular injury, they 
also release substances that promote tissue repair and influence the reactivity of vascular 
and blood cells in angiogenesis and inflammation (Jurk & Kehrel, 2005). At the site of the 
injury, platelets release an arsenal of potent inflammatory and mitogenic substances which 
are involved in all aspects of the wound healing process. Based on these facts, platelet 
releasate in the form of activated platelet gel has been extensively used for the topical in loco 
therapy of various clinical conditions (Borzini & Mazzucco, 2007). The purpose of this 
chapter is to review the current laboratory and clinical findings related to the therapy of 
these diseases with the use of platelet gel derived growth factors. 
3. Platelet activation 
Platelets are normally circulating in the blood in their resting form (Gresele at al., 2002). 
Non-activated platelets contain a complete array of presynthesized protein molecules 
important for platelet function, among which the high presence of cytoskeletal proteins, 
signalling proteins, membrane proteins, protein processing proteins and cytoskeleton 
regulatory proteins is noted (Garcia et al., 2004; Anitua et al., 2004). These molecules are 
synthesized already in the megakaryocytes and packaged into the granules. Three major 
storage compartments in platelets are alpha granules, dense granules and lyzosomes. The 
majority of the substances are contained in alpha granules (Rendu & Brohard-Bohn, 2001). 
(See Tab. 1). 
Hematopoietic Stem Cell 
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Category Term Biological activities 
Adhesive proteins VWf + propeptide, Fg, Fn,Vn,TSP-1, laminin-8 
Cell contact interactions, 





Factor V/Va, factor XI, multimerin, 
gas6, protein S, high-molecular weight 
chininogen, antithrombin, tissue factor 
pathway inhibitor (TFPI) 





Plasminogen, PAI-I, u-PA, osteonectin, 
α2-antiplasmin, histidine rich 
glycoprotein, TAFI, α2-macroglobulin 




Tissue inhibitor of metalloprotease-4 
(TIMP-4), matrix metalloproteinases 
MMP-1,-2,-3, -4, -9, platelet inhibitor of 
FIX, protease nexin-2, C1 inhibitor, α1-
antitripsin 
Potentiation of aggregation, 
angiogenesis, vascular 
modelling, regulation of 





PDGF, TGFβ1 and 2, EGF, IGF-1, VEGF 
(A and C), bFGF and FGF-2, hepatocyte 
GF, RANTES, IL-8, MIP-1α, growth 
regulated oncogene-α, ENA-78, MCP-3, 
angiopoietin-1, Il-1β, IGF BP-3, 




Basic proteins and 
others 
PF4, β-thromboglobulin, platelet basic 
protein, connective tissue activating 
peptide III, neutrophile activating 
peptide-2, endostatins 
Regulation of angiogenesis, 
vascular modelling, cellular 
interactions. Endostatin is an 
endogenous inhibitor of 
angiogenesis and the growth 




Bactericidal and fungicidal 
properties 
Others -chondroitin 4-sulfate, albumin, immunoglobulins Diverse 
Membrane 
glycoproteins 
αIIbβ3, α β3, GPIb, PECAM-1, most 
plasma membrane constituents, 
receptors for primary agonists, CD40L, 
tissue factor, P-selectin 
Platelet aggregation and 





Table 1. The contents of the platelet alpha-granules 
When adhered to exposed endothelium or activated by agonists, platelet change their shape 
and secrete the contents of the granules (including ADP, fibrinogen and serotonin), which is 
followed by the platelet aggregation. The initiation of the signalling event within the platelet 
leads to the reorganization of the platelet cytoskeleton , which is seen as an extremely rapid 
shape change (See Figure 2).  
 




Legend: Resting platelets are smooth and disc shaped (left). Activated platelets have an irregular shape with many 
protruding pseudopodia (right). 





Fig. 3. Schematic representation of intracellular events during platelet activation - ”outside 
in” and “inside out” signalling 
Initiation of the signalling event within the platelet leads to the reorganization of the platelet 
cytoskeleton , which is seen as an shape change. Aggregation of platelets is mediated by 
molecules of fibrinogen or vWf, which connect platelets by bridging complexes of 
glycoprotein IIb/IIIa (integrin αIIb3) on adjacent platelets, forming a platelet aggregate. In 
order to bind the fibrinogen and vWf, GP-IIb/IIIa initially has to be converted from a low 
affinity/avidity state to a high affinity/avidity state by a process described as “inside-out 
signalling” that is initiated during and after platelet activation. Some of the substances 
GP I/V/IX 
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released by these cells – in particular adenosine diphosphate, serotonin, thromboxane and 
others – can, in an autocrine and paracrine fashion, further enhance platelet activation and 
aggregation (See Figure 3.). Under these conditions there is also activation of the coagulation 
cascade; therefore thrombin is formed, which also markedly stimulates the platelet 
activation in a positive feedback loop fashion (Gresele et al., 2002). 
4. Platelet receptors and antigens  
It has been proposed that the original function of the mammalian platelets resembled the 
function of primitive haemocytes in certain lower organisms such as caterpillars, in which 
they mostly act as a defence against foreign organisms by adhering and aggregating to 
foreign bodies. This is probably the reason why human platelets also possess many features 
of classical inflammatory cells. As such, they can undergo chemotaxis, release potent 
inflammatory mediators such as platelet factor PF4 and histamine, they can phagocytose 
foreign particles, interact with neutrophils, stimulate basophiles, excrete a number of 
mediators, cytokines, growth factors and other proteins and even interact with bacteria and 
parasites. Platelet membranes also bear some immune molecules, such as MHC Class I 
molecules, Fc receptors and complement binding molecules. The platelet membrane also 
incorporates AB0 and some other polysaccharide blood group Antigens, which are very 
important in blood transfusion (Rožman, 2002).  
The membrane of the resting platelet can modify considerably after the activation following 
adhesion. This stimulus causes numerous intracellular molecules that are a part of the 
lyzosomes, granules and other cellular compartments, to appear on the platelet surface. 
These molecules are therefore considered as markers of platelet activation. A short 
description of more than 45 distinctive platelet membrane structures found on resting 
platelets is given in Table 2. They are usually divided into five groups: adhesion molecules, 
immune molecules, receptors, blood group antigens and some other molecules. 
An extensive review of all molecules found on platelets and their precursors is given in 
references (Kishimoto et al., 1997). The CD designations of all integral molecules of the 
platelet membrane, as agreed upon at the 9th HLDA (Human Leukocyte Differentiation 
Antigens) workshop in 2010., can also be found on the internet addresses: http://hcdm.org. 
Many antigenic systems that are typical for erythrocytes and leukocytes, are also present on 
platelet membranes, including ABO and HLA antigens. Some others are exclusively found 
on platelets and their precursors. They are called human platelet alloantigens (HPA) and 
located on the platelet glycoproteins GPIa/IIa, GPIIb/IIIa and GPI/V/IX as a polymorphic 
part of the aminoacid chain. These polymorphisms are usually caused by a single nucleotide 
and the consequent aminoacid substitutions. The polymorphisms that cause 
alloimmunisation following transfusion and pregnancy were classified into the 
immunogenetic system of HPA (human platelet alloantigens) (Santoso & Kiefel, 1998). (see 
Table 3. and EMBL EBI immune polymorphysm database at the  http://www.ebi.ac.uk). 
For transfusion and transplantation, AB0, HPA and HLA antigens are important due to their 
capability of inducing an immune response in antigen- negative recipients. This could play a 
role in the allogeneic platelet gel settings, but surprisingly we could not find any immune 
consequences of the allogeneic platelet gel use in observed patients, treated topically with 
allogeneic platelets, as will be discussed later. 
 
Advances in Regenerative Medicine 326 
















CD41 (Integrin αIIb 
subunit, GPIIb) 
Associates with GPIIIa into GPIIb/IIIa complex. 
The complex binds fibrinogen, vWf, fibronectin, 
vitronectin, thrombospondin 
CD61 (Integrin β3 
subunit) 
GPIIIa; associates with CD41 (into the GPIIb) or 
CD51 (into the vitronectin receptor) 
CD49a (Integrin α1 
subunit) 
Associates with CD29 (β1 subunit) into VLA-1 
(GPIIa), binds to collagen and laminin 
CD49b (integrin α2 
subunit)  
GPIa or VLA-2α, associates with CD29 (GPIIa), 
binds collagen, laminin,  
CD49e (integrin α5 
subunit) 
α subunit of VLA-5 (vitronectin receptor), GPIc' 
subunit, of GPIc'/IIa, binds fibronectin 
CD49f (integrin α6 
subunit) 
VLA-6α subunit, GPIc, associates with CD29 (1) 
into VLA-6 (CD49f/CD29), binds laminin 
CD29 (integrin β1 
subunit) 
Associates with CD49a in VLA-1 integrin (GPIIa) 
on platelets 
CD51 (integrin αV 
subunit) 
Associates with CD61 into the vitronectin 
receptor. A receptor for RGD-containing proteins 
(fibrinogen, vWf, fibronectin, laminin, 
thrombospondin). 
Selectins CD62 (P-selectin) 
Binds sialyl Lewisx, mediates the interaction of 
platelets with neutrophils, monocytes and a 






CD42bα (GPIbα) Binds to the von Willebrand factor, receptor for thrombin 
CD42bβ (CD42c) 
(GPIbβ) Subunits of the GPIb-IX-V complex, bind to the 




CD54 (ICAM-1) Interactions with integrins, receptor for rhinovirus 
CD31 (PECAM-1) Interactions with integrins, inhibiting neutrophile migration 
CD44 variants CD44 isoforms Adhesion to the extracellular matrix 
TM4 
superfamily 
CD9 Tetra spanning membrane protein, regulation of integrin function 
CD165 (AD2, gp37, 
A108) 














S MHC class I. HLA-A, B, C Immune recognition 
Fc receptors CD32 (FcRII) Low affinity Fc receptor for aggregated Ig/immune complexes; activation 




CD55 - DAF (decay acc. 
factor)  
Blocking and deactivating components of 
complement and inhibition of lysis 
CD59 - MIRL 
C8bp (C8-binding 
protein) 
CD46 - MCP (membr. 
cof. prot.) 
 













Mediate activation by agonistic ligands through 
different mechanisms 
High affinity thrombin 
rec. 
Epinephrine receptor 














Prostaglandin I2 (PGI2) 
rec. 
Multipurpose 
receptors CD36 (GPIV) 
Adhesion receptor for collagen and 
thrombospondin, receptor for  




CD151 (PETA-3) Activates platelets upon stimulation with MAbs 
CD110 (TPO R, MPL) 
Thrombopoietin receptor,  
megakaryocyte proliferation and  
differentiation 
















S AB0 A,B,H 
Oligosaccharides 
Le Lea, Leb 


















ceramide) Activation, release of granules 
Oligosacchari
des CD60 Oligosaccharide, present on gangliosides 
α-granules 






Liposomal membrane protein translocated to the 







Tetra spanning membrane protein, liposomal 
membrane protein translocated to the cell surface 
after activation  
CD82  
Tetra spanning membrane protein, suppresses 




Platelet activation factor, GR56,  
Gova/b alloantigen on platelets 
Table 2. Molecules on the non-activated platelet membrane 
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Glutamic acid505  
Lysine505  
CD49b 




Glutamine489  CD61 




Alanine407  CD61 




Cysteine636  CD61 




Methionine837  CD41 




Glutamine62  CD61 




Histidine633  CD61 
 HPA-12bw 0.4% GPIb G119 A119 
Glycine15  
Glutamic acid15  CD42c 




Methionine799  CD49b 




deletion  CD61 





































 HPA-21bw <0.1% GPIIIa 
G1960 
A1960 
Glutamic acid628  
Lysine628 
CD61 
*Nucleotide change - numbers are given in relation to the reference sequence in the NCBI database 
Table 3. Human platelet alloantigens (HPA) (Modified from Metcalfe et al. 2003 and IPD HPA 
database http://www.ebi.ac.uk/ipd/hpa/freqs_1.html  
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5. Platelet growth factors 
As already stated, intact platelets contain alpha-granules and other granular bodies in which 
important mediator molecules are stored, and are released from the platelet following 
activation. Among these are the growth factors (GFs), which when released from activated 
platelets, exhibit an extensive tissue forming ability, such as the initiation and modulation of 
wound healing in both soft and hard tissues (Anitua et al., 2004; Harrison & Cramer, 1993; 




 stimulates lymphocyte proliferation  
 influences collagenase activity 
IL-8, Interleukin 8 
 chemotactic for all known types of migratory immune cells 
 specifically activates neutrophile granulocytes 








 stimulates angiogenesis, endothelial cell proliferation , collagen 
synthesis, wound contraction, matrix synthesis, epithelization, 




 most potent GF identified thus far for skin keratinocytes playing 




 growth and development of progenitors of granulocytes and 
macrophages, stimulates myeloblasts and monoblasts and triggers 
their irreversible differentiation, synergises with EPO in the 
proliferation of erythroid and megakaryocytic progenitor cells, in 
combination with another colony stimulating factor, M-CSF, 
synergically suppresses the generation of macrophage-containing 
cell colonies 
 for some types of blast cells acute myeloid leukemia acts as an 
autocrine mediator of growth.  
 a strong chemoattractant for neutrophils, enhances microbicidal 
activity, oxidative metabolism, and phagocytic activity of 










 a growth factor for normal fibroblasts, promotes the synthesis of 
collagenase and prostaglandin E2 in fibroblasts, may function also 
as an autocrine growth modulator for human chronic lymphocytic 
leukemia cells in vivo, an autocrine growth modulator for 
neuroblastoma cells, the autocrine growth-promoting activity is 




 Besides its immune functions, TNF is a potent promoter of 
angiogenesis in vivo. TNF-alpha is a growth factor for human 
fibroblasts, where it promotes the synthesis of collagenase and 
prostaglandin E2 
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 promotes the proliferation of astroglial cells and microglial cells 
and therefore may be involved in pathological processes such as 
astrogliosis and demyelinisation.  
PDGF A 
Platelet derived 
growth factor A 
 PDGF isoforms are potent mitogens for connective tissue cells, 
including dermal fibroblasts, arterial smooth muscle cells, 
chondrocytes and some epithelial and endothelial cells 
 chemotactic and mitogenic for fibroblasts and smooth muscle cells, 
neutrophils and mononuclear cells 
 activates TGF-β, stimulates neutrophils and macrophages, 
stimulates chemotaxis, mitogenesis of fibroblasts and smooth 
muscle cells, collagen synthesis and collagenase activity, 
angiogenesis 
 a major mitogen for connective tissue cells and certain other cell 
types 
 stimulates cell growth, but also changes cell shape and motility; 
induces the reorganization of the actin filament system and 
stimulates chemotaxis, i.e., a directed cell movement toward a 
gradient of PDGF  
PDGF B 
Platelet derived 
growth factor B 
 regulates the proliferation and the differentiation of multiple cell 
types. TGF found in platelets is subdivided into TGF α and , 
which are the more generic connective tissue growth factors 
involved with matrix formation influencing osteoblasts to lay 
down bone matrix through the process of osteogenesis.  
 TGF1 and TGF2 activate fibroblasts, endothelial and osteoprogenitor 
cells, chondroprogenitor cells and mesenchimal stem cells. A 
chondroprogenitor cell will further differentiate and produce the 
matrix for cartilage. A mesenchymal stem cell stimulated to mitose 
provides wound healing cells
TGF-α, 
Transforming 
growth factor alpha 




growth factor ß1 
 stimulates monocytes to secrete FGF, PDGF, TNF– α , Interleukin-1  
 stimulates fibroblast chemotaxis and proliferation  
 stimulates collagen synthesis  




 highly specific mitogen for vascular endothelial cells 
 influences vascular permeability and is a strong angiogenic protein and 
probably also plays a role in neovascularisation under physiological 
conditions 
 in endothelial cells, VEGF induces the synthesis of von Willebrand 
factor.  
 a potent chemoattractant for monocytes and thus has procoagulatory 
activities.  
 in microvascular endothelial cells induces the synthesis of plasminogen 
activator and plasminogen activator inhibitor type 1. 
 induces the synthesis of the metalloproteinase, interstitial collagenase, 
which degrades interstitial collagen type 1, collagen type 2, and 
collagen type 3 under normal physiological conditions. 
Table 4. Platelet growth factors ( Modified from http://www.copewithcytokines.de/cope.cgi) 
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Growth factors modulate the functional activities of individual cells and tissues, mediate 
interactions between cells directly and regulate processes taking place in the extracellular 
environment in autocrine, paracrine, iuxtacrine or retrocrine fashion. GFs work by binding 
to specific cell surface receptors and can target cells in a number of recognized ways or 
modes. Release of these substances into the blood stream allows them to get to distant 
targets (endocrine mode), diffuse over short distances to affect other cells (juxtacrine mode), 
and to influence neighbouring cells (paracrine mode). Growth factors can even act on the 
cell in which they are produced (autocrine mode). These different modes are all likely to be 
operative during tissue repair.  
The most important GFs released by the platelets are PDGF (the platelet derived growth 
factor), TGF-α & β (transforming growth factor alpha & β), EGF (epidermal growth factor), 
FGF (fibroblast growth factor), IGF (insulin growth factor), PDEGF (platelet derived 
epidermal growth factor), PDAF (platelet derived angiogenesis factor), IL-8 (interleukin-8), 
TNF-α (tumour necrosis factor alpha), CTGR (connective tissue growth factor), GM-CSF 
(granulocyte macrophage colony stimulating factor), KGF (keratinocyte growth factor), and 
Ang-2 (angiopoetin) (Frechette et al., 2005; Borzini & Mazzucco, 2005; Westerhuis et al., 
2005; Everts et al., 2006) (see Table 4.). Beside these GFs, there are at least 60 different 
biologically active substances in the platelets that are involved in tissue repair mechanisms 
such as chemotaxis, cell proliferation and differentiation, angiogenesis, extracellular matrix 
deposition, immune modulation, antimicrobial activity, and remodelling (Borzini & 
Mazzucco, 2007). All these functions have been demonstrated in numerous in vitro (Phillips 
et al., 1994; Dankert, 1995; Brill et al., 2004; Cenni et al., 2005; Kark et al., 2006) and in vivo 
experiments (Debus et al., 2001; Kevy et al., 2004). 
6. Therapeutic platelet products 
Even the topically applied fibrin glue itself improves the haemostasis, reduces blood loss, 
and tightens the sealing of sutures due to fibrin formation, providing a stabilized matrix for 
ingrowing fibroblasts and therefore promoting the support of the granulation tissue, 
revascularization and re-epithelization. Further inclusion of growth factor containing 
platelets into this concept of tissue regeneration provided and increased tissue repair and 
regeneration. Various types of platelet products, such as platelet rich plasma, platelet-
leukocyte gel and platelet gel, derived from autologous or allogeneic peripheral blood, have 
been tested for tissue repair. 
6.1 Platelet-rich plasma  
Platelet-rich plasma (PRP) is defined as a portion of the plasma fraction of autologous blood 
having a platelet concentration above baseline. Usual product of blood banking is the 
allogeneic platelet concentrate or platelet-rich plasma, obtained from random blood donors. 
Autologous platelet rich plasma preparations involve the procurement of 50-100ml of blood 
drawn from the patient at the point of care. The blood is processed using PRP devices 
yielding 5-10ml of concentrated PRP (3 to 5X baseline levels). PRP serves as a growth factor 
vehicle and has both mitogenic and chemotactic properties. It contains a high level of 
platelets and a full complement of clotting and growth factors (Lacci & Dardik, 2010). The 
PRP is then activated and applied to the wound site or mixed with bone material for 
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implantation. This procedure is usually performed in under an hour by a well trained and 
qualified technician. 
6.2 Platelet gel  
Autologous platelet-gel (PG) is the result of harvesting one‘s own cells (platelets) that are 
concentrated by means of centrifugation and exposed to an agonist, which induces 
activation resulting in the release of intrinsic substances that are applied to the target area 
where they accelerate wound healing. Autologous PG is attractive because it concentrates a 
large number of biologically active substances, which are primarily proteins that participate 
in a complex series of mechanisms involved in inflammation and wound healing (Everts et 
al., 2006; Stammers et al., 2009; Tschon et al., 2011; Mehta & Watson, 2008). Lately, the 
possible use of allogeneic PG with similar results was demonstrated in our study (Smrke et 
al. 2007). 
6.3 Platelet-leukocyte gel  
Platelet-leukocyte gel contains high concentrations of platelets and leukocytes. As 
leukocytes play an important role in the innate host-defence, PLG might have antimicrobial 
properties. A unit of whole blood is centrifuged to obtain platelet-leukocyte-rich plasma (P-
LRP). The PLG is then formed by mixing P-LRP with a thrombin-calcium chloride 
preparation. Similar to PG, the treatment with PLG provides a source of concentrated 
platelets, with granules that contain growth factors. In addition the high content of non-
activated leukocytes, present in the PLG, promotes anti-microbial activity at the wound site 
through the destruction of bacteria and foreign materials and the removal of damaged tissue 
(Everts et al, 2006b; Everts et al. 2008). 
Platelet gel can be nowadays prepared using a range of commercially available instruments 
from a number of manufactures. There are no uniform manufacturing standards for platelet 
gel in existence, which has disturbed the classical blood banking. The existing literature 
adds controversies to the use of PLT concentrates. When talking about platelets and their 
products, a great number of variables have to be considered. These variables are mainly 
related to the PRP preparation methods, the type of activators used, intra- and inter-species 
variability, types of pathology to be treated, the ways and times of administration and the 
association of PRP or PG with other treatments. The improved knowledge on the variables 
affecting therapeutic efficacy will surely help in addressing the best combination of factors 
implied in the different steps of PLT concentrate preparation and use (Mazzucco et al., 
2009). 
7. Activation of PRP and the formation of the gel 
The typical source of platelet GFs is platelet-rich plasma (PRP) – Figure 4A. Platelet gel (PG) 
is formed after the PRP is exposed to a strong coagulation stimuli, which is usually the 
addition of thrombin and calcium (to counteract the anticoagulant citrate if plasma is 
citrated) ( Mazzucco et al., 2004; De Somer et al., 2006) or some other fibrinogen-digestion 
based activator, such as batroxobine from the viper Bothrops atrox snake venom ( Carr et al., 
2003; Mazzucco et al., 2008).  
Consequently, platelet activation and a coagulation cascade follow in a positive loop 
fashion, which finally results in the formation of a thrombus-like gelatinous substance – 
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platelet gel. (See Figures 4B, 4C). In the gel, activated platelets are trapped in a fibrin 
network and they release their active substances, which slowly diffuse into the 
surroundings. The final result – platelet gel – can be shaped according to the needs, put on 
different vehicles such as medical gauze or even advanced types of biocompatible carriers 
and scaffolds, such as fibrin or hyaluronic acid, and used topically. It can be used as a 
vehicle for the stem cells and ground cancellous bone transplant, allowing the formation 
and shaping of grafts with determined shapes (See Fig. 4D). 
 
     
          A.            B. 
     
           C.           D. 
Legend: A. Platelet rich plasma; B.Platelet gel; C: Microscopical view of the platelet gel. Inverted microscope 
Nikon Eclipsete 300, 10x enlarged.; D: Graft with the shape used for mandibular deffects, containing PG, stem 
cells and cancellous bone 
Fig. 4. Platelet gel 
At the beginning autologous PRP/platelet gel was developed as a by-product of 
multicomponent apheresis (Rosenthal et al, 1975). Later several systems became available to 
prepare PRP and from this, the platelet gel. These systems produce two- to six-fold platelet -
enriched concentrations. Very few data have been reported on the kinetics of growth factor 
release from PRP-gels. The bioavailability of growth factors in tissue healing depends on the 
amount of growth factors stored in the platelets but a portion of these is lost during platelet 
manipulation. In one report, three commercially available devices (Fibrinet, RegenPRP-Kit, 
Plateltex) and one manual procedure (home-made) were evaluated with reference to the 
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resulting platelet concentration, growth factor content and the kinetics of growth factor 
release from the gel. Similar methods for platelet gel preparation have revealed different 
performances concerning the growth factor recovery and the kinetics of its release from the 
gel. It is unclear whether these noticeable differences are important for clinical management 
(Mazzucco et al., 2009). 
Some research groups have successfully engineered kits for platelet gel formation, such as 
REGENLAB® and PLATELTEX®, which include sodium carboxymethylated cellulose fibres 
(Hydrofibre™) as a biocomposite-scaffold, entrapping human platelets in PRP. The 
PLATELTEX® activation kit, popular in Europe, ensures very rapid gelation and the 
production of platelet and fibrin gel for acute and chronic ulcer treatment. This reduces 
spillage of the gel during topical application. The new generation of PRP activation, 
provides for excellent platelet recovery, collection efficiency and PDGF-AB availability. 
Gelation of the PRP is induced by the enzyme batroxobin, which does not exert 
pharmacological activity after topical gel administration. In Europe, clinical trials have been 
authorised using PRP-gel preparation including activation with batroxobin. PRP-gel has not 
been considered a somatic cell therapy product. 
Platelets treated with thrombin become activated and they release their growth factors 
quickly. Furthermore, thrombin-platelet interaction is a physiological mechanism that 
hastens the clot-retraction rate. On the contrary, platelets treated with batroxobin do not 
become activated; they are passively entrapped within the fibrin network, and their growth 
factor release occurs slowly. In these conditions, the clot retraction takes longer to occur. 
According to these differences between thrombin and batroxobin, it is expected that 
batroxobin-induced PRP activation will tailor the slow release of the platelet content, thus 
providing longer in loco availability of trophic factors. In selected clinical conditions, this 
durable anabolic factor availability might be preferable to a quick thrombin-induced growth 
factor release (Mazzucco et al, 2008). 
An alternative means of PRP activation was documented in 2007, when PRP was pulsed 
with one 300ns pulse with an electric field of 30kV/cm, platelets aggregated and a platelet 
gel was produced (Zhang et al., 2008). 
The lack of effective delivery and the efficient targeting specificity limits clinical applications 
of platelet gel. In 2008, heparin possessing PDGF binding domain was crosslinked to the 
collagen-based demineralized bone matrix (DBM) for the delivery of human PDGF. In in 
vitro experiments, heparin improves the binding of PDGF to collagen. The in vitro activity 
assay indicates that the collagen-heparin-PDGF (CH-PDGF) complex promotes human 
fibroblasts to proliferate on collagen gel. In addition, CH-PDGF stimulates cells to migrate 
into DBM scaffolds after implantation. The histological analysis shows that CH-PDGF 
promotes the vascularization of the implants. In summary, heparin-DBM/PDGF could 
prevent the diffusion of PDGF, prolong its activity, and promote the cellularization and 
vascularization of the scaffold (Sun et al., 2009). 
Recent findings on multiple biological properties of human umbilical cord blood (UCB) and its 
high level of viral safety prompted some authors to investigate the characteristics of its 
platelets and the possibility of producing PG from cord blood. UCB-derived PG releases high 
levels of vascular endothelial growth factor (VEGF) and platelet-derived growth factor-BB 
(PDGF-BB), substantial amounts of fibroblast growth factor (FGF), hepatocyte growth factor 
(HGF) and transforming growth factor-beta 1 (TGFbeta1), and minimal amounts of PDGF-AB. 
These findings suggest that UCB-derived PG can be a preferable tool for tissue engineering 
applications where high levels of VEGF and PDGF may be desirable (Parazzi et al., 2010). 
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8. The results of recent clinical research 
The results of clinical research indicate that platelet-derived growth factors act in synergy 
with plasma-derived factors to activate a complex network of autocrine functions that 
modulate and enhance healing. Therefore, autologous platelet rich plasma (PRP) in the form 
of activated platelet gel and recombinant morphogenic proteins have been used for healing 
all kinds of tissues with various results. 
8.1 Chronic wounds  
When the fibroblasts were sealed in the wound with fibrin to which platelet releasate was 
added, a cellular infiltrate that had characteristics of granulation tissue invaded the wound 
space. Platelet releasate appeared to be an additional requirement for the early induction of 
granulation tissue and for enhanced granulation tissue accumulation. It is now widely 
accepted that the correct strategy to promote the wound-healing cascade is to prepare an 
autologous PRP/platelet gel that contains growth factors, and administer it directly to sites 
of surgical interventions or injuries. 
Patients suffering from diabetes mellitus, are seventeen times more likely to develop 
gangrene and five out of six major limb amputations occur in diabetic patients. In the United 
States, the diabetic foot problem accounts for 20% of all diabetic hospital admissions and 
50% of all non-traumatic amputations. Ulcers occur in 15% of diabetics, and 6-20% of all 
hospitalized diabetic patients have foot ulcers. The topical use of platelet rich plasma may 
play an important role in the initiation of the repair process of chronic wounds. Many 
patients can be treated at home without difficulty, requiring only periodic outpatient 
examination (Steed et al., 1992; Millington and Norris, 2000; Borzini, 2006). Although some 
of the earlier studies resulted in poor outcomes (Reutter et al.,1999), newer studies tend to 
produce much better results. 
8.2 Bone  
Platelet gel is very effective in formation of new bone when applied together with cancellous 
bone containing stem cells for treatment of non healing of long bone fractures (Smrke et al., 
2007). Platelet gel enhanced the bone formation contrary to the using of plasma alone as 
measured by quantity of incorporated bone both in vitro and in vivo (Geuze et al., 2009). In 
an article presented in 2010, 115 patients with finger amputations or wounds were treated 
with platelet gel. Loss of bone tissue represented an obstacle to the total tissue recovery, but 
the aesthetic results were satisfactory in nearly all cases, the recovery of soft tissue in all 
patients ranged from 80 to 100% (Balbo et al., 2010). However, platelet gel was ineffective for 
the spinal fusions where it failed to enhance fusion rate when added to autograft in patients 
undergoing instrumented posterolateral spinal fusion so several authors do not recommend 
its use to supplement autologous bone grafting during instrumented posterolateral spinal 
fusion ( Castro, 2004; Burkus, 2005; De Somer et al., 2006; Savarino et al., 2006). 
8.3 Tendons and ligaments  
Tendons and ligaments naturally have poor blood supply. Damage most often occurs in the 
knee, ankle, shoulder, elbow, wrist, biceps, calf, hamstrings and Achilles tendons. The use of 
platelet gel has been generally well tolerated by the patients and it resulted in significant 
increase of healing parameters. Platelet injection therapy has changed the way orthopedic 
specialists treat sports injury patients. Usually PRP is injected into the damaged area using 
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minimally invasive protocols that involve ultrasonically guided platelet rich plasma (PRP) 
injections. (Everts et al. 2007; Everts et al.,2008; Gardner et al., 2006). 
8.4 Aesthetic surgery 
There is especially extensive marketing for the use of PRP in aesthetic surgery and lifting 
(Bhanot & Alex, 2002; Powell et al., 2001). Private organisations tend to offer this therapy 
throughout the world. They offer PRP delivery by various instruments into the skin tissues, 
rendering good aesthetic effects (see Figure 5). The indications include facelifts, browlifts, 
the creation of flaps, blepharoplasty, mammaplasties, and abdominoplasties. PRP enhanced 
grafts generally had a higher graft acceptance and better graft retention than traditional fat 
grafting techniques, along with decreased swelling and bruising in the donor sites (Sclafani 
et al., 2005;Brown et al, 2006). 
 
     
           A               B 
     
          C               D 
Legend: A: The instrument Mesogun for delivering PRP (U225)as marketed by company Boland; B: The needle 
depth can be accurately set for precise delivery; C: An example of kit for PRP preparation and application from 
Omnimed (Pty)., Ltd., JHB, South Africa; D: An example of platelet gel activation kit PLATELTEX® 
(http://www.bolandcell.co.za/platelet.htm)  
Fig. 5. Use of autologous platelet-rich plasma (PRP).  
8.5 Cardiovascular  
Wound infection is a devastating complication after cardiovascular surgery. This can lead to 
surgical reoperation, prolonged intensive care unit stay, and increased mortality promoting 
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the raising the cost of cardiac surgery while decreasing the patient quality of life. The 
antimicrobial action of white blood cells and platelets, both found in the platelet gel, may 
reduce the potential for infection to develop during cardiac surgery. Various protocols have 
documented such an improved healing of surgical wound in cardiac surgery (Mogan and 
Larson, 2004; Trowbridge et al,2005; Englert et al., 2008; Gunyaqdin et al., 2008) 
8.6 Oral and craniofacial surgery 
As mentioned, the oral surgeons were the leading community in the use of platelet gel for 
transplantation of artificial and natural grafts. Platelet gel reached a huge popularity in 
maxillofacial settings where it is considered standard treatment of bone defects, artificial 
endosseal implants, oral reconstructions, maxillary sinus augmentation, etc. (Marx et al., 
1998; Belli et al., 2005; Pomerantz and Dutton, 2005; Mendez et al., 2006). 
8.7 Other applications 
Platelet gel has been successfully used for ocular diseases, such as for enhanced healing of 
corneal surface and ocular surgery (Koffler, 2006; Liu et al.,2006; Lee & Kang, 2011). 
Lately, the studies of PG use addressed some unexpected fields of medicine. For instance, PG 
was used as a safe and effective tool in the management of mucosal skin lesions related to the 
graft- versus-host disease GVHD. Six patients with multiple lesions involving dermis, 
subcutaneous or oral mucosa and related to GVHD underwent PLT gel as local therapy. After 
the second PLT gel application, the pain disappeared in all cases and the granulation tissue 
was observed in the four patients, five of six patients showed a complete response, while one 
patient with a partial response died early from multiorgan failure (Picardi et al., 2010). 
Platelet gel mixed with centrifuged fat tissue has been successfully applied for the patients 
affected by Parry - Romberg Syndrome (progressive hemifacial atrophy and volumetric 
deficit), which is an uncommon degenerative and poorly understood condition. It is 
characterized by a slow and progressive atrophy affecting one side of the face. The atrophy 
progresses slowly for several years and becomes stable. After stabilization of the disease, 
plastic surgery of autologous fat grafts can be performed. Study suggested a therapeutic 
plan comprised of two sequential treatments: acquisition of platelet gel from a small volume 
of blood (9 ml) followed by the Coleman technique for reconstructing the three-dimensional 
projection of the face contour, restoring the superficial density of the facial tissues. The 
results obtained prove the efficacy of these two treatments combined, and the satisfaction of 
the patient confirms the quality of the results. (Cervelli & Gentile, 2009). 
Recently it is surprisingly becoming clear that platelets have a definite role in the cancer, 
which is probably due to their pro-angiogenesis stimulation and regulation of new blood 
vessel growth through numerous stimulators and inhibitors of angiogenesis, such as 
endostatin and VEGF, by several pathways. Cancer cells probably preferentially stimulate 
platelets to secrete their pro-angiogenic payload, which is counteracted by the anti-platelet 
agent aspirin that inhibits the platelet-mediated angiogenesis (Elisabeth et al., 2011). 
9. Pros and cons of platelet gel therapies 
The common advantages of the PG driven healing can be summarized as follows: there 
seems to be a complete absence of keloid formation, as far as pathologic hyperplasia, 
metaplasia or dyschromia of the healed lesion (Pomerantz et al., 2005, Lundblad & White, 
2005). Other advantages are comfort and pain diminution (Pomerantz et al., 2005, Mendez et 
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al., 2006), less oedema and ecchymosis (Powell et al., 2001; Mendez et al., 2006; Brown et al., 
2006). Particularly valuable advantages are reported through literature: reduced mortality 
after cardiac surgery (Trowbridge et al., 2005), reduced infection rate after cardiac and 
orthopaedic surgery (Gilsanz et al., 2001; Salvadè et al., 2010), reduced transfusion supply 
and hospital stay after orthopaedic surgery (Gardner et al., 2006), reduced amputation rate 
in diabetic foot (Knighton et al., 1990). PRP therapy became very popular in the USA, which 
was due to the fact that it attracted enormous attention after the Super Bowl finals in 2009, 
when the athletes promoted it on TV (Donald, 2011). 
Drawbacks of PG therapies are far less pronounced. It is interesting that besides the 
considerable variability of the clinical studies, PG therapy had practically no or only minute ill 
effects when compared to standard therapies. Owing to the high heterogeneity of the products, 
a need for standardization is a commonly shared sentiment. Heterogeneous production 
generates heterogeneous products which, in turn, have distinct biological properties and 
healing capacities (Zimmermann et al., 2003; Eppley et al., 2006; Fried et al., 2006). 
Considering that heterogeneity involves products, clinical conditions, tissues to be cared for, 
treatment protocols and probably many other minor variables, authors strongly support the 
project for the establishment of a clinical database in order to collect enough data for 
multivariate analysis of the clinical results (Kantor & Margolis, 2000). 
10. The dilemma of allogeneic vs. autologous platelet gel 
In the majority of clinical applications autologous platelets were used for the platelet gel 
formation. As mentioned previously, autologous PG products are prone to enormous 
variability, resulting in scientific scepticism and disbelief regarding the actual value of this 
method. In our study in 2007, we used instead allogeneic PRP. We reported a case of a 50-
year-old type II diabetic male with a comminuted fracture of the tibia and delayed union 
after insufficient initial osteosynthesis with a resulting pseudarthrosis, who was treated 
operatively by using a graft composed of allogeneic platelet gel mixed with autologous 
cancellous bone. Due to a history of diabetes, allogeneic instead of autologous platelets that 
were ABO and RhD matched, leukocyte depleted, irradiated and activated by human 
thrombin were used. No side effects were observed and no immune reactions such as 
platelet- or HLA-class I antibodies were detected (Smrke et al., 2007). 
We explored several advantages of allogeneic platelets, as compared to the classical 
autologous setting. Allogeneic platelet units from the blood bank are available in larger 
quantities, they are safe and affordable, they are highly standardized in terms of platelet, 
residual leukocyte and red blood cell content, the centrifugal forces used for their isolation, 
the temperature of the centrifugation, techniques of separation and processing and the 
composition of the preservative solution, as mandated by international standards in USA 
and Europe. In addition, they are constantly resuspended on agitators in a standard manner 
(Brecher, 2005; Council of Europe, 2011). On the other hand, autologous platelet 
preparations are subject to enormous variability, which hinders serious clinical studies. 
The extensive use of allogeneic platelets could, beside the regenerative medicine, influence 
the blood transfusion policies in future. The platelet units have a short shelf life of 3 – 7 days 
and are therefore prone to outdating, regardless of the best practices performed. In 2001 in 
USA, at least 1,234.000 out of a total of 12,898.000 produced platelet units (9.5%) were 
outdated and discarded (Sullivan et al, 2007). In another study, expiry rates of platelet units 
were different in various hospitals, ranging between 2% and 13.8% (Novis et al, 2002). It is 
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clear from these figures that a considerable amount of platelet units are routinely discarded, 
which could be reversed by the utilization of frozen units in regenerative purposes, such as 
platelet gel preparation.  
Besides, the use of platelet gel could have an important impact on economy of medicine. Let 
us focus only at the therapy of chronic wound with the platelet gel. Ulcer secondary to 
venous hypertension and venous insufficiency is the most common chronic wound with 57-
80% incidence of all chronic wounds. Average incidence is 15-30 in 100.000 persons and they 
account for nearly 70% of all leg ulcers (Margolis et al., 2001). All these conditions are more 
prevalent in elderly population, which represents 20% of the total, a figure that is likely to 
increase to 25% by 2020. In addition, the increased occurrence and longevity of these ulcers 
are further compounded by the detrimental effects ageing has on the skin and the wound 
healing process. Chronic wounds significantly impair the quality of life of more than 9 
million of people worldwide and account for a disproportionate share of healthcare 
expenditures: it is estimated that yearly treatment cost for health care systems averages 9 – 
12 k€ per each patient. Even with increasing knowledge and the development of more 
sophisticated interventions, many clinicians encounter wounds that are hard-to-heal where, 
despite best efforts, wound healing is prolonged or never achieved (Moffatt, 2008). Indeed, 
chronic and hard-to-heal wounds are a challenge to the health care professionals. Thus, in 
the frame of progressively ageing population, the efficient therapy for chronic wounds and 
tissue reparation promises improving life quality and combating rising healthcare costs. 
Currently available and practiced therapies such as wound dressings, pentoxifylline, laser 
and intermittent pneumatic compression treatments applied in concomitance with 
compressive bandages have shown rather disappointing overall outcomes except some 
encouraging results obtained by combination of compression and bilayer of artificial skin 
(Palfreyman et al., 2006).  
11. Conclusion 
Platelets are intriguing cellular particles that have, in the course of human and animal 
evolution, beside their specialisation into the haemostasis, kept some other abilities of 
their predecessors - universal blood cells – the abilities of immune defence and tissue 
forming. For the purpose of tissue forming, platelets can also be used therapeutically. 
Autologous or allogeneic blood can be used for this purpose and centrifuged to produce a 
platelet concentrate, which is then further in vitro activated to form a thrombus-like 
gelatinous substance – the platelet gel. Many in-vitro studies have established that 
platelet- derived growth factors accelerate proliferation of an array of cells involved in 
soft and bony tissue regeneration. These effects have also been evaluated and confirmed 
by numerous in vivo, both in animal and human clinical studies. Consequently, we can say 
that the platelet-derived products currently represent a valuable therapeutic modality, 
offering opportunities for various applications in regenerative medicine and tissue 
engineering.  
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1. Introduction 
Mesenchymal stem cells (MSCs) are multipotent, adult stem cells that show clinical potential 
as therapeutic agents in regenerative medicine(Bruder et al., 1994; Barry, 2003; Alhadlaq & 
Mao, 2004; Gangji et al., 2005; Cha & Falanga, 2007). They are also known as marrow 
stromal cells and are derived from mesodermal tissues. The clonal nature of a sub-
population of marrow nucleated cells was discovered in the 1960’s (Becker et al., 1963). 
These cells were later assayed and renamed “colony forming fibroblasts”(Friedenstein et al., 
1974). Experiments through the 1980’s and 1990’s demonstrated that environmental clues 
assisted MSCs in differentiating into different cell types. For example, culturing with 
ascorbic acid, inorganic phosphate, or dexamethasone could differentiate cells to osteoblasts, 
while culturing in the presence of TGF-beta caused cells to differentiate into chondrocytes 
(Alhadlaq & Mao, 2004). More recently it has been shown that bone marrow MSCs are 
actually a heterogeneous population of similar cells rather than one distinct cell type (Zhou 
et al., 2005). As a result, there is still no uniformly accepted definition of an MSC. Despite 
this issue, some groups have attempted to provide a definition which consists of adherence 
to plastic, MSC specific cell surface markers consistent with MSCs, as well as multi-lineage 
mesodermal tissue differentiation (Schauwer et al., 2010).  
2. Cell source matters 
MSCs can be easily isolated from many anatomic locations, including whole marrow aspirate, 
marrow mobilized whole blood, muscle biopsy, adipose liposuction aspirate, and other tissues 
(Alhadlaq & Mao, 2004). For orthopedic uses, these sources have been compared by many 
authors for their ability to heal bone and cartilage with differences being uncovered. As a rule, 
the closer the source tissue is to the target tissue being treated, the more effective the MSCs 
appear to be at differentiation to the target tissue type. For example, Vidal compared equine 
MSCs derived from bone marrow (bm-MSCs) vs. adipose tissue (a-MSCs) for chondrogenic 
potential and found that bm-MSCs produced a more hyaline like matrix and had improved 
glycosaminoglycan production (Vidal et al., 2008). Additional animal studies demonstrated 
that bm-MSCs produced better repair of a tibial osteochondral defect when compared to a-
MSCs (Niemeyer et al., 2010). Keeping with this trend, Yoshimura determined that MSCs 
derived from the synovial tissue of the knee (closest to the target tissue of chondral cartilage) 
had better chondrogenesis than bm-MSCs (Yoshimura et al., 2007).  
Significant controversy exists over whether adipose or bone marrow are better sources for 
orthopedic tissue repair (Frisbie et al., 2009). While adipose MSCs are more prevalent and 
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are capable of orthopedic tissue differentiation, obtaining orthopedic tissues from these type 
of cells requires the use of considerably more growth factors. In addition, as stated above, 
the native chondrogenic potential of adipose derived MSCs doesn’t appear to be as robust as 
bone marrow derived MSCs.  
3. MSC culture expansion  
A limited amount of cells can be obtained from any tissue. In many instances, the number 
that can be harvested from the source tissue is less than the quantity of cells needed for 
tissue repair. One method of obtaining more cells is culturing to obtain larger numbers. 
However, a delicate balance exists between length of time in culture (which produces more 
cells) and adverse consequences to the cells (such as genetic transformation).  
MSCs are usually culture expanded via monolayer culture, which is a process that involves 
seeding a certain density of cells onto a specialized flask and allowing the MSCs to attach to 
a plastic surface and begin to form colonies. In this way, MSCs are selected from the marrow 
nucleated cell population through adherence. The MSC’s that are adherent are then fed via a 
nutrient broth that is maintained above the growing cells. Oftentimes flasks are used with 
multiple surfaces to enhance cell production versus available incubator space. Because 
MSCs are contact inhibited, they will grow on this surface until they become confluent and 
then abruptly stop propagating. It is commonly believed that this “contact inhibition” 
property of MSCs is a key feature of their enhanced safety profile over other stem cell types 
that will propagate indefinitely without exhibiting contact inhibition. To keep MSCs 
proliferating in culture, when the colonies are near confluence, the non-adherent cells in the 
media are discarded and an enzyme is used to detach the MSCs from the plastic surface. The 
MSCs are then re-plated in a similar flask and fresh media added with this process being 
known as a “passage”. Most MSCs in culture are grown to the 2nd to 5th passage, as some 
studies have shown decreased differentiation if MSCs are grown for prolonged periods in 
culture with a higher chance of genetic mutation (see Fig. 1)(Banfi et al., 2000; Crisostomo et 
al., 2006; Izadpanah et al., 2008). Thus MSC culture is a balance between being able to grow 
additional cells for therapy without culturing for prolonged periods. Most studies consider 
that a “pure” MSC population is obtained after approximately the second passage.  
 
 





4. How MSC’s effect tissue repair  
Animal studies have demonstrated the multipotency of MSCs, and how they can 
differentiate into muscle, bone, cartilage, tendon, and various cells of internal organs. 
However, these cells also act via paracrine mechanisms to assist in tissue repair. For cell 
therapy, paracrine is defined as the production of certain growth factors and cytokines by 
the MSCs which can assist in tissue repair (Ladage et al., 2007). These growth factors include 
TGF-beta, VEGF, FGF, and other signaling factors that can help recruit other cells to the local 
area. In this way, MSCs can act as a coordinator of the repair response without having to act 
directly through differentiation to repair tissue. In fact, some have questioned whether most 
of the positive repair effects observed in experimental MSC therapies are due more to this 
paracrine signaling than differentiation of cells. In the end, it may not matter if MSCs act 
through differentiation or orchestrate the repair response, as long as the robustness of the 
repair meets the clinical need.  
5. Donor vs. autologous MSC sourcing 
Autologous stem cells obviously do not have the same communicable disease transmission 
risk as donor allogeneic cells. However, there may be practical reasons why donor cells are 
attractive. For example, some studies have shown a decreased differentiation potential for 
MSCs obtained from older patients (Zhou et al., 2008). In addition, somatic genetic variants 
(i.e. trisomy V and VII) have been demonstrated in the MSCs and osteoprogenitors of some 
patients with osteoarthritis (Broberg et al., 1998). In addition, allogeneic cells could be able 
to be mass produced in bioreactors, providing a ready supply of cells for therapy. On the 
other hand, some concerns have been raised about the use of allogeneic stem cells. As an 
example, Ueda recently discovered that stem cells transplanted from the bone marrow of 
elderly mice bred to have osteoporosis were able to induce osteoporosis in young healthy 
mice, indicating that the stem cells themselves may be a genetic disease vector (Ueda et al., 
2007). In addition, many have argued that allogeneic MSCs are immune-privileged as they 
lack major histocompatibility complexes; however, Prigozhina has found that allogeneic 
MSCs lose their immunosuppressive potential in a mismatched setting (Prigozhina et al., 
2008). In addition, Huang recently noted that MSCs transplanted for cardiac repair lost their 
immune-privileged status and transitioned to an immunogenic state after differentiation, 
limiting their usefulness in cardiac repair (Huang et al., 2010). In summary, while allogeneic 
MSCs may solve some issues such as cell availability on demand and mass distribution, they 
also present many hurdles that have to be overcome to allow lab to bedside translation.  
6. MSC use in orthopedic specific conditions 
6.1 Fibrocartilage-meniscus repair 
The challenge in repairing the meniscus is due to the poor blood supply of the inner 2/3’rds 
(where many tears occur) versus the good blood supply of the outer 1/3 (red zone-where 
fewer non-healing tears are observed) (Hennerbichler et al., 2007). As a result of these 
differences in meniscus blood and nutrient supply, surgical repair of a meniscus tear is more 
likely to be successful in the outer 1/3 than the inner 2/3rd’s. To overcome this limited 
healing ability of the inner 1/3rd of the meniscus, many surgeons often perform a partial 
mensectomy for tears of this area, which can lead to significant biomechanical abnormalities 
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in the knee (Sturnieks et al., 2010). The promise of stem cells if used to enhance surgery may 
thus be in allowing the surgeon to repair the inner meniscus. For example, Izuta et al 
demonstrated that cultured MSCs may be able to overcome this problem of poor repair in 
the avascular zone. His group was able to demonstrate meniscus repair in the white zone 
when MSCs were transplanted into this area using a fibrin matrix (Izuta et al., 2005). Of 
note, Agung et al (2006) reported a murine model of intra-articular injection after acute 
injury of multiple knee structures, including the meniscus. This model demonstrated that 
for blind intra-articular injection (rather than the local adherent model proposed by Koga), 
the number of cells injected was related to their ability to be found in the meniscus. For 
example, at a dose of 1 X 106 MSCs, none were found in the injured meniscus but at a dose 
of 1 X 107 cells, MSCs were generally found in this area. This may fit well with Koga’s 
hypothesis that MSCs act primarily where they physically attach, as a higher number of cells 
injected into the joint would make it more likely that cells would be able to attach at the site 
in need of repair (Koga et al., 2008). Horie et al (2009) reported that synovial derived MSCs 
that were injected into massive rat meniscus tears were able to differentiate and repair 
meniscal tissue. Of note, the authors also demonstrated that these cells did not migrate out 
of the knee to distant organs, further enhancing their theoretical safety profile for clinical 
use. Finally, Yamasaki et al (2005) validated that MSCs were capable of repopulating the 
meniscus. This investigator cryogenically treated the meniscus to kill the living cells and 
then reseeded it with cultured MSCs. The resulting tissue had appropriate biomechanical 
properties approximating the normal meniscus.  
6.2 Hyaline cartilage: chondral defects 
Some of the earliest models of cartilage repair used autologous, cultured chondrocytes 
(Brittberg et al., 1994). However, the complications of using chondrocytes for cartilage repair 
included hypertrophy, graft failure, long culture times, and the invasiveness of the implant 
procedure (Nejadnik et al., 2010). Because MSC’s are multi-potent and have shown to have 
innate cartilage repair properties through both differentiation and paracrine signaling, 
animal models of cartilage repair using MSCs started to appear in the literature in the early 
1990’s (Caplan, 1991). In these studies an osteochondral defect (OCD) was created 
experimentally and the MSCs were implanted into the lesion, often in a hydrogel or other 
carrier or at times through local adherence (Minas & Nehrer, 1997; Buckwalter & Mankin, 
1998; Angele et al., 1999; Johnstone & Yoo, 1999). Partial to robust healing of the OCD takes 
place over weeks to months (Alhadlaq & Mao, 2004). The cartilage produced by these cells 
was very much like native hyaline cartilage, but subtle differences have been observed 
(Katakai et al., 2009). 
6.3 Biologic scaffolding 
MSCs can be delivered to the lesion area in many different biologic scaffolds including 
hydrogels, fibrin, in native extra-cellular matrix, collagen, or in a suspension. A scaffold is 
a matrix with properties that support cell migration, attachment, three dimensional 
position, and engraftment. Based on unpublished data, we have noted that stiffer biologic 
scaffolds (like dense fibrin glue) tend to reduce MSC viability as they limit MSC 
movement through the material. On the other end of the spectrum is implanting MSCs 
without scaffolding. In this method, cells are delivered in a liquid suspension and slowly 





example, Fig 2 shows histology adapted from Koga et al (2008) demonstrating minimal 
cartilage repair with a control saline injection, minimal repair with MSC’s injected  
intra-articular, and robust repair when MSCs were allowed to attach to the lesion via 
gravity.  
Based on the published data showing the importance of MSC attachment to a lesion, we 
would hypothesize that exact placement of MSCs in a joint is very important. For example, 
blind intra-articular injection of MSCs or the placement of cells into the intra-articular cavity 
after surgery is likely to be less effective for facilitating repair than placement of cells at or 
near a lesion in need of repair. This exact placement of cells has been already used in daily 
orthopedics practice, for example in the Autologous Chondrocyte Implantation procedure 
(ACI) as well as in knee micro fracture. The knee ACI procedure depends on exact 
placement of cultured chondrocytes into an osteochondral defect through injection under a 
surgically prepared periosteal flap. The micro fracture procedure also relies on the surgeon 
creating holes in the osteochondral plate of an OCD (Osteochondral Defect) which allows 
whole marrow and a limited number of MSCs to clot in the defect.  
 
 
Fig. 2. Histology of chondral cartilage repair after staining, showing little repair in a control 
injection, some repair in a blind intra-articular injection of stem cells, and robust repair 
when cells were dripped on the lesion. 
While existing cell based procedures for the knee have some reported success, both of 
these techniques seem to be more effective in younger, athletic patients. In addition, in 
both procedures, the cartilage produced by either chondrocytes or the low concentration 
of MSCs in a micro fracture clot tends more toward non-native fibrous cartilage versus the 
more hyaline like cartilage produced by higher concentrations of cultured MSCs 
(Mobasheri et al., 2009). Recently, McIlwraith et al have improved upon the standard 
micro fracture concept in an equine model by adding MSC’s to the joint after surgery, 
demonstrating better cartilage repair with a combination of micro fracture plus MSCs 
than microfracture alone (McIlwraith, 2010). In this study, the repaired tissue was 
significantly firmer and had higher levels of aggrecan, a molecule that provides 
compressive stiffness to cartilage. 
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6.4 Tendon repair 
Tendon tears are often difficult to treat without a high level of morbidity or re-rupture. 
This may be because of the high tensile strength tendons are required to bear as well as 
the fact that sutures in the tendon itself may reduce local blood flow, further impeding the 
repair process. Awad has published a rabbit model demonstrating that cultured MSCs 
were able to assist healing and produced better tendon appearance than non-MSC treated 
tendons. The MSC treated tendons had better maximum stress, modulus, and strain 
energy density as well as minor improvements in the histological appearance, including 
an increased number of tenocytes and larger and more mature-looking collagen fiber 
bundles (Awad et al., 1999). The same author later published that the seeding density of 
MSCs in the biologic scaffold and control over the rate of contraction of the healing 
tendon were important for successful MSC mediated tendon repair (Awad et al., 2000). 
Chong also demonstrated improved modulus in resected rabbit Achilles tendons treated 
with MSCs and morphometric changes, concluding that MSCs can improve the 
histological and biomechanical parameters in the early stages of tendon-healing (Chong et 
al., 2007). On the other hand, Gulotta was unable to demonstrate efficacy for an animal 
model of surgical rotator cuff tendon healing which showed no differences between MSC 
treated and untreated groups (Gulotta et al., 2009).  
6.5 Intervertebral disc repair 
Traditional spinal surgery treatments for degenerated intervertebral discs continue to show 
disappointing results (Deyo et al., 1993; Elias et al., 2000; Fritzell et al., 2003). While animal 
models of disc repair using MSCs are abundant, human data isn’t readily available. For 
example, Sakai et al (2003, 2006) have published several animal models whereby MSCs are 
usually combined with atellocollagen and inserted into an experimentally created 
degenerative disc. This group of authors has observed encouraging improvements in MRI 
disc hydration, height, and morphology. Richardson et al (2004) and Risbud et al (2004) 
have investigated the co-culturing of MSCs with cells from the nucleus pulposis (NP) 
showing that this technique can produce partially differentiated cells that are capable of 
repopulating the NP in an animal model. Risbud et al (2004) has also used different methods 
for MSC differentiation toward the NP phonotype including using MSC exposure to 
hypoxia and TGF-beta in culture. Zhang et al (2005) has shown that MSCs injected into discs 
without pre-conditioning or co-culture can help to increase proteoglycan production in the 
NP. Finally, Miyamota et al (2010) recently demonstrated that intra-discal transplantation of 
synovial derived MSCs prevented disc degeneration through suppression of catabolic genes 
and perhaps proteoglycan production. In summary, while the results from animal models 
are impressive, questions remain as to whether a quadruped disc with its very different load 
characteristics can serve as an adequate model for bipedal disc repair. In addition, in all of 
the animal models studied to date, an artificially created degenerated disc (acute disc stab 
model) is used as a surrogate for the chronic degenerated discs normally encountered in 
patients (Yoshikawa et al., 2010). 
7. Cell delivery in orthopedics 
Delivery of cells into a joint to treat orthopedic injuries could take two common routes used 





into a confined space such as infiltrating into soft-tissues will likely result in the MSC’s that 
stay local to the injection site. However, as discussed above, injecting in a large joint 
presents some concerns, as multiple animal models have shown that cells may or may not 
find their way into the damaged areas(Agung et al., 2006). Because MSC’s function through 
local attachment to the damaged site, MSCs dripped on a lesion surgically or through a 
needle are another possible implant route. Other injection based methods may involve using 
MSCs tagged with ferrous nanoparticles and magnetic fields to encourage attachment to the 
damaged site (Kobayashi et al., 2008). Finally, since MSCs are capable of chemotaxis, placing 
certain growth factors on the injured tissue may result in more MSCs accumulating at the 
lesion (Fiedler et al., 2002).  
Another challenge in MSC delivery is that most arthroscopic surgery is performed in a 
water environment. For cells in suspension, this presents a challenge, as the MSCs would 
easily be whisked away by the action of arthroscopy pumps meant clear debris from the 
operative site. To overcome this problem, Nejadnik et al (2010) have used a surgical 
approach similar to autologous chondrocyte implantation, where MSCs are placed in a 
dense hydrogel and sutured under a protective membrane. While this technique has 
promise, it’s also more surgically invasive with likely higher morbidity than injection. 
Another alternative method is to adapt the MSC properties to be better suited for the water 
arthroscopy environment. For example, MSCs can be cultured to form a tissue engineered 
construct (TEC) by allowing the cells to produce their own extracellular matrix. The result is 
a pea sized implant with a paste like consistency that can be placed under water arthroscopy 
into a lesion or defect (Ando et al., 2007).  
8. From the bench to the bedside in orthopedics 
The clinical translation of MSCs from the lab to the bedside is clearly imminent. For 
example, our use of MSCs in orthopedics began in 2005 and we have published case studies 
in which positive MRI changes in cartilage and meniscus were observed in knees treated 
with culture expanded MSCs and hips treated with nucleated cell concentrates, 
corresponding with symptomatic improvement (Centeno et al., 2006; Centeno et al., 2008; 
Centeno et al., 2008). We have also noted that the complication rate of expanded MSC 
injection procedures is no greater than other needle-based interventional techniques 
directed at peripheral joints (Centeno et al., 2010). In a submitted and recently accepted 
publication on 339 patients, this safety profile was continued at up to three years post MSC 
reimplantation with over 200 MRI’s of the reimplant sites showing no evidence of ectopic 
tissue or tumor formation (see Fig 3). Other authors have described similar safety profiles 
using more invasive surgical implant techniques. Wakatani described effective treatment of 
cartilage defects in 9 knees with culture expanded MSCs (Wakitani et al., 2007). These 
authors also published an 11-year prospective study of 45 knees (in 41 patients) treated with 
autologous cultured, bone marrow MSCs, with results indicating both safety and efficacy 
(Wakitani et al., 2010). Nejadnik recently described a comparison between surgically 
implanted chondrocytes versus cultured MSCs placed by needle in 72 knees of older 
patients.(Nejadnik et al., 2010) The MSC treated knees demonstrated good safety, less donor 
site morbidity, and better efficacy when compared with an autologous chondrocyte 
implantation procedure. Finally, Haleem has noted that autologous, cultured bm-MSCs re-
implanted into articular cartilage defects in platelet rich fibrin demonstrated evidence of 
healed cartilage in most patients at 12 months post-operative.(Haleem et al., 2010) 
 




Fig. 3. Number of negative MRI follow-ups at re-implant sites for each end-point for 50 
patients tracked after orthopedic MSC reimplantation. 
While very little has been published on intervertebral disc repair in humans, some clinical 
data is available. Yoshikawa recently published on two patients who were treated with 
surgically implanted MSCs that were cultured using a serum free technique (Yoshikawa et 
al., 2010). After two years, no complications were noted and both patients showed modest 
improvements in vacuum phenomena on follow-up MRI. The only other human data of 
which we are aware is that produced by our group from 2005-2010 under IRB supervision 
and now being readied for publication (unpublished data). Our experience demonstrated 
that placing a bone marrow nucleated cell fraction (an enriched MSC population with other 
cells) into the disc via percutaneous means produced no measureable clinical or MRI results 
in patients with degenerative disc disease. Replicating the Sakai study (Sakai et al., 2003), 
where cultured MSCs were placed into the disc in a similar patient population also 
produced little measureable results. Finally, a third case series was performed where 
changes were made in culture and injection technique as well as the diagnosis being treated 
(changed from DDD to chronic disc bulge causing lumbar radiculopathy). This last model 
showed encouraging clinical and imaging results. 
9. Implications in real world clinical applications  
To consider the real world implications of viable cell based alternatives to more invasive 
orthopedic surgeries, total knee arthroplasty (TKA) is an apt model.  Knee replacement 
surgery, also called knee arthroplasty, has been employed increasingly over the past 10 





from discharge data from the Nationwide Inpatient Sample (NIS) of the Healthcare Cost and 
Utilization Project (HCUP), that the number of partial and total knee replacement 
procedures among U.S. patients 65 years and older increased dramatically from 178,653 in 
2000 to 357,472 in 2008 (HCUP, 2008). Knee arthroplasty is associated with substantial 
mortality and morbidity; applying rates derived from 2000 data resulted in an estimated 
4,964 TKA related deaths, 2,788 pulmonary emboli, 2,908 myocardial infarcts, and 4,670 
cases of pneumonia (Mahomed NN, 2005). In contrast, we have recently submitted for 
publication a large case series of 202 knee and hip osteoarthritis patients treated with 
percutaneous injection of MSC’s. As an example, while 2/3’rds of the knee patients were 
TKA candidates, only 6 knee patients reported TKA within an average total surveillance 
period of >2 years despite the injection. In addition, statistically significant differences in 
reported outcome between the treatment and an untreated control were observed. Finally, 
complications rates were minimal compared to TKA.  
10. Regulatory processes 
The regulatory environment in the United States and Europe for stem cells that are more 
than minimally manipulated considers these cells in the same regulatory category as mass 
produced drugs. This “drug” category includes cultured cells, using any cell for a non-
homologous use (for example an adipose MSC for an orthopedic indication), and cells that 
have significant processing beyond a simple centrifugation. This regulatory posture has led 
to a prolonged approval process to bring these technologies from the bench to the bedside. 
While this approach may certainly make sense for mass produced cells being distributed en 
masse in vials, this same approach is also applied to autologous cells where the lot size is 
one patient. As a result, real world clinical knowledge on the clinical use of stem cells in 
patients is largely accumulating outside the U.S. and Europe. Many stem cell clinics have 
proliferated worldwide in countries with less stringent regulatory structures. 
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1. Introduction  
During the last years, several major progresses and improvements have been introduced in 
orthopaedic surgery as innovative and attractive approaches for potentially solving many of 
the limitations of the current therapies. Natural processes of bone repair are sufficient to 
restore the skeletal integrity for most lesions. However, this auto-regenerative potential has 
dimensional limits which require manipulation of natural healing mechanisms to be 
overcome.  
In bone tissue engineering, biomaterials have been therefore proposed as scaffolds to direct 
and guide bone regeneration and to deliver stem cells in anatomical sites where the 
regenerative process is defective. Although material science technology has resulted in clear 
improvements, no ideal bone substitute has been developed yet and hence large bone 
defects still represent a major challenge for orthopaedic and reconstructive surgeons.  
In the past years, scaffolds design has evolved from the obsolete, first-generation “spare-
part” concept, to second-generation bio-inert “cell carriers”, where biomaterials had to 
provide mechanical strength, durability, and possibly operate as cell delivery vehicles to 
achieve the regeneration of the target tissue- up to a third-generation of bio-functional 
materials that seek to incorporate instructive signals into scaffold nanostructures to 
modulate cellular functions, direct cell fate, and finally govern tissue regeneration in vivo. 
They should finally be resorbed in vivo, as soon the neo-formed tissue is able to fully 
substitute the graft.  
The most intriguing concept in modern biomaterials is thus obtaining materials able to 
mimic a specific pre-existing microenvironment and, therefore, inducing cells to 
differentiate in a predetermined manner and to regenerate by themselves the desired tissue 
(i.e. bone tissue) according to physiological pathways.  
In order to reach this ambitious task, intelligent biomaterials should be properly designed 
and an informative microenvironment, mimicking a physiological niche, provided. Any 
material has to be considered informative in the sense that its intrinsic nature (i.e. chemical 
composition) and structure (i.e. macro- micro- nano-architecture) will anyway transmit a 
signal that will be read and decoded by colonizing cells. We still know very little of how to 
create local microenvironments, or artificial niches, that will govern stem cells behaviour 
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and their terminal fate. However, it has been highlighted in the last years that stem and 
progenitor cells are able to modify their behaviour and fate when loaded onto specific 
substrates (Hench and Polak 2002; Dalby, Gadegaard et al. 2007; Hunt 2008).  
Among basic requirements for the design and generation of bone substitute materials, there 
is the development of biomimetic scaffolds with (i) an internal architecture able to favour 
cell migration and in vivo vascularisation, and (ii) a chemical composition permissive to cell 
attachment, selective differentiation and maintenance of cellular functions. 
In this context, the bioengineering challenge become ambitious, since the complex cell-
biomaterial interaction moves on multiple spatial and temporal scales. The micro-
environmental cues, such as chemical environmental variables, are able to stimulate specific 
cellular responses at the molecular level already at early time points (Goshima, Goldberg et 
al. 1991; Ohgushi, Dohi et al. 1993; Fabbri, Celotti et al. 1995; Kon, Muraglia et al. 2000; Erbe, 
Marx et al. 2001; Endres, Hutmacher et al. 2003; Kasten, Luginbuhl et al. 2003; Livingston, 
Gordon et al. 2003; Niemeyer, Krause et al. 2003; Arinzeh, Tran et al. 2005; Kotobuki, Ioku et 
al. 2005; Kondo, Ogose et al. 2006; Fan, Ikoma et al. 2007; Mygind, Stiehler et al. 2007; 
Gigante, Manzotti et al. 2008; Ng, Tan et al. 2008; Bernhardt, Lode et al. 2009; Saldana, 
Sanchez-Salcedo et al. 2009). For example, ceramic scaffolds (i.e. hydroxyapatite) are able to 
induce a faster and more efficient cell adhesion. However, the cell-signalling pathways 
involved in the variation of gene expression are yet to be fully elucidated. Recently, it has 
been reported that cells loaded onto biomaterials are also able to decode the topographic 
cues of the scaffold, and respond to the shape of the micro- environment priming a specific 
cell differentiation pathway (Lenza, Vasconcelos et al. 2002; Dalby, Gadegaard et al. 2007; 
Huang, Lin et al. 2007; Wei and Ma 2008).  
Tissue development and regeneration implies a spatio-temporal assembly of differentiating 
cells organized to create functional structures. This process is finely tuned, progressing 
gradually through cell-matrix and cell-cell interactions. Biomechanical forces generated by 
the contact among the differentiating cells within the tissue or with the ECM, have a 
profound impact on tissue growth, development, maintenance, and repair by providing the 
required metabolic support, strength, and endurance.  
In this chapter, we will discuss about those biomaterials that are being designed and 
manufactured to gain the informative status necessary to drive proper molecular cross-talk 
and cell differentiation. In particular, we will explore: (i) how to develop intelligent 
informative scaffolds, (ii) how stem/progenitor cells decode biomaterials, (iii) promising 
bone substitutes in a tissue-engineering scenario.   
2. How to develop informative scaffolds 
Progress in biomaterials design and engineering are converging to enable a new generation 
of instructive materials to highlight as candidates for regenerative medicine. An emerging 
philosophy aims to overpass the traditional approach of recreating the complexity of living 
tissues ex vivo; in this context, the most ambitious strategy attempts to develop synthetic 
materials that establish key interactions with cells in ways that unlock the body’s innate 
powers of organization and self-repair. The complex cell-biomaterial interaction moves on 
multiple spatial and temporal scales. Therefore, in order to influence effectively the cell 
behaviour, scaffolding materials must bear complex information, coded in their physical and 
chemical structures. In particular, bio-scaffolds must be properly designed to mimic the 
spatial organization of stem cells and their niche physiological structure.  
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Stem cell niche is defined as a dynamic microenvironment that balance stem cells activity to 
maintain tissue homeostasis and repair throughout the lifetime of the organism (Voog and 
Jones 2010). In principle, stem cells in their niche make decisions to either remain in a 
quiescent state, undergo self-renewal, or to exit the niche upon exposure to local or systemic 
stimuli. These signals are actively coordinated and presented in a temporally and spatially 
regulated manner. Proper microenvironmental cues given by the biomaterial may become 
“informative” for cells, stimulating specific cellular responses (Fig.1). 
 
 
Fig. 1. Cell-biomaterial interaction.  
The influence of chemical environmental variables on cell activity (i.e. chemical conditioning) 
was already probed (Goshima, Goldberg et al. 1991; Ohgushi, Dohi et al. 1993; Yuan, Yang 
et al. 1998; Yuan, Kurashina et al. 1999; Boo, Yamada et al. 2002; Kasten, Luginbuhl et al. 
2003; Niemeyer, Krause et al. 2003; Arinzeh, Tran et al. 2005; Fan, Ikoma et al. 2007; 
Nakamura 2007; Guarino, Causa et al. 2008; Cheng, Ye et al. 2009; Saldana, Sanchez-Salcedo 
et al. 2009). For example, ceramic scaffolds (i.e. hydroxyapatite) allow a faster and more 
efficient cell adhesion (Goshima, Goldberg et al. 1991; Ohgushi, Dohi et al. 1993; Yuan, Yang 
et al. 1998; Yuan, Kurashina et al. 1999; Kasten, Luginbuhl et al. 2003; Arinzeh, Tran et al. 
2005; Fan, Ikoma et al. 2007; Cheng, Ye et al. 2009; Saldana, Sanchez-Salcedo et al. 2009).  
The synthesis of complex inorganic materials mimicking natural structures offers exciting 
avenues for the chemical construction of macrostructures and a new generation of 
biologically and structurally inspired scaffolds for tissue engineering.  
Besides chemical conditioning, progenitor cells fate is also affecting by topographic cues of 
the scaffolds (i.e. topological conditioning). Recently, it has been reported that cells loaded 
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onto biomaterials are able to decode the topographic signals of the scaffold, and respond to 
the shape of the microenvironment priming a specific cell differentiation commitment 
(Dalby, Gadegaard et al. 2007). Thus, nanostructured biomaterials such as nanoparticles, 
nanofibers, nanosurfaces, and nanocomposites have gained increasing interest in 
regenerative medicine, since they offer a temporary ECM for regenerative cells (Hollister, 
Maddox et al. 2002; Balasundaram and Webster 2007; Wei and Ma 2008; Zhang and Webster 
2009). 
Recent studies have also shown that in the absence of adhesion peptides, cells interact with 
scaffolds by means of adsorbed protein, and in this regard topography and hydrophilicity 
are key considerations. For example, fibrous meshes with nanoscale fibre diameters have 
shown selective take-up of proteins relevant for cell attachment, such as fibronectin and 
vitronectin (Place, Evans et al. 2009). And whereas hydrophobic scaffolds tend to adsorb 
protein in sub-optimal configurations (with hydrophobic residues displaced towards the 
scaffold surface), hydrophilic polymers adsorb protein in a hydrated interfacial phase 
wherein the proteins are more likely to retain their native conformation (Place, Evans et al. 
2009).  
If the chemical and topographical cues imprint the progenitor/stem cell fate at early time 
points, by reproducing a proper stem cell niche, the 3D architecture design (i.e. pore size, 
total porosity, surface area) of the scaffolds plays a pivotal role at prolonged time of cell-
biomaterial interaction (i.e. macro-micro architecture conditioning). During this phase, as soon 
cells are addressed towards their differentiative fate, it may be beneficial for a biomaterial to 
provide adequate space (porosity) and appropriate surface to foster and direct new tissue 
formation. 
In the bone tissue engineering, for instance, pores are necessary to allow migration and 
proliferation of osteoblasts and mesenchymal cells, as well as vascularization (Gauthier, 
Bouler et al. 1998; Boyde, Corsi et al. 1999; Lu, Flautre et al. 1999; Chang, Lee et al. 2000; 
Hollister, Maddox et al. 2002; De Oliveira, De Aguiar et al. 2003; Karageorgiou and 
Kaplan 2005; Mastrogiacomo, Scaglione et al. 2006). In addition, macroporosity has a 
strong impact on the amount of newly formed bone tissue; moreover, a porous surface 
may improve mechanical interlocking between the implant biomaterial and the 
surrounding natural bone. 
During the newly tissue formation, the internal structure of the scaffolds at a micro-macro 
scale may still influence the pattern of newly tissue formed: whenever a graded and 
geometrically ordered scaffold is offered to the cells as template for bone tissue 
regeneration, lamellar bone tissue is newly formed. Conversely, if neither biomechanical 
cues nor geometrical rules are applicable a bone tissue lacking in structural organization 
will be deposited within the implanted scaffolds (Scaglione et al. 2011). 
2.1 Design of the chemical structure  
A range of responses, such as cell adhesion, viability and differentiation, can be 
differentially affected by particular natural/synthetic substrates. Ideally, the chemical 
structure design of scaffolds for tissue engineering should meet the following criteria: (1) the 
surface should permit cell adhesion, promote cell growth, and allow the retention of 
differentiated cell functions; (2) the scaffolds should be biocompatible, neither the material 
nor its degradation by-products should provoke inflammation or toxicity in vivo; (3) the 
scaffold should be biodegradable and eventually eliminated. 
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In the last years, the generation of biologically and structurally inspired scaffolds 
mimicking the chemical construction of natural structures has been proposed and carried 
out. In many cases, biomimetic strategies do not set out to copy directly the structures of 
biological materials but aim to abstract key concepts from the biological systems that can 
be adapted within a synthetic context. The simplest biomimetic approach involves the 
design of single component systems that mimic the chemistry of the targeted biological 
material. 
In the field of bone tissue engineering, a wide range of biomaterials, whose composition is 
such that they mimic natural bone, has been tested to stimulate ossification and to improve 
the osteogenic potential of osteo-progenitor cells. Calcium and phosphate ions are important 
components during the mineralization phase of the ossification process. Materials composed 
of calcium phosphate such as hydroxyapatite (HA) and tricalcium phosphate (TCP) are 
attractive candidates for bone substitutes (Bruder, Kraus et al. 1998; Gauthier, Bouler et al. 
1998; Boyde, Corsi et al. 1999; Flautre, Anselme et al. 1999; Marcacci, Kon et al. 1999; Kon, 
Muraglia et al. 2000; Dong, Kojima et al. 2001; Dong, Uemura et al. 2002; Livingston, Gordon 
et al. 2003; Gauthier, Muller et al. 2005).  They are also particularly advantageous for bone 
tissue engineering applications as they induce neither immune nor inflammatory responses 
in recipient organisms (Erbe, Marx et al. 2001; Livingston, Ducheyne et al. 2002; El-Ghannam 
2005).  
HA is a natural component of bone tissue and therefore has been considered the ideal 
material to build bone substitutes. The ceramic performs as a mechanical support, an 
osteomimetic surface and as a template for the newly formed bone tissue. On the other 
hand, cells recognize the ceramic surface as pre-existing bone (osteo-mimesis) and 
differentiate into osteoblasts depositing bone extracellular matrix.  
HA coatings have been also proposed to improve the outcome of prosthetic implants, 
improving the interaction between natural bone and implanted device. Porous HA ceramics 
support bone formation by marrow mesenchymal stem cells in vitro and in vivo. However, 
its brittleness and poor resorbability limits its application in the regeneration and repair of 
bone defects.  
To avoid these limitations, polymer materials have received increasing attention and have 
been widely used for tissue engineering applications; in addition to biodegradability they 
also offer an eased processability. There are two kinds of polymer materials: synthetic 
polymer, and naturally derived polymers. The main biodegradable synthetic polymers 
include polyesters, polyanhydride, polyorthoester, polycaprolactone, polycarbonate, and 
polyfumarate.  The polyesters such as polyglycolic acid (PGA), polylactic acid (PLA), and 
their copolymer of polylactic-co -glycolic acid (PLGA) are most commonly used for tissue 
engineering. The naturally derived polymers include proteins of natural extracellular 
matrices such as collagen and glycosaminoglycan, alginic acid, chitosan, and polypeptides. 
Biocompatible polymers have also been regarded as candidates for bone substitutes (Ren, 
Ren et al. 2005; Williams, Adewunmi et al. 2005; Jiang, Abdel-Fattah et al. 2006; Wu, Shaw et 
al. 2006; Bonzani, Adhikari et al. 2007). However, a number of practical problems still 
persist, such as the difficulty in controlling the in vivo degradation of bio-resorbable 
polymers, low efficiency of cell seeding, cytotoxicity of the breakdown products produced 
during scaffold degradation, in addition to poor mechanical properties, incomparable with 
natural hard tissues. 
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To overcome these limitations, ceramic/polymer composite materials have been explored 
(El-Amin, Botchwey et al. 2006; Kim, Park et al. 2006; Leung, Chan et al. 2006; Kretlow and 
Mikos 2007; Ren, Zhao et al. 2007). When used in blends with other polymers, HA particles 
exposed on the surface of scaffolds favour focal contact formation of osteoblasts. A bone-like 
mineral film, consisting mainly of calcium apatite, when layered onto the surface of 
polymeric-based substrates, does not achieve the same effect as when HA is incorporated 
into the bulk material.  
Interestingly, heterogeneous composite scaffolds consisting of two distinct, but integrated 
layers, have been proposed to induce cells towards different lineages, (i.e. cartilage and 
bone) and possibly generate heterogeneous tissues, such as osteochondral grafts (Sherwood, 
Riley et al. 2002; Martin, Miot et al. 2007; Grayson, Chao et al. 2008; Tampieri, Sandri et al. 
2008; Harley, Lynn et al. 2010; Kon, Delcogliano et al. 2010; Lynn, Best et al. 2010). Within 
these informative biomaterials, cells may recognize the differently designed surfaces of the 
graft as pre-existing bone/cartilage tissue (biomimesis) and deposit bone/cartilage 
extracellular matrix accordingly to their specific localization in the scaffold. Experimental 
evidences confirmed that the proper design of layered scaffolds containing distinct 
compositional and structural features that reflect the functional environment of the native 
tissues is able to address progenitor cells to alternate differentiation pathways, thus 
inducing a simultaneous regeneration of multiple tissues (Sherwood, Riley et al. 2002; 
Tampieri, Sandri et al. 2008; Harley, Lynn et al. 2010; Kon, Delcogliano et al. 2010; Lynn, 
Best et al. 2010). 
2.2 Design of the architectural structure  
Porous three-dimensional (3D) scaffolds fabricated from synthetic and naturally derived 
materials have been widely used in different tissue engineering applications, such as 
cartilage, bone, skin, and ligament. Depending on the specific targeted tissue, the internal 
architecture has been intelligently designed and the density, pore shape, pore size and pore 
interconnection pathway of the material predetermined. A key structural parameter, which 
is also common for a wide number of tissue substitutes, is the total porosity, which is 
mandatory for a massive cellular induced tissue formation within the implanted scaffold. 
In the last decade, several methods have been developed to prepare these kinds of porous 
3D scaffolds, including gas foaming (Mooney, Mazzoni et al. 1996; Harris, Kim et al. 1998), 
three-dimensional printing (Hutmacher 2000), phase separation (Schugens, Maquet et al. 
1996; Nam and Park 1999)  and porogen leaching (Mikos, Sarakinos et al. 1993).  
The gas-foaming technique uses high-pressure CO2 gas processing and dissolved gas 
molecules create the macropores noted post processing. The porosity and pore structure is 
dependent on the amount of gas dissolved in the polymer/ceramic structure, the rate and 
type of gas nucleation and the diffusion rate of gas molecules through the material to the 
pore nuclei. The advantages of this method are a large surface area for cell attachment and a 
rapid diffusion of nutrients in favour of cell survival and growth. The drawback of this 
method might be a lack of structural stability of the final scaffold. 
To improve the pore structure, a combination of different techniques may be carried out, 
such as gas foaming and particulate leaching. After expansion, the salt particulates are 
leached out to yield macropores within the scaffold. The overall porosity and level of pore 
connectivity can be regulated by the ratio of material/salt particulates and the size of the 
salt particulates.  
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3D printing is a solid free-form fabrication process, which produces components by inkjet 
printing a binder into sequential powder layers. The part is built sequentially in layers. The 
binder is delivered to the powder bed producing the first layer, the bed is then lowered to a 
fixed distance, powder is deposited and spread evenly across the bed, and a second layer is 
built. This is repeated until the entire part, e.g. a porous scaffold, is fabricated. 
The phase-separation technique is based on thermodynamic demixing of a homogeneous 
polymer-solvent solution into a polymer-rich phase and a polymer-poor phase, usually by 
either exposure of the solution to another immiscible solvent or cooling the solution below a 
bimodal solubility curve.  Solvent is removed by freeze-drying, leaving behind the polymer 
as foam. Morphology is controlled by any phase transition that occurs during the cooling 
step, i. e. liquid-liquid or solid-liquid. 
The porogen leaching method involves the casting of a mixture of polymer solution and 
porogen in a mold, drying the mixture, followed by a leaching out of the porogen with 
water to generate the pores. Usually, water-soluble particulates such as salts and 
carbohydrates are used as the porogen materials. The pore structures can easily be 
manipulated by controlling the property and fraction of the porogen, and the process is 
reproducible. This technique provides easy control of the pore structure and has been well 
established. 
Such hierarchical porous architectures not only define the mechanical properties of the 
scaffold, but also the initial void space that is available for regenerating cells to form new 
tissues (including new blood vessels) as well as the pathways for mass transport via 
diffusion and/or convection (Gauthier, Bouler et al. 1998; Boyde, Corsi et al. 1999; Lu, 
Flautre et al. 1999; Chang, Lee et al. 2000; Hollister, Maddox et al. 2002; De Oliveira, De 
Aguiar et al. 2003; Karageorgiou and Kaplan 2005; Mastrogiacomo, Scaglione et al. 2006). 
While interconnected macroporosity of a biomaterial is important to provide sufficient space 
for cellular activity and tissue deposition, interactions between cells and biomaterials occur 
at the interface, i.e., the entire internal pore walls of a 3D scaffold. Microporosity is thus 
another key parameter of the architectural structure design of the scaffolds. Moreover, an 
incomplete pore interconnection or a limiting calibre of the interconnections could represent 
an important constraint to the overall biological system by limiting blood vessels invasion 
(Mastrogiacomo, Scaglione et al. 2006).  
Besides macro-micro porosity, the design of a proper surface morphology/topography may 
directly and significantly affect cell-scaffold interactions and ultimately tissue formation and 
function (Woo, Chen et al. 2003; Smith and Ma 2004; Woo, Jun et al. 2007; Smith, Liu et al. 
2008). Cells in vivo are exposed to adhesive contacts in all three-dimensions, thus bio-
scaffolds must be organized to mimic the spatial organization of the stem cells niche. 
Extensive efforts have been therefore made to identify scaffolds that resemble the natural 
extracellular matrix (ECM). As well as requiring information from each other, cells derive a 
vast wealth of information from their environments, including the material that surrounds 
and separates them within tissues, the ECM. An informative material scaffold must take on 
this instructive role to some degree in order to maintain cell viability and control cell 
behaviour.  
Advanced manufacturing techniques can be used to control the spatial sub-micrometric 
internal architecture in engineered tissues, manipulating the scaffold topography on the length 
scale of the stem cell niche and smaller. It has been demonstrated that nanofibrous polymeric 
scaffolds offer to the cells biomimetic configurations that resembles ECM collagen fibers in 
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their ability to support the differentiation of progenitor/stem cells along adipogenic, 
chondrogenic, and osteogenic lineages (Yang, Murugan et al. 2005; Badami, Kreke et al. 2006; 
Erisken, Kalyon et al. 2008; Bashur, Shaffer et al. 2009; Wise, Yarin et al. 2009).  
Nanotechnology, or the use of nanomaterials, may help to realize materials mimicking 
surface properties (including topography, energy, etc) of natural tissues. For these reasons, 
different approaches toward the formation of nano-fibrous materials have emerged in the 
last years: self-assembly, electrospinning and phase separation (Jayaraman, Kotaki et al. 
2004; Vasita and Katti 2006; Barnes, Sell et al. 2007; Smith, Liu et al. 2008; James, Toti et al. 
2011). Each of these approaches is very different but has a unique set of characteristics 
which lends to its development as a scaffolding system  with a potential to accommodate 
cells and guide their growth and subsequent tissue regeneration.  
For instance, self-assembly can generate small diameter nano-fibers in the lowest end of the 
range of natural extracellular matrix collagen, while electrospinning has only generated 
large diameter nano-fibers on the upper end of the range of natural extracellular matrix 
collagen. Moreover, electro-spinning can be used to generate polymeric scaffolds with 
aligned nano-scale fibers that direct spatial adhesion and orientation of cells upon 
differentiation. Phase separation, on the other hand, has generated nano-fibers in the same 
range as natural extracellular matrix collagen and allows for the design of macropore 
structures. 
In addition to the dimensional similarity to tissue compartments, nanomaterials also exibit 
unique surface properties due to their significantly increased surface area and roughness 
compared to conventional or micron structured materials. Material surface properties 
mediate specific proteins adsorption and bioactivity, further regulating cell behaviour and 
tissue regeneration (Sato and Webster 2004; Balasundaram and Webster 2006; Liu and 
Webster 2006). 
3. How stem/progenitor cells decode biomaterials  
Although the identification of mesenchymal stem cells (MSC) is currently a matter of 
discussion, these cells have become attractive targets for clinical applications and a large 
number of studies on use in regenerative medicine have been produced (Tonti and 
Mannello 2008). The classic paradigm for tissue engineering considers seeding an 
appropriate cell source, like MSC, on or within a scaffold that facilitates cells growth, 
organization and differentiation into a specific and functional tissue. 
Regardless of the topography and of the chemistry of the scaffolds, the constructs must also 
provide some level of physical support from the moment of implantation, to assist cell 
attachment and provide room for the deposition of new matrix, if needed for tissue 
reconstitution. This clearly implies close contact between matrix proteins, either of 
endogenous (cellular) or exogenous (secreted) origin, and the scaffold, a “play-of-three” that 
is extremely relevant for the cell. 
In living tissues the main extracellular matrix constituents are comprised within a few 
macromolecule classes, such as collagens, elastin, proteoglycans, hyaluronic acid -and its 
derivatives- and adhesion glycoproteins (among which fibrinogen and fibronectin, tenascins 
and thrombospondins). Alternative splicing and secretion of different proportions of the 
ECM components allow the generation of a wide range of matrices, ranging from basal 
lamina to bone. Often the prototypical scaffolds for the cell-based repair of mesenchymal 
tissues (mainly cartilage or bone, or both), whether composed of ceramic or biodegradable 
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polymers, can be tailored to support cell adhesion and to degrade at rates coincident with 
new tissue development. However, on both scaffold types, the mechanism of cell adhesion 
is indirect and relies onto the deposition of extracellular matrix proteins by the seeded cells 
(Murphy, Hsiong et al. 2005; Chastain, Kundu et al. 2006). As a result, ceramic or 
biosynthetic scaffolds may lack at first the specificity of the original tissues, i.e. the 
exogenous proteic signals that ease cell adhesion, undermining the recognition of the local 
microenvironment by the cells and the consequent repair processes. For engineered tissue 
repair, then, it is critical to understand the mechanisms by which cells first recognize the 
surfaces and structures on which they are seeded and how these, in turn, may govern cell 
functions and influence cell-mediated remodelling events at the interfaces between the cell-
seeded constructs and the host tissues. 
3.1 The role of cell adhesion molecules as active mechanosensors 
Cells normally sense the microenvironment elasticity as they anchor and pull on their 
surroundings. These processes relay in part on specific adhesion proteins- myosin, integrins, 
cadherins- able to transmit forces to the substrates. Considerable attention has been posed in 
understanding the cell responsiveness to external forces, ranging from fluid flow to 
stretching and twisting (Alenghat and Ingber 2002).  However the cells respond also to the 
sensed resistance, whether it comes from normal tissue matrix or from synthetic substrata, 
with cytoskeletal alterations.  The most recent literature points out to the existence of a 
feedback loop, in which cell-exerted forces are coupled to microenvironmental elasticity able 
to induce subsequent and additional changes to cellular responses (Discher, Janmey et al. 
2005). Typically four protein families are involved in the adhesion processes: IgCAM, 
selectins, cadherins and integrins. The first three interact with complementary 
proteins/ligands on the partner cells surfaces, whereas integrins bind prevalently to 
extracellular matrix proteins. The expression of restricted isoforms of each of these classes of 
proteins allows specific interactions among cells and extracellular matrix, an essential 
requisite for embryonic development, tissue regeneration and force transmission. However, 
in the light of scaffold surface recognition, integrins and cadherins are of paramount 
importance for sensing the microenvironment external to the cell. Integrins are 
heterodimeric receptors made of two transmembrane chains, α and , both contributing to 
binding specificity. A combinatorial strategy allows the vertebrate cells to express several 
sub-sets of integrins by selective combinations of 18 different α chains and additional 8 
different  chains. At least 24 different dimers are so far known. The cytoplasmic tails of the 
intergrins, extracellularly linked to ECM components, bind to actin filaments of the 
cytoskeleton to generate focal contacts, through the concerted action of talin and vinculin. 
Another adaptor protein, paxillin, binds the integrins to recruit Src and FAK (focal 
adhesion) tyrosin-kinases, (Critchley 2000; Turner 2000). This chain of events promotes, 
within minutes, a rise of the intracellular Ca2+ concentration and the development of 
mature focal contacts, named focal adhesion sites, anchoring the actin stress fibers to the cell 
membrane. The tension generated by the organized stress fibers on the adhesion sites is 
maintained during cell movement and migration. Cell adhesion onto a specific substrate 
depends, then, on the integrin density on the cell surface, on the ligand concentration on the 
substratum surface and on their reciprocal affinity. The rapid association/dissociation of the 
integrin/ligand complexes allows the cell to redefine the interactions with the ECM during 
anchoring, movement and migration (Bercoff, Chaffai et al. 2003). 
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The importance of sensing the mechanical properties of the ECM within the cell 
surroundings has been clearly established in studies with tumor cells and fibrobroblasts 
(Discher, Janmey et al. 2005; Paszek, Zahir et al. 2005). Indeed tumors (often detected as a 
rigid mass within softer tissues) display a peculiar rigidity, in part due to the interstitial 
pressure caused by a perturbed vascular structure, in part due to fibrosis, but in part also 
due to an increase of the elastic module of transformed cells as a consequence of an altered 
cyto-architecture (Beil, Micoulet et al. 2003). A current understanding is that cells take 
advantage of actinomyosin contractility for dual interactions with the matrix. Cell 
contraction at integrin-based adhesion sites is essentially resisted by the matrix, and is 
followed by the accumulation of additional molecules at the sites involved. This process 
comes to a balance when tension forces are equilibrated at the cell-matrix interface. 
Regardless of the non-malignant or malignant nature of the cells, the mechanotransducing 
functions of integrins represent a major focus of several researches (Bershadsky, Balaban et 
al. 2003), Integrins are known to regulate Rho- and growth factors-ERK (Extracellular signal-
regulated kinase) dependent growth (Lee and Juliano 2004). At the same time ERK influence 
ROCK (Rho-associated protein kinase) and myosin activity (Huang, Kamm et al. 2004). 
Interestingly matrix stiffness modulates growth factor signalling and Rho GTPase activity 
(Wang, Weaver et al. 1998); moreover, Rho activity is elevated in stiff tumors and is linked 
to cell invasivness, although single members of the Rho family are differently involved in 
branching and lamellipodia broadening (Vega, Fruhwirth et al. 2011); instead ROCK 
activation contributes to  cell contractility by inhibiting depolimerization of actin filaments 
(Paszek, Zahir et al. 2005). In epithelial morphogenesis, for example, matrix stiffness clusters 
integrins and these, in turn, enhance ERK activation and ROCK-generated contractility and 
focal adhesion. Indeed non-malignant mammary epithelial cells can be induced to form 
normal polarized and growth-arrested acinar structures in basal membrane, laminin-
containing collagen I gels that match stiffness of normal mammary gland stroma. However 
even a small increase in matrix stiffness (by changing the gel cross-linker ratios) significantly 
compromises tissue organization, inhibits lumen formation and disrupts adherens junctions, 
as testified by a diffused  -catenin and non co-localized E-cadherin and  -catenin. Integrin 
α31 and talin are involved in the normal adhesion machinery, both on soft and stiff 
substrata; however epithelial cells interacting with a soft matrix assemble focal complexes 
and express high amounts of total and active Src family kinase, whereas on a stiff matrix, 
cells spread and assemble stress fibers, activate more ERK in response to growth factors, and 
form focal adhesion sites with FAKpY397 and vinculin (Paszek, Zahir et al. 2005). These 
events are in compliance with altered levels of integrin expression in stiff tumors (Guo, Ma 
et al. 2009) as well as in rigid 2D substrata with respect to 3D matrices (Yeung, Georges et al. 
2005). Interestingly a similar behaviour was also observed in fibroblasts, where a 
phosphorylated FAKpY397 and vinculin were recruited to α51 adhesion sites on stiff gels, 
although in this case force-dependent integrin aggregation precedes the appearance of 
FAKpY397 (Nicolas, Geiger et al. 2004). Force-dependent integrin anisotropy, as a result of 
matrix stiffness sensing, was demonstrated to be of relevance using integrin mutants 
(V737N) that promoted self-association through enhanced hydrogen bonding in the 
transmembrane domain of the protein. Although integrin clustering was not induced on 
stiff substrata, on soft gels V737N integrin-expressing cells spread significantly more, 
formed larger adhesion sites, expressed FAKpY397 and activated more ERK in response to 
growth factors (Paszek, Zahir et al. 2005). A mechanoregulatory circuit, then, integrates 
physical cues from the extracellular matrix with focal adhesion sites, through ERK- and 
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Rho-dependent cytoskeletal contractility, and regulates cells and tissue phenotype. 
Unbalance in integrin expression was also detected when placent-derived mesenchymal 
stromal cells were induced toward angiogenesis; VEGF-mediated adhesion and migration of 
placental-derived MSC onto fibronectin correlated with enhanced expression of α51; at the 
same time anti- α5 or anti- 1 antibodies inhibited angiogenesis when cells were cultured 
on chick corioallantoic membranes (Lee, Huang et al. 2009). 
In fibroblasts fluorescence imaging has shown that F-actin fibers and stress fibers become 
increasingly organized if cells are cultured on increasingly stiffer substrates (Discher, 
Janmey et al. 2005). Contractile myotubes, instead, display strong focal adhesion and stress 
fibers when cultured on stiff gels or on glass micropatterns; they will however display 
actomyosin striation if cultured on top of a first layer of muscle cells (Discher, Janmey et al. 
2005), Similarly, heart cells pulling on equally stiff heart cells can generate a positive 
feedback on their cytoskeletal organization that may not occur when the substratum is a 
scaffold or a different cell type. However variations and differences between cell types 
imply active and regulated responses, rather than a universal need of cells to exert traction 
forces; differences may depend in part on the expression and engagement of adhesion 
molecules, like it happens in the generation of shell-to-core cell aggregates obtained when 
randomly mixing two different cell types. Such an event was detected when mixing 
cardiomyocytes and retinal cells and is currently explained by the generation of surface 
tension at the interfaces of cell layers originated from low and high N-cadherin expressing 
cells (Discher, Janmey et al. 2005).  
Cadherin-mediated interactions are prevalently homophylic, Ca2+-dependent and are 
responsible of driving cells into close contact through the organization of adherent junctions 
and desmosomes. Their common structural characteristic is the CAD domain, a folded 
structure organized in 7 -sheets. Calcium ions bind between two CAD adjacent domains 
rendering the structure stiff, but the domains are free to rotate if the if the ions are not 
bound. Several cadherins display more than 5 extracellular CAD domains, arranged for 
trans or cis binding with other cadherin partners on the opposite cell (He, Cowin et al. 2003).  
Cadherins contribute to growth contact inhibition; their cytoplasmatic tails bind adaptor 
proteins of the catenin family, linking cell-to-cell recognition to signal transduction 
pathways (Hamidouche, Hay et al. 2008). Cadherin-mediated adhesion was in fact linked to 
GTPase-cytoskeleton signalling (Delanoe-Ayari, Al Kurdi et al. 2004). Interestingly this 
process presents similarities with the self-organizing condensing mesenchymal cells that 
drive the growth of the pre-cartilagineous anlage in limb bud development through growth 
factor diffusion-processes and aptotaxis, although contribution from the latter seems relative 
(Christley, Alber et al. 2007).  
In vitro chondrogenesis of MSC offers additional cues to dissect the pathways involved in 
cell shape-mediated commitment to differentiation. Chondrogenesis of MSC is induced 
when cells are cultured in high-density micromass pellets and stimulated with transforming 
growth factor  (Mackay, Beck et al. 1998). Rac1, another small GTPase, displayed a much 
higher activity in MSC undergoing smooth-muscle cell differentiation if compared to the 
same cells induced to chondrogenesis. Rac1 further regulated N-cadherin expression, a 
known requirement for smooth-muscle cell differentiation (Gao, McBeath et al. 2010). 
However it should be remembered that a dominant negative Rac1 was not sufficient to 
inhibit N-cadherin upregulation in the presence of TGF  3, thus suggesting the possible 
presence of additional contributor proteins. The cytoplasmic domain of N-cadherin is 
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indirectly linked to the cytoskeleton via the α-,  - and p120-catenin complex; deletion 
mutants of N-cadherin, lacking the  -catenin binding site, failed to support smooth-muscle 
cell differentiation of MSC, highlighting the role of these protein complexes in cell fate. 
Indeed cadherins are known to be implicated in mesenchymal condensation, although their 
expression is normally downregulated during chondrocytic differentiation (Oberlender and 
Tuan 1994). Possibly a concerted action of N-cadherin and Rac1 is necessary for myogenic 
differentiation of MSC, ensuring cell-to-cell contact; this may be a transient requirement that 
becomes unnecessary once cells get separated and encased in extracellular matrix during 
chondrogenic maturation. 
3.2 Progenitor cells’ lineage commitment: A matter of feeling 
Transient signals, then, may be responsible of limited (time-wise and intensity-wise) cellular 
responses: other factors, such as soluble inducers in the growth medium, may also couple to 
matrix anchorage, as it was demonstrated for fibroblasts (Nakagawa, Pawelek et al. 1989), 
also  derived from mesenchymal progenitors. 
It is well known that differentiated cells of mesenchymal origin adhere and contract not only 
within soft tissues, but also on a variety of substrates in vitro, such as on collagen-coated 
acrylamide gels and glass (Engler, Sen et al. 2006). Such a wide range of possible adhesion 
substrates parallels a wide variation in matrix stiffness sensing, which in turns influences 
focal adhesion structures and the cell cytoskeleton (Cukierman, Pankov et al. 2001; Discher, 
Janmey et al. 2005). However, for tissue engineering purposes, pluripotent stem cells, rather 
than terminally differentiated ones, represent the gold standard for current and potential 
clinical applications (Peters, Schell et al. 2010; Ding, Shyu et al. 2011). In the last years it has 
been shown that stem cells or progenitor cells can be isolated from almost every tissue of the 
body (Bianco and Robey 2001), including menstrual blood (Ding, Shyu et al. 2011). Under 
the correct conditions, these cells can be stimulated to form new tissue, by using a simple 
biomaterials-based approach (Bianco and Robey 2001; Boo, Yamada et al. 2002; Cancedda, 
Bianchi et al. 2003; Barrilleaux, Phinney et al. 2006; Hutmacher, Schantz et al. 2007; Gigante, 
Manzotti et al. 2008; Hunt 2008) 
In principle, stem cells in their niche undergo self-renewal, or exit the niche upon exposure 
to local or systemic stimuli. During tissue development and repair these signals are actively 
coordinated and are presented in a temporally and spatially regulated manner (Connelly, 
Garcia et al. 2008; Santiago, Pogemiller et al. 2009); for example the ECM surrounding 
osteogenically differentiating MSC is dynamically remodelled: biglycan is first detected in 
bone marrow surrounding MSC but not in unmineralized or in mineralized bone matrices; 
fibronectin and versican are observed in the regions of early mesenchymal condensation but 
they disappear in mature bone; decorin is present in unmineralized matrix but absent in 
mineralized bone (Hoshiba, Kawazoe et al. 2009). Indeed, bone marrow-derived 
mesenchymal stem cells (BMSC) represent a widely used class of progenitors, due to their 
ability to differentiate into several lineages (for ex, osteogenic, chondrogenic, myogenic or 
neurogenic), each of which is characterized by different matrix microenvironments and 
anchorage-dependent requirements (Goessler, Bieback et al. 2006; Djouad, Delorme et al. 
2007; Boskey, Doty et al. 2008). At the tissue level, in fact, matrix stiffness accounts for 
distinctive ranges (Engler, Sen et al. 2006).  The resistance that a cell feels when it deforms 
the ECM can be measured by the elastic constant of the matrix microenvironment, E, with 
values that range from 0.1-1.0 kPa (soft tissues, for example brain), to 1.0-20.0 kPa (muscle) 
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up to >25.0 kPa for bone. By controlling the matrix elasticity in polyacrylamide gels through 
the cross-linker (bis-acrylamide) concentration, and by providing adhesion by coating the 
gels with collagen I, known to support myogenic and osteogenic differentiation, Engler and 
co-workers (2006) demonstrated that matrix stiffness, in spite of the same culturing 
conditions and medium supplements, can specify MSC lineage differentiation. 
Among the cell’s cytoskeletal motors, the non-muscle isoforms of myosin II (NMM II) (Kim, 
Kovacs et al. 2005) are suitable candidate mechanotransducers, able to generate signals 
proportional to the matrix deformation. The three existing isoforms (non-myosin II A, B or 
C) are involved in tensioning cortical actin structures linked to focal adhesion sites. These 
actin bridges transmit the force from the cell inside to the elastic matrix (Tamada, Sheetz et 
al. 2004) and are associated with signalling molecules (Bershadsky, Balaban et al. 2003). A 
counterproof of the involvement of non-myosin II in sensing matrix stiffness in MSC derives 
from the use of a specific NMM II-inhibitor, blebbistatin, which does not exerts its function 
on any other form of MSC myosin, other than myosin VI (Limouze, Straight et al. 2004). The 
administration of this molecule during MSC plating on different matrices blocks cell 
branching, elongation and spreading, but it has no relevant effect if exposure is carried out 
after cells have already spread and adopted a specific morphology, or 24 hrs post-seeding. 
Within this time frame, in fact, blebbistatin, was shown to inhibit the actin-dependent 
activation of the NNM II ATPase activity; these results were also confirmed by the use of an 
additional inhibitor specific for the myosin light chain kinase (MLCK), known to activate 
NNM II (Dhawan and Helfman 2004).  Results lead to the conclusion that indeed NNM II 
appears to be necessary for matrix-elasticity driven lineage specification in MSC. 
Traction stresses also modify the surrounding matrix around the cells. Although larger 
tractions are exerted on stiffer surfaces, typical tractions (τ ~ 1KPa) exceed by far the viscous 
traction exerted by culture fluid on the cells. Moreover if matrix strain is relatively constant, 
cells need to be less contractile on soft gels than on stiff ones. Thus their adhesion will not be 
as strong, as it has consistently been measured by reduced forces needed to peel off cells 
from gels versus glass (Engler, Griffin et al. 2004). 
Local sensing of force and/or geometry are therefore transduced into biochemical signals 
that regulate cell growth, differentiation shape and even cell death (Vogel and Sheetz 2006). 
Stiffness sensitivity and consequent cytoskeletal reorganization, however, not only interest 
the membrane/cytoplasmic compartment: nuclear deformations also take place in response 
to cytoskeletal modifications, cell cycle and division. Chromatin and laminin B contribute to 
the viscoelastic properties of the somatic cell nucleus, with single contributions prevailing 
according to the swelling condition of the nucleus. The nucleus is stiff and resists distortion 
at short times, whereas it undergoes deformation at longer times, providing essentially an 
infinite spectrum of timescales for structural reorganization and genome expression kinetics 
(Dahl, Engler et al. 2005). Nuclear deformation was also reported in response to culture 
conditions of MSC; static or perfusion cultures on 3D poly(ethylene terephthalate) scaffolds 
affected the ability of MSC to synthesize and deposit and organized ECM network, but, at 
the same time, affected nuclear shape: only cells in perfusion cultures displayed uniform 
spherical nuclei. Interestingly, cells in perfusion systems down-regulated Rex-1 and Oct-4 
stemness-related genes, implying that a less primitive stem cell phenotype was retained in 
the perfusion cultures (Zhao, Grayson et al. 2009). This is in accordance with a possible 
stiffness sensing-dependent lineage commitment previously described, which would couple 
a stiff scaffold with a loss of the pluripotency and with an osteogenic-oriented MSC 
differentiation. 
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Once naive MSC are exposed to specific matrix stiffness, then, their gene transcription 
machinery up- or down-regulates specific gene subsets; immunostaining of cytoskeletal 
markers and transcription factors across the range of the tested matrix stiffnesses proved 
consistent with the lineage profiling in the experiments carried out by Engler and 
collaborators (2006): gene expression of markers for neurons, muscle or bone was induced 4- 
to 6-fold on the corresponding substrate with high specificity. Only stem cells grown on soft 
substrates with brain-like compliances expressed a phosphorylated form of neurofilament 
heavy chain. By converse myoD, a marker of muscle differentiation, and CBFα1, a 
transcription factor required for osteogenic differentiation, were expressed by cells grown 
on intermediate or rigid substrates, respectively. However it should be noted that 
expression levels for other markers was limited to only 50% of the standard level in 
terminally differentiated culture cells; muscle lineage-specific integrins expression was 
furthermore absent, evidencing that matrix stiffness compliance can drive the progenitor 
cells toward a developmental route but may not be sufficient per se to ignite terminal 
differentiation. Interestingly a bioinformatic approach also revealed that in mesenchymal 
stem cells genes regulated by high ECM stiffness included those indicative of the activation 
of two transcription factors downstream the Hippo signalling pathway, a highly conserved 
pathway involved in restraining cell proliferation and promoting apoptosis: YAP (Yes-
associated protein) and TAZ (a transcriptional co-activator with a PDZ-binding motif, also 
known as WWTR1). Stiff surfaces induce nuclear translocation and activation of both 
factors, whereas their location was predominantly cytoplasmic and inactive in cells grown 
on soft matrices (Dupont, Morsut et al. 2011). In spite of the participation to the Hippo 
pathway, nuclear localization of the transcription factors was mainly due to the activity of 
the already cited Rho GTPase activity. Both factors are known to bind to Runx2, a 
transcription factor essential for osteogenic differentiation of mesenchymal cells. In a 
relevant set of experiments Dupont and co-workers (2011) demonstrated that depletion of 
YAP and TAZ prevented osteogenic differentiation of MSC cultured on stiff matrices and 
conversely promoted their adipogenic differentiation, thus elucidating the primary role of 
these factor in translating the cell mechanosensitivity from the cytoplasmic machinery to the 
nuclear/gene expression level.  
3.3 Topography and surface chemistry: links to the mechanosensitivity of the cell  
The optimization of the interactions between a scaffold matrix and the cell counterparts of 
the constructs can also be pursued by a specific biomimetic functionalization and/or 
nanostructuration of the interface. For prosthetic applications in orthopaedics, for example, 
cell attachment to grooved materials (Eisenbarth, Velten et al. 2007) and to nanocristalline 
coatings (Nicula, Luthen et al. 2007) has been documented since long. Indeed the interaction 
of the cells with the surrounding materials is within the nanometer scale. Thus nanoscaled 
topography of synthetic materials has attracted raising consideration because of its 
resemblance to in vivo surroundings, and mammalian cells were demonstrated to response 
to topographical surface variations (Silva, Czeisler et al. 2004; Dalby, McCloy et al. 2006; 
Dalby, McCloy et al. 2006). For articular chondrocytes, cell motility was increased when cells 
were cultured on 8 µm-deep grooved plastic-ware. Cells spread and oriented along the long 
axis of the groove. F-actin condensation was evident along the groove/ridge boundaries, 
correlated with a doubled velocity at which cells moved and was associated with a loss of 
the cell chondrogenic potential. Conversely 750 nm-deep grooves induced a reduced 
migratory capacity (Hamilton, Riehle et al. 2005; Hamilton, Riehle et al. 2005). 
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 Although transdifferentiation of mesenchymal stem cells to neuronal lineages can be forced 
through specific induction media (Woodbury, Schwarz et al. 2000; Deng, Obrocka et al. 
2001; Qian and Saltzman 2004) the mechanisms are not well understood. Nonetheless 
cultures of human MSC on nano-patterned plastic-ware, with gratings of 350 nm linewidth, 
an order of magnitude lower than the cells size, showed morphological changes in cell 
bodies and nuclei. A substantial confirmation of a new phenotype came from gene 
expression and microarray studies, in which microtubule associated protein 2 (MAP2) and 
β–tubulin III (Tuj1), both neuronal markers, were detected (Yim, Pang et al. 2007).  
In the light of these results, it is reasonable to suppose that specific nano-patterning(s) may 
be compliant to or guide specific distribution(s) of the cell adhesion molecules within the 
cell surface. This distribution mirrors the one that cells would adopt in response to specific 
stiffness and elasticity of an underlying contact surface. The overall result is that nano-
patterning may anticipate the cell response to a specific substratum and induce the 
consequences of cells adhesion onto it. 
Clearly, once a cell has somewhat “decoded” its substrate and has ignited a new gene 
expression program in response to exogenous/endogenous stimuli, the secreted 
extracellular matrix protein will contribute to modify the microenvironment and to further 
drive the cell along a specific differentiation pathway. For example passive adsorption of 
two matrix protein like vitronectin (VN) and type collagen I (Col I) onto polymeric 
substrates were shown to mediate MSC adhesion and differently induced activation of 
mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K) signal 
transduction pathways (Kundu and Putnam 2006). Recent findings reveal that the de novo 
synthesis and deposition of ECM proteins by MSC alters the chemical identity of the 
polymeric substrate, stimulating changes in the integrin expression profiles. In turn these 
changes promote modifications in the MAPK and PI3K signalling pathways, therefore 
influencing the osteogenic differentiation of the seeded cells. Increasing amounts of 
fibronectin and Col I and decreased amounts of VN are in fact being deposited on 
poly(lactic) glycolic acid scaffolds over a 28-day period. The cell receptors pattern changed 
accordingly, providing higher levels for α51 and α21 integrins, (receptors for fibronectin 
and Col 1, respectively) and reduced levels for αV3 integrin (VN receptor). 
Mechanistically, cell adhesion to Col I and fibronectin has been shown to induce the MAPK 
cascade, in particular the activation of the ERK1/2 system, critical for the activation of the 
osteogenic transcriptional factor Runx2 (Xiao, Jiang et al. 2000; Franceschi and Xiao 2003). 
Specific integrins then seem to be preferred or even required for the osteogenic 
differentiation of MSC. It should be remembered, though, that multiple integrins can bind a 
single ECM protein and that multiple ECM proteins can bind a single integrin (Miranti and 
Brugge 2002). Therefore a biofunctionalization of a scaffold surface should not focus on the 
presentation of a uniform coating to engage a single receptor, but rather identify the 
properties that control the presentation of integrin-specific epitopes within the coatings 
(Keselowsky, Collard et al. 2005). 
Clearly several additional chemical modifications can be introduced and applied to almost 
any specific substrata, provided that the proper chemistry is used; indeed many strategies 
and approaches are currently being tested (Fu, Wang et al. 2011), ranging from simple 
coatings onto specific substrates (Uygun, Stojsih et al. 2009), to the contemporary use of  
genetic engineering and structural approaches (Benoit, Schwartz et al. 2008; Gorsline, 
Tangkawattana et al. 2010), to combinations of matrix-mimicking ligands and engineered 
structured nanomatrices (Anderson, Kushwaha et al. 2009). The same natural extracellular 
 
Advances in Regenerative Medicine 
 
378 
matrix is per se able to induce specific cell commitment (Chen, Dusevich et al. 2007). Thus 
the combination of topographical and chemical cues may result in a synergistic effect, in 
some cases useful enough even to direct cell differentiation of adult MSC stem cells to non-
canonical pathways, such as neuronal differentiation. Interestingly the effects of growth 
conditions onto a nano-patterned surface were stronger than the single biochemical 
induction on controls grown on un-patterned surfaces (Yim, Pang et al. 2007).   
4. Promising bone substitutes in the tissue-engineering scenario  
Ideal skeletal reconstruction depends on regeneration of normal tissues that result from 
initiation of progenitor cell activity. In this context, cells are considered as a key element to 
achieve the regeneration of the target tissue, since very few biomaterials are osteoinductive 
by themselves (Goshima, Goldberg et al. 1991; Ohgushi, Dohi et al. 1993; Boo, Yamada et al. 
2002; Cancedda, Bianchi et al. 2003; Endres, Hutmacher et al. 2003; Livingston, Gordon et al. 
2003; Derubeis and Cancedda 2004; Warren, Nacamuli et al. 2004; Arinzeh, Tran et al. 2005; 
Kimelman, Pelled et al. 2006; Bernhardt, Lode et al. 2009; Matsushima, Kotobuki et al. 2009).  
The most intriguing concept in modern biomaterials is thus obtaining materials able to 
mimic a specific eventually pre-existing microenvironment and, therefore, inducing 
stem/progenitor cells to differentiate in a predetermined manner and to regenerate by 
themselves the bone tissue according to physiological pathways.  
Several researches have been conducted using autologous bone marrow-derived osteo-
progenitors to repair critical size segmental defects (Bianco and Robey 2001; Cancedda, 
Bianchi et al. 2003). The results of all these studies were in good agreement suggesting an 
important advantage in bone formation and, therefore, in the healing of the defect when 
cells were delivered together with a proper biomaterial scaffold. It is surprising that after the 
initial enthusiasm demonstrated by the flourishing of very encouraging large animal 
studies, only two pilot clinical studies have been performed (Quarto, Mastrogiacomo et al. 
2001; Vacanti, Bonassar et al. 2001). Although material science technology has resulted in 
clear improvements in the field of regenerative medicine, no ideal bone substitute has been 
developed yet and hence large bone defects still represent a major challenge for orthopaedic 
and reconstructive surgeons. We are now aware, though, that the intended clinical use 
defines the desired properties of engineered bone substitutes. Anatomical defects in load 
bearing long bones, for instance, require devices with high mechanic stability whereas for 
craniofacial applications, initially injectable or moldable constructs are favorable. Therefore, 
the most intriguing concept is obtaining materials able to mimic a specific eventually pre-
existing microenvironment, thus priming the natural processes of bone regeneration driven 
by cells.  
5. Conclusion  
In summary, a suitable scaffold for tissue engineering applications must have a structure 
correctly designed at different spatial scales to mimic the complex SC niche (Dellatore, 
Garcia et al. 2008). While it will probably not be necessary to mimic all aspects of the niche 
to enhance stem cells self-renewal and differentiation, it will almost certainly be necessary to 
simultaneously mimic multiple components of the niche (chemical and multi-scale 
architectural cues) to induce a specific cell differentiation and tissue ingrowth. 
Proper surface sensing, then, has raised as a new requirement for progenitor cells lineage 
differentiation. Indeed precommitment of MSC grown on a specific matrix cannot be 
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overcome by the addition of soluble factors to the growth medium. The osteogenic 
differentiation of MSC seeded onto electrospun poly(ε-caprolactone)/ECM scaffolds is 
maintained even in the absence of dexamethasone in the culture medium, a molecule 
normally required in standard osteogenic induction of plastic-adherent MSC cultures 
(Thibault, Scott Baggett et al. 2010). This observation is therefore of paramount relevance for 
tissue engineering applications of MSC, considering that specific tissue repair applications, 
such as bone reconstruction, often lead cell-based applications to relevant rounds of ex-vivo 
cell duplications, normally performed on standard disposable culture plastic-ware. In this 
respect, the most recent literature brings new insights onto the sensitivity of stem cells to the 
mechanical microenvironment, but also raises relevant questions regarding the induction 
strategies and the physical environments of in vivo and ex vivo microenvironments. 
Significantly recent findings have also raised the possibility that an injured 
microenvironment may lose compliance due to insufficient sensitivity and remodelling 
options of stem cells once in a non-inducing environment such as a fibrotic scar (Berry, 
Engler et al. 2006). Moreover the current paradigm implies that tissue homeostasis is 
favoured by a compliant matrix and a relative low integrin-mediated cytoskeletal tension, 
whereas an elevated integrin-ERK-Rho activity favours a tumorigenic/proliferating 
behaviour, although an excessively stiff matrix or integrin-dependent activity would 
promote the generation of stable focal adhesion sites, ultimately antagonizing cell 
spreading. 
Whether all these approaches and specific aspects, (scaffold stiffness compliance, surface 
topography and tridimensionality, scaffold chemistry) can be integrated into scaffold 
engineering to properly foster tissue regeneration remains to be seen; these aspects, 
however, have become even more relevant if the same pluripotent progenitor cells are used 
within tissue engineered composites proposed for multiple tissue repair, such as in the case 
of osteochondral defects. Microenvironmental changes may indeed influence the repair 
outcomes of the different tissues (Djouad, Delorme et al. 2007): the challenge, then, is to 
provide the proper cell “pre-commitment” in vitro to partially overcome an inappropriate 
pathological in vivo microenvironment. 
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1. Introduction  
No bone without vasculature. Current research reveals the molecular biology behind this 
simple statement. Bone formation and regeneration and the associated physiological and 
pathologically altered angiogenesis is not only of vital importance in the omnipresent 
fracture repair but also plays a constantly growing role in the diagnosis and treatment of 
chronically infected bone or osteonecrosis. The jaw and especially the mandible with its 
exceptional vascularisation in the human body are prone to these diseases. 
The understanding of the molecular mechanisms of osteogenic-angiogenic coupling is the 
fundament of a sufficient diagnosis and therapy. 
From the description of the physiological vascularisation of the jaw bones to pure 
autologous tissue engineering in the context of regenerative medicine we follow the process 
of bone formation under the influence of a sufficient angiogenesis with special regard to the 
key protagonist VEGF, the osteogenic-angiogenic interface and their interaction. 
2. Vascular anatomy of the jaw bones  
Head and neck are supplied with blood by branches of the external carotid arteries (ECA). 
The anterior and posterior superior alveolar arteries originate from the maxillary artery and 
provide the nutrient supply for the upper jaw and teeth; the inferior alveolar artery supplies 
the mandible and lower teeth. The jaw bones are drained of blood by the correspondent 
veins and eventually by the subclavian and the jugular vein. 
The outline of the bony vasculature is closely related to the mechanism of osteogenesis. The 
comparison between upper and lower jaw is the most striking example for this correlation in 
the human body: the ramified vessel system of the maxilla is a direct consequence of its 
intramembraneous ossification. In contrast, the mandible is supplied by a central artery and 
vein in the wake of a partly enchondral ossification as observed in long bones. This 
difference is of vital importance for physiological or iatrogenic bone regeneration. 
Coupling interface of bone and vasculature is the periosteum. It provides osteoprogenitor 
cells and keeps the capillary vessel system. 
Age dependent changes in the vascular and bony anatomy are the vertical and sagittal bone 
loss in the edentulous jaw, circulatory disorders, osteoporosis or bisphosphonate associated 
osteonecrosis. These alterations pose a challenge for successful regenerative intervention. 
 




The base of any form of growth and development is the continuous and sufficient supply 
with (progenitor) cells, oxygen and nutrients.  
The first appearance of a primitive vessel formation happens shortly after gastrulation, 
between the 19. and 21. day of embryonal growth. At this moment the first cells that express 
a VEGF receptor can be visualized. These cells proliferate in the yolk sac, form so called 
blood islands with endothelial and hemapoetic cells and expand to the first vessel network, 
the capillary plexus (Ferkowicz et al., 2003). 
In a parallel development, first angioblasts form the pairs of dorsal aortas following the 
midline of the embryo (Lawson et al., 2002). 
With the onset of heartbeat and the permanent presence of erthyroblasts in the newly 
formed vessel structures, the first vascular network is established. 
From now on a permanent remodelling and adaptation process set in, that lasts during the 
whole lifetime of the individual.  
Mechanical signals from the blood flow are pivotal factors in the differentiation of the vessel 
system, of the development of veins and arteries, their walls and the diameters of the 
growing vasculature.  
The head and neck vasculature derives from the first three aortal arches. 
2.2 Anatomy 
The carotid artery develops as a self-contained vessel from the ventral aorta. 
The external carotid artery (ECA) provides the blood supply for the face and the jaws.  
The maxillary artery as a terminal branch of the ECA supplies the profound regions of the 
face. It rises behind the mandibular neck to the pterygopalatine fossa; its course is  
divided into three portions: the mandibular, the pterygoid and the pterygopalatine 
portion.  
The facial bones are supplied by the superior and inferior alveolar artery, branches of the 
maxillary artery. 
The posterior superior alveolar artery divides into numerous branches to supply the upper 
teeth and the jawbone. The anterior superior artery originates from the infraorbital artery 
and supplies the upper incisor and canine teeth. Between these branches ramify many 
anastomoses. 
The inferior alveolar artery runs with the inferior alveolar nerve through the mandibular 
canal, divides into incisor and mental branch and provides the nutrient supply for the bone, 
the pulp of the lower teeth and the lower lip. 
In striking contrast to the ramified vessel system of the upper jaw, the mandible is perfused 
by the inferior alveolar artery alone. 
The venous drainage occurs via concomitant homonymous veins and anastomoses in the 
jugular and subclavian veins finally (Bouthillier et al., 1996). 
Figure 1 illustrates the arterial vascularisation of the upper and lower jaw originating from 
the internal carotid artery. 
2.3 Remodelling 
During foetal development the circulation is not only essential to provide the vital oxygen; 
the mechanical caused by the blood stream exert fundamental impact on the maturating 
vessel network. 
 




Fig. 1. Vascularisation of the jaw 
The development and maturation of the vessel system varies significantly form embryos to 
adults. One important and often neglected factor is the mechanical influence of an intact 
blood circulation on vessel anatomy and remodelling. 
Vascular remodelling in adults in a physiological surrounding is basically influenced by 
shear stress and circumferential stretch. These mechanical forces are relevant factors in 
vessel development and maturation. The molecular mechanisms of transforming a 
mechanical requirement to a histological response of the involved cells are so far not fully 
understood (Jones et al., 2011).  
3. Basic course of osteogenesis 
Bone tissue formation rests upon the balanced interaction between the secretory function of 
osteoblasts and the degrading activity of osteoclasts. There is intramembraneous and 
enchondral ossification: both processes are dependent on vascular ingrowth. Most of the 
facial bones, flat cranial bones, parts of the mandible and the clavicle are formed by 
enchondral ossification. It combines the growth potential of cartilage and bone to promote 
skeletal formation and development.  
Intramembraneous ossification is the direct ossification of the mesenchym, the primitive 
connective tissue. It starts with the invasion of capillaries into the mesenchymal zone, where 
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the resident cells transform into mature osteoblasts and begin to deposit bone matrix 
extracellularly. The growing bone formations build woven bone, which is eventually 
organized in stable lamellar bone. 
Osteogenesis in general takes place in the vicinity of neo-vessels that mediate the delivery of 
osteoprogenitors, secrete mitogen for osteoblasts, and transport nutrient and oxygen.  
Blood vessels provide a conduit for the recruitment of cells involved in resorption and bone 
deposition and are therefore a crucial condition for any bone formation or regeneration. 
Decisive factor of the rate of bone increase is the level of vascularisation of the growth plate. 
Bone is the rigid form of connective tissue. It is a dynamic construct, composed of 
secretory cells, the osteocytes, degrading cells, the osteoclasts and the surrounding matrix, 
the osteoid. The interaction of its major constituents define its mechanical characteristics: 
collagen type I guarantees its elasticity; calcium/ phosphate as structural components 
stand for stability and resistance; dermatan- and chondroitinsulfate represent together 
with collagen the main part of the extracellular matrix and determine the structural 
integrity of the tissue. 
Skeletal bone is the reservoir of calcium and phosphate that can be activated and released 
under endocrinological control. Its dynamic (re)modelling is a result of a permanent 
adaptation to changing physiological and pathological requirements. A fine-tuned balance 
of (physiological) stress and phases of regeneration leads to a continuous coexistence of 
osteogenesis and bone degradation and simultaneously to a corresponding vasculature 
(Martin et al., 2008). 
Osteogenesis takes place not only during foetal development but also in the course of 
facture healing or during infection. One differentiates chondral and intramembranous 
ossification. 
Essential osteoblastic markers are collagen type I, alpha 1 (Col1a1) and alkaline phosphatase 
(ALP); osteoclasts are characterized by the presence of tartrate-resistant acid phosphatase 
(TRAP), cathepsin K and dendritic cell-specific transmembrane protein (DC-STAMP) 
(Suzuki et al., 2007). 
3.1 Chondral ossification 
The bone formation on the basis of a cartilaginous scaffold is the basic principle of chondral 
ossification. 
One has to distinguish between an enchondral and a perichondral process.  
The course of enchondral ossification starts with the ingrowth of nutritive blood vessels in 
the growth centre of the epiphyseal growth plate. The blood supplies the tissue not only 
with oxygen and nutrients but also provides a new cell population: Chondroclasts to 
disintegrate the chondral gantry and osteoblasts and –clasts to construct the bone. 
Histologically, the growth area of enchondral ossification is characterized by a pillar-like 
alignment of the chondrocytes in an ascending order from reposing chondral cells to 
secreting ripe chondrocytes. These active cells produce the initial osteoid that is 
subsequently mineralized by the locally proliferating osteoblasts. The apoptosis of 
hypertrophic chondrocytes induces their replacement by osteoblasts in combination with 
endothelial progenitor cell invasion. 
The proliferative chondrocytes produce among other growth and transcription factors VEGF 
that regulates the vascular ingrowth.  
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Parts of the os petrosum maturate via chondral ossification. 
Perichondral ossification concerns the shafts of the long bones in the extremities: osteoblasts 
deriving from the well-perfused perichondrium build a three-dimensional cell collar around 
the cartilage and start to form bone appositionally (Berkowitz et al., 2002). 
3.2 Intramembranous ossification 
Intramembranous ossification describes the direct bony transformation of the primitive 
connective tissue and affects mainly the flat bones. 
Starting point is the compaction of mesenchymal cells into ossification centres. The cells 
differentiate to osteoblasts and start to produce the bony matrix, the osteoid. With the 
emplacement of calcium and phosphate the developing bone maturates; the osteoblasts 
become resting osteocytes.  
Intramembranous ossification takes place in the flat bones of the skull, for example the os 
frontale (Berkowitz et al., 2002). 
3.3 Ossification of the mandible 
The skull structures develop from the first and second branchial arch. These mesenchymal 
tissue areas appear during the fourth week of embryonic growth and determine the base of 
the individual facial features.  
The central vessel/ nerve bundle characterizes the anatomy of the mandible. This special 
anatomical feature determines the course of the bony development of the lower jaw. 
First ossification centres in the mandible can be detected in the area of the branching 
mandibular nerve in close relation to the developing mental foramen. From here the 
Meckel´s cartilage indicates course and direction. The Meckel´s cartilage is a transient 
chondral check rail derived from the first brachial arch to guide the developing bony 
mandible. It degrades until the 24. week of embryonal development. From its posterior 
remnants the auditory ossicles malleus and incus are formed. 
From the mental foramen to the base of the condylar processus, the course of the 
mandibular nerve with its corresponding vessels defines the guardrail for the maturating 
bone. The growing nerval structure with its concomitant vessel system and the tide of 
growth factors seems to influence and guide the bone maturation. 
In an investigation of 25 fetuses the prenatal development and remodelling af the mandible 
was studied with regard to the morphometry, the histological evaluation of the remodelling 
processes and a 3D analysis. 
The results suggest a strong influence of Meckel´s cartilage configuration and dental 
primordial on the later anatomy, the signal cascading and specific role of the involved 
growth and transcription factors in the 3D moulding of the human mandible are not clear 
(Radlanski et al., 2003). 
Another region of interest as far as the ossification of the mandible is concerned, is the 
mental foramen, the area where nerve, vessels and surrounding extracellular matrix pass the 
bone. The mental foramen is a centre of bone development and remodelling of the 
mandible. The pattern of bone configuration and dynamics around the mental foramen 
differs from the ossification in the bony gutter. 
The presence and proximity of the nerve and concomitant vessels does have significant 
impact on mandibular ossification (Radlanski et al., 2004). 
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3.4 Role of VEGF in the growth plate 
The vital importance of a sufficient VEGF induced vessel formation in the physiological 
morphological progression of the growth plate was underlined impressively by the work of 
Gerber et el. 1999: in an mouse model the inactivation of VEGF via soluble antibodies 
resulted in a significant reduction of vascularisation and consequently ossification. Their 
data suggests that VEGF-dependent angiogenesis is essential for the processing of he 
growth plate, cell differentiation and the coupling of chondral degradation and bone 
formation. 
The lack of trabecular bone and the hypertrophy of the chondrocytes were reversible after 
cessation of VEGF suppression (Gerber et al. 1999).  
4. Angiogenic cascade 
VEGF and its receptors are the key regulators of angiogenesis. 
Angiogenesis is the growth of new blood vessels from pre-existing vasculature that occurs 
in physiological and pathological contexts. This process is often triggered by a signalling 
cascade that occurs upon ligand-receptor binding between vascular endothelial growth 
factor (VEGF) and its receptors (VEGFR1/Flt-1, VEGFR2/KDR). These receptors are 
expressed by endothelial cells that line the blood vessels. Most potent trigger for 
angiogenesis is hypoxia. 
Angiogenesis, the complex physiological sequence of vasodilatation, degradation of 
basement membrane, endothelial cell migration, chemotaxis, increasing vascular 
permeability and eventually endothelial cell proliferation and vessel formation is regulated 
by VEGF(R).  Osteogenic and angiogenic cascade are inseparably interconnected by the 
functional alliance of endothelial cells, osteoblasts and growth factors. 
Angiogenesis is defined as the growth of new blood vessels on the base of existing vascular 
structures in contrast to vasculogenesis, the development of a new vessel system by 
sprouting, differentiating endothelial cells. These pivotal processes mark the starting point 
of any form of vascular development or regeneration processes. In malignant growth, the 
appearance of new vessels can be a determinant of progression and poor prognosis, whereas 
a lack of vasculature inevitably leads to loss of functional efficiency and tissue necrosis from 
the brain to the limbs. 
The fine-tuned balance of vasculo- and angiogenesis is controlled by many growth and 
transcription factors (Pandya, Dhalla et al., 2006). 
4.1 Angiogenic cascade – in vitro 
The angiogenic cascade in vitro follows a characteristic course of events: Initiation, 
proliferation or invasion and maturation.  
The starting point – the initiation - is the release of angiogenic factors, VEGF, basic fibroblast 
growth factor (bFGF) or tumour necrosis factor alpha (TGF). These mitogens and 
stimulators are released by or inflammatory cells. 
Proliferation and invasion includes the degradation and remodelling of the extracellular 
matrix, the chemotaxis of endothelial (progenitor) cells and the altered expression of 
adhesion molecules. During the maturation phase, the newly formed vessel ripens, a lumen 
develops and finally the basal lamina envelops the structure. 
These processes can be retraced in vitro: 
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After the sterile preparation of endothelial cells from an umbilical cord vein according to 
standard procedure follows the adhesion and proliferation of endothelial cells in their 
culture well under defined conditions. 
After 5 to 7 days a (sub-) confluence of the proliferating cells and formation of a monolayer 
can be observed. 
The formation of circular ring-structures with characteristic cell-cell contacts marks the 
angiogenic potency of the cultured cells. Special marker of the cell-cell contact is VE-
Cadherin, CD 144 antigen.  
The adjustment of the culture conditions influences the tissue architecture: in a three 
dimensional scaffold the formation of a network of capillaries can be observed. 
Immunohistochemical markers to characterize the proliferating cell population are CD 31 or 
von Willebrand factor, for example. 
Growth and proliferation of endothelial cells and their surrounding matrix in the course of 
angiogenesis are governed by a multitude of regulating factors (Fraisl et al., 2009). 
4.2 Angiogenic growth factors 
Stimulators and inhibitors govern Angiogenesis. The most important pro-angiogenic factors 
are VEGF, Angiopoietin-1, β-Estradiol, bFGF, IL-8, Leptin, MMPs, NOS, PDGF-BB, TNF-α, 
Angiogenin and TGF. They exert their influence on different stages during the angiogenic 
cascade. 
Table 1 subsumes the respective function of the most prominent angiogenic factors. 
 
Factor Function 
VEGF Cell mitogen, vascular permeability 
Angiopoietin-1 Maturation, stability 
Angiotropin Cell migration 
bFGF Angiogenesis in wound healing 
IL-8 Chemotaxis, inflammation  
NOS Vasodilatation 
PDGF-BB Chemotaxis, proliferation 
Angiogenin Indirect stimulation, release of angiogenic factors 
TGF Mitogen, differentiation of endothelial cells 
Table 1. Pro-angiogenic factor 
The variety of different angiogenic factors with similar functions implies the idea of 
redundancy: the quick and undisturbed succession of events of angiogenesis is too 
important for the function of the whole organism to take the risk of relying on unique 
regulators or promoters. 
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The interconnection of angio- and osteogenesis is reflected in the expression of angiopoietin 
by osteoblasts. The role of angiopoietin in bone formation is not yet clear. The results of in 
vivo studies suggest that one essential osteogenic effect is the induction of angiogenesis. An 
over expression of angiopoietin led to an augmentation of bone mass  (Suzuki et al., 2007).  
The anti-angiogenic antagonists are among others angiostatin, anti-angiogenic anti-
thrombin III, canstatin, endostatin (collagen XIII fragment), fibronectin fragment, 
heparinases, IFN-α,β,χ IL4, IL12, IL18, plasminogen activator inhibitor or pigment 
epithelium derived factor, PEDF.  
Their function is to balance angiogenesis and to interfere with excessive vessel formation. 
The most important inhibiting factors with their functions are summarized in table 2. 
Angiogenesis in vivo is a complex, multilayer process involving the degradation of the 
vessel basement lamina, the migration and proliferation of endothelial cells and the 
formation of luminal structures. It includes the cell interaction – activation and silencing by 
a variety of different growth and transcription factors – and depends on the information and 
provided by the extracellular matrix. Excessive growth has the same devastating 
pathological impact as a deficient vasculature (Klagsbrun et al., 1991). 
 
Factor Function 
TGFß Inhibition of endothelial cell motility 
Canstatin Collagen IV, inhibitor 
Endostatin Collagen XVIII, inhibitor 
Platelet factor IV Inhibitor of growth factor-dependent 
endothelial stimulation 
TNF Inhibitor of endothelial cell proliferation 
Protamin Block of heparin-binding growth factors 
PEDF Inductor of endothelial cell apoptosis 
Table 2. Anti-angiogenic factors 
Another pivotal factor in the regulation of angiogenesis is the microRNA (miRNA) 
expression. MiRNAs are noncoding small RNAs the modulate postransscriptional gene 
expression. Their up- and down-regulation is partly regulated by hypoxia and is involved in 
the stimulation or inhibition of VEGF or other (anti-)angiogenic factors. The most prominent 
angiogenic miRNAs are miR-126 and miR-27b, anti-angiogenic miRNAs are miR-221 or 
miR-20a (Fraisl et al., 2009). 
4.3 Oxygen sensing 
How is a lack of oxygen and therefore an urgent need for further vascularisation  
detected? 
VEGF is release is controlled by hypoxia, oxidative stress, pH or glucose concentration. 
VEGF binds to membrane tyrosine kinase receptors and initiates chemotaxis, cell migration 
and vascular permeability (Bikfalvi et al., 2002). 
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The key of oxygen sensing lies in the HIF transcription factor complex. Oxygen-dependent 
enzymes, the prolyl-hydroxylases (PHDs) bind oxygen and couple it to HIF1-. Von Hippel 
Lindau (VHL) protein attacks this complex and initiates its degradation. Decreasing levels of 
oxygen lead to a rising concentration of HIF1 (Riddle et al., 2009). 
HIF initiates pronounced tissue oxygenation, among many other factors by the stimulation 
of VEGF expression.  
In addition, a tight osteogenic-angiogenic coupling was demonstrated by an increase of 
bone mass and volume up to 70% after HIF1 activation. 
The pharmacological activation of the HIF pathway resulted in an accelerated bone healing 
(Wang et al., 2008, Wan et al., 2007,  Towler, 2008). 
Under hypoxic conditions the expression of a variety of genes is altered, adapted to the 
reduced oxygen supply. Among the hypoxia-induced genes there are not genes involved in 
metabolism, angiogenesis, erythropoiesis, chondrocyte differentiation and the development 
and maturation of  the collagen matrix (Araldi et al., 2010). 
5. Interaction between endothelial cells and osteoblasts on different matrix 
structures 
The potency of the matrix has an enormous impact on the development of the new tissue. It 
influences cell adhesion, spreading and signalling, cell growth and migration as well as the 
differentiation of the extracellular matrix and the tissue morphogenesis. 
One decisive prerequisite of a matrix structure – especially in the context of regenerative 
medicine - is the ability to support the growth of blood vessels. 
As biological surfaces, collagen membranes are accepted as reliable surfaces to support the 
growth and adherence of endothelial cells. 
Titanium emerged as an artificial surface, which clearly supports the growth and adhesion 
of endothelial cells and therefore complies with the basic requirements for osseointegration 
of titanium implants. 
The differentiation, growth and function of cellular systems not only relies on their 
interaction and the interference by synthesized soluble factors but also to a considerable 
extent on the alloplastic or autologous surfaces of the scaffold on which they are supposed 
to proliferate. This undisturbed or even conducive environment is the precondition for any 
healing process where the application of any form of implant is involved. 
The biological properties of autologous and alloplastic surfaces have been under scrutiny. 
5.1 Collagen 
The successful clinical application of materials should involve detailed investigations on 
interaction between them and tissue with which they will contact.  
One relevant approach to gain information about the influence of the scaffold on the 
proliferating cells is to observe the behaviour of endothelial cells on a collagen material, 
using histological and immunohistochemical methods.  
In an in-vitro essay, isolated human umbilical cord vein cells (HUVECs) identified by means 
of endothelial-specific antibodies were cultivated to perform the trials.  
Cells were seeded in a standard density on a collagen membrane (Lycoll, Resorba, 
Nuernberg, Germany) and on gelatin-coated control plastic surfaces, after two passages. 
These were maintained for periods of 1, 7, or 14 days. The cells adhered, spread and 
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proliferated. Within 24 hours the HUVECs started forming a subconfluent monolayer. It 
could be observed that the cultured cells expressed integrins and synthesized fibronectin.  
The results suggested that the collagen material supported growth and attachment of 
endothelial cells. In addition, the attachment seemed to be related to the fibronectin 
synthesized by the cells and to its highly expressed receptor, the α5β1 integrin. (Breithaupt-
Faloppa et al., 2006). 
The undisturbed growth and proliferation on a collagen scaffold is the basis of standard 
tissue engineering protocols.  
5.2 Titanium 
Osteogenesis on titanium surfaces is the prerogative of any form of osseointegration of 
alloplastic titanium implants from the knee to the teeth.  
The mechanisms of cell-cell interaction and dependence meet the prerequisites and 
requirements of an alloplastic interface with its special mechanical and biochemical material 
properties of the surface, such as roughness or hydrophilicity.  
The coculture of osteoblast-like and endothelial cells on titanium surfaces represents a 
reliable experimental model to evaluate their biological behaviour. It is a simple and 
reduced model of osteo- and angiogenesis without the complexity of an in vivo 
investigation. 
The cellular integrity and their function ability are measured by the synthesis of 
characteristic cell markers via immunohistochemistry. 
Gene expression of osteo- and angiogenic factors is used to consolidate and quantify the 
histological results.  
In an in vitro trial the endothelial cell behaviour on a titanium surface was investigated by 
the immunhistochemical detection of characteristic endothelial markers CD 31 and 
von Willebrand factor, fibronectin and its receptor, vitronectin and its receptor and VE 
cadherin. 
The results indicated that the attachment of ECs on titanium could be related to cellular-
derived fibronectin and the binding to its specific receptor, the α5β1 integrin. It was 
observed that titanium effectively serves as a suitable substrate for endothelial cell 
attachment, growth and proliferation in the initial phase. It is suggested to describe this 
feature of titanium if not angiogenic then at least angio-conductive.  
Nevertheless the studied cells did not show the physiological cytological development after 
titanium contact of 7 days. These findings do not correlate with good clinical results. 
The high degree of biocompatibility of titanium and its alloys is intimately related to the 
passively formed oxide film on the metallic surface (Breithaupt-Falloppa et al., 2008). 
6. Influence of angiogenesis during osteogenesis 
The level of angiogenesis is a pivotal element of osteogenesis. The vasculature provides the 
transport of oxygen, nutrients, growth regulating factors and metabolites to all tissues in the 
body. 
Many factors act as key protagonists of bone angiogenesis: VEGF, especially its isoforms 
VEGF120, 164 and 188, bFGF, TGFβ, HIF are the most potential ones. VEGF in its isoforms 
with the corresponding receptors have emerged as the decisive coupling factors between 
epi- and metaphyseal vascularisation and cartilage development and therefore enchondral 
ossification. 
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The angiopoietins Ang-1 and Ang-2, hepatocyte growth factor HGF, platelet-derived 
growth factor PDGF, the IGF family and the neurotrophins NGFs also have angiogenic 
properties.  
The course of osteogenesis paves the way for the vascular anatomy: anastomosing vessel net 
or central artery and vein. 
6.1 VEGF in angiogenesis 
The development of a new vessel network provides multipotent mesenchymal cells, 
endothelial progenitor cells and the substrates for any form of regeneration. The sprouting 
of vessels from surrounding local bone tissue into a defect or regeneration area is considered 
to be a decisive factor for undisturbed osteogenesis. Quality of bone in traumatology is 
assessed mostly by its structure and mechanical stability. In the treatment of many other 
diseases of the skeleton the clinical evaluation of the bony vascularisation is the benchmark 
for its quality. 
The latter is especially disturbed in most patients needing solid and reliable bone 
regeneration: in clinical routine it is the problem of patients with osteomyelitis, tumour 
patients after radiation, or patients after trauma in whom local vascularisation is 
considerably disturbed and not predictable. 
For this reason, extensive evaluation of this part of the regeneration process is of great 
significance as a means of gaining basic information for specific therapy. 
Not only the physiological environment of an intact sprouting vessel system, but also its 
special stimulation by decisive growth and differentiation factors has an enormous impact 
on the development and maturation of the surrounding bone. The outstanding and field-
tested in this context is VEGF. Many publications underline its efficacy in angiogenesis. 
The stimulation of bone regeneration by rhVEGF165 was investigated, among many other 
trials, in a rabbit animal model. 
Mandibular critical size defects in 56 animals were treated with VEGF-laden collagen 
carriers. The significant effects of the stimulation became most obvious during the phase of 
physiological regression during the regeneration process:  
This physiologic process, activated by hyperoxygenation caused by hyperperfusion led to 
delamination of endothelial cells from the basal membrane and endothelial apoptosis. 
The effect of rhVEGF165 as an endothelial cell survival factor led to persisting angiogenesis 
in the study group, extending beyond day 14. Morphologic and structural effects of 
angiogenesis on osteogenesis could not be observed until after at least 28 days, because 
maximum bone regeneration occurs at that time.  
In addition to the indirect influence of the increased supply of osteogenic progenitor cells by 
the developing vascular system, the increased expression of osteogenic growth factors 
expressed by endothelial cells seemed to play a crucial role in this experimental setting 
(Kleinheinz et al., 2005). 
6.2 Impact of osteoid 
In addition to established angiogenic growth stimulators the microenvironment of secretory 
osteoblasts shows a significant pro-angiogenic effect. The produced extracellular matrix 
influences demonstrably migration, proliferation and differentiation of endothelial 
progenitor cells. 
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Cell culture investigation proved the significant stimulation of endothelial cells to form 
vessels-like structures. 
Post-translationally glycosylated collagen I was unmasked as decisive factor concerning the 
effective activation of endothelial stimulation via p38/MAPK signalling pathway. 
It was demonstrated that the adhesion of endothelial cells to collagen I, one of the major 
constituents of osteoid, not only supports their growth but represents an essential condition 
to perform the angiogenic switch. 
In cell culture observations the role glycosylated collagen type I became clear:  
It induces the expression of molecules like MMP-2 and IL-12. These factors were connected 
with an increased vessel networking, at the same time an increasing amount of mature bone 
tissue. The close connection of these processes seems to be linked by the many involved 
growth factors as well as the variety of progenitors and regenerative cells (Palmieri et al., 
2010). 
7. Autologous bone tissue engineering 
Today approaches to restore the osseous integrity of such primarily non-regenerating 
lesions rely either on the integration of autologous bone or on the implantation of substitute 
materials. Autologous bone chips or bars reducing the defect size below the critical 
threshold enable primary healing processes, but their supply is limited.  
Bone tissue engineering subsumes an abundance of approaches to the artificial engineering 
of osseous structures based on the principle of an extracorporeal linking of cells, matrix and 
bioactive factors.   
As the supply of nutrition and oxygen via diffusion in three-dimensional tissue formations 
is restricted to an area of 150 µm around the nutritive capillary, resorption and 
devitalisation in the center of the implant lead to a loss of mechanical stability. A successful 
approach to bone tissue engineering therefore has to incorporate both osteogenic and 
vascular development as a combination of osteogenic and angiogenic processes will lead to 
an improved and accelerated regeneration with simultaneous proliferation of the new 
complex tissue of these cell types.  
A pure autologous combination of all components with an autologous scaffold seems to be 
of elementary importance for further improved cell behaviour.  
Promising approaches concentrate mainly on fibrin as the best possible basis for  
tissue engineering as fibrin plays an important role in haemostasis and also  
represents a physiological temporary scaffold for the cell invasion in the following healing 
process. 
Large bone defects or osseous deficiency caused by congenital malformation, trauma, 
tumour surgery or osseous infection exceeding a critical threshold and showing no signs of 
spontaneous healing are still a great challenge to reconstructive surgery. These critical size 
defects (CSDs) are individually determined for every species and vary by age, size and sex 
(Cima et al., 1991, Glowacki et al., 2004). 
Today approaches to restore the osseous integrity of such primarily non-regenerating 
lesions rely either on the integration of autologous bone or on the implantation of substitute 
materials. Autologous bone chips or bars reducing the defect size below the critical 
threshold enable primary healing processes, but their supply is limited. Xenogenous or 
alloplastic materials seem to be a simple and gentle method with bone regeneration from the 
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surrounding bone, but malresorption and decreased osteogenic potency of substitute 
material affect the stability of the defect area.  
Besides the repair and reconstruction the in vivo – regeneration of lost tissue using the 
activation of local regeneration cascades therefore seems to be the most promising method. 
Bone tissue engineering subsumes an abundance of approaches to the artificial engineering 
of osseous structures based on the principle of an extracorporal linking of cells, matrix and 
bioactive factors.  Many approaches to promote the adherence and proliferation of 
transplanted, osteopotent cells expressing of extracellular matrix proteins (ECM) used 
xenogenous or alloplastic scaffolds such as corals (Putnam et al., 1996), collagen (Saadeh et 
al., 2001), PLA/PGA or fibrin glue, but there is no record for the use of autologous scaffolds. 
Despite the success in some parts of the substitute materials such as the avoidance of donor 
site morbidity, optimization of the three-dimensional configuration of the transplant and 
healing processes, infection and non-integration of the implanted materials occur (Frerich et 
al., 2000). 
The potency of the matrix has an enormous impact on the development of the new tissue. 
This potency should include: a) an optimal scaffold for specific tissue engineering, b) matrix 
biodegradation with contemporaneous new tissue formation, c) a guaranteed interaction of 
newly formed tissue with new specific cells forming coherent structures with mechanical 
function and stability. 
As the supply of nutrition and oxygen via diffusion in three-dimensional tissue formations 
is restricted to an area of 150 µm around the nutritive capillar, resorption and devitalisation 
in the center of the implant lead to a loss of mechanical stability. A successful approach to 
bone tissue engineering therefore has to incorporate both osteogenic and vascular 
development as a combination of osteogenic and angiogenic processes will lead to an 
improved and accelerated regeneration with simultaneous proliferation of the new complex 
tissue of these cell types (Pellisier et al., 2003).  
A pure autologous combination of all components with an autologous scaffold seems to be 
of elementary importance for further improved cell behaviour.  
Promising approaches concentrate mainly on fibrin as the best possible basis for tissue 
engineering as fibrin plays an important role in haemostasis and also represents a 
physiological temporary scaffold for the cell invasion in the following healing process 
(Nolting et al., not published yet).  
8. Conclusion  
Chronic infections of the bone, necrosis and drug associated osteomyelitis are diseases that 
will become of growing dominance in the coming decades. These pathologies result not only 
from a deficient bone formation or regeneration but are closely related to an impaired 
vasculature. 
To understand and to better evaluate the co-dependence of developing or regenerating 
bone and its accompanying vasculature it is of vital importance to retrace their serial 
interface from fetal development to adulthood, from macroscopic anatomy to biomolecular 
processes. 
The future of regenerative approaches to bone healing and regeneration will inevitably 
combine the field-tested strategies of tissue engineering with modern biomolecular 
techniques in the scientific environment of stem cells and gene therapy. 
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Our work showed conclusively the enormous reciprocal impact of angio- and osteogenesis. 
To stimulate the osteogenesis one clearly has to optimize – or at least: incorporate – the 
vascular regeneration in the context of regenerative medicine.  
Promising approaches for the near future will investigate the potential of stem and 
regenerative cells: mesenchymal stem cells or cells from the dental pulp have been 
examined particularly with regard to their ability to differentiate in an angio- or osteogenic 
direction. The experimental results encourage further experimental work in this field of 
regenerative medicine to develop an applicable therapeutic strategy of personalized 
regenerative medicine. 
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